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Summary 
The rise of antibiotic-resistant pathogens such as methicillin-resistant Staphylococcus aureus 
(MRSA) strains and drug-resistant forms of Mycobacterium tuberculosis is one of the major 
problems modern medicine faces and constitutes a severe threat to human health. The 
successful treatment of infections caused by drug-resistant bacteria now and in the future, 
requires the urgent development of novel antibacterials. 
Whereas most currently used antibiotics act by interfering with essential bacterial processes, 
a smaller group of antibacterials disturbs the integrity of the cell membrane. Since fatty acids 
are a vital component of membrane phospholipids, the type-II fatty acid biosynthesis 
pathway (FAS-II) of bacteria constitutes a promising drug target. The front-line anti-
tuberculosis prodrug isoniazid blocks the FAS-II pathway in M. tuberculosis thereby leading 
to morphological changes and finally to cell lysis. When it became evident that the enoyl-
ACP reductase in the FAS-II pathway is the target of the activated isoniazid, several programs 
were initiated to develop novel inhibitors directed against this protein in different 
pathogens. 
The S. aureus enoyl-ACP reductase (saFabI) is of particular interest since three promising 
drug candidates inhibiting this homologue have reached clinical trials. However, despite 
these prospects, no crystal structures of saFabI were publicly available at the time the 
present work was initiated. Thus, one major goal of this thesis was the generation of high-
resolution atomic models by means of X-ray crystallography. The development of a highly 
reproducible approach to co-crystallize saFabI in complex with NADP+ and diphenyl ether-
based inhibitors led to crystal structures of 17 different ternary complexes. Additional 
crystallographic experiments permitted the view into two apo-structures and two atomic 
models of saFabI in complex with NADPH and 2-pyridone inhibitors. Based on the 
established saFabI structure, molecular dynamics (MD) simulations were performed to 
improve our understanding of the conformational mobility of this protein. Taken together, 
these investigations of the saFabI structure and its flexibility served as an ideal platform to 
address important questions surrounding substrate and inhibitor recognition by this enzyme. 
Intriguingly, our saFabI structures provide several vastly different snapshots along the 
reaction coordinate of ligand binding and hydride transfer, including the closure of the 
flexible substrate binding loop (SBL). The extraordinary mobility of saFabI was confirmed by 
MD simulations suggesting that conformational motions indeed play a pivotal role during 
substrate delivery and turnover. A water chain linking the active site with a water-basin 
inside the homo-tetrameric enzyme was found likely to be crucial for the closure and 
opening of the SBL and, thus, for the catalyzed reaction. Notably, the induced-fit ligand 
binding process involves a dimer-tetramer transition, which could be related to the observed 
positive cooperativity of cofactor and substrate binding. Overall, saFabI displays several 
unique characteristics compared to FabI proteins from other organisms that might be 
necessary for the synthesis of branched-chain fatty acids, which in turn are required for S. 
aureus fitness in vivo. This finding may explain why S. aureus is sensitive to FAS-II inhibitors 
even in the presence of exogenous fatty acids. Accordingly, saFabI remains a valid drug 
target and our structures can be used as a molecular basis for rational drug design efforts. In 
fact, binding affinity trends of diphenyl ether inhibitors and, more importantly, the 
correlated residence times could be rationalized at the molecular level. Furthermore, the 
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structure of saFabI in complex with the 2-pyridone inhibitor CG400549 revealed unique 
interactions in the wider binding crevice of saFabI compared to other FabI homologues 
explaining the narrow activity spectrum of this clinical candidate with proven human 
efficacy. In summary, these studies provide an ideal platform for the development of new, 
effective saFabI inhibitors as exemplified by the promising 4-pyridone PT166. 
In the context of this dissertation, crystal structures of the condensing enzyme KasA in 
complex with several analogs of the naturally occurring inhibitor thiolactomycin have been 
solved. KasA is an essential enzyme involved in the FAS-II system of M. tuberculosis, which is 
capable of producing very long fatty acid chains. The solved structures help to clarify the 
mechanism of the catalyzed reaction and, importantly, reveal successive snapshots of an 
induced-fit binding mechanism enabling the uptake of the long and hydrophobic acyl-
substrate. Intriguingly, a phospholipid molecule was found to be trapped inside the acyl-
binding channel, thus permitting the observation which conformational changes in the 
capping region of the protein are necessary to enable binding of the acyl-chain. 
The different conformational states observed in this study for the two FAS-II enzymes saFabI 
and KasA likely represent intermediate structures of the proceeding enzymatic reactions 
and, thus, provide ideal starting points for the rational optimization and design of small 
molecules that are active against S. aureus and M. tuberculosis infections. 
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Zusammenfassung 
Die Zunahme Antibiotika-resistenter pathogener Erreger stellt eines der größten Probleme 
der modernen Medizin dar. Eine besondere Gefährdung für die Gesundheit der Bevölkerung 
sind methicillin-resistente Staphylococcus aureus (MRSA) und Antibiotika-resistente 
Mycobacterium tuberculosis Bakterien. Um die Behandlung von Infektionen, die von diesen 
Bakterien verursacht werden, auch in Zukunft gewährleisten zu können, werden dringend 
neue antibakteriell wirksame Substanzen benötigt. 
Während die Wirkung der meisten gebräuchlichen Antibiotika auf einer Beeinträchtigung 
wichtiger bakterieller Prozesse beruht, wirken manche Substanzen durch die Störung der 
Zellmembran-Struktur. Da Fettsäuren ein essentieller Bestandteil von Membran-
Phospholipiden sind, stellt die bakterielle Fettsäurebiosynthese II (FAS-II) einen relativ wenig 
erforschten, aber dennoch vielversprechenden Angriffspunkt für die Entwicklung neuer 
Antibiotika dar. Das wichtige Antituberkulotikum Isoniazid blockiert die mykobakterielle 
Fettsäurebiosynthese und ruft dadurch morphologische Änderungen sowie letztlich die Lyse 
des Bakteriums hervor. Eine wichtige Erkenntnis war, dass Isoniazid den letzten Schritt des 
FAS-II Elongationszyklus inhibiert, der durch die Enoyl-ACP Reduktase katalysiert wird. 
Darauf aufbauend wurden mehrere Programme ins Leben gerufen, die sich zum Ziel gesetzt 
hatten, neue Moleküle zu entwickeln, welche dieses Protein verschiedener Pathogene 
hemmen. 
Die S. aureus Enoyl-ACP Reduktase (saFabI) ist von besonders großem Interesse, da drei 
vielversprechende Inhibitoren dieses Proteins entwickelt werden konnten, die momentan in 
klinischen Studien eingehend untersucht werden. Trotz dieser Erfolgsaussichten waren zum 
Zeitpunkt, als die vorliegenden Arbeiten aufgenommen wurden, keine Kristallstrukturen von 
saFabI öffentlich verfügbar. Daher war es eines der Hauptziele dieser Doktorarbeit, auf der 
Basis von kristallographischen Experimenten atomar aufgelöste Modelle für dieses wichtige 
Protein zu erzeugen. Durch die Entwicklung einer verlässlichen Methode zur Kristallisation 
von saFabI im Komplex mit NADP+ und Diphenylether-Inhibitoren konnten Kristallstrukturen 
von 17 verschiedenen ternären Komplexen gelöst werden. Weitere kristallographische 
Experimente ergaben zwei apo-Strukturen sowie zwei Strukturen von saFabI im Komplex mit 
NADPH und 2-Pyridon-Inhibitoren. Basierend auf der nun bekannten saFabI-Struktur 
konnten Molekulardynamik-Simulationen durchgeführt werden, um zusätzliche Erkenntnisse 
über die Flexibilität dieses Proteins zu erhalten. Die so gewonnenen Informationen über die 
Struktur und Beweglichkeit des Enzyms dienten in Folge als ideale Grundlage dafür, den 
Erkennungsprozess von Substrat und Inhibitor zu verstehen. Besonders bemerkenswert 
dabei ist, dass die verschiedenen saFabI Kristallstrukturen Momentaufnahmen entlang der 
Reaktionskoordinate der Ligandenbindung und des Hydrid-Transfers repräsentieren. Dabei 
verschließt der so genannte Substratbindungsloop das aktive Zentrum des Enzyms 
allmählich. Die außergewöhnlich hohe Mobilität von saFabI konnte durch 
molekulardynamische Simulationen bestätigt werden. Dies legt nahe, dass die beobachteten 
Änderungen der Konformation tatsächlich an der Aufnahme und Umsetzung des Substrates 
beteiligt sind. Eine Kette von Wassermolekülen zwischen dem aktiven Zentrum und einer 
wassergefüllten Kavität im Inneren des Tetramers scheint für die Beweglichkeit des 
Substratbindungsloops und somit für die katalysierte Reaktion von entscheidender 
Bedeutung zu sein. Außerdem wurde die erstaunliche Beobachtung gemacht, dass der 
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adaptive Substratbindungsprozess mit einem Dimer-Tetramer Übergang gekoppelt ist, 
welcher die beobachtete positive Kooperativität der Ligandenbindung erklären kann. Alles in 
allem weist saFabI im Vergleich zu FabI Proteinen aus anderen Organismen mehrere 
außergewöhnliche Eigenschaften auf, die für die Synthese von verzweigten Fettsäuren nötig 
sein könnten, welche wiederum für die Überlebensfähigkeit von S. aureus im Wirt von 
Bedeutung sind. Diese Erkenntnis könnte erklären, warum S. aureus selbst bei Anwesenheit 
von exogenen Fettsäuren von FAS-II Inhibitoren abgetötet werden kann. Somit können die 
gewonnenen atomaren saFabI Modelle einen entscheidenden Beitrag zur Entwicklung neuer 
Hemmstoffe dieses validierten Angriffszieles leisten. Tatsächlich konnten die neuen 
Strukturen genutzt werden, um die Bindungsstärken sowie die Verweilzeiten verschiedener 
saFabI Inhibitoren molekular zu erklären. Die Struktur von saFabI im Komplex mit dem 2-
Pyridon Inhibitor CG400549 hingegen enthüllte spezifische Wechselwirkungen in der 
geweiteten Bindetasche des S. aureus Enzyms, welche das geringe Aktivitätsspektrum dieses 
derzeit klinisch erprobten Inhibitors erklären. Diese Studien schaffen somit eine ideale 
Voraussetzung für die Entwicklung neuer wirksamer saFabI Inhibitoren, was am Beispiel des 
4-Pyridons PT166 belegt werden kann. 
Im Rahmen der vorliegenden Dissertation konnten außerdem die Strukturen des Enzyms 
KasA im Komplex mit mehreren Derivaten des Naturstoffs Thiolactomycin gelöst werden. 
Dieses Protein ist ein essentielles, an der Fettsäurebiosynthese von M. tuberculosis 
beteiligtes Enzym, welches in der Lage ist, sehr lange Fettsäuren zu produzieren. Die 
gelösten Strukturen leisten einen entscheidenden Beitrag dazu, den Mechanismus der 
katalysierten Reaktion zu verstehen. Gleichzeitig legen sie einen adaptiven Bindungsprozess 
des langen hydrophoben Acyl-Substrates nahe. Ein Phospholipid-Molekül bindet dabei 
innerhalb des langen Acyl-Kanals und ermöglicht somit die Beobachtung der 
Konformationsänderungen des Proteins, die für die Bindung der Acyl-Kette nötig sind. 
Die verschiedenen Zustände, die in dieser Studie für die beiden FAS-II Enzyme saFabI und 
KasA beobachtet wurden, repräsentieren aller Wahrscheinlichkeit nach während der 
enzymatischen Reaktion auftretende Strukturen und bilden somit eine gute Grundlage für 
das rationale Design neuartiger Wirkstoffe gegen S. aureus und M. tuberculosis Infektionen. 
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1 Introduction 
1.1 Antibiotic Resistance 
1.1.1 Clinically Relevant Classes of Antibacterial Drugs 
The treatment of infectious diseases becomes increasingly difficult due to the development 
of antibiotic resistances (20). Alarmingly, resistances have been reported for all clinically 
relevant antibacterials (1). The antibiotics currently in use block a limited number of 
essential biological processes to harm the pathogenic bacterium which is the underlying 
cause for certain human infections (1). Most antibacterial drugs interfere with ribosomal 
protein biosynthesis, DNA replication and transcription, nucleotide biosynthesis and cell wall 
synthesis or disturb the integrity of the cell membrane (Table 1-1) (1-4). 
 
 
 
Interestingly, most antibiotics (70%) were derived from natural products and only some 
classes are completely synthetic in origin (e.g. oxazolidinones, fluoroquinolones) (2,20). 
Thus, new antibacterial chemical scaffolds with novel mechanisms of action are required to 
combat the increasing threat of antibiotic-resistant pathogens (20). 
1.1.2 Resistance Mechanisms 
Understanding the underlying principles of antibiotic resistance is key to prevent its initial 
occurrence or to specifically target the resistance mechanism (21). The bacterial cell 
envelope constitutes a physical barrier that hinders the penetration of several xenobiotics 
into the cell. In particular, Gram-negative bacteria are intrinsically resistant to many 
antibiotics due to an additional membrane layer outside of the peptidoglycan layer (21). In 
addition to a reduced influx, an enhanced efflux of the antibacterial agent can lead to 
resistance (21). Due to the reduced uptake of the antibiotic and its export via efflux pumps, 
it is particularly difficult to develop novel effective antibiotics to treat infections caused by 
multidrug-resistant Gram-negative pathogens such as Pseudomonas aeruginosa, 
Acinetobacter baumannii, Klebsiella pneumoniae and Escherichia coli (20). Similarly, 
Mycobacterium tuberculosis - the causative agent of tuberculosis (TB) - is intrinsically 
resistant to most commonly used antibiotics due to its lipid-rich waxy cell wall (for further 
details see also chapters 1.1.4 and 1.3.5) (22-24). 
Table 1-1. Antibiotic classes and their targets (1-4).
Cellular target Antibiotic classes 
ribosomal protein biosynthesis 
macrolides, tetracyclines, aminoglycosides,  
streptogramins, oxazolidinones, chloramphenicol,  
lincosamides 
cell wall biosynthesis 
β-lactams (penicillins, cephalosporins, carbapenems,
monobactams), glycopeptides, fosfomycin 
DNA replication and transcription quinolones, rifamycins
nucleotide biosynthesis sulfonamides
cell membrane integrity lipopeptides, polymyxins
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Although import of antibiotics is more easily achieved for Gram-positive bacteria, diverse 
other resistance mechanisms are known which render pathogens such as Staphylococcus 
aureus a major threat to human health (see also chapter 1.1.3) (20). Antibiotics can be 
inactivated by specific enzymes which modify the antibacterial agent. For instance, β-
lactamases hydrolyze the 4-membered ring of β-lactam antibiotics (21,25). The associated 
resistance genes presumably developed already two billion years ago, which explains the 
almost instantaneous occurrence of resistance in S. aureus after the introduction of penicillin 
to the market (4,21). In contrast, the formation of resistance against vancomycin was 
believed to be highly unlikely since this glycopeptide antibiotic acts outside the cell via its 
interaction with lipid II (21,26). However, after 33 years of clinical vancomycin usage, first 
resistant Enterococcus strains (VRE) were reported in 1988 (4,27). This resistance is based on 
the modification of the entire peptidoglycan biosynthesis pathway, which finally results in 
the production of lipid II molecules containing a C-terminal D-lactate or D-serine instead of 
D-alanine, which in turn leads to a 1,000-fold reduction in affinity towards vancomycin 
(21,26). In most cases less complex mechanisms are operative in order to modify the cellular 
target of an antibiotic. For instance, overexpression as well as single or multiple mutations of 
a target protein can cause resistance to an antibacterial agent (21,28). 
1.1.3 Methicillin-resistant Staphylococcus aureus (MRSA) 
The Gram-positive bacterium Staphylococcus aureus readily acquires resistance genes and, 
thus, methicillin-resistant Staphylococcus aureus (MRSA) strains have been reported already 
two years after the market launch of this β-lactam antibiotic (29). Unfortunately, MRSA 
strains are often additionally insensitive to other β-lactam antibiotics, aminoglycosides, 
tetracyclines, macrolides, lincosamides and/or fluoroquinolones, which complicates the 
treatment of infections caused by these strains (29). Today, MRSA constitutes a major 
clinical problem all over the world - methicillin-resistance rates were 70%, 64% and 24% for 
S. aureus isolates from hospitals in Korea (1998), the USA (2003) and Australia/New Zealand 
(2008), respectively (30-32). In Europe, resistance rates vary between 0 and 50% (2007) with 
the maximal occurrence in the southern countries (29). 
S. aureus colonizes approximately 50% of all adults and can mainly be found in the anterior 
nares (29). This bacterium can cause manifold diseases such as skin infections, nosocomial 
pneumonia or severe bloodstream infections (29). The risk to acquire a S. aureus infection is 
increased in elderly, immuno-compromised patients (32,33). According to a study performed 
in Australia and New Zealand, the mortality rate of S. aureus infections ranges from 2.5 to 
40% depending on the group of people (32). In the case of MRSA infections, the mortality 
rates are increased compared to infections caused by methicillin-sensitive S. aureus (MSSA) 
(29). Hence, MRSA infections cause approximately 19,000 deaths annually in the USA 
(20,34). Serious MRSA infections can be treated with the "antibiotic of the last resort" 
vancomycin. However, the initial emergence of vancomycin-resistant S. aureus strains 
(VRSA), which likely arose via a horizontal gene transfer from VRE to MRSA in co-infected 
patients, will further aggravate the treatment of such infections in the future (29,33). 
In recent years, the epidemiology of MRSA changed and the related infections are not 
limited to hospitals anymore (29). Community-acquired MRSA (CA-MRSA) can cause diseases 
in otherwise healthy persons which account for approximately 1,400 deaths per year in the 
USA (29,34). In addition, animals were identified as a reservoir for the zoonotic MRSA strain 
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ST398 which has the ability to cause re-infections in humans (29,34). In the Netherlands, a 
country with otherwise low MRSA proportions, over 30% of all pigs at the slaughterhouse 
were found to be colonized by this S. aureus strain (29). In the light of these developments it 
will be critical to discover new antibiotics to ensure an effective treatment of S. aureus 
infections in the future. 
1.1.4 Tuberculosis 
At the beginning of the 20th century, 12 % of all deaths were caused by tuberculosis (TB) 
(35). After the "golden era" of antibacterial discovery between 1945 and 1960 it was 
believed that this disease might soon be eradicated (see also chapter 1.2.1) (36). However, in 
2011 the WHO estimated an annual rate of 8.7 million new infections and 1.4 million TB-
related deaths (37). Over time, M. tuberculosis, the pathogen inducing this disease, 
developed resistances against several anti-mycobacterial drugs. Infections caused by 
multidrug-resistant M. tuberculosis (MDR-TB), which are insensitive to the most important 
first-line drugs isoniazid and rifampicin, have to be treated for 2 years and can account for 
up to 40% of all TB-infections in certain parts of the world (20,36,38). Even more severely, 
extensively drug-resistant forms of this pathogen (XDR-TB) are additionally insensitive to 
several second-line drugs and "totally drug-resistant" M. tuberculosis (TDR-TB) strains were 
initially reported in 2009 underlining the urgent need for novel remedies allowing for an 
effective and shortened treatment of tuberculosis (39). 
1.2 Antibacterial Drug Discovery 
1.2.1 History of Antibacterial Discovery 
The increasing occurrence of antibiotic-resistant pathogens is not only one of the major 
challenges modern medicine faces, but also a main driving force for antibacterial 
development (21). Whereas infectious diseases had often been fatal in the 19th century, the 
development of anti-infectives starting with the 20th century resulted in effective remedies 
to cure bacterial infections (3). Most antibiotics currently in use were identified during the 
"golden era" of antibacterial discovery between 1945 and 1960 (21). In the following two 
decades, the scaffolds of these antibiotics were improved via medicinal chemistry efforts 
(20,21). However, no new major classes of antibacterials were introduced to the market 
between 1962 and 2000 and, even more worryingly, no new antibiotics were discovered 
after 1987 (4,20). The estimated rate of success to market an antibacterial agent (0.17%) is 
rather low compared to other therapeutic areas (1). This raises the questions why 
antibacterial drug development is such a challenging task and what we can learn from the 
failures after 1987. 
1.2.2 Challenges of Antibacterial Discovery 
The sequencing of the first bacterial genome (Haemophilus influenzae) in 1995 raised hope 
for the identification of novel targets and associated drugs that block the function of these 
entities (1,3). In an extensive genomics-based study, GlaxoSmithKline (GSK) identified 127 
essential bacterial genes among the 258 genes investigated between 1995 and 2001 (1). 
Although 67 high-throughput screening (HTS) campaigns were undertaken with large 
compound libraries (260,000 to 530,000 molecules per screen), hits could be identified for 
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only 16 targets which in turn led to the development of lead compounds in 5 cases. In 
relation to the long duration of these studies and the huge investments made, this is a very 
disappointing result (1). Nevertheless, the identified lead compounds could be the starting 
point for the development of new classes of antibiotics. GSK synthesized lead compounds 
that target the peptide deformylase (PDF) as well as the methionyl- and phenylalanyl-tRNA 
synthetases (MetRS and PheRS, respectively) (1). Moreover, lead compounds with related 
whole-cell activity could be developed for two targets of the fatty acid biosynthesis pathway 
- the enoyl-acyl carrier protein (ACP) reductase (FabI) and the 3-ketoacyl-ACP synthase III 
(FabH). Out of these five projects, GSK decided to only further pursue the PheRS target (1). 
As only narrow-spectrum compounds could be developed for FabI and MetRS, these projects 
were outsourced to the biotechnology industry (Affinium Pharmaceuticals and Replidyne, 
respectively) (1,4). Compounds inhibiting FabH did not gain drug-like properties and those 
inhibiting PDF were replaced by more promising drug candidates originating from structure-
based drug design efforts (1). 
Although the genomics and HTS-based approach was not as successful as expected, 
important lessons can be learned from the failures within the past two decades (1,3,4). It is 
necessary but not sufficient that a chosen target is essential for the survival of the pathogen 
of interest. In addition, it has to be druggable and different, absent or nonessential in 
humans (2). Furthermore, drug candidates have to exhibit important characteristics such as 
high-affinity and specific inhibition of the target with related antibacterial activity, drug-like 
properties and a low propensity for the formation of resistances (2,4). Although many orally 
bioavailable drugs fulfill the "Lipinski's rules of five" (40), antibacterials are an exception of 
this rule and possess different physicochemical properties that are likely necessary for the 
drug to penetrate the bacterial cell which differs from its mammalian counterpart (1,2). In 
particular, antibiotics are characterized by a higher molecular weight and increased polarity 
(2). However, the physicochemical property space of the HTS libraries applied by the 
pharmaceutical industry does not fully match these requirements as those libraries tend to 
contain molecules which are too lipophilic for antibacterial research (1,2). This limitation in 
the chemical space may in part explain the relatively low success of the GSK study described 
above (1,4). 
1.2.3 New Concepts and Strategies of Antibacterial Drug Development 
In order to combat multidrug-resistant pathogens, new concepts and strategies are required 
to develop novel antibiotics after the failure of the genomics-based approach (3). Clearly, it 
will be central to broaden the chemical diversity of the current HTS libraries and to adapt 
them with respect to the stringent requirements of antibacterials (1,2,4). Thus, one focus 
must be on the synthesis of new molecules combined with screening for potential 
antibacterial properties in whole-cell instead of target-specific HTS campaigns (1). It might 
be advantageous to search for novel bacteriocidal compounds rather than looking for novel 
targets because it is usually easier to elucidate the mode of action of an antibiotic than to 
tailor an in vivo active antibiotic for a given target (1). 
On the other hand, known lead compounds of validated drug targets have to be improved to 
render them efficacious against multidrug-resistant pathogens (1). The usage of the 
structure-based drug design (SBDD) approach has been advocated for this task (1,3,4). 
During this iterative and highly interdisciplinary approach, structural information of drug-
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target complexes is used to rationally improve the properties of a lead compound using 
computational and experimental means (Figure 1-1) (41,42). SBDD has already been used 
successfully for the design of anti-(retro)viral drugs such as the influenza therapeutic 
zanamivir (GSK) and the HIV protease inhibitor amprenavir (GSK) (3,4). 
For the success of SBDD efforts, target selection will be of particular importance. Clearly, the 
classical targets of antibacterials such as 
the ribosome are still very promising (see 
also Table 1-1) (1,3). Furthermore, 
naturally occurring antibiotics can hint at 
the suitability of a selected target. To 
ensure the prolonged applicability of a 
developed antibiotic, the target should 
be characterized by a low propensity to 
form resistances (4). The success of 
glycopeptides and the long duration until 
resistance formation, suggests that 
extracellular targets are ideally suited to 
fulfill this requirement (1,4,27). In 
addition, compounds which interfere 
with multiple instead of just a single 
target usually are characterized by a 
reduced rate of resistance formation 
(1,4). Drug combinations should be used 
to suppress the formation of resistances 
for single enzyme targets (20). For 
instance, combination therapies have 
been shown to be efficacious and are 
routinely used for the treatment of 
tuberculosis and malaria (20,43). 
1.2.4 Importance of Drug-Target Kinetics 
The availability of a reliable in vitro early-stage indicator for the in vivo efficacy of a 
compound is pivotal for effective drug design efforts. Classically, many researchers optimize 
the thermodynamic affinity Kd or the related metrics Ki and IC50 (10,44). However, in an open 
in vivo system, the drug concentration will decrease over time and rebinding only occurs 
efficiently as long as the drug concentration is above the Kd (10). Hence, the drug-target 
residence time is a very important kinetic quantity because the drug will only be active as 
long as it is bound to its target (10). Importantly, slowly dissociating compounds stay bound 
to their receptor despite the decreasing in vivo drug concentration and, thus, the duration of 
efficacy might be enhanced for molecules with long dissociative half-lifes (10,44,45). Indeed, 
the drug-target residence time has been shown to be a suitable predictor of in vivo activity 
for several targets (10,45). A recent example demonstrates the applicability of this concept 
for antibacterial research - the residence times of several slow-off inhibitors targeting the F. 
tularensis FabI protein (ftFabI) were shown to be highly correlated with the survival rate in a 
mouse model of infection (46). In addition to a prolonged pharmacological effect, long 
 
Figure 1-1. The structure-based drug design approach. 
A drug-target complex structure is used to design 
improved inhibitors using computational methods. After 
the synthesis of the most promising compounds, they 
are evaluated with respect to the properties which are 
aimed to be improved. Several further cycles of this 
iterative approach can lead to the identification of drug 
candidates. The inner circle contains an example of this 
work (saFabI inhibition by the diphenyl ether inhibitors 
triclosan (cyan) and 5-ethyl-2-phenoxyphenol (yellow)) 
(see also chapter 2). 
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residence times can also lead to improved drug selectivity and safety if the low off-rates are 
unique for the investigated target and dissociation occurs faster in the case of secondary 
targets (45,47). Consequently, a relatively large proportion of the drugs approved by the FDA 
between 2001 and 2004 (26% of all drugs with known target) exhibit slow-off characteristics 
highlighting the importance of drug-target kinetics for future drug discovery efforts (10). 
The residence time tR, which is 
used to quantify the lifetime of a 
receptor-ligand complex, is defined 
as the reciprocal of the dissociation 
rate constant koff of this complex 
and is related to the dissociative 
half-life, which is given as ln2/koff 
(10,44,45). Usually, the residence 
times of enzyme-bound substrates 
or products are rather short 
ranging from milliseconds to 
seconds (47,48). High-affinity 
rapid-reversible inhibitors typically 
exhibit residence times of a few 
seconds, whereas slow-onset 
inhibitors are characterized by 
residence times ranging from 
minutes to several days (10,44,45). 
In extreme cases the (in vitro) 
residence time can even be longer - 
for instance, the basic pancreatic trypsin inhibitor stays bound to its target for approximately 
6 months (47). 
Despite the importance of drug-target kinetics for drug discovery, it still remains very 
challenging to modulate the residence time using a rational approach (10,44). Accordingly, it 
is pivotal to unravel the molecular characteristics which determine a long dissociative half-
life (44). The dissociation rate constant koff can be decreased (and thus tR increased) by 
either stabilizing the EI ground state and/or destabilizing the EI‡ transition state (TS) along 
the reaction coordinate of the inhibitor binding process (Figure 1-2) (10). Whereas the 
relative free energy of the EI ground state is classically minimized during affinity 
optimization, the rational modulation of the relative free energy of the TS is much more 
challenging (10,44). In this regard the lack of structural information about the TS is a major 
obstacle and techniques such as (time-resolved) X-ray crystallography and molecular 
dynamics (MD) simulations may provide valuable information about such transient 
conformational states (44). 
1.3 Bacterial Fatty Acid Biosynthesis as a Drug Target 
1.3.1 Fatty Acid Biosynthesis 
Fatty acids are pivotal for life and play important roles as integral components of cell 
membranes, in energy metabolism and storage, and as second messengers (12,49-51). Due 
 
Figure 1-2. Energy plot for the formation of an enzyme-
inhibitor complex via a simple one-step mechanism (10). E = 
enzyme, EI‡ = transition state (TS) of EI formation, EI = enzyme-
inhibitor complex, Ki = koff/kon. The residence time, which is 
defined as the reciprocal of koff, can be increased by decreasing 
the relative free energy G of EI and/or increasing the relative 
free energy of EI‡ (indicated by bold black arrows). A 
superimposed second energy plot is depicted for a hypothetical 
inhibitor with increased residence time (colored in black).
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to its essentiality, the bacterial fatty acid biosynthesis pathway provides a promising target 
for the development of new antibacterial agents (52). Isoniazid, one of the most effective 
anti-tuberculosis drugs, is in clinical use since 1952 and successfully inhibits the type II fatty 
acid biosynthesis (FAS-II) in M. tuberculosis, thus validating this pathway as an attractive 
target for antibacterial discovery (Table 1-2, compound 10) (38,53-55). Importantly, the FAS-
II pathway in bacteria, plants and protozoa differs fundamentally from the mammalian type I 
fatty acid synthesis (FAS-I) and can therefore be inhibited selectively (7,12,19,50). Whereas 
the mammalian fatty acid synthase (mFAS) is a large homo-dimeric multifunctional protein 
(Figure 1-3A), separate monofunctional enzymes are responsible for the synthesis of fatty 
acids in the FAS-II system (Figure 1-4) (7,12,51). 
 
 
 
Despite these differences in the structural organization, the single catalytic steps necessary 
for the synthesis of fatty acids are conserved among all organisms (12). As the nucleophile 
during the C-C bond forming reactions, the malonyl-acyl carrier protein (ACP; see also 
chapter 1.3.2) plays a central role in this pathway and provides two additional carbon atoms 
in each elongation cycle (Figure 1-4). In bacteria, malonyl-ACP is generated from acetyl-
coenzyme A (CoA) via the subsequent actions of AccABCD and FabD. The acetyl-CoA 
carboxylase AccABCD carboxylates acetyl-CoA to yield malonyl-CoA, which subsequently is 
transferred onto the acyl carrier protein by the malonyl-CoA:ACP transacylase FabD (see also 
Figure 2-1) (12,54). In the mammalian FAS-I system, the mFAS malonyl-acetyl transferase 
(MAT) domain catalyzes the corresponding transfer of the malonyl group onto ACP (12). In 
the final initiation step of the FAS-II pathway, the β-ketoacyl-ACP synthase III (KAS III) FabH 
Figure 1-3. The mammalian fatty acid synthase (12). (A) Crystal structure of the mammalian fatty acid synthase (mFAS). 
The overall homo-dimeric structure of the mammalian fatty acid synthase (source: pig; PDB-code: 2VZ8) is characterized 
by an "X"-like shape. The reaction steps leading to the formation of fatty acids are catalyzed by several distinct domains: 
the malonyl-acetyl transferase (MAT), β-ketoacyl-ACP synthase (KS), β-ketoacyl-ACP reductase (KR), β-hydroxyacyl-ACP 
dehydratase (DH), and enoyl-ACP reductase (ER) domains. During fatty acid biosynthesis the substrate is tethered to the 
acyl carrier protein (ACP) domain, which was not identified in the crystal structure (the site at which ACP is attached is 
highlighted by red arrows and the proposed location of this small domain is indicated by the word "ACP" in red) (12). (B) 
Superimposition of the S. aureus enoyl-ACP reductase FabI (gray; PDB-code: 4ALI) with the mFAS ER domain (yellow; 
PDB-code: 2VZ9) (12,19). Although the Rossmann-fold (lower right part of the structures as indicated in black), which 
builds up the NADPH binding site, is structurally conserved between S. aureus FabI and the mFAS ER domain, the active 
site located above the Rossmann-fold differs between the two structures. The box contains the cofactors and (proposed) 
active site residues for each structure and highlights the fundamental differences between the mFAS ER domain and S. 
aureus FabI. (C) Superimposition of the M. tuberculosis β-ketoacyl-ACP synthase KasA (gray; PDB-code: 2WGD) with the 
mFAS KS domain (cyan; PDB-code: 2VZ8) (12,17). The thiolase fold as well as the active site residues are highly conserved 
between both structures (insert). 
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catalyzes the Claisen condensation reaction between malonyl-ACP and an acyl-CoA primer, 
which can differ based on the organism (see also Figure 2-1) (56,57). In addition to the KAS III 
enzyme, two additional types of bacterial condensing enzymes are known, which catalyze 
the analogous reaction within the elongation cycle of the FAS-II pathway (Figure 1-4), 
namely KAS I (usually referred to as FabB; KasA in M. tuberculosis) and KAS II (usually 
referred to as FabF; KasB in M. tuberculosis) (18,58,59). Whereas the mFAS β-ketoacyl-ACP 
synthase (KS) domain as well as the KAS I and KAS II enzymes utilize acetyl-ACP as the 
electrophile during the condensation reaction, the bacterial KAS III enzyme FabH is unique 
with respect to its selectivity towards acyl-CoA substrates (12,18,58). 
During the elongation cycle, the β-keto group of the generated β-ketoacyl-ACP is reduced to 
a methylene group via the 
subsequent actions of a β-
ketoacyl-ACP reductase (KR), a 
β-hydroxyacyl-ACP dehydratase 
(DH) and an enoyl-ACP 
reductase (ER) (Figure 1-4) 
(12,60). The FAS-II system 
contains a single KR termed 
FabG (MabA in M. tuberculosis), 
which catalyzes the NADPH-
dependent reduction of the β-
keto function to a hydroxyl 
group (51,54,61). Subsequently, 
one of the two bacterial DH 
enzymes (FabZ and FabA; 
HadAB and HadBC in M. 
tuberculosis) dehydrates the β-
hydroxyacyl-ACP to yield an 
enoyl-ACP (8,60,62). This is the 
substrate for the last enzyme of 
the elongation cycle, the enoyl 
reductase FabI or one of its 
isoforms FabK, FabL and FabV 
(63-66), which reduce the 
trans-2-enoyl double bond to a single bond (12,60,67). The enoyl-ACP reductase of M. 
tuberculosis, InhA, has been shown to be the target for the front-line anti-tuberculosis 
prodrug isoniazid after its activation by the mycobacterial catalase/peroxidase KatG (for 
details see Table 1-2, 10-11) (55,68-71). Overall, the fatty acid synthesis elongation cycle 
generates a fatty acyl substrate which is elongated by two carbon atoms and the next round 
is subsequently initiated by the condensing KAS I/II enzymes (54). 
1.3.2 The Acyl Carrier Protein 
During the mammalian and bacterial fatty acid biosynthesis elongation cycles, all fatty acyl 
intermediates are tethered to the acyl carrier protein (ACP), which transports the substrates 
to the different catalytic centers (12,72). Whereas this small acidic protein is an integral part 
Figure 1-4. Elongation cycle of the type II fatty acid biosynthesis 
pathway. The inner circle contains the overall structures of the 
involved enzymes β-ketoacyl-ACP synthase (KS) (KasA of M. 
tuberculosis is shown exemplarily, PDB-code: 2WGG), the β-ketoacyl-
ACP reductase (KR) (MabA of M. tuberculosis is depicted, PDB-code: 
1UZM), the β-hydroxyacyl-ACP dehydratase (DH) (FabZ of Plasmodium 
falciparum is shown, PDB-code: 1ZHG) and the enoyl-ACP reductase 
(ER) (FabI of S. aureus is depicted, PDB-code: 4ALL, this work). The 
targets of this work are highlighted in light blue (KS and ER). The KS, KR, 
DH and ER enzymes of S. aureus and M. tuberculosis are FabF, FabG, 
FabZ and FabI or KasA/B, MabA, HadAB/BC and InhA, respectively (7,8). 
R = alkyl chains of different lengths (elongated by 2 carbons per cycle). 
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of the mammalian fatty acid synthase, ACP is a separate entity in the FAS-II system. To reach 
the buried active sites of the involved enzymatic domains/proteins, the substrate is attached 
to the terminal thiol group of a long and flexible 
4'-phosphopantetheine (PPant) linker which in 
turn is esterified with a conserved serine of ACP 
(Figure 1-5) (72-75). This highly abundant and 
conserved protein is structurally organized in a 
4-helix bundle with a right-handed twist (76,77). 
During the bacterial fatty acid synthesis, the 
acyl substrate must be released from the ACP and injected into the binding pocket of the 
individual enzymes (74). Accordingly, two slightly different crystal structures have been 
reported for E. coli butyryl-ACP with the acylated PPant buried in a hydrophobic cavity or 
exposed to the solvent, respectively (77). Thus, a 3-step substrate binding and turnover 
process is currently envisioned - a weak interaction between ACP and its partner enzyme 
induces a conformational change in ACP leading to the injection of the substrate into the 
binding site, followed by catalysis and removal of the product, which in turn is re-buried 
inside the hydrophobic ACP cavity (74,77). In this regard, it is discussed controversially 
whether the FAS-II enzymes specifically interact with those ACP molecules modified with the 
correct partner substrate or whether the different intermediates are rather distinguished 
upon injection into the binding crevice (76). 
Despite the importance of the ACP molecule for fatty acid biosynthesis, only little is known 
about the interactions between FAS-II enzymes and ACP (74). In part, this might be due to 
the fact that ACP interacts with a plethora of different enzymes involved in fatty acid, 
polyketide, non-ribosomal peptide and vitamin biosynthesis (74,77). To enable this 
multitude of interactions with different enzymes, ACP is a very flexible and thus adaptable 
protein (76). Moreover, the interactions between ACP and FAS-II enzymes are usually rather 
weak (reported Kd and KM values are in the low µM range), which additionally aggravates 
successful crystallographic studies (18,74,76,78,79). Nevertheless, evidence is accumulating 
that the helix α2 in ACP provides a common binding site for enzymes of different functional 
backgrounds (including FAS-II) (76,80-82). In contrast, combined computational, biochemical 
and biophysical studies with E. coli FabH and FabG suggested that no conserved ACP binding 
motif exists among the different FAS-II enzymes themselves (74,76). Instead, the acidic helix 
α2 in ACP is presumably recognized by a basic, hydrophobic surface patch close to the 
binding site entrance of FAS-II enzymes (74,76). 
1.3.3 Diversity in the Fatty Acid Synthesis Pathway 
Although fatty acid biosynthesis is a vital cellular process for most bacteria, in recent years 
an increasing number of species-specific differences were recognized (83,84). For instance, 
different organisms contain different isoenzymes, which catalyze the required biochemical 
reactions during the synthesis of fatty acids (7). In part, the necessity for additional enzymes 
can be explained by the requirement of certain bacteria (such as E. coli) to synthesize 
unsaturated fatty acids (UFA) (72). Gram-negative bacteria usually contain additional FabA 
and FabB enzymes (see also Figure 2-1), which are responsible for the synthesis of UFA. The 
dehydratase FabA dehydrates and isomerizes β-hydroxydecanoyl-ACP to the associated cis-
3-enoyl-ACP, which is directly condensed with malonyl-ACP through the action of FabB 
 
Figure 1-5. ACP esterified with an acylated 4'-
phosphopantetheine moiety. The substituent R 
varies depending on the intermediate (see also 
Figure 1-4). 
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without prior reduction of the double bond (63,72). In contrast, the Gram-positive organism 
Streptococcus pneumoniae does not contain FabA and FabB and thus produces UFA via an 
alternative mechanism (83). The DH enzyme FabZ dehydrates β-hydroxydecanoyl-ACP to 
yield the corresponding trans-2-enoyl-ACP, which in turn is isomerized to the cis-3-decenoyl-
ACP by an additional enzyme termed FabM. As for E. coli, the reductive step, which is 
catalyzed by FabK instead of FabI, is skipped and the cis-double bond is maintained after the 
FabF-catalyzed condensation reaction (83). 
Certain Gram-positive bacteria including S. aureus lack FabA, FabB and FabM and thus are 
not able to synthesize UFA (7,72,85). Whereas membrane fluidity in most bacteria is 
controlled via phospholipids containing UFA, some species utilize methyl-branched fatty 
acids (BCFA) for this purpose; S. aureus contains 81% of these fatty acids (72,86). In 
particular, the Gram-positive Bacillus and Staphylococcus as well as the Gram-negative 
Legionella genera are members of the relatively small family of BCFA-synthesizing bacteria 
(86). For such bacteria UFA are not pivotal, but BCFAs were shown to be essential for Bacillus 
subtilis instead (86,87). The requirement for different fatty acids might in part explain the 
diversity in the fatty acid biosynthesis pathway found among various bacteria. 
1.3.4 Essentiality of the Bacterial Fatty Acid Biosynthesis 
The heterogeneity of bacterial species with respect to the synthesis of fatty acids also raises 
the question whether the FAS-II pathway is essential, and thus a valid target, for all or just 
for certain bacteria (88). For Gram-negative bacteria, the FAS-II pathway has been shown to 
be essential due to their need to synthesize β-hydroxy fatty acids as lipid A precursor 
molecules (89). In contrast, Brinster et al. recently have shown that the Gram-positive 
bacterium Streptococcus agalactiae can take up exogenous fatty acids from the host blood 
serum during a septic infection to circumvent the inhibition of the FAS-II pathway (90). 
Initially, these findings were extrapolated to all Gram-positive bacteria despite the lack of in 
vivo data supporting this conclusion (90). However, two proximate studies provide 
compelling evidence that this generalization does not hold true for S. aureus (88,89). Parsons 
et al. have demonstrated that, in contrast to S. pneumoniae, the uptake of exogenous fatty 
acids cannot fully compensate for the synthesis of endogenous fatty acids in S. aureus (89). 
Accordingly, only 50% of the endogenous fatty acids of S. aureus were replaced by 
exogenous fatty acids (89). In the case of S. pneumoniae, for which a full replacement of 
endogenous fatty acids is feasible, exogenous fatty acids genetically or biochemically block 
the AccABCD catalyzed reaction. Due to the resulting depletion of malonyl-CoA levels, ACP 
accumulates since it is not consumed in the malonyl-CoA:ACP transacylation reaction and, 
thus, can be used for the incorporation of exogenous fatty acids into bacterial phospholipids 
(Figure 2-1). The absence of a comparable mechanism in S. aureus, which down-regulates 
the synthesis of endogenous fatty acids and simultaneously triggers the incorporation of 
exogenous fatty acids, provides the metabolic basis for the susceptibility of this organism to 
FAS-II inhibitors (89), which has been demonstrated in several in vivo models of infection 
(50,88,91,92). 
1.3.5 Mycolic Acid Synthesis in Mycobacteria 
Mycobacteria are an additional striking example highlighting the diversity of the bacterial 
fatty acid biosynthesis. The waxy mycobacterial cell wall, which confers intrinsic antibiotic 
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resistance (see also chapter 1.1.2) (23), consists of three covalently linked macromolecular 
structures - the peptidoglycan is attached to an arabinogalactan layer, which in turn is 
esterified with mycolic acids (24,58,93). Mycolic acids are C60 - C90 α-alkyl-β-hydroxy fatty 
acids that are essential for the survival of M. tuberculosis and related mycobacteria (Figure 
1-6) (23). 
 
 
 
To enable the synthesis of these very long fatty acids, mycobacteria require both, the FAS-I 
and the FAS-II system (11). During mycolate synthesis, the 640 kDa homo-dimeric fatty acid 
synthase of the FAS-I system generates short acyl-CoA primers (C16 - C18), which are then 
elongated via the FAS-II pathway to yield C50 - C56 meromycolate chains (for further details 
see also chapter 6.4 and Figure 6-1) (11,22,23). Thus, the mycobacterial FAS-II system is 
unique amongst bacteria since it does not enable the de novo synthesis of fatty acids but 
rather elongates medium-chain precursors to very long fatty acids (23). In this regard, the M. 
tuberculosis KAS III enzyme (mtFabH) plays a pivotal role as it links the two biosynthetic 
pathways and specifically utilizes medium-chain acyl-CoA primers instead of acetyl-CoA 
(58,94). Moreover, the mycobacterial ACP (termed AcpM) contains an extended flexible C-
terminus, which was suggested to be required for the transport and delivery of long-chain 
substrates, and thereby differs from common bacterial ACPs (75). In addition, growing 
evidence indicates that the mycobacterial FAS-II enzymes are organized in distinct 
complexes and that certain proteins might act as assembly chaperons (in M. tuberculosis this 
role was proposed for the chaperon GroEL1 during biofilm maturation) (38,95,96). 
1.4 Targeting Key Steps of the FAS-II Pathway 
1.4.1 The Enoyl-ACP Reductase FabI of S. aureus and other Bacteria 
Based on the findings that the antibacterial agent triclosan and the front-line anti-TB drug 
isoniazid target the enoyl-ACP reductase FabI (EC 1.3.1.9/10; also referred to as ENR (63,97) 
and InhA in M. tuberculosis) (71,98,99), this enzyme was the major focus among all FAS-II 
components (67). However, with the identification of the FabI isoforms FabK, FabL or FabV in 
several important pathogenic bacteria such as S. pneumoniae, Enterococcus faecalis, P. 
aeruginosa, Listeria monocytogenes and Vibrio cholerae it became clear that FabI inhibitors 
will not exhibit broad-spectrum characteristics (64-66,100) and, consequently, major 
pharmaceutical companies such as GlaxoSmithKline (see also chapter 1.2.2) lost their 
interest in this target (1). However, given the urgent need for novel antibiotics for specific 
pathogens such as S. aureus (see also chapter 1.1.3), the development of narrow-spectrum 
antibiotics is strongly advocated (20). Alarmingly, it appears to be difficult in general to 
discover new broad-spectrum antibacterials due to the heterogeneity of bacteria. For 
instance, an ideal antibiotic for the treatment of lung infections should be active against S. 
aureus, S. pneumoniae, Haemophila influenzae, Moraxella catarrhalis, Legionella 
pneumonphila and Mycoplasma pneumoniae. Unfortunately, already S. pneumoniae and H. 
influenzae differ genetically more than humans differ from paramecia, a freshwater 
  Figure 1-6. α-Mycolic acid. The α-mycolic acid is the most abundant mycolic acid in M. tuberculosis (11). 
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protozoon (1). Hence, small-spectrum antibiotics should be developed and applied in 
combination with improved diagnostic methods. In this regard, S. aureus FabI (saFabI) 
constitutes a very promising target since it is the sole trans-2-enoyl-ACP reductase in this 
organism (100-102) and, consequently, three inhibitors are currently investigated in clinical 
trials (for details see chapter 1.4.2) (103). Although these compounds inhibit a single target, 
resistance frequencies were shown to be rather low (surrounding 10-9) (89,92,100). Since 
bacterial counts can reach 1010 during a human infection, an ideal antibiotic should display 
resistance rates below 10-10, which is usually only achieved for antibiotics which interfere 
with multiple targets (4). Thus, saFabI inhibitors might be used in combination with other 
antibacterials to further reduce the probability of resistance formation. For instance, 
combination therapy is successfully used for the treatment of malaria and tuberculosis and 
was recommended to enable the application of antibiotics with relatively high resistance 
frequencies (20,43). 
Similar to the second reductase of the FAS-II cycle, FabG, the FabI protein is a member of the 
short-chain dehydrogenase/reductase (SDR) superfamily and usually exists as homo-
tetramer (Figure 1-4) (51). Each monomer is characterized by a chair-like structure 
containing an extended Rossmann-fold, which consists of a 7-stranded parallel β-sheet 
surrounded by 3 α-helices on either side (Figure 2-2B) (67,72,104,105). Although the 
Rossmann-fold, which defines the binding site for NAD(P)H, is also present in the mFAS ER 
domain (12), the primary sequence identity shared with saFabI is low (11.6%, calculated with 
ClustalW (106)). Accordingly, a superimposition of the mFAS ER domain with saFabI reveals 
major differences in the substrate binding region residing above the Rossmann-fold (Figure 
1-3B). 
The tube-like FabI substrate binding cavity is in contact with the surrounding solvent at both 
ends and, based on the extent of solvent-exposure, the two entries were termed minor and 
major portal, respectively (Figure 5-2B) (70,101,107). The NAD(P)H cofactor is located at the 
bottom of this binding channel and is oriented with the nicotinamide and adenine rings 
pointing towards the minor and major portals, respectively (Figure 5-2B). Whereas most FabI 
enzymes utilize NADH as reducing agent, saFabI prefers to bind NADPH in a cooperative 
fashion (51,52,78,108). Cofactor binding is followed by the uptake of the enoyl-ACP 
substrate according to an ordered bi-bi mechanism, which is probably common to all SDR 
proteins (105,109,110). Whether ACP delivers the enoyl-substrate via the minor or major 
portal of FabI is currently not clear due to conflicting findings (see also chapter 5) (70,107). 
As a consequence, also the mechanism of the FabI-catalyzed reaction is discussed 
controversially. 
Usually, the FabI catalytic triad consists of Tyr147, Tyr157 and Lys164 (saFabI numbering). 
Similar to other SDR members, the very conserved active site lysine likely plays a pivotal role 
in the correct positioning of the NAD(P)H nicotinamide ribose (70,105,111). However, it is 
currently unclear whether Tyr147 or Tyr157 binds the enoyl-ACP thioester carbonyl group 
and what the role of the remaining catalytic residue might be (70,107). These two 
possibilities correspond to the delivery of the substrate via the minor or major portal, 
respectively. Irrespective of which active site tyrosine binds the thioester carbonyl, FabI 
catalyzes the last step of the FAS-II elongation cycle via the transfer of the pro-4S hydride ion 
of NAD(P)H to the 3-carbon of the trans-C2-C3 double bond of the enoyl-ACP substrate 
(51,78,108,112,113). Subsequently, the generated enolate anion is protonated at the C2 
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carbon, forming an acyl-ACP, which is elongated by two carbon atoms with respect to the 
educt of this particular FAS-II elongation round (113). Similar to other SDR members, FabI 
proteins contain a flexible loop which is usually disordered in the apo-enzymes and becomes 
ordered upon ligand binding (6,105). Despite the importance of this substrate binding loop 
(SBL) for substrate recognition and specificity, little is known about the conformational 
states sampled along the reaction coordinate of substrate binding and turnover (114,115). 
1.4.2 FabI Inhibition 
The substrate binding loop of FabI was not only found to be important for the binding of 
substrates, but is also involved in the recognition of FabI inhibitors (67). Since more than 40 
years the FabI inhibitor triclosan is used as antibacterial agent in many consumer products 
and antiseptic soaps to reduce MRSA colonization of the human skin in hospitals (Table 1-2, 
compound 1) (72,97-99,116,117). Triclosan and related diphenyl ether inhibitors were found 
to be slow-binding inhibitors of FabI and this property was attributed to the closure of the 
SBL (for details about slow-binding inhibition, see chapter 1.2.4) (67). Although the small 
triclosan molecule exhibits remarkable affinity towards most FabI enzymes, the 
metabolically labile hydroxyl group complicates the application of such inhibitors as 
antibiotics (6,102,118). Consequently, the pharmaceutical company Mutabilis introduced a 
fluorine para to the hydroxyl moiety to prevent metabolic conjugation reactions (119). 
Based on the lead compound triclosan, Mutabilis developed the potent inhibitor 
MUT056399 (Table 1-2, compound 2), which is currently analyzed in clinical trials and is 
active against S. aureus and several clinically important Gram-negative pathogens for which 
FabI is the sole enoyl-ACP reductase such as E. coli, H. influenzae and M. catarrhalis (92). 
Using an alternative strategy, CrystalGenomics developed the clinical trial inhibitor 
CG400549 by replacing the phenol A-ring of the diphenyl ether scaffold by a 2-pyridone to 
overcome the pharmacokinetic drawback of these compounds (Table 1-2, compound 3) 
(103). In contrast to MUT056399, this inhibitor is Staphylococcus-specific and thus might be 
used as a narrow-spectrum antibiotic (31,100). The third clinical candidate AFN-1252 with a 
completely different scaffold (Table 1-2, compound 4) originated from the work of GSK and 
Affinium Pharmaceuticals (see also chapter 1.2.2) and is similarly specific for Staphylococci 
(4,101,103). Importantly, these three clinical trial compounds were shown to possess in vivo 
efficacy in murine models of infection (92,100,101). 
 
Table 1-2. Inhibitors of the enoyl-ACP reductase FabI. 
Compound a Inhibition 
characteristics b 
Antibacterial activity 
 
 
 
Ki = 50 pM (saFabI, chapter 3) 
 
Ki = 7 pM (ecFabI) (97) 
Ki = 51 pM (ftFabI) (46) 
Ki = 100 nM (pfENR) (120) 
Ki = 220 nM (InhA) (69) 
MIC = 0.03 µg/ml 
(S. aureus) (78,121,122) 
 
 
IC50 = 12 nM (saFabI) (92) 
 
IC50 = 58 nM (ecFabI) (92) 
MIC90 = 0.03 - 0.12 µg/ml 
(S. aureus) (92) 
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Ki = 1 nM (saFabI, chapter 4) 
 
Ki = 82 nM (ecFabI, chapter 4) 
MIC90 = 0.25 µg/ml 
(S. aureus) (31,100) 
 
 
 
Ki = 13 nM (saFabI) (101) 
MIC90 = 0.015 µg/ml 
(S. aureus) (4,101) 
 
 
 
not available MIC = 1.25 µg/ml 
(E. coli) (67) 
 
 
 
IC50 = 250 nM (saFabI) (121) 
 
IC50 = 6.4 µM (ecFabI) (121) 
MIC = 8 µg/ml 
(S. aureus) (121) 
 
 
 
IC50 = 110 nM (saFabI) (122) 
 
IC50 = 4.2 µM (ecFabI) (122) 
MIC = 0.5 µg/ml 
(S. aureus) (122) 
 
MIC = >64 µg/ml 
(E. coli) (122) 
 
 
 
IC50 = 220 nM (ecFabI) (123) 
MIC = 0.25 µg/ml 
(S. aureus) (123) 
 
 
 
IC50 = 3.0 µM (ecFabI) (124) 
MIC = 0.75 µg/ml 
(S. aureus) (124) 
 
Activation of the prodrug isoniazid (60): 
Ki = 750 pM (InhA) (69,125) 
MIC = 0.05 µg/ml 
(M. tuberculosis) (69) 
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IC50 = 3.2 µM (saFabI) (110) 
MIC = 16-32 µg/ml 
(S. aureus) (110) 
 
 
 
IC50 = 900 nM (saFabI) (126) 
MIC = 32 µg/ml 
(S. aureus) (126) 
 
 
14-methyl-9(Z)-pentadecenoic acid (n = 1, MPDA) 
15-methyl-9(Z)-hexadecenoic acid (n = 2, MHDA) 
 
IC50 = 16.0 µM (saFabI) (127) 
IC50 = 16.3 µM (saFabI) (127) 
MIC = 32 µg/ml 
(S. aureus) (127) 
 
 
 
IC50 = 6.0 µM (saFabI) (128) 
MIC = 128 µg/ml 
(S. aureus) (128) 
 
a. Compounds 6, 7, 8 and 9 are amongst the most potent inhibitors of large series of 1,4-disubstituted 
imidazoles, 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles, 4-pyridones, and thiopyridines, 
respectively. 
b. saFabI = S. aureus FabI, ecFabI = E. coli FabI, ftFabI = F. tularensis FabI, pfENR = Plasmodium falciparum 
enoyl-ACP reductase, InhA = M. tuberculosis enoyl-ACP reductase. 
 
In addition, several other potent FabI inhibitors such as diazaborines (67), 1,4-disubstituted 
imidazoles (121), 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles (122), 4-pyridones 
(123) and thiopyridines (124) were developed (Table 1-2, compounds 5-9). Importantly, after 
the activation by the catalase/peroxidase KatG isoniazid (INH) is a slow-binding inhibitor of 
the mycobacterial FabI homologue InhA (Table 1-2, 10-11) (125). The suitability of FabI as a 
drug target is further emphasized by the identification of several natural product FabI 
inhibitors such as Aquastatin A (isolated from the fungus Sporothrix sp. FN611) (110), 
Vinaxanthone (isolated from a Penicillium sp.) (126), two different methyl-branched fatty 
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acids (isolated from Streptomyces sp. A251) (127) and Phellinstatin (isolated from the fungus 
Phellinus linteus) (128) (Table 1-2, compounds 11-14). 
1.4.3 M. tuberculosis KasA 
Table 1-3. Inhibitors of the FAS-II condensing enzymes. 
 
Compound Inhibition characteristics Antibacterial activity 
 
 
 
IC50 = 20 µM (KasA) (129) 
 
IC50 = 90 µM (KasB) (129) 
IC50 = 12 µM (E. coli FabB) (59) 
IC50 = 5 µM (E. coli FabF) (59) 
MIC = 25 µg/ml 
(M. tuberculosis) (130) 
 
 
 
IC50 = 4.5 µM (KasA) (129) 
 
IC50 = 9.5 µM (KasB) (129) 
IC50 = 160 nM (E. coli FabF) (131) 
IC50 = 48 nM (S. aureus FabF) (131) 
MIC = 12 µg/ml 
(M. tuberculosis) (129) 
 
MIC = 0.5 µg/ml 
(S. aureus) (131) 
 
 
 
IC50 = 3 µM (E. coli FabB) (132) not available 
 
 
 
Kd = 25 µM (E. coli FabB) (133) not available 
 
 
 
IC50 = 270 nM (E. faecalis FabH) (134) not available 
 
Similar to the isoniazid target InhA, the β-ketoacyl-ACP synthase I of M. tuberculosis (KasA) 
has been shown to be essential for the survival of this pathogen, which confirms KasA as a 
promising drug target (22,135). In contrast to KasA, the mycobacterial KAS II enzyme KasB is 
non-essential. In the model organism Mycobacterium smegmatis, the depletion of KasA 
leads to changes in the composition of cell wall mycolates, morphological alterations and 
finally to cell lysis (135). Importantly, all three KAS enzymes (KasA, KasB and mtFabH in the 
case of M. tuberculosis) are inhibited by the natural product thiolactomycin (TLM, Table 1-3, 
compound 16) (24,58,136,137). Such compounds which block multiple targets are 
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particularly promising for the development of new antibiotics due to the reduced propensity 
for the formation of resistances (see also chapter 1.2.3) (4). However, since the inhibition of 
several targets by one common molecule concomitantly implies reduced specificity, special 
attention must be paid on the existence of potential secondary targets, which might lead to 
side effects during the application of such compounds. Indeed, KasA shares 22.2% primary 
sequence identity, a common fold and the catalytic triad with the mFAS KS domain (Figure 
1-3C) (12,106). Accordingly, McFadden et al. were able to design TLM-analogs which inhibit 
the mFAS KS domain and thereby display anticancer and weight loss effects (138). 
Furthermore, a second naturally occurring β-ketoacyl-ACP synthase inhibitor, cerulenin, does 
also inhibit both, the bacterial and mammalian fatty acid synthesis (Table 1-3, compound 18) 
(132). Nevertheless, distinct differences between bacterial KAS enzymes and the mFAS KS 
domain allow the development of selective and very promising inhibitors as exemplified by 
thiolactomycin (4,130,138). 
The homo-dimeric KasA protein contains a thiolase fold and catalyzes the condensation 
reaction via a ping-pong bi-bi mechanism (13,17,59). First, acyl-AcpM binds to the KasA 
enzyme and acylates the active site cysteine (Cys171). After the deacylated AcpM left the 
KasA binding site, malonyl-AcpM can enter and delivers its malonyl group, which is 
decarboxylated and subsequently condenses with the acyl-chain esterified with Cys171. 
Finally, the formed β-ketoacyl-AcpM leaves the binding site and KasA including the 
nucleophile Cys171 are restored for additional rounds of catalysis (13,17,59,131). The 
catalytic triad of KasA is completed by the two histidines His311 and His345 (17,59,139,140). 
However, it is currently debated controversially whether and how both histidines are 
involved in the decarboxylation of the malonyl-substrate, and further studies with the acyl-
enzyme intermediate are necessary to reveal the exact location of the malonyl group in the 
catalytically competent complex (for details see chapter 6) (141). Since the preparation of a 
homogenous acyl-KAS enzyme for crystallographic studies turned out to be problematic, an 
active site cysteine mutant is commonly used (C171Q for KasA) which mimics the acylated 
form of the KAS-enzyme (13,17,131). 
1.4.4 Inhibition of the FAS-II Condensing Enzymes 
Interestingly, the natural products thiolactomycin (isolated from Nocardia and Streptomyces 
sp.) and platensimycin (isolated from Streptomyces platensis) preferably inhibit the acyl-
intermediates rather than the apo-forms of condensing enzymes (59,131). Despite its 
moderate MIC values, TLM displayed in vivo efficacy against Serratia marcescens and K. 
pneumoniae in murine models of infection (59,137). Moreover, the small size, moderate 
polarity (logP = 3) and broad-spectrum activity of this molecule underscores the potential of 
TLM as a lead compound for the development of a new antibiotic (Table 1-3, compound 16) 
(138,142). Platensimycin constitutes the most potent KAS-inhibitor currently known - the 
IC50 towards S. aureus FabF is 48 nM (Table 1-3, compound 17) (131). In addition, promising 
antibacterial activities have been reported for S. aureus (MIC = 0.5 µg/ml) and M. 
tuberculosis (MIC = 12 µg/ml) (129,131). In contrast to TLM and platensimycin, the natural 
product cerulenin (isolated from Cephalosporium caerulens) is a covalent inhibitor of KAS-
enzymes (Table 1-3, compound 18) (23,132). Mechanistically, the nucleophilic active site 
cysteine attacks the C2 atom of the electrophilic epoxide ring to yield a covalent protein-
inhibitor adduct (132). In addition to the naturally occurring antibacterial agents, some 
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completely synthetic KAS-inhibitors have been developed. For instance, the aminothiazole 
derivative 2-phenylamino-4-methyl-5-acetylthiazole was identified by means of virtual 
screening and was found to inhibit the E. coli FabB enzyme with a Kd value of 25 µM (Table 
1-3, compound 19) (133). In addition, a high-throughput screening campaign (with 2,500 
compounds) and subsequent hit optimization resulted in a series of benzoylaminobenzoic 
acids with IC50 values for the E. faecalis FabH enzyme in the high nM to low µM range (Table 
1-3, compound 20) (134). 
1.5 Research Objective 
During this work, some of the key questions surrounding the important drug targets saFabI 
and KasA were addressed. For this purpose, we used a highly interdisciplinary and 
collaborative structure-based drug design approach which included methodologies such as 
X-ray crystallography, molecular dynamics simulations, computational modeling, 
biochemistry, mass spectrometry, chemical synthesis, enzyme kinetics and microbiology 
(individual experimental contributions are listed in the preamble of chapters 2, 3, 4, 5 and 6). 
1.5.1 General Questions Concerning the FAS-II Pathway 
• Does saFabI differ from other enoyl-ACP reductases given the unique capability of the 
staphylococcal FAS-II system to generate BCFAs? Does KasA differ from orthologous 
β-ketoacyl-ACP synthases in the light of its special competence to turnover long-
chain mycolic acid precursors? Is the diversity in fatty acid synthesis thus also 
reflected in these key enzymes? For details on this topic see also chapters 1.3.3 and 
1.3.5. 
• Why does S. aureus differ from other Gram-positive organisms and established a 
(protective?) mechanism which does not allow the bypass of its FAS-II system 
through the complete uptake of exogenous fatty acids leading to the sensitivity of 
this organism to FAS-II inhibitors (88,89)? For which other Gram-positive pathogens 
does the FAS-II pathway constitute a valid target? For details on this topic see also 
chapter 1.3.4. 
1.5.2 Questions Concerning SaFabI, KasA and their Natural Substrates 
• What are the determinants for the unique NADPH specificity of saFabI? 
• Does the thioester carbonyl of the saFabI enoyl-substrate bind to Tyr147 or Tyr157? 
For details on this topic see also chapter 1.4.1. 
• What are the substrate binding modes of the enoyl-, acyl-, and malonyl-substrates? 
Where is the phosphopantetheine linker located in the catalytically competent saFabI 
and KasA complexes? 
• Which reaction mechanisms are operative in saFabI and KasA? What is the proton 
source for the protonation of the enolate intermediate formed during the saFabI 
catalyzed reaction? How is the malonyl-group positioned within the KasA active site 
and which residue is responsible for the decarboxylation of the second AcpM 
substrate? For details on this topic see also chapters 1.4.1 and 1.4.3. 
• Where does the acyl carrier protein bind on the surface of saFabI and KasA? For 
details on this topic see also chapter 1.3.2. 
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• How do the saFabI and KasA enzymes recognize their ligands? Which conformational 
changes occur upon substrate binding? Can we target such conformational states 
along the reaction coordinate? For details on this topic see also chapters 1.4.1 and 
1.4.3. 
• How does KasA achieve recognition and binding of very long and hydrophobic 
mycolic acid precursors? For details on this topic see also chapters 1.3.5 and 1.4.3. 
• How do saFabI and KasA differ from orthologous proteins given their unique 
capability to turnover BCFA or mycolic acid precursors, respectively? Can this 
knowledge be used for the design of new antibacterials? 
1.5.3 Questions Concerning the Inhibition of SaFabI and KasA 
• What are the binding modes of saFabI diphenyl ether and pyridone inhibitors? Do 
these two inhibitor scaffolds differ with respect to their binding poses and inhibitory 
mechanisms despite their structural similarity? How does the saFabI-NADPH-
CG400549 ternary complex look like? Can the observed intermolecular interactions 
be related to binding affinity? Can we rationalize the residence time of these 
inhibitors? For details on this topic see also chapters 1.2.4 and 1.4.2. 
• Is the Staphylococcus-restricted activity spectrum of CG400549 and AFN-1252 
reflected in the affinity of these molecules towards FabI enzymes of different 
organisms? Why does MUT056399 display a broader antibacterial activity spectrum? 
For details on this topic see also chapter 1.4.2. 
• What are the key features of high-affinity FabI inhibitors? Can we rationally improve 
the affinity and residence time of saFabI inhibitors? What can we learn from our 
saFabI case study for the residence time concept in general? Can we use the 
combined knowledge about saFabI to derive new promising inhibitors which are 
active against MRSA? For details on this topic see also chapters 1.2.4 and 1.4.2. 
• How do C3-substitued TLM-derivates bind to KasA? Do these findings correlate to 
binding affinity trends (16)? For details on this topic see also chapter 1.4.4. 
• How can the TLM scaffold be rationally improved with respect to its inhibitory 
properties? For details on this topic see also chapter 1.4.4. 
• Can we derive alternative strategies to target saFabI or KasA? 
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2 Staphylococcus aureus FabI: Inhibition, Substrate 
Recognition, and Potential Implications for In Vivo 
Essentiality 
 
This chapter is based on the following publication: 
 
Schiebel, J.*, Chang, A.*, Lu, H., Baxter, M. V., Tonge, P. J., and Kisker, C. (2012) 
Staphylococcus aureus FabI: Inhibition, Substrate Recognition, and Potential Implications for 
In Vivo Essentiality. Structure 20, 802-813 
 
Copyright: 
 
Reprinted with permission from (19). Copyright 2012 Elsevier. 
 
Author contributions with respect to data collection: 
 
Schiebel, J.:  Expression and purification‡, X-ray crystallography‡, analytical size  
   exclusion chromatography 
Chang, A.:  Enzyme kinetics, mutagenesis 
Lu, H.:   Enzyme kinetics 
Baxter, M.V.:  Synthesis of branched-chain fatty acid substrate analogs 
 
*These authors contributed equally 
‡Initial work had already been performed in the context of the diploma thesis (the main 
result was the low-resolution P212121 saFabI-NADP+-triclosan crystal structure) and provided 
a basis for these studies. 
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2.1 Summary 
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a serious health 
threat worldwide, and novel antibiotics are therefore urgently needed. The enoyl-ACP 
reductase (saFabI) is essential for the S. aureus fatty acid biosynthesis and, hence, serves as 
an attractive drug target. We have obtained a series of snapshots of this enzyme which 
provide a mechanistic picture of ligand and inhibitor binding including a dimer-tetramer 
transition combined with extensive conformational changes. Significantly, our results reveal 
key differences in ligand binding and recognition compared to orthologous proteins. The 
remarkable observed protein flexibility rationalizes our finding that saFabI is capable of 
efficiently reducing branched-chain fatty acid precursors. Importantly, branched-chain fatty 
acids represent a major fraction of the S. aureus cell membrane and are crucial for its in vivo 
fitness. Our discovery thus addresses a long-standing controversy regarding the essentiality 
of the fatty acid biosynthesis pathway in S. aureus and validates saFabI as a drug target. 
2.2 Highlights 
• Insights into saFabI ligand binding including a dimer-tetramer transition 
• Identification of a loop motif that determines altered cofactor specificity 
• Increased flexibility modulates substrate and inhibitor recognition 
• Ability of saFabI to reduce branched-chain fatty acid precursor molecules 
2.3 Introduction 
Resistant strains of the Gram-positive human pathogen Staphylococcus aureus emerged only 
two years after the introduction of the antibiotic methicillin in 1959. Since then, methicillin-
resistant S. aureus (MRSA) infections have become an increasing problem in hospitals 
worldwide. To treat severe MRSA infections, vancomycin is currently used as the drug of last 
resort (29). Thus, the initial occurrence of a vancomycin-resistant S. aureus (VRSA) strain in 
June 2002 is especially alarming (143). Unfortunately, antibiotic resistance has drastically 
outpaced new antibiotic discovery, which flourished between the 1940s and 1960s. Between 
1962 and 2000 only a few novel scaffolds like the carbapenems were approved, and novel 
antibiotics with alternative modes of actions are therefore urgently needed. Accordingly, 
from 2000 onwards oxazolidinones (e.g. linezolid), the lipopeptide daptomycin and the 
mutilins were introduced (20). 
One strategy that targets the bacterial cell envelope involves the inhibition of the type II 
fatty acid biosynthesis pathway (FAS II), which is responsible for the de novo production of 
phospholipid precursor molecules (50). In contrast to the large multifunctional mammalian 
FAS I synthase, the FAS II system of bacteria, protozoa and plants consists of individual 
monofunctional enzymes, allowing selective inhibition (7). In this pathway, the fatty acid 
chain, which is attached to the acyl carrier protein (ACP), is elongated by two carbon atoms 
per cycle (Figure 2-1). The final reduction is catalyzed by the NAD(P)H-dependent trans-2-
enoyl-ACP reductase (FabI), which is known to play a key regulatory role in this pathway 
(63,78). This enzyme is highly conserved across many pathogens, however, the S. aureus 
enoyl-ACP reductase (saFabI) is the only known FabI with a clear preference for NADPH 
(51,78,108,144). The clinical success of FabI inhibitors, such as the first-line tuberculosis 
prodrug isoniazid (67) and several compounds currently in phase I clinical trials (103), 
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validates this enzyme as an attractive drug target. Furthermore, the FabI diphenyl ether 
inhibitor triclosan (TCL) is recommended as topical antiseptic to reduce MRSA skin 
colonization (116). 
 
 
Figure 2-1. The bacterial type II fatty acid biosynthesis pathway as a drug target. S. aureus enzymes are shown 
in red, while isoforms in other organisms are depicted in black (7). Initiation of fatty acid biosynthesis requires 
malonyl-ACP, formed from acetyl-CoA by acetyl-CoA carboxylase (Acc) and malonyl-CoA:ACP transacylase 
(FabD). The β-ketoacyl-ACP synthase FabH (KAS III) performs the first Claisen condensation yielding a β-
ketoacyl-ACP from malonyl-ACP and an acyl-CoA primer. The two carbons originating from malonyl-ACP are 
shown in cyan and the first two primer carbons in red. Subsequently, the β-ketoacyl-ACP is converted to a 
saturated acyl-ACP by the actions of the NADPH-dependent reductase FabG, the dehydrase FabZ, and the 
mostly NADH-dependent enzyme FabI. The saturated acyl-ACP is a substrate for additional rounds of 
elongation in which FabF catalyzes the condensation reaction. The long-chain acyl-ACP products are 
subsequently partially transformed into membrane lipids (a typical S. aureus phosphatidylglycerol is shown 
(89)). Most bacteria use acetyl-CoA as the primer which results in straight-chain fatty acids (C14 and C16) (56), 
however, S. aureus FabH prefers branched-chain acyl-CoAs which yield branched-chain fatty acids (57). The 
branched-chain primers isobutyryl-CoA, isovaleryl-CoA and 2-methylbutyryl-CoA are derived from valine, 
leucine and isoleucine, respectively, through the actions of the branched-chain aminotransferase BAT (ilvE 
(145)), and the branched-chain α-ketoacid dehydrogenase BKD (lpd, bkdA1, bkdA2 and bkdB (146)). The 
branched-chain acyl-CoAs yield iso-C14 and iso-C16 (isobutyryl), iso-C15 and iso-C17 (isovaleryl), and anteiso-C15 
and anteiso-C17 (2-methylbutyryl) fatty acids (56). Exogenous fatty acids are converted into acyl-ACPs by the 
acyl-ACP synthetase (AAS) for incorporation into cell membranes. Typical fatty acids of the human blood 
plasma are palmitic (21.3%) and linoleic acid (23.7%) (147). For S. aureus, exogenous oleic acid was only 
incorporated in the 1-position of phosphatidylglycerol (89). Inhibitors of the NADPH-dependent FabI from S. 
aureus (saFabI) used in this study include 5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan), 5-chloro-2-
phenoxyphenol (CPP) and 5-ethyl-2-phenoxyphenol (EPP) (78). See also Figure S 2-1. 
Recently, however, Brinster et al. challenged the validity of FAS II inhibitors as Streptococcus 
agalactiae can utilize exogenous fatty acids from the host blood serum to survive inhibition 
of its FAS II machinery (90). Whether this resistance mechanism extends to all Gram-positive 
bacteria including S. aureus is currently controversially discussed (88,89). Importantly, S. 
aureus remains sensitive to FabI inhibitors in vivo, as shown in several rodent models 
(50,88,91,92). 
To investigate the suitability of saFabI as a drug target, we have structurally and 
biochemically characterized this enzyme with respect to inhibitor binding, conformational 
flexibility, ligand binding mechanism, cofactor and substrate specificity, quaternary structure 
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and cooperativity. We identified significant differences in the S. aureus and Bacillus FabIs 
compared to the classical FabI proteins from organisms such as Escherichia coli, Burkholderia 
pseudomallei and Francisella tularensis; and of our structures with respect to the recently 
determined S. aureus FabI structures in complex with triclosan and in its apo-state (144). 
Importantly, our analysis revealed that the substrate specificity of saFabI displays an 
increased specificity for branched-chain (BCFA) relative to straight-chain fatty acid (SCFA) 
precursors (Figure S 2-1), consistent with the high content of BCFAs in the membranes of 
Staphylococci and Bacilli (86). Since BCFAs, which are barely found in human serum (147), 
are likely required for S. aureus fitness in vivo, we conclude that saFabI is a suitable target 
for drug discovery. 
2.4 Results 
2.4.1 Overall Structure 
 
Figure 2-2. Overall structure and flexibility of saFabI. (A) Homo-tetrameric structure of saFabI. Each subunit of 
the TCL-2 structure is shown in a different color. The three perpendicular 2 fold non-crystallographic symmetry 
axes P, Q and R are indicated. The interfaces spanned by the axes P and R (Q and R) are referred to as the PR- 
(QR-) interface. (B) Structure of the saFabI monomer. α-Helices are shown in red, β-strands in yellow, loops in 
green, cofactor and inhibitor as space-filling models in grey. The chair-like structure consists of the Rossmann-
fold (seat, lower part) and the active site (back, upper part). (C) Flexibility of the saFabI active site in its ligand-
free form. Multi-rmsd values were calculated for the Cα atoms of the apo-1 (one subunit), apo-2 (all subunits) 
and TCL-2 (one subunit) structures using LSQMAN (148). These values varied from 0.2 to 20.5 Å and are 
represented by color (from blue to red) and width of the TCL-2 model (residues 2-256). Rmsd-values for the 
missing residues 199-201 were interpolated in a linear fashion based on the values for the two adjacent amino 
acids 198 and 202. See also Figure S 2-2. 
To provide a molecular basis for the rational design of compounds that target saFabI, we 
solved the structures of ternary FabI complexes with the cofactor NADP+ and the diphenyl 
ether inhibitors triclosan (TCL), 5-chloro-2-phenoxyphenol (CPP) or 5-ethyl-2-phenoxyphenol 
(EPP), respectively (Figure 2-1, Figure S 2-1 and Figure S 2-2). As a member of the short-chain 
dehydrogenase/reductase (SDR) superfamily, saFabI contains an extended Rossmann-fold 
comprised of a central seven-stranded parallel β-sheet surrounded by three α-helices on 
either side (Figure 2-2B) (67,105). Furthermore, the structures of our saFabI inhibitor 
complexes clearly show the presence of homo-tetramers (Figure 2-2A) as observed in other 
organisms (51). The closest relationship is found with the FabI structures from the Gram-
positive organisms Bacillus anthracis and B. subtilis as well as with the incorrectly designated 
"FabL" from B. cereus which is 100% identical to B. anthracis FabI (Figure 2-3). 
In addition, we solved two apo saFabI structures which display unexpected flexibility in close 
proximity to the binding site (Figure 2-2C). In one of the two apo structures all four 
 Substrate and Inhibitor Recognition by SaFabI  
25 
 
monomers (apo-2; nomenclature of all structures according to Table S 2-1 and Table S 2-2) 
differ in their active site (pairwise rmsd of 0.84 Å) and display conformations that, to our 
knowledge, have never been observed before. Compared to the inhibitor-bound complexes, 
three regions - the active site and two substrate-binding loops (Figure 2-3) - are either 
disordered or visible in a rearranged architecture. In contrast, previously published apo 
structures of FabI proteins from Gram-negative bacteria (PDB codes: 2JJY, 2P91, 2WYU, 
3EK2, 3GRK, 3K2E) show disorder in only one region, the substrate-binding loop. 
 
 
Figure 2-3. Secondary structure of saFabI and alignment with similar proteins. Secondary structure matching 
(SSM) was performed for the TCL-2 structure using PDBe Fold (149). The secondary structure of saFabI is shown 
in the first line according to the program DSSP (150). Secondary structure elements participating in the QR and 
PR-interfaces are depicted in red and blue, respectively. Amino acids highlighted in red are conserved. The 
alignment comprises the 7 best SSM hits (Q-scores are indicated behind the sequences) including bsFabL and 
saFabG. The first two letters of the protein names indicate the bacterial source (sa = S. aureus, ba = Bacillus 
anthracis, bc = B. cereus, bs = B. subtilis, ft = Francisella tularensis, tt = Thermus thermophilus, ec = Escherichia 
coli, aa = Aquifex aeolicus). PDB codes and subunits are given in parentheses. Blue, red and cyan stars mark 
residues interacting with the cofactor, inhibitor or cofactor and inhibitor, respectively. Disordered or 
rearranged regions in all four available saFabI apo structures (apo-1, apo-2, 3GNS, 3GNT) are marked with a 
continuous line, regions which are additionally disordered or rearranged for distinct apo structures are 
represented by a dashed line. This Figure was prepared with ESPript (151). 
2.4.2 SaFabI Inhibition 
 
Table 2-1. Potency of saFabI inhibition by diphenyl ether analogues. 
Inhibitor Ki*,app (nM)
CPP 161.2 ± 8.4
EPP 106.6 ± 7.9
Triclosan 60.9 ± 5.6 
 
In contrast to the previously described saFabI-NADP+-TCL structure (PDB code: 3GR6) (144), 
our high-resolution saFabI complex structures with the unsymmetrically substituted 
inhibitors EPP and CPP unequivocally reveal a similar binding mode of diphenyl ethers 
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including triclosan to saFabI as reported for homologous FabI proteins (67,78) which allows 
the formation of two key hydrogen bonds connecting the A-ring hydroxyl group to Tyr157 
and to the 2'-OH of the nicotinamide ribose at 2.5 ± 0.1 and 2.6 ± 0.1 Å, respectively (Figure 
2-4B). TCL, CPP and EPP bind to a pocket composed of NADP+ and several mainly 
hydrophobic residues with average distances of 3.8 ± 0.4 Å (Figure 2-4B and Figure 2-4C). 
Notably, the carbonyl oxygen of Ala97 forms a geometrically favorable halogen bond (152) 
with the TCL B-ring chlorine at position 4 (3.2 ± 0.1 Å). At the same time the chlorine is 
weakly hydrogen bonded to the amide NH group of Ala97 (3.2 ± 0.1 Å, Figure 2-4B). 
Accordingly, TCL exhibits an almost 3-fold lower Ki*,app value as compared to CPP, which 
lacks the two B-ring chlorines and is rotated by 11 ± 2° into the binding crevice (Table 2-1, 
Figure 2-4D and Supplemental Results). 
 
 
 
Figure 2-4. SaFabI inhibition with diphenyl ethers. (A) Dose-response curves of diphenyl ether analogues. The 
steady-state reaction velocities (vs) at various inhibitor (CPP, EPP, triclosan) concentrations are plotted as a 
fraction of the uninhibited reaction velocity (vu). Each plot is fitted to the standard binding isotherm. R
2 = 0.88, 
0.75 and 0.73 for the best fit curves to the binding isotherm for CPP, EPP and triclosan, respectively. (B) 
Schematic representation of all residues interacting with triclosan (TCL in red). The interaction pattern was 
derived from the TCL-2 structure. Directional interactions are depicted explicitly (black residues), amino acids 
creating the hydrophobic pocket are included in 1-letter code (residues in blue boxes). R = adenosine 
diphosphate. (C) Fit of triclosan in its binding pocket. Triclosan is shown as space filling model in grey. Ala95, 
Phe96, Ala97, Leu102, Tyr147, Tyr157, Met160, Ile207 and NADP+ are shown in surface representation in blue. 
Additionally interacting residues Ser197, Ala198, Val201 and Phe204 are located within the substrate-binding 
loop (SBL). (D) Comparison of the TCL and CPP inhibitor binding modes. The TCL-2 structure is shown in grey 
and yellow, the CPP structure in blue. The cofactor and some protein regions are omitted for clarity. Arrows 
indicate differences between the two structures. The B-ring is rotated by ~11 ± 2° upon removal of the two 
chlorine atoms. Simultaneously, the Cα atoms of Ala97, Leu102, Ser197 and Ala198 move towards the inhibitor 
by about 0.4 ± 0.1 Å, 0.3 ± 0.1 Å, 0.3 ± 0.1 Å and 0.2 ± 0.1 Å, respectively, and the side chain of Met160 rotates 
away from the inhibitor by ~13 ± 3°. 
2.4.3 Induced Fit Ligand Binding 
SaFabI undergoes several major conformational changes upon cofactor and inhibitor 
binding, which have, to our knowledge, never been observed previously for its Gram-
negative FabI orthologs, thus allowing us to describe a fundamentally expanded mechanism 
for ligand binding. All residues interacting with the diphenyl ether inhibitors are located in 
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three distinct regions (Figure 2-3), which exhibit substantial flexibility prior to cofactor and 
inhibitor binding. As described for numerous FabI orthologs and other SDR proteins, the 
substrate-binding loop (SBL, 194-204) is disordered or rearranged in our apo structures 
(6,105). In contrast to other FabI structures, however, the saFabI structures reveal flexibility 
of a second substrate-binding loop (SBL-2, 94-108) as well as the active site loop (ASL, 147-
157). 
Superposition of the apo-1 structure with TCL-2 shows that the active site is wide open prior 
to cofactor and inhibitor or substrate binding (Figure 2-5A). In addition to the three 
aforementioned loop regions, the C-terminal SBL extension α7 is disordered. The apo-2 
structure provides informative snapshots of α7's motion on its way to the ternary complex 
conformation as every subunit shows a different arrangement of this helix (Figure 2-5B-F and 
Movie S 2-1). In one subunit, this helix is shifted ~13 Å away from the active site (Figure 
2-5B). When helix α7 moves towards the protein core, it is still rotated about 105° relative to 
the ternary complex conformation (Figure 2-5C) and assumes its final conformation via 
rotation angles of 70° and 20° (Figure 2-5D-F). Intermittently, the adjacent helix α8 is 
elongated by up to two turns (Figure 2-5C-D). Finally, the N-terminally attached SBL closes 
upon actual cofactor and inhibitor binding. 
 
 
Figure 2-5. Cofactor and inhibitor binding mechanism. Panels A to F show consecutive conformations of saFabI 
proposed to be adopted during cofactor and inhibitor binding. The three regions undergoing the most 
extensive conformational changes are highlighted (SBL-2 in cyan, ASL in dark blue and the C-terminally 
extended SBL in red as in Figure 2-3). One subunit of TCL-2 is continuously shown as a reference in yellow. (A) 
Superposition of the apo-1 and TCL-2 structures. Apo-1 is shown in light blue. (B-E) Superposition of the apo-2 
and TCL-2 structures. Subunits B, C, A and D of apo-2 are shown in light blue. (F) Final ternary complex 
conformation. The hydrogen bonded residues Arg194 and Asn205 can act as a hinge for SBL-1 closure and are 
displayed in a larger scale in the black box (153). (G) Peptide flip mechanism and SBL-2 closure observed upon 
superposition of TCL-2 (yellow) with apo-2 (light blue, subunit A). The carbonyl oxygen of Ala95 flips between 
Ser121 in the apo structure and a water molecule bound to Ser197 in the ternary complex (a rotated view is 
displayed in the insert). See also Figure S 2-4 and Movie S 2-1. 
During this process, the ASL is visible inside the ligand-binding pocket (Figure 2-5D) and SBL-
2 adopts an entirely α-helical conformation (Figure 2-5B). Subsequently, SBL-2 is split into 
the 310-helices η2 and η3 and adopts a more open conformation (Figure 2-5D,G). A 
comparison with the ternary complex structure TCL-2 shows that a backbone flip of Ala95 
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propagates the movements of adjacent residues and leads to the subsequent closure of SBL-
2 (Figure 2-5G). This peptide flip may be induced by the ordering of Ser197 located on the 
SBL, which allows the formation of a water-mediated hydrogen bond interaction with the 
carbonyl oxygen of Ala95. Simultaneously, the movement of Phe96 creates space for the 
binding of the TCL B-ring and establishes an elongated acyl-channel. During NADP+ binding, a 
similar peptide flip mechanism was observed for the NADPH-dependent β-ketoacyl-ACP 
reductase ecFabG, which also belongs to the SDR family of proteins (154). 
We speculate that the concerted closure of both SBLs, instead of just the classical SBL, is the 
conformational change corresponding to the slow step of the slow-binding inhibition (67). 
Based on sequence similarities, this mechanism should mainly be feasible for Staphylococci, 
several Bacilli and some Listeria strains since they contain a serine at position 197, which 
connects the SBLs (Figure 2-5G). Most other Gram-negative and Gram-positive bacteria 
harbor an alanine at this position and, thus, lack the required hydrogen bond acceptor 
(Figure 2-3). Consistently, all structurally characterized FabIs from Gram-negative organisms 
contain just a single flexible SBL (PDB codes: 2JJY, 2P91, 2WYU, 3EK2, 3GRK, 3K2E), as 
opposed to Bacillus FabIs (3OIF, 3OJE) and the related proteins bsFabL (3OIC) and ecFabG 
(1I01) which all feature three disordered or rearranged regions in their apo structure. 
2.4.4 Dimer - Tetramer Transition 
The apo FabI structures from Gram-negative bacteria contain homo-tetramers, whereas 
bcFabI/baFabI, in the absence of cofactor and inhibitor, were reported to be dimers in the 
crystal and in solution (155). So far, reports regarding the oligomeric state of saFabI have 
been inconsistent. It was noted that the published apo structures of saFabI (3GNS, 3GNT) are 
comprised of dimers, though the enzyme was found to be a tetramer in solution (144,155). 
Therefore two questions arose: What is the oligomeric state of saFabI prior to ligand 
binding? If dimers are present, does tetramerization and active site formation occur in a 
concerted fashion with cofactor and inhibitor binding as hypothesized for bsFabL (156)? 
Our results clearly show that NADP+ and triclosan binding to dimeric saFabI induces 
simultaneous active site formation and tetramerization. In contrast to a previous report but 
in accordance with the respective apo saFabI structures (3GNS, 3GNT) (144), we identified a 
dimer through analytical size exclusion chromatography (SEC) experiments at pH 8.0 (Figure 
S 2-3A), whereas tetramers are present at pH 5.6 (see Experimental Procedures for details). 
We performed further analytical SEC experiments with the dimeric enzyme in its apo form or 
incubated with NADP+, NADPH or NADP+ and TCL. Our results unambiguously demonstrate a 
transition between dimers and tetramers upon both inhibitor and cofactor binding (Figure S 
2-3B), whereas binding of oxidized or reduced cofactor alone is not sufficient to induce 
tetramerization. 
A structure and interface analysis of all available saFabI structures provides snapshots of the 
dimer - tetramer transition in the order 3GNT, 3GNS, apo-1, apo-2, TCL-2 (Figure 2-6 and 
Movie S 2-2). During this process, the buried surface area of the QR-interface, about which 
the association occurs, increases significantly, as does the number of hydrogen bonds and 
salt bridges between interface residues (Figure 2-6C). The QR-interface is established via a 4-
helix bundle comprising the long helices α4/α5 (kinked) and α6 (Figure 2-6, last column). 
Additionally, the corresponding N-terminal extensions η3 and η4 further stabilize this 
interface (Figure 2-3). Since the SBL-2 and ASL regions including these 310-helices are 
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disordered in our apo structures, the QR-interface is destabilized and the dimers move 
slightly (~2 Å) away from one another. During the ordering of the ASL, the full tetramer 
interface and the catalytic active site are simultaneously established (Figure S 2-4). The 3GNS 
structure clearly contains dimers due to the additionally disordered α4 region (Figure 2-3). 
This helix is therefore essential for the maintenance of the QR-interface. Whereas helix α6 of 
3GNS is almost completely structured and just slightly shifted, the N-terminal portion of this 
helix is unstructured and partially disordered in 3GNT. 
 
 
 
Figure 2-6. Dimer - tetramer transition. From left to right the QR-interface in the saFabI crystal structures 
3GNT, 3GNS (144), apo-1, apo-2 and TCL-2 is shown to illustrate tetramer association and dissociation (view as 
in Figure 2-2A). The two associating dimers are shown in grey and yellow with the respective QR-interface 
residues (according to the PDBe PISA server (157)) in cyan and red. (A) Front view of the dimer - tetramer 
transition. (B) Side view of the dimer - tetramer transition. (C) Close up view of the upper QR-interface half. 
Buried surface areas of the monomeric QR-interface (BSAQR) as well as the numbers of the corresponding 
hydrogen bonds (NHB) and salt bridges (NSB) are given below according to PISA. See also Figure S 2-3 and Figure 
S 2-5 as well as Movie S 2-2. 
2.4.5 Cooperativity 
We hypothesize that the dimer - tetramer transition also applies to substrate binding, 
representing the molecular basis for the previously reported positive cooperative binding of 
NADPH to saFabI (108). Our data clearly show that NADPH binds cooperatively to saFabI with 
an approximate Hill coefficient h = 2 (Figure S 2-5). Additionally, trans-2-octenoyl-CoA bound 
cooperatively to saFabI with a Hill coefficient h = 2.3. However, glutamate, which enhances 
the catalytic activity of the enzyme (Supplemental Discussion), was found to alter the 
cooperativity of binding to saFabI. In the presence of 1 M potassium glutamate, no 
cooperativity was observed for the binding of NADPH or trans-2-octenoyl-CoA to saFabI. 
Since cooperativity was still observed in the presence of 250 mM potassium glutamate, 
which is an upper limit estimate of the average S. aureus intracellular glutamate 
concentration (158,159), it is likely to be physiologically relevant. Mechanistically, the 
observed positive cooperativity of substrate binding could be transferred via the ligand-
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interacting SBL-2 and ASL regions and the attached long helices α4 and α6, which primarily 
constitute the QR-interface. The formation of such an interface would enhance cofactor and 
inhibitor/substrate binding due to the rearrangement of the two loop regions and vice versa. 
Cooperativity has, to our knowledge, never been observed for NADH-dependent wild-type 
FabI enzymes, which already exist as tetramers in their apo forms (72). In contrast, a similar 
FabI tetramerization process might be possible for Bacillus species as α4 is additionally 
disordered in the dimeric bcFabI/baFabI apo structure (PDB code: 3OJE:A) (155). Similarly, 
the twisted tetramer architecture of the bsFabL apo structure (3OIC:A) comprises N-
terminally shifted α4 and α6-helices and therefore links this protein to saFabI (156). 
2.4.6 Cofactor Specificity 
 
 
 
Figure 2-7. Structural basis of NADPH specificity. (A) The 2'-phosphate binding motif. NADP+ is shown in grey, 
saFabI (CPP structure) in yellow. Additional parts of the protein are omitted for clarity. (B) Superposition of 
saFabI and ecFabI. SaFabI is shown in yellow, ecFabI (1QSG:A) in green. Asn41 is shifted 2.8 ± 0.3 Å towards the 
solvent compared to Lys41 preventing 2'-phosphate stabilization by an Asn41 backbone interaction. 
The studies described above reveal fundamental differences between saFabI and classical 
FabI proteins. Hence, we also investigated cofactor specificity since, in contrast to all Gram-
negative FabI homologues studied thus far, saFabI prefers NADPH instead of NADH as the 
reducing agent (51,108). Our structural analysis confirmed that the positively charged side 
chains of Arg40 and Lys41 are important for binding the additional 2'-phosphate of NADPH 
(78,144) (Figure 2-7A). However, we identified an RKXXS-motif that confers this unique 
specificity to saFabI. While the R40Q/K41N saFabI double mutant exhibited a drastically 
decreased kcat/Km value for NADPH, the specificity constant remained low for NADH (78). Our 
structures revealed Ser44 as a third crucial residue for NADPH specificity. The serine 
hydroxyl group forms a hydrogen bond to one of the phosphate oxygen atoms at a distance 
of 2.9 ± 0.1 Å, while the Ser44-bound phosphate oxygen forms additional hydrogen bonding 
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interactions with the backbone amide nitrogens of Arg40 and Lys41, which are located in a 
tight loop between β2 and α2 (Figure 2-7A). 
Unlike saFabI, the enoyl-ACP reductase from E. coli (ecFabI) is NADH-dependent (111). 
Superposition of saFabI with ecFabI shows that Leu44 and Gln40 clash with the 2'-phosphate 
of a hypothetically bound NADPH (shortest distances of 1.7 ± 0.1 and 1.5 ± 0.2 Å, Figure 
2-7B). Bulky substituents at position 44 (numbers according to saFabI), such as Leu or Phe 
(Figure 2-3), appear to shrink the adenine ribose-binding pocket, thus decreasing the affinity 
towards NADPH. 
 
Table 2-2. Kinetic parameters for saFabI wild-type, double and triple mutant utilizing NADPH (top) and NADH 
(bottom) at saturating trans-2-octenoyl-CoA concentrations (150 µM). 
 Km,NADPH (µM) kcat (min-1) kcat/Km,NADPH (min-1 µM-1) 
wt saFabI 189.4 ± 20.9 2171.2 ± 123.3 11.5 ± 1.41
saFabI R40Q/K41N > 300 0.066 ± 0.0012 
saFabI R40Q/K41N/S44L > 300 0.0038 ± 0.00022 
 
 Km,NADH (µM) kcat (min-1) kcat/Km,NADH (min-1 µM-1) 
wt saFabI > 300 4.7 ± 0.22
saFabI R40Q/K41N 139.8 ± 23.2 1852.1 ± 132.6 13.2 ± 2.4 
saFabI R40Q/K41N/S44L 72.2 ± 26.4 1846.6 ± 266.3 25.6 ± 10.1 
 
1Agrees with the linear slope (11.1 ± 0.3) of the Michaelis-Menten plot at low [NADPH] 
2Estimated based on linear slope of the Michaelis-Menten plot at low [NAD(P)H] 
 
To test the hypothesis that the RKXXS-motif is responsible for cofactor specificity, we 
generated a triple mutant with all three phosphate-interacting amino acids replaced by the 
respective E. coli residues (R40Q/K41N/S44L). Interestingly, compared to results reported in 
the absence of glutamate (78), there is only a 2.5-fold increase in the specificity constant of 
wild-type saFabI for NADPH relative to NADH in the presence of glutamate (Table 2-2). The 
glutamate-containing conditions also strongly affected the specificity constant of the 
R40Q/K41N mutant for NADH, which recovered to that of the wild-type enzyme for NADPH. 
Additionally, the specificity constant of the double mutant for NADH was 200-fold higher 
than for NADPH, compared to the 19-fold difference reported in the absence of glutamate. 
The triple mutant displayed an even more dramatic inversion of cofactor specificity with the 
specificity constant for NADPH nearly 10,000-fold lower than for NADH. This was driven 
mostly by a decrease in the ability to utilize NADPH, consistent with our prediction that 
Leu44 would clash with the 2’-phosphate. Interestingly, the Km,NADPH of wild-type saFabI is 
higher than the Km,NADH of the triple mutant (Table 2-2 and Table S 2-3) and other FabI 
homologues (109,160) which correlates well with the estimated higher microbial 
intracellular pool of NADPH compared to NADH (161,162). 
Using BLAST and PHI-BLAST searches (163) with the newly identified RKXXS-motif, we found 
that this preference for NADPH links saFabI to all Staphylococcus and some Bacillus FabIs, as 
well as FabL and FabG, rather than to classical NADH-dependent FabIs. 
 Substrate and Inhibitor Recognition by SaFabI  
32 
 
2.4.7 Branched-Chain Substrate Specificity 
What is the underlying biological significance of the structural variations we observed for the 
FabIs from Staphylococci and Bacilli? Notably, the membranes of Staphylococcus and Bacillus 
genera contain branched-chain fatty acids (BCFA) as a major component (86). In contrast, 
most other bacteria (86) predominantly synthesize straight-chain fatty acids (SCFA). For the 
more common SCFA family members, membrane fluidity is controlled by unsaturated fatty 
acids (UFA), whereas, for BCFA family members, 12-methyltetradecanoic acid (anteiso-C15) 
primarily fulfills this purpose (86). Thus, we speculated that the increased mobility of FabI 
from Staphylococci and Bacilli allows the preferential binding of branched-chain substrates. 
In addition to different straight-chain substrates (see Supplemental Results), we analyzed 
two branched-chain substrate analogues - trans-5-methyl-2-hexenoyl-CoA and (±)-trans-4-
methyl-2-hexenoyl-CoA, which contains the precursor analog to the anteiso fatty acids found 
predominantly in the S. aureus membrane (89). Among the first-round substrates (Figure 
2-1), the ratio of specificity constants is approximately 1:24:1 (straight = trans-2-butenoyl-
CoA : iso : anteiso) (Table 2-3), although the substrate specificity of the anteiso-substrate 
may be higher depending on the stereospecificity of the enzyme. Considering that FabI is the 
rate-limiting enzyme in the FAS II pathway (63), this ratio is likely to be physiologically 
significant in determining the composition of fatty acids synthesized and incorporated into 
the cell membrane. Moreover, since the pool of first-round substrates entering the FAS II 
cycle is generated by the branched-chain specific S. aureus FabH enzyme, the synthesis of 
BCFAs should be highly favored in this pathway (see Supplemental Results for further details) 
(57). To substantiate the relevance of this observation, we explored the branched-chain 
substrate specificity of the NADH-dependent FabI enzyme from the Gram-negative pathogen 
F. tularensis (ftFabI). The ratio of specificity constants (Table S 2-3) for the shortest chain 
substrates is approximately 800:72:1 (straight : iso : anteiso) and hence fundamentally 
different from saFabI. 
 
Table 2-3. Kinetic parameters for wild-type saFabI utilizing various trans-2-enoyl-CoA substrates. See also 
Figure S 2-1 and Table S 2-3. 
 Km,acyl-CoA (µM)1 kcat (min-1)1 kcat/Km,acyl-CoA (min-1 µM-1)
trans-2-butenoyl-CoA 1278.3 ± 120.2 40.1 ± 1.8 0.031 ± 0.003 
trans-2-hexenoyl-CoA 138.6 ± 18.8 588.3 ± 25.3 4.2 ± 0.6 
trans-2-octenoyl-CoA 20.7 ± 2.7 2645.4 ± 107.3 127.8 ± 17.5 
trans-2-decenoyl-CoA 29.1 ± 7.5 323.7 ± 29.5 11.1 ± 3.0 
trans-5-methyl-2-
hexenoyl-CoA (iso-) 
307.0 ± 41.5 172.9 ± 8.1 0.56 ± 0.08 
(±)-trans-4-methyl-2-
hexenoyl-CoA (anteiso-) 
599.2 ± 119.1 13.8 ± 1.2 0.023 ± 0.005 
 
1Km,acyl-CoA and kcat values were determined at a fixed NADPH concentration (350 µM) 
 
2.5 Discussion 
Our combined results clearly indicate that saFabI possesses distinct characteristics that 
markedly differentiate it from classical FabI enzymes, while exhibiting similarities to 
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Staphylococcus and Bacillus FabIs and FabL. We identified an RKXXS-motif, which is 
responsible for the preferential binding of NADPH to saFabI and most likely to FabI proteins 
of other Staphylococci and some Bacillus species. Our analysis also reveals a fundamental 
extension of the classical inhibitor binding mechanism including conformational changes in 
three regions and a dimer - tetramer transition upon cofactor and inhibitor binding that may 
also be applicable for FabI enzymes of related Staphylococcus and Bacillus species. The 
oligomeric transition is coupled to ligand binding and hence may provide the mechanistic 
underpinnings for the observed cooperativity upon substrate binding. Glutamate was shown 
to influence cofactor differentiation and to increase the activity of saFabI while reducing the 
cooperativity of substrate binding. Nevertheless, cooperativity was still observed at a 
physiologically relevant glutamate concentration, suggesting that glutamate may function as 
an intracellular metabolite that regulates enzyme activity (for further details see 
Supplemental Discussion and Figure S 2-5). 
In contrast to many other bacteria including Streptococci, the cell membranes of 
Staphylococcus and Bacillus species mainly comprise branched-chain fatty acids (85,86,88-
90,164). We propose that S. aureus FabI, as well as Bacillus FabI and FabL proteins, have 
evolved differently compared to classical FabI proteins to enable the production of BCFAs. 
The additional flexibility observed in the saFabI structures and other characterized Bacillus 
FabIs may play a role in altering the substrate specificity to accommodate the more bulky 
branched-chain substrates. Accordingly, Ser197 in saFabI, which links the two flexible 
substrate binding loops after ligand binding (Figure 2-5G), is conserved in Staphylococci, 
several Bacilli and some Listeria. Furthermore, we found that FabI enzymes capable of 
utilizing NADPH belong mostly to the BCFA family of organisms, however, the rationale 
behind this observation is currently not clear. To generate a membrane containing mostly 
branched-chain fatty acids, S. aureus and B. subtilis FabH enzymes are known to prefer 
branched-chain acyl-CoA primers instead of acetyl-CoA (Figure 2-1, Supplemental Results) 
(57,165). Our data clearly show that this preference is carried on in the FAS II cycle as the 
substrate specificity for the first-round branched-chain substrates relative to the first-round 
straight-chain substrate is markedly increased for saFabI compared to FabIs from organisms 
producing mainly SCFAs. 
Since BCFAs are known to be important for the in vivo fitness of S. aureus and Listeria 
monocytogenes (146,166), the requirement of some organisms for these fatty acids may 
explain the different susceptibility of Gram-positive bacteria to inhibitors of the fatty acid 
biosynthesis pathway. Importantly, only a minimal amount of BCFAs are present in the 
human and murine blood (1% of all plasma fatty acids in humans (147) and less than 1% in 
mice (167,168)). It is known that the modulation of membrane lipids enables bacteria to 
survive under distinct stress situations (146). Even though both types of fatty acids serve to 
increase the fluidity of the membrane bilayer, the structural and morphological membrane 
characteristics differ for BCFAs and UFAs (169). Hence, compared to UFAs, supplementing 
with BCFAs did not confer the same level of fitness to E. coli UFA auxotrophs in response to 
cold stress (170). Similarly, other evidence suggests that S. aureus and L. monocytogenes 
fitness is reduced in the absence of BCFAs. The survival of branched-chain α-ketoacid 
dehydrogenase (BKD) deficient mutant strains in murine animal models was significantly 
reduced (146,166). Nevertheless, future experiments should clarify whether the defined 
composition of the human blood lipid pool, comprising mainly SCFAs and UFAs, can fulfill the 
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in vivo survival and virulence requirements of Staphylococci and other BCFA family members 
(90,147). 
As the essentiality of the FAS II pathway for S. aureus infection in vivo is re-validated, a 
detailed structural and kinetic characterization of targets within the pathway becomes 
increasingly relevant. FabI is one such target, which has spurred many inhibitor discovery 
efforts. We have shown that the drug target FabI in S. aureus and closely related pathogens 
differs from its homologous proteins with respect to cofactor and substrate specificity, 
cofactor/inhibitor binding and quaternary structure. Knowledge of these differences, as well 
as the structures solved here and in similar studies, can aid in the development of antibiotics 
specifically targeting FabI enzymes from the important human pathogens S. aureus, S. 
epidermidis, B. anthracis and B. cereus, which all synthesize branched-chain fatty acids. 
Remarkably, three saFabI inhibitors are in phase I clinical trials since 2009, providing 
substantial hope for new MRSA drugs (103). 
2.6 Experimental Procedures 
2.6.1 Cloning, Expression and Purification 
We optimized the saFabI purification protocol with respect to plasmid usage, E. coli 
expression strain, cultivation and buffer composition (see Supplemental Experimental 
Procedures for further details) based on previously described procedures (78,144). A 
detailed description of the protocols is provided in Table S 2-4. FtFabI was prepared as 
described previously (46). 
2.6.2 Site-directed Mutagenesis, Expression and Purification of SaFabI 
Mutants 
Site-directed mutagenesis was performed using the QuikChange Mutagenesis Kit from 
Stratagene to add a single point mutation (S44L) to the previously constructed saFabI 
R40Q/K41N mutant (primers: 5’-ACCAGAACGAACGTCTGCGTAAAGAGCTTGAA-3’ and 5'-
TTCAAGCTCTTTACGCAGACGTTCGTTCTGGT-3') (78). The sequence of saFabI 
R40Q/K41N/S44L was confirmed by DNA sequencing. Expression and purification of the 
double and triple mutant was performed as described in Table S 2-4. 
2.6.3 Crystallization, Data Collection and Structure Determination 
Prior to co-crystallization utilizing the vapor diffusion method, purified saFabI was incubated 
for 2 h at 4 °C with a 10-fold molar excess of NADP+ (100 mg/ml stock solution in water) and 
a 20-fold molar excess of the respective inhibitor supplemented as solid powder or dissolved 
in DMSO (for the P1 structures, 100 mg/ml stock solutions), respectively. The complexes 
were crystallized by the hanging drop vapor diffusion method using different precipitants 
(see Supplemental Experimental Procedures). Diffraction data of the flash-frozen crystals 
were collected at BESSY II (Berlin) or the ESRF (Grenoble), respectively. All structures were 
solved by molecular replacement with baFabI (2QIO) as the initial search model (see 
Supplemental Experimental Procedures and Table S 2-1 and Table S 2-2 for further details). 
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2.6.4 Analytical Size Exclusion Chromatography 
SaFabI was dialyzed into a buffer containing 20 mM Tris pH 8.0 and 200 mM NaCl. Equal 
sample volumes were applied to a calibrated 10/300 Superdex 200 GL column (GE 
Healthcare) pre-equilibrated with dialysis buffer. Prior to analytical SEC the protein (5 
mg/ml) was supplemented with a 10-fold molar excess of NADP+, NADPH or an equal volume 
of water and a 20-fold molar excess of TCL (100 mg/ml stock solution in DMSO) or an equal 
volume of DMSO, respectively. All four samples (apo, NADP+, NADPH and NADP+/TCL) were 
incubated at 20 °C for 2 h. Experiments were performed in triplicate and the peak shift 
confirmed for a different protein batch at pH 8.0 (Figure S 2-3B). Additionally, one saFabI 
sample was analyzed at pH 5.6 in 20 mM trisodium citrate pH 5.6, 500 mM NaCl and 100 mM 
EDTA (Figure S 2-3A). 
2.6.5 Synthesis of trans-2-enoyl-CoA Substrates 
Trans-5-methyl-2-hexenoic acid and (±)-trans-4-methyl-2-hexenoic acid were synthesized 
from isovaleraldehyde (Sigma-Aldrich) and (±)-2-methylbutyraldehyde (Sigma-Aldrich), 
respectively, via a Horner-Wadsworth-Emmons reaction with methyl 
(triphenylphosphoranylidene)acetate, as described previously (171). 
Trans-2-enoyl-CoA substrates were synthesized from their respective trans-2-enoic acid 
using the mixed anhydride method (160). Products were characterized by electrospray 
ionization mass spectrometry. Trans-2-butenoyl-CoA was purchased from Sigma-Aldrich. 
2.6.6 Steady-state Kinetic Assays 
Kinetic experiments were performed on a Cary 100 spectrophotometer (Varian) at 20°C in 
50 mM potassium phosphate, 150 mM NaCl and 1 M potassium glutamate pH 7.5 containing 
8% glycerol (v/v) and 0.1 mg/mL bovine serum albumin (BSA). Reaction velocities were 
measured by monitoring the oxidation of NAD(P)H to NAD(P)+ at 340 nm (ε = 6220 M-1 cm-1). 
Kinetic parameters for saFabI were determined by measuring initial velocities at varying 
concentrations of one substrate, holding the other substrate concentration constant (for 
further details see Supplemental Experimental Procedures). 
2.6.7 Inhibition Kinetics 
Progress curves were used to determine the steady-state inhibition of saFabI by the slow-
onset inhibitors TCL, EPP and CPP. The final reaction mixture contained saFabI (100 nM), 
trans-2-butenoyl-CoA (1.5 mM), NADPH (350 µM), NADP+ (400 µM) and inhibitor (2% v/v 
DMSO). Ki*,app values, corresponding to the final steady-state inhibition following slow 
isomerization of the initial enzyme-inhibitor complex, were determined by plotting the 
fractional steady-state velocities as a function of inhibitor concentration and fitting to the 
standard isotherm equation (Equation 1). 
vs
vu
=
1
1+ [I]
Ki
*,app
     (1) 
where vu is the initial velocity of the uninhibited reaction (for further details see 
Supplemental Experimental Procedures). 
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2.7 Accession Numbers 
The coordinates and structure factors of saFabI in its unliganded form (space groups P32 and 
P43212) as well as in complex with NADP+ and triclosan (space groups P212121 and P1), CPP or 
EPP have been deposited in the PDB with the codes 4ALN, 4ALM, 4ALL, 4ALI, 4ALJ and 4ALK, 
respectively. 
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2.9 Supplemental Information 
2.9.1 Supplemental Data 
 
Figure S 2-1, related to Figure 2-1. Substrate and inhibitor structures. The chemical structures of the saFabI 
substrates and inhibitors, which were analyzed in this study, are shown. 
 
 
Figure S 2-2, related to Figure 2-2. Inhibitor and cofactor electron densities. (A-C) 2Fo-Fc omit maps of triclosan 
(CPP, EPP) and NADP+ in the TCL-2 (CPP, EPP) structure (subunit H) contoured at one time the standard 
deviation of the mean electron density. 
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Figure S 2-3, related to Figure 2-6. Quaternary structure of saFabI in solution. (A) Dimeric and tetrameric 
structure of saFabI. Overlay of two different analytical SEC chromatograms using buffers at pH 5.6 (20 mM 
trisodium citrate pH 5.6, 500 mM NaCl and 100 mM EDTA) shown in red, or at pH 8.0 (20 mM Tris pH 8.0 and 
200 mM NaCl) shown in blue, respectively. (B) Dimer - tetramer transition. Four different analytical SEC 
chromatograms and the respective cropped SDS-PAGE gel bands for the peak fractions (elution volumes of 14.0 
and 16.0 ml) running at the same height (~33 kDa, calculated monomeric saFabI molecular mass is 31 kDa) are 
shown with apo saFabI in black, and saFabI treated with NADP+, NADPH or NADP+ and TCL in red, orange or 
blue, respectively. The front peak corresponds to a molecular mass of 131 kDa, the middle peak to 47 kDa. 
Excess of unbound NADP+ and NADPH elutes at 19.8 ml. 
 
 
 
Figure S 2-4, related to Figure 2-5. Active site formation. Superposition of the apo-2 (blue, subunit A) and TCL-
2 (yellow) structures. All three active site residues are depicted as stick representations for both structures. TCL 
and NADP+ are shown in grey. The three active site residues (Tyr147, Tyr157, Lys164) move significantly upon 
cofactor and inhibitor binding. Tyr147 is shifted by ~5 Å out of the nicotinamide binding pocket whereas Tyr157 
rotates about 130° towards the TCL hydroxyl group (70,144). At the same time, the 80° rotation of Lys164 
allows the correct placement of the cofactors nicotinamide ring (70). 
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Figure S 2-5, related to Figure 2-6. Cooperativity of substrate binding to saFabI. Reaction velocities with 22 
nM saFabI are plotted as a function of substrate concentration, holding the other substrate concentration 
constant. (A) In the absence of potassium glutamate, cooperative binding of NADPH at 100 µM trans-2-
octenoyl-CoA can be observed. To approximate the Hill coefficient (h) despite the truncated data set, best-fit 
curves to h = 1, 2, 3 and 4 are displayed. Note that h = 2.2 was previously reported for the binding of NADPH to 
saFabI (108). (B) In the presence of 1 M potassium glutamate, h = 0.9 ± 0.1 for the binding of NADPH at 100 µM 
trans-2-octenoyl-CoA. (C) In the absence of potassium glutamate, h = 2.3 ± 0.3 for the binding of trans-2-
octenoyl-CoA at 350 µM NADPH (R2 = 0.99). (D) In the presence of 250 mM, 500 mM and 1 M potassium 
glutamate, h = 2.4 ± 0.4, 1.4 ± 0.3 and 1.1 ± 0.3, respectively, for the binding of trans-2-octenoyl-CoA at 350 
µM NADPH (R2 = 0.99 for each curve-fit). In addition, note the rise in Vmax as the concentration of glutamate 
increases. (E) Potential glutamate binding site. The ambiguous density of the 2Fo-Fc omit map (CPP structure, 
subunit G) contoured at one time the standard deviation of the mean electron density is shown between 
Arg103 located on SBL-2 (cyan) and Asn205 located on SBL (red). The remainder of the protein is omitted for 
clarity. 
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Table S 2-1, related to Experimental Procedures. Data collection and refinement statistics (apo structures). 
 Apo-1 Apo-2
Data collection 
Cell dimensions 
a, b, c (Å) 123.8, 123.8, 190.1 87.5, 87.5, 307.2
α, β, γ (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0
Space group P32 P43212
Resolution1 (Å) 50.0-3.05 (3.20-3.05) 50.0-2.45 (2.60-2.45) 
Observed reflections 160,521 (21,802) 319,536 (52,121)
Unique reflections 61,623 (8,296) 44,583 (7,185)
Completeness (%) 99.3 (99.7) 98.9 (99.8)
Average redundancy 2.6 (2.6) 7.2 (7.3)
Rmerge2 (%) 11.7 (49.9) 8.8 (78.0)
<I / σ(I)> 6.8 (2.1) 16.4 (2.8)
Monomers per AU 12 4
Refinement 
Resolution (Å) 44.3-3.05 48.2-2.45
Rcryst3 (%) 20.3 18.5
Rfree (%) 24.6 25.1
Twin fraction 0.33 -
Number of atoms 20,062 7,820
rmsd bond lengths (Å) 0.015 0.007
rmsd bond angles (°) 1.482 0.980
Average B-factor (Å2) 67.1 62.9
Ramachandran-plot4 
Favored (%) 91.5 96.7
Allowed (%) 7.9 3.1
Outliers (%) 0.6 0.2
Maximum likelihood based 
estimated coordinate error 
(Å) 
0.28 0.30
PDB code 4ALN 4ALM
 
1Values in parenthesis refer to the highest resolution shell 
2  −=
hkl i
i
hkl i
imerge IIIR  
3  −=
hkl
obs
hkl
calcobscryst FFFR  
4According to Molprobity (172) 
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Table S 2-2, related to Experimental Procedures. Data collection and refinement statistics (ternary complex 
structures). 
 TCL-1 TCL-2 CPP EPP 
Data collection   
Cell dimensions   
a, b, c (Å) 83.5, 111.9, 111.6 90.0, 94.8, 94.9 90.2, 94.8, 94.8 90.2, 95.1, 95.3 
α, β, γ (°) 90.0, 90.0, 90.0 98.1, 112.0, 97.3 98.0, 112.4, 97.4 98.2, 112.3, 97.3
Space group P212121 P1 P1 P1 
Resolution1 (Å) 42.9-2.80 (2.95-2.80) 38.5-2.10 (2.21-2.10) 49.1-2.20 (2.32-2.20) 49.3-1.90 (2.00-1.90)
Observed reflections 119,875 (17,343) 640,244 (92,983) 249,699 (35,984) 427,322 (63,042)
Unique reflections 22,827 (3,361) 161,229 (23,385) 135,192 (19,491) 206,602 (30,427)
Completeness (%) 87.2 (89.6) 97.8 (97.0) 94.4 (93.2) 92.1 (92.6) 
Average redundancy 5.3 (5.2) 4.0 (4.0) 1.8 (1.8) 2.1 (2.1) 
Rmerge2 (%) 15.3 (35.7) 14.1 (84.3) 8.2 (34.8) 6.9 (40.4) 
Rpim3 (%) 6.8 (16.2) 8.2 (48.8) 8.2 (34.8) 6.4 (38.0) 
<I / σ(I)> 6.5 (2.5) 8.0 (2.0) 5.9 (1.9) 6.4 (2.0) 
Monomers per AU 4 8 8 8 
Refinement   
Resolution (Å) 79.0-2.80 38.5-2.10 49.1-2.20 40.9-1.90 
Rcryst4 (%) 21.4 14.9 15.8 15.0 
Rfree (%) 26.2 19.8 21.9 19.3 
Twin fraction - - - - 
Number of atoms 8,101 18,131 17,947 18,573 
rmsd bond lengths (Å) 0.013 0.013 0.012 0.015 
rmsd bond angles (°) 1.591 1.839 1.788 1.767 
Average B-factor (Å2) 66.4 31.3 47.7 30.1 
Ramachandran-plot5   
Favored (%) 96.2 96.3 96.8 97.0 
Allowed (%) 3.6 3.6 3.2 3.0 
Outliers (%) 0.2 0.1 0.0 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 
0.38 0.12 0.14 0.09 
PDB code 4ALL 4ALI 4ALJ 4ALK 
 
1Values in parenthesis refer to the highest resolution shell 
2  −=
hkl i
i
hkl i
imerge IIIR  
3 ( )[ ]   −−=
hkl i
i
hkl i
ipim IIINR
2/111  (173) 
4  −=
hkl
obs
hkl
calcobscryst FFFR  
5According to Molprobity (172) 
 
 
Table S 2-3, related to Table 2-3. Kinetic parameters for ftFabI utilizing NADH and various trans-2-enoyl-CoA 
substrates. 
 Km (µM) kcat (min-1) kcat/Km,acyl-CoA (min-1 µM-1) 
trans-2-butenoyl-CoA 353 ± 5 1140 ± 60 3.2 ± 0.2 
trans-2-octenoyl-CoA 33.3 ± 0.4 1200 ± 60 36.0 ± 1.9 
trans-2-decenoyl-CoA 11.2 ± 0.8 1260 ± 60 112.5 ± 9.7 
trans-2-dodecenoyl-CoA 1.7 ± 0.1 1200 ± 60 705.9 ± 54.5  
trans-5-methyl-2-hexenoyl-
CoA (iso-) 
  0.287 ± 0.0071 
(±)-trans-4-methyl-2-
hexenoyl-CoA (anteiso-) 
  0.0040 ± 0.00021 
NADH 18.8 ± 0.6 1140 ± 60 60.0 ± 6.0 
 
1Estimated based on linear slope of the Michaelis-Menten plot at low [NADH] 
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Table S 2-4, related to Experimental Procedures. Details of the saFabI purification protocols.* 
 A B C D E 
Plasmid pET-16b(+) pETM-11 pETM-112 pETM-11 pETM-11 
E. coli strain BL21 (DE3) pLysS BL21 (DE3) BL21 (DE3) BL21 (DE3) BL21 (DE3) 
antibiotics 100 µg/ml 
ampicillin and 34 
µg/ml 
chloramphenicol 
50 µg/ml 
kanamycin 
50 µg/ml 
kanamycin2 
50 µg/ml 
kanamycin 
50 µg/ml 
kanamycin 
cultivation 
temperature, 
time 
28 °C, 5 h 18 °C, 18 h 18 °C, 18 h2 18 °C, 18 h 18 °C, 18 h 
lysis buffer 50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl 
50 mM Tris-HCl 
pH 8.0, 200 mM 
NaCl, 2 mM β-
mercaptoethanol, 
5% glycerol 
wash buffer 50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl, 10 mM 
imidazole 
50 mM Tris-HCl 
pH 8.0, 1 M NaCl 
50 mM Tris-HCl 
pH 8.0, 1 M NaCl2 
50 mM Tris-HCl 
pH 8.0, 1 M NaCl 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl, 2 mM β-
mercaptoethanol, 
5% glycerol 
elution buffer 100 mM 
trisodium citrate 
pH 5.6, 500 mM 
NaCl, 100 mM 
EDTA 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl, 250 mM 
imidazole 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl, 250 mM 
imidazole 
50 mM Tris-HCl 
pH 8.0, 500 mM 
NaCl, 250 mM 
imidazole 
50 mM Tris-HCl 
pH 8.0, 200 mM 
NaCl, 2 mM β-
mercaptoethanol, 
5% glycerol, 250 
mM imidazole 
TEV cleavage no yes1 no no no 
storage buffer 20 mM trisodium 
citrate pH 5.6, 
500 mM NaCl, 
100 mM EDTA 
20 mM trisodium 
citrate pH 5.6, 
500 mM NaCl, 
100 mM EDTA 
20 mM trisodium 
citrate pH 5.6, 
500 mM NaCl, 
100 mM EDTA3 
20 mM trisodium 
citrate pH 5.6, 
280 mM NaCl, 1 
mM EDTA, 280 
mM K-glutamate 
25 mM Tris-HCl 
pH 8.0, 200 mM 
NaCl, 1 mM DTT 
final 
concentration 
9.8 mg/ml (0.32 
mM) 
38.6 mg/ml (1.24 
mM) 
13.0 mg/ml (0.42 
mM) 2,3 
15.0 mg/ml (0.48 
mM) 
15.2 mg/ml (0.49 
mM) 
 
1After Ni2+ affinity chromatography the protein sample was incubated with TEV-protease in 50 mM Tris pH 8.0 
and 500 mM NaCl at 4 °C for 10 h, yielding a 50% removal of the His6-tag. Subsequently, the sample was re-
applied to Ni-TED followed by size exclusion chromatography as described above. 
 
2Alternatively (C'), the saFabI mutants were expressed and purified (final concentrations of 1.0 mg/ml) using 
the pET-16b(+) plasmid, 100 µg/ml ampicillin, a cultivation temperature of 25 °C and the wash buffer described 
in procedure A. 
 
3Alternatively (C''), the storage buffer of the pooled SEC-fractions was exchanged to 20 mM trisodium citrate 
pH 5.6, 150 mM NaCl and 1 mM EDTA before concentrating to 8.5 mg/ml (0.27 mM). 
 
*In general, the procedure described in the Supplemental Experimental Procedures was applied to obtain ≥ 
95% pure saFabI protein. The crystals leading to the TCL-1, apo-1 and apo-2 structures were obtained using 
purifications A, B or C'', respectively. For the EPP, TCL-2 and CPP complex structures a FabI batch was used 
which was obtained by procedure D. The analytical size exclusion chromatography experiments were 
performed with protein batches E and C. The double and triple mutants were purified applying procedure C'. 
 
Movie S 2-1, related to Figure 2-5. Ordering of the substrate binding loop region. This model is based on the 
TCL-2 structure (one monomer is shown in cyan, TCL in yellow and NADP+ in green). Helix α7 was rearranged in 
PyMol according to the different geometries of the apo-2 structure. The motion of helix α7 was visualized by 
interpolating between these different arrangements. The loop region between α7 and α8 was omitted for 
clarity (the associated termini are shown in red). The initial states of the SBL (shown in green), cofactor and 
inhibitor were not obtained directly in our apo structures. Conformational changes in additional regions (SBL-2 
and ASL) were omitted in the animation. This animation was prepared using PyMol, VirtualDub and Xvid (174). 
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Movie S 2-2, related to Figure 2-6. Dimer - tetramer transition. This animation was prepared using the 
structures 3GNT, 3GNS, apo-1, apo-2 and TCL-2. One dimer is shown in blue, the other in red. All structures 
were superimposed using the lower left monomer. LSQMAN was used to interpolate between Cα positions of 
consecutive structure pairs for the amino acids which were ordered in both structures (148). Cα traces of these 
consecutive states were visualized using PyMol, VirtualDub and Xvid (174). 
2.9.2 Supplemental Results 
2.9.2.1 Inhibition Kinetics 
Based on the relative Ki*,app measurements, the gain in affinity from the additional buried 
surface area (BSA) for the inhibitors CPP and EPP (BSATCL = 72.9%, BSACPP = 74.7%, BSAEPP = 
76.2%) does not completely compensate for the loss of the halogen bond observed for TCL 
(Table 2-1 and Figure 2-4). The relative affinities of the diphenyl ether analogues for saFabI 
increase in the order CPP < EPP < TCL. Ki*,app includes the affinity of the more potent 
enzyme-inhibitor complex (E-I*) formed following slow isomerization of the initial, rapid-
reversible enzyme-inhibitor complex (E-I; affinity described by Kiapp), according to a two-step 
slow-binding mechanism of inhibition. Since saFabI exhibited greatly improved activity and 
stability in the presence of glutamate (see Supplemental Discussion), we were able to 
perform a more reliable progress curve-based analysis of steady-state inhibition as 
compared to previous studies (78,108). 
2.9.2.2 Reduction of Straight-chain Substrates by SaFabI 
Among the straight-chain fatty acyl substrates, we observed an increase in the specificity 
constant as the chain length increases from 4 to 8 carbons (Table 2-3), consistent with 
previous results noting a preference for longer chain substrates in the case of S. aureus FabI 
(78). However, in contrast to other FabI homologues, the specificity constant decreases 
beyond a chain length of 8 carbons. These variations are driven by both an increase in kcat 
and a decrease in Km, as opposed to ftFabI (Table S 2-3) and ecFabI, where changes in 
straight-chain substrate specificity are driven primarily by changes in Km (107,175). 
2.9.2.3 Substrate Specificity of SaFabI 
The ratio of specificity constants amongst the first-round straight- and branched-chain 
substrates of saFabI was approximately 1:24:1 (straight : iso : anteiso) (Table 2-3). Since the 
ratio of velocities vX : vY for competing substrates SX and SY is equal to the ratio of [SX] 
kXcat/KXm to [SY] kYcat/KYm, the available substrate pool also determines the membrane fatty 
acid composition (176). FabH, which catalyzes the initial condensation reaction in the FAS II 
pathway, controls the pool of substrates that enter the FAS II cycle (Figure 2-1). Accordingly, 
S. aureus and B. subtilis FabH exhibit a preference for branched-chain acyl-CoA primers over 
the typical acetyl-CoA primer (57,165). Since the S. aureus membrane is composed mostly of 
anteiso-C15 fatty acids (89), our results are consistent with the current thought that FabH is 
the main determining factor in branched-chain fatty acid biosynthesis. For the SCFA family of 
organisms, FabH tends to prefer the acetyl-CoA primer, resulting in a smaller pool of 
available branched-chain substrates (57). Although FabIs from these organisms are capable 
of utilizing branched chain (iso-) substrates (165,177), the relative rate of BCFA substrate 
reduction catalyzed by SCFA FabIs like ftFabI is much lower than for the BCFA family member 
saFabI (Table S 2-3). Thus, as expected, the pool of substrates and specificity constants both 
heavily favor the synthesis and incorporation of straight-chain fatty acids by this organism. 
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2.9.3 Supplemental Discussion 
2.9.3.1 Glutamate Sensitivity 
We investigated the glutamate sensitivity of saFabI as glutamate is known to be present at 
high intracellular concentrations (> 100 mM) in Gram-positive organisms, such as S. aureus, 
and has been found to increase the in vitro activity of S. aureus gyrase and topoisomerase IV 
(158,159). Glutamate markedly improved the catalytic activity of saFabI (~5-fold for 1 M 
potassium glutamate, ~4-fold for 500 mM potassium glutamate), such that the maximum kcat 
obtained was similar to other FabI homologues with CoA-based substrates (kcat > 500 min-1; 
Table 2-3) (78,107,108,160,175). In contrast, the catalytic activity of ftFabI is unaffected by 
glutamate. The reaction velocity of 25 nM ftFabI with 10 µM oct-CoA and 250 µM NADH was 
11.25 µM/min both in the presence and absence of 1 M glutamate. To screen for salt effects, 
we performed single-point reaction velocity measurements. Unlike the S. aureus gyrase and 
topoisomerase IV enzymes (159), the activation of saFabI by glutamate is not cation-specific 
though K+ is slightly preferred over Na+. Among the anions tested, glutamate provided the 
greatest rate enhancement. At 50 nM saFabI with 30 µM oct-CoA and 200 µM NADPH, the 
reaction velocities relative to sodium glutamate were 0, 0.16, 0.22, 0.49 with sodium 
chloride, sodium aspartate, sodium acetate and sodium ADA, respectively. Thus, 
enhancement of activity is not a general salt effect but appears to be mediated by a 
carboxylate motif. Interestingly, there is evidence of this effect in the literature. To avoid 
protein precipitation, previous saFabI purification protocols required buffers containing 100 
mM EDTA (78,108). Furthermore, some saFabI inhibition assays were performed in the 
presence of 100 mM sodium ADA pH 6.5 (50). 
Notably, there is a physiological link between glutamate and BCFA synthesis - the first step of 
BCFA biosynthesis is the transamination of branched-chain amino acids to α-ketoglutarate, 
forming the corresponding α-keto acid and glutamate (Figure 2-1) (56). We have shown that 
glutamate not only enhances enzyme activity but also affects the cofactor specificity as well 
as the cooperativity of substrate binding (Figure S 2-5). In fact, the dimer-tetramer transition 
may provide a mechanism of regulation by glutamate or similar metabolites. Based on 
ambiguous densities in the saFabI P1 crystal structures (Figure S 2-5E) obtained in the 
presence of the saFabI-stabilizing anions glutamate, citrate and EDTA which share the 
glutaric acid motif, a potential glutamate binding site is located between Arg103 of SBL-2 
and Asn205 of SBL. Molecules occupying this site could interconnect the SBLs, thereby 
enhancing substrate binding and stabilizing the tetrameric state. However, future 
experiments should clarify the role of glutamate and similar metabolites for saFabI 
functioning in vivo. 
2.9.4 Supplemental Experimental Procedures 
2.9.4.1 Cloning 
SaFabI from the S. aureus strain NCTC 8325 was purified using the safabINCTC8325:pET-16b(+) 
plasmid (78). We also amplified the same safabI gene from S. aureus strain N315 via PCR 
(originating from safabIN315:pET-16b(+)) and cloned it into pETM-11 (EMBL) using the NcoI 
and HindIII (New England Biolabs) restriction sites (primers: 5‘-
CGAAGGTCGTCCCATGGTAAATCTTGAAAAC-3‘ and 5'-CCAATAACGTGAACAAAGCTTCTGAATG-
3' (Biomers)). The saFabI isoform from S. aureus NCTC 8325 was used only for kinetic 
 Substrate and Inhibitor Recognition by SaFabI  
44 
 
experiments. It differs from the S. aureus N315 isoform by a single amino acid (G191S). 
Although residue 191 is positioned in close proximity to the nicotinamide ring of NADPH, the 
Km of saFabI-G191 with respect to NADPH was identical to that reported previously under 
similar assay conditions for saFabI-S191 (78). 
2.9.4.2 Expression and Purification 
E. coli BL21 (DE3) bacteria (Novagen) containing the safabI:pETM-11 plasmid were grown in 
Luria-Bertani (LB) medium (Lennox) supplemented with 50 µg/ml kanamycin at 37 °C. After 
induction with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) at an OD600 nm of 0.6 
the temperature was reduced to 18 °C. Cells were harvested after 18 hours post-induction, 
resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl) and lysed through a cell 
disruptor at 1.5 kbar. The lysate was centrifuged at 50,000 g and the supernatant loaded 
onto a Protino Ni-TED column (Macherey-Nagel). After washing (50 mM Tris-HCl pH 8.0, 1 M 
NaCl), the protein was eluted (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 250 mM imidazole). A 
buffer exchange with PD-10 desalting columns (Amersham Biosciences) was followed by size 
exclusion chromatography (SEC) on a HiLoad 26/60 Superdex 200 pg column (GE Healthcare) 
pre-equilibrated with storage buffer (20 mM trisodium citrate pH 5.6, 280 mM NaCl, 1mM 
EDTA, 280 mM potassium glutamate). Protein containing fractions were pooled and 
concentrated to 15 mg/ml prior to shock-freezing in liquid nitrogen and storage at -80 °C. For 
further details see also Table S 2-4 (this protocol refers to procedure D in Table S 2-4). 
2.9.4.3 Crystallization, Data Collection and Structure Determination 
In a vapor diffusion experiment containing equal amounts of protein and precipitant solution 
(0.1 M K/Na-phosphate pH 6.5, 35% 2-methyl-2,4-pentanediol (MPD)), a single TCL-1 crystal 
(nomenclature according to Table S 2-2) of space group P212121 grew within 3 weeks. 
Diffraction data of the directly flash-frozen crystal were collected to 2.8 Å at the MX 
beamline 14.1 at BESSY II (Berlin) utilizing a MarMosaic 225 detector (λ = 0.976 Å, T = 100 K). 
Data were processed with iMosflm (178) and Scala (179). Phases were determined with 
Phaser (180) by molecular replacement using the FabI structure of B. anthracis (PDB code: 
2QIO:A) as search model (6). Alternate cycles of maximum likelihood refinement and model 
building were performed in Refmac 5 (181) and Coot (Table S 2-2) (182). Refinement was 
improved with the implementation of TLS-refinement and NCS-restraints excluding Met99. 
After the first rounds of refinement triclosan, NADP+ and water molecules were included 
into the model according to the Fo-Fc map. 
Rod-shaped apo-1 crystals of space group P32 were obtained in a vapor diffusion setup using 
0.61 M NH4H2PO4, 9% t-butanol, 0.01 M EDTA pH 7.0 as precipitant. For data collection at ID 
29 (λ = 0.919 Å, T = 100 K) of the European Synchrotron Radiation Facility (ESRF, Grenoble) 
the crystals were briefly transferred into cryoprotectant solution (0.61 M NH4H2PO4, 9% t-
butanol, 0.01 M EDTA pH 7.0, 25% glycerol) and cryocooled in liquid nitrogen. After data 
processing with XDS (183), twinning was detected using Phenix.xtriage (184). Phaser 
molecular replacement was performed with the TCL-1 structure omitting regions 95-108, 
149-158 and 190-221 of the protein as well as all small molecules. To avoid model bias due 
to high non-crystallographic symmetry (12 molecules per asymmetric unit) and twinning, 
Rfree flags were assigned in 20 thin resolution shells. Model building in Coot was alternated 
with a combined refinement using Phenix.refine (185) and Refmac 5 (Table S 2-1). As no 
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additional electron density for the cofactor and inhibitor was observed, this structure is 
referred to as the apo-form. 
Cube-shaped apo-2 crystals of space group P43212 grew in 1.15 M (NH4)2SO4, 0.1 M sodium 
acetate pH 5.0, 1% ethanol as precipitant in a vapor diffusion experiment. Crystals were 
cryocooled (30% glycerol) and diffraction data were collected to 2.45 Å at beamline ID 29 
(ESRF) using an ADSC Quantum Q315r detector (λ = 0.919 Å, T = 100 K). Data were analyzed 
as described for the apo-1 structure and refined (including TLS refinement) with 
Phenix.refine (Table S 2-1). As in the case of apo-1, no interpretable cofactor or inhibitor 
density was present. 
Ternary saFabI-NADP+-EPP crystals were obtained with 0.1 M K/Na-phosphate pH 6.5 and 
36% MPD as precipitant. Data were collected with an ADSC Quantum Q315r detector at 
beamline ID 14-4 (ESRF, λ = 0.980 Å, T = 100 K) and were processed to 1.9 Å using iMosflm 
and Scala. Molecular replacement was performed with Phaser using the TCL-1 structure 
lacking all small molecules as search model. Refinement (including TLS refinement (186)) and 
model building were performed using Refmac 5 and Coot (Table S 2-2). NADP+ and EPP were 
included in the model (187) after molecular replacement and initial refinement. Additionally, 
the Fo-Fc map indicated an alternative conformation of the amino acid stretch 99-105. The 
second conformation was modeled for all subunits with clear densities for this feature. 
A vapor diffusion experiment with TCL-treated saFabI protein and a similar precipitant 
solution (0.1 M K/Na-phosphate pH 6.5 and 38% MPD) resulted in TCL-2 crystals of space 
group P1. Diffraction data were collected to 2.1 Å at beamline 14.1 (BESSY II) using a 
MarMosaic 225 detector (λ = 0.918 Å, T = 100 K) and processed with iMosflm and Scala. The 
EPP structure without alternative conformations served as a search model for molecular 
replacement in Phaser. Refmac 5 and Coot were used for refinement (including TLS 
refinement) and model building (Table S 2-2). 
Similarly, CPP crystals of saFabI were grown with a precipitant solution containing 0.1 M 
K/Na-phosphate pH 6.5 and 35% MPD. Diffraction data of a directly cryocooled crystal were 
collected at beamline ID 29 (ESRF) with a PILATUS 6M detector (λ = 0.976 Å, T = 100 K). 
Indexing and integration were performed with the XDS package. Scala was used for scaling. 
Structure determination and refinement followed the procedure as described for TCL-2 
(Table S 2-2). 
As saFabI crystallized in space group P1 with similar cell parameters for the different 
inhibitors, comparability is warranted (Table S 2-2). For further analysis we used the subunits 
H of the different structures which display no significant crystal contacts at the active site 
and therefore approximate the natural state in solution despite the increased flexibility that 
results in weaker electron densities. Distances and angles were measured for all subunits 
and are given as mean values ± standard deviations. 
To avoid model bias, omit maps were calculated directly after molecular replacement and an 
initial refinement prior to inclusion of any small molecule (Figure S 2-2). All structural figures 
were prepared with PyMol (174). 
2.9.4.4 Steady-state Kinetic Assays 
Kinetic parameters for the wild-type saFabI catalyzed reduction of trans-2-octenoyl-CoA 
(oct-CoA) using NADPH were determined by varying the concentration of oct-CoA at several 
fixed concentrations of NADPH. Previous mechanistic studies suggest that saFabI catalyzes 
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its reaction via an ordered Bi Bi mechanism with the fatty acyl substrate binding first (78). 
However, our structural studies suggest that NADP+ likely binds first, followed by the 
inhibitor. We believe this extends to substrate binding with NADPH binding before the fatty 
acyl substrate, in accordance with other FabI homologues. Thus, the data were fitted to 
equations 2 and 3, assuming an ordered Bi Bi system with NADPH binding first. Kinetic 
parameters for saFabI R40Q/K41N/S44L using oct-CoA and NADH were determined in the 
same way. The exact Km,NADH and Km,NADPH values for the wild-type enzyme and triple mutant, 
respectively, could not be accurately calculated because of the maximum usable absorbance 
range of the UV/VIS instrument. Instead, the specificity constants were estimated via the 
linear slope of the Michaelis-Menten plot at low NAD(P)H concentrations and saturating 
acyl-CoA substrate. 
Vmax
app
=
Vmax[NADPH]
Km,NADPH + [NADPH]
    (2) 
 
Km,oct −CoA
app
=
Ki,NADPHKm ,oct−CoA +Km,oct −CoA [NADPH ]
Km ,NADPH + [NADPH ]
  (3) 
 
To compare kinetic parameters for wild-type saFabI using various fatty acyl-CoA substrates, 
initial velocities were plotted as a function of fatty acyl substrate concentration [S] at a fixed 
concentration of NADPH (350 µM). These data were fit to the ordered Bi Bi velocity equation 
(Equation 4). In the case of oct-CoA, Km,Sapp remained constant at varying NADPH 
concentrations, which indicates that Km,NADPH with this substrate approximates the actual 
value of Ki,NADPH. By the definition of kinetic constants in an ordered Bi Bi system, Km,NADPH 
decreases when utilized with fatty acyl substrates exhibiting lower enzyme kcat values. Since 
most fatty acyl substrates exhibit a lower kcat than oct-CoA, we are confident that the true 
values of Vmax and Km for these substrates were determined at 350 µM NADPH. 
v =
Vmax[NADPH][S]
Ki,NADPHKm,S +Km,S[NADPH]+Km,NADPH[S]+ [NADPH][S]
  (4) 
 
To test for cooperative binding of substrate to saFabI, data were fit to a Hill plot (Equation 
5). 
v = Vmax[S]
h
K '+[S]h
       (5) 
Kinetic experiments with ftFabI were conducted as described previously (46). All plots and 
curve-fits were generated using KaleidaGraph 4.1. 
2.9.4.5 Inhibition Kinetics 
The assay buffer is the same as described above, excluding BSA. For dissociation progress 
curves, saFabI (1 µM), NADP+ (500 µM), inhibitor and DMSO were pre-incubated overnight at 
20°C prior to dilution (1:100). Reactions were allowed to proceed until the progress curve 
reached a steady-state velocity, within the limits of the linear control. Progress curves were 
fit to the integrated rate equation (Equation 6). 
      (6) At = A0 − vst −
vi − vs
kobs
[1− e−kobs t ]
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where vi and vs are the respective initial and steady-state velocities and kobs is the pseudo-
first order rate constant. 
Since these are tight-binding inhibitors of saFabI, the value of Ki*,app determined in this assay 
may conceal the true affinity of these compounds, particularly in the case of the most potent 
compound, triclosan. Although we were unable to obtain the recommended data points to 
accurately fit the dose-response curves to the Morrison equation, the curvature of the dose-
response plots suggest that the inhibitors are not sufficiently potent to titrate the enzyme at 
the concentrations used in the assay (Figure 2-4A). Thus, we can reasonably expect the true 
Ki*,app value for each inhibitor to lie close to the fitted value using the standard isotherm 
equation (Equation 1). 
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3 Rational Optimization of Drug-Target Residence Time: 
Insights from Inhibitor Binding to the Staphylococcus 
aureus FabI Enzyme-Product Complex 
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3.1 Keywords 
residence time; fatty acid biosynthesis; Staphylococcus aureus FabI; enoyl-ACP reductase; 
enzyme kinetics; crystallography; structure-based drug design 
3.2 Abstract 
Drug-target kinetics has recently emerged as an especially important facet of the drug 
discovery process. In particular, prolonged drug-target residence times may confer enhanced 
efficacy and selectivity in the open in vivo system. However, the lack of accurate kinetic and 
structural data for series of congeneric compounds hinders the rational design of inhibitors 
with decreased off-rates. Therefore, we chose the Staphylococcus aureus enoyl-ACP 
reductase (saFabI) - an important target for the development of new anti-staphylococcal 
drugs - as a model system to rationalize and optimize the drug-target residence time on a 
structural basis. Using our new, efficient and widely applicable mechanistically informed 
kinetic approach, we obtained a full characterization of saFabI inhibition by a series of 20 
diphenyl ethers complemented by a collection of 9 saFabI-inhibitor crystal structures. We 
identified a strong correlation between the affinities of the investigated saFabI diphenyl 
ether inhibitors and their corresponding residence times, which can be rationalized on a 
structural basis. Due to its favorable interactions with the enzyme, the residence time of our 
most potent compound exceeds 10 hours. In addition, we found that affinity and residence 
time in this system can be significantly enhanced by modifications predictable by a careful 
consideration of catalysis. Our study provides a blueprint for investigating and prolonging 
drug-target kinetics and may aid in the rational design of long-residence-time inhibitors 
targeting the essential saFabI enzyme. 
3.3 Introduction 
When developing lead compounds against a validated drug target, the traditional drug 
discovery paradigm has focused primarily on optimizing drug-target thermodynamics and in 
vivo pharmacokinetics (45). However, there has been a recent realization that efficacy and 
selectivity may also be driven by drug-target kinetics, an overlooked dimension in the 
conventional SAR profile (10,45,189). In particular, drug-target residence time, which is 
defined as the reciprocal of the dissociation rate constant, has been shown to be a promising 
early stage indicator of in vivo drug activity. In agreement with this proposal, 26 % of the 
drugs approved by the FDA between 2001 and 2004 exhibit time-dependent inhibition of 
their targets (10,45). 
In a recent study, the residence time of inhibitors targeting the Francisella tularensis enoyl-
ACP reductase (ftFabI) was strongly correlated with survival rate in a tularemia mouse model 
of infection (46). Understanding the molecular interactions that modulate the rate of 
dissociation from the FabI enzyme would, therefore, greatly aid in the design of new and 
effective antibiotics, which are urgently needed. 
Staphylococcus aureus is a particularly dangerous pathogen in settings such as hospitals 
because it is carried by healthy people, mostly in the anterior nares, and is readily 
transferred to immunocompromised patients (190,191). The evolution of antibiotic-resistant 
strains is, hence, of particularly grave concern since it can very rapidly lead to uncontrolled 
nosocomial outbreaks (192). Unfortunately, methicillin-resistant strains (MRSA) are 
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widespread, and the severity of this problem has been further compounded by the 
development of resistance against vancomycin, the “drug of last resort” (193-195). Thus, 
there is an urgent need for new drugs against orthogonal targets to combat these constantly 
adapting pathogens. 
The type II fatty acid biosynthesis pathway (FAS II), which is involved in the endogenous 
production of lipids to be incorporated into the bacterial cell membrane, is a promising 
source for new drug targets (Figure 3-1). There has been a recent controversy regarding the 
essentiality of this pathway for septic infections caused by Gram-positive bacteria, such as S. 
aureus, given the lipid-rich environment of human serum (90). However, several studies 
have emerged in support of FAS II as a valid drug target in S. aureus by demonstrating in vivo 
efficacy in animal models of infection and revealing heterogeneity in the incorporation and 
composition of fatty acids among Gram-positive bacteria (19,88,89). Among the FAS II 
enzymes, FabI, which catalyzes the final step in the catalytic cycle, has garnered the most 
attention as an antibacterial target (67). This was spurred by the discoveries that 
diazaborines, triclosan and isoniazid, the latter a front-line anti-tuberculosis prodrug, all 
target this enoyl-ACP reductase (54,67,71,117,196). In fact, three separate S. aureus FabI 
(saFabI) inhibitors are currently in clinical trials (92,100,101,197). 
 
 
 
Figure 3-1. The bacterial fatty acid biosynthesis pathway in S. aureus. FabI is the enoyl-ACP reductase in the 
pathway. 
Here, we aim to rationally improve the residence time of saFabI inhibitors by analyzing a 
series of enzyme-product-drug ternary complex inhibitors using X-ray crystallography and a 
simple, widely applicable mechanistic approach for kinetics-informed drug discovery efforts. 
We identified a strong correlation between the affinities of the investigated saFabI diphenyl 
ether inhibitors and their corresponding residence times, which could be rationalized on a 
structural basis. The mechanistic insights garnered through a consideration of both catalysis 
and inhibition may prove significant in the rational improvement of small molecules 
targeting saFabI. 
3.4 Experimental Procedures 
Compound synthesis. Synthesis of PT51, PT55, PT52, PT103, PT53, PT01, PT02, PT03, PT04, 
PT05 and PT13 were described previously (69,97,198). PT68, PT89, PT162, PT446, PT447, 
PT448 and PT119 were synthesized from their corresponding A-rings with 2-fluoro-
benzonitrile in the presence of K2CO3/dimethylformamide at 170 °C. Similarly, PT104 was 
synthesized from 1-fluoro-2-methoxy-4-nitro-benzene and phenol at 120 °C. Finally, all the 
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compounds were demethylated using BBr3. Triclosan was purchased from EMD Millipore 
Chemicals. 
 
Expression and purification of saFabI. SaFabI was expressed and purified as described 
previously (19). Briefly, we expressed the safabi gene in Escherichia coli BL21 (DE3), lysed the 
cells and isolated the saFabI enzyme via Ni2+ affinity chromatography. Finally, size exclusion 
chromatography yielded > 95% pure protein in 20 mM trisodium citrate pH 5.6, 280 mM 
NaCl, 280 mM potassium glutamate and 1 mM EDTA. 
 
Crystallization, data collection and structure determination. As described previously, saFabI 
was concentrated to 15 mg/ml for co-crystallization experiments (19). Prior to crystallization, 
saFabI was incubated for 2 hours at 4 °C with a 10-fold molar excess of NADP+ and a 20-fold 
molar excess of the respective diphenyl ether inhibitor. In vapor diffusion experiments, 
diffraction-quality crystals of space group P1 were obtained using a precipitant solution 
composed of 0.1 M Na/K-phosphate pH 6.5 and 35 - 47% 2-methyl-2,4-pentanediol (MPD). 
In order to obtain saFabI-NADP+-PT55 crystals, the protein had to be incubated with the 
ligands in 25 mM Tris pH 8.0 and 200 mM NaCl at 20 °C prior to concentrating the enzyme 
from 1 to 15 mg/ml. After directly flash-freezing the crystals in liquid nitrogen, diffraction 
data were collected to a resolution ranging from 2.15 to 2.50 Å at the MX beamline 14.1 at 
BESSY II (199) (λ = 0.918 Å, T = 100 K) utilizing a MarMosaic 225 detector (PT02, PT04, PT13, 
PT55, PT68, PT70 and PT119), beamlines ID14-1 (λ = 0.933 Å, T = 100 K) with an ADSC 
Quantum Q210 detector (PT03) and ID29 (λ = 0.976 Å, T = 100 K) equipped with a Pilatus 6M 
detector (PT53) at the ESRF as well as on a Rigaku MicroMax-007 HF X-ray generator (λ = 
1.542 Å, T = 100 K) using a R-Axis HTC detector (PT53). Data processing was performed with 
Imosflm (178) and Scala (179) (PT02, PT04, PT13, PT55, PT68, PT70 and PT119) or the XDS 
package (183) (PT03, PT53), respectively. The structures were solved by molecular 
replacement with Phaser (180) using our previously published saFabI structure as search 
model (PDB-code: 4ALK) (19). Maximum likelihood refinement with Refmac 5 (181) 
(including TLS refinement (200)) was alternated with model building in Coot (182) to obtain 
the final structures including NADP+ and inhibitors, which were unambiguously identified in 
the resulting electron density maps. Data collection and refinement statistics are given in 
Table S 3-1. Structure analysis was performed as described previously (19) and Figures were 
prepared with PyMOL (201). The model coordinates and structure factors for the saFabI-
NADP+-inhibitor ternary complexes have been deposited in the Protein Data Bank with the 
codes 4BNF (inhibitor PT02), 4BNG (PT03), 4BNH (PT04), 4BNI (PT13), 4BNJ (PT53), 4BNK 
(PT55), 4BNL (PT68), 4BNM (PT70), and 4BNN (PT119). 
 
Thermal shift assay. ThermoFluor experiments were carried out in 96-well plates (Concord) 
using the CFX96 Real-Time PCR Detection System and C1000 Thermal Cycler (Bio-Rad). 
Samples contained 7.4 µM saFabI, 2.5 mM NADP+ or NADPH, 25 μM inhibitor (2% DMSO) 
and 5X Sypro Orange (Sigma) in 20 µL final volume of 50 mM potassium phosphate pH 7.5, 
150 mM NaCl, 1 M potassium glutamate and 8% glycerol. The plates were sealed with 
Microseal ‘B’ Film (Bio-Rad) and heated from 25 to 90 °C in increments of 0.2 °C/10 s. Data 
were processed by the Bio-Rad CFX Manager. 
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Progress curve kinetics. Kinetic experiments were performed on a Cary 100 
spectrophotometer (Varian) at 20 °C. Reaction velocities were measured by monitoring the 
oxidation of NADPH to NADP+ at 340 nm (ε = 6220 M-1 cm-1). The reaction mixture for 
forward progress curve experiments has been described previously (19). In the absence of 
inhibitor, the time window of progress curve linearity was generally limited by substrate 
consumption rather than enzyme stability (Figure S 3-1). The resulting progress curves were 
analyzed via the Morrison & Walsh integrated rate equation (Equation 1) (202), 
 
ܣ௧ = ܣ଴ − ݒௌݐ − ሺݒ௜ − ݒ௦ሻ ∙ ቆ
1 − ݁ି௞೚್ೞ௧
݇௢௕௦
ቇ (Eq 1) 
where At and A0 are the absorbance at time t and time 0, vi and vs are the initial and steady 
state velocities and kobs is the pseudo-first order rate constant for the approach to steady-
state. Kiapp values, which correspond to the steady-state inhibition IC50, were determined by 
plotting the fractional steady-state velocities as a function of inhibition concentration and 
fitting to the isotherm equation (Equation 2), 
 
 
(Eq 2) 
where vu is the control, uninhibited reaction velocity. To calculate k-1, which corresponds to 
the dissociation rate (koff) of the inhibitor, from each progress curve, we used Equation 3. 
 ݇ିଵ = ݇௢௕௦ ∙
ݒ௦
ݒ௜
 (Eq 3) 
We can also determine k-1 by fitting the kobs values from each progress curve to Equation 4. 
 ݇௢௕௦ = ݇ିଵ ∙ ቆ1 +
[ܫ]
ܭ௜
௔௣௣ቇ (Eq 4) 
The commonly used jump dilution assay (45,202,203) was used to monitor the recovery of 
enzyme activity following ternary complex 
formation. 10 μM saFabI, 15 μM inhibitor 
and 500 μM NADP+ were preincubated 
overnight at room temperature followed by 
1:200 dilution into reaction buffer (50 mM 
potassium phosphate pH 7.5, 150 mM NaCl, 
1 M potassium glutamate, 8% glycerol) 
containing 1.5 mM crotonyl-CoA (Sigma; 
Advent Bio) and 350 μM NADPH. The 
resulting progress curve was fitted to Eq 1. 
All curve fitting was performed using 
KaleidaGraph Version 4.1. 
 
Kinetic modeling. A set of ordinary 
differential equations were constructed 
based on the kinetic mechanism depicted in 
Figure 3-2 and numerically solved using 
Wolfram Mathematica 8 (204). The rationale 
behind the chosen kinetic parameters is provided in Table S 3-2. 
vs
vu
=
1
1+ [I ]
Ki
app
 
Figure 3-2. Mechanistic model for slow-binding 
kinetics. Three possible mechanisms (A, B and C) of 
slow-binding inhibition are depicted. In addition, the 
detailed kinetic mechanism for inhibition of saFabI by 
diphenyl ethers is shown below. 
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32P dissociation kinetics. A mixture of 15 μM saFabI R40Q/K41N/S44L, 20 μM NAD+, 32P-
NAD+ (800 Ci/mmol) and 200 μM inhibitor in reaction buffer was preincubated at room 
temperature overnight. Following gel filtration to remove excess free ligand, 500 μL of the 
mixture was rapidly diluted into 60 mL reaction buffer to initiate dissociation of the ternary 
complex. 600 μL aliquots of the diluted mixture were withdrawn at various time points, 
followed by immediate loading onto an ultrafiltration spin column (Sartorious, 10 kDa) and 
centrifugation at 13,400 rpm for 90 seconds. The amount of 32P in the flow through was 
quantified by a scintillation counter. Data was fit to Equation 5, 
 
 ܥሺݐሻ = ܥሺ0ሻ + ܥ௠௔௫ ∙ ൫1 − ݁ି௞೚೑೑௧൯ (Eq 5) 
 
where C(t) and C(0) are the radioactive counts (cpm) at time t and time 0, Cmax is the 
maximum radioactive count and koff is the inhibitor dissociation rate. 
3.5 Results 
Diphenyl ethers bind to the E-NADP+ complex generated via catalysis. Triclosan and its 
diphenyl ether analogues are slow-binding inhibitors of the FabI enzymes from a number of 
organisms, including S. aureus and F. tularensis (46,78,108). Although we have previously 
used the Morrison and Walsh equations to analyze the slow-binding inhibition of ftFabI, we 
are cognizant that the integrated equations used to analyze progress curve data for slow-
binding inhibitors were originally developed for a simple model in which a single-substrate 
reaction is competitively inhibited by a substrate analog (46,202). To confirm that the 
Morrison and Walsh integrated equations can be used to analyze the more complex 
inhibition of FabI, it was first necessary to elucidate a more precise mechanism of inhibition 
by diphenyl ethers. 
FabI catalyzes an ordered Bi Bi reaction, and diphenyl ethers bind uncompetitively with 
respect to the product NAD(P)+ (78,108). To determine the primary origin of the E-NADP+ 
complex relevant for inhibitor binding, progress curves were obtained for a slow-binding 
inhibitor (PT53) in the presence of 400 and 2000 μM NADP+. These curves were essentially 
identical (Figure S 3-2B), suggesting that the product of the catalytic cycle rather than 
binding of NADP+ to the free enzyme was the dominant source of E-NADP+ under the assay 
conditions. The significance of the E-NADP+ complex generated via catalysis for saFabI 
inhibition has been hinted at in a recent publication (102), and is consistent with the very 
weak NADP+ product inhibition of the free enzyme (Figure S 3-2A). Additionally, the onset 
and degree of inhibition increased when using substrates with higher kcat (data not shown), 
consistent with a higher steady-state concentration of E-NADP+ generated via catalysis. 
Previous studies proposed that diphenyl ethers bind preferentially to the E-NAD(P)+ complex 
but still exhibit potent binding to the E-NAD(P)H complex (46,78,97,109,205). However, 
thermal shift assays revealed exclusive binding of the diphenyl ethers to the saFabI E-NADP+ 
complex (Figure 3-3). Mechanistic models operating under the assumption that diphenyl 
ethers bind to the E-NAD(P)H complex are, therefore, erroneous. Instead, the most accurate 
model is depicted in Figure 3-2, which was initially proposed for the inhibition of saFabI by 
triclosan (108). Kinetic rate constants were rationally derived for each step of the model on 
the basis of broad experimental data. By numerically solving the system of differential 
equations, a set of progress curves was generated for a hypothetical inhibitor with 
predetermined k1 and k-1. Analysis of this theoretical set of curves by the Morrison and 
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Walsh equations resulted in a reliable estimate of k-1 (Table S 3-3). This validated the direct 
use of these equations to analyze the more complex case of FabI inhibition despite its 
derivation from a simple mechanistic scheme. Surprisingly, accurate estimates of k-1 can be 
obtained at inhibitor concentrations lower than the enzyme concentration without even 
accounting for tight-binding inhibition. This is due to the fact that the steady-state 
population of E-NADP+ at the given reaction velocity is much lower than the concentration of 
free enzyme. 
 
Figure 3-3. Diphenyl ethers bind preferably to the E-NADP+ binary complex. Representative thermal shift 
curves of saFabI bound to NADPH, NADP+ and/or inhibitor (PT119). The measurement variability is 
approximately ± 0.2 °C. 
Diphenyl ethers bind to saFabI via an induced-fit mechanism. Progress curves 
corresponding to inhibition of saFabI by diphenyl ethers exhibited curvature characteristic of 
slow-binding kinetics (Figure 3-4). Slow-binding inhibition generally encompasses one of 
three kinetic mechanisms (Figure 3-2; top) (10,202,206). The most basic mechanism involves 
a one-step process with slow inhibitor association accounting for slow formation of the EI 
complex (Figure 3-2; Mechanism A). A two-step process, which is most often encountered 
for slow-binding inhibitors, involves rapid formation of EI followed by a slow induced-fit 
conformational change to the more potent EI* (Figure 3-2; Mechanism B). Alternatively, a 
two-step process may entail a slow conformational change to an enzyme form that rapidly 
binds inhibitor (Figure 3-2; Mechanism C). To elucidate the mechanism of slow-binding 
inhibition, kobs was plotted as a function of inhibitor concentration (Figure 3-4C). The 
increasing linear plot unambiguously rules out the possibility of a conformational selection 
mechanism (Mechanism C) (47). Typically, this is characteristic of a single-step slow-binding 
mechanism of inhibition, whereas the two-step induced-fit mechanism is generally 
characterized by a hyperbolic relationship. However, the one-step mechanism is kinetically 
indistinguishable from a special case of the two-step mechanism where EI* is much lower in 
free energy than EI. In this situation, initial inhibition is not detected at low inhibitor 
concentrations that still affect the steady-state velocity. In a recent report, we structurally 
characterized the extensive rearrangements that build the active site upon ligand binding 
(19). Based on these results, binding of the diphenyl ether inhibitors may induce a 
directional structural change in the enzyme (special case of Mechanism B). Since the results 
are analyzed in accordance with Mechanism A (Figure 3-2), k1 and k-1 would, in the special 
 Inhibition of SaFabI by Diphenyl Ethers  
56 
 
case of Mechanism B, represent the respective overall apparent association and dissociation 
rate constants between E + I and EI*. 
 
Figure 3-4. Progress curve analysis of saFabI inhibition by diphenyl ether analogues. (A) Representative 
example of progress curves generated with varying concentrations of PT52 (). Theoretical curves (—) have 
been superimposed on the experimental data. These curves were generated using the kinetic parameters in 
Table 3-1 and Equation 1. R2 (goodness of fit between theoretical curves and experimental data) = 0.99, 0.95, 
0.97 and 0.93 for 250, 500, 750 and 1000 nM PT52, respectively. (B, C) These plots display the corresponding 
fractional steady-state velocity (vs/v0) and pseudo-first order rate constant (kobs) as a function of inhibitor 
concentration. Theoretical curves (—) have been superimposed on the experimental data. These curves were 
generated using the kinetic parameters in Table 3-1 and Equation 2 or 4. R2 (goodness of fit between 
theoretical curves and experimental data) = 0.93 and 0.90 for the IC50 and kobs plots, respectively. 
Diphenyl ether residence time strongly correlates with affinity. A detailed understanding of 
the mechanism and interactions that modulate drug-target residence time is particularly 
important for future drug discovery programs. However, the rational design of inhibitors 
with decreased off-rates is still very challenging. This task is further hampered by the lack of 
accurate kinetic data for large compound series (10). Using a mechanistically informed 
kinetic approach, we analyzed a series of 20 saFabI inhibitors (Table 3-1). The kinetic barrier 
to dissociation can be increased by either stabilizing the ground state enzyme-inhibitor 
complex or destabilizing the transition state (Figure 3-5A) (10). Interestingly, the dissociation 
rate displays a strong linear correlation to Ki in a double logarithmic plot, suggesting that the 
energetics involved in residence time differentiation are related to stabilization of the final 
enzyme-inhibitor complex (Figure 3-5B). In addition, the association rate is very similar 
across the diphenyl ether series, indicating a similar barrier to the transition state. 
Importantly, this highlights the fact that the following structural rationale for binding affinity 
trends also applies to residence time. 
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Table 3-1. Kinetic and thermodynamic parameters for inhibitors of saFabI a 
Name Structure Ki
app (nM) Ki (nM)
 k1 (x 10
10 M-1
hr-1) h k-1(hr
-1) tR (min)
i 
PT51 
 
24515.0 ± 
1359.8 18.86 ± 1.05 ≥ 0.30
 rapid e ≤ 1 
PT55 
 
1851.8 ± 
127.4 1.42 ± 0.10 0.68 ± 0.23
 
9.67 ± 3.14 b 
25.36 ± 2.45 c 
6.2 b 
2.4 c 
PT104 
 
1933.4 ± 
345.2 1.49 ± 0.27 0.61 ± 0.46 9.03 ± 6.58 
b 6.6 b 
PT52 
 
161.2 ± 8.4 0.12 ± 0.01 1.37 ± 0.27 
1.70 ± 0.30 b 
2.33 ± 0.03 c 
2.13 ± 0.41 d 
35.3 b 
25.8 c 
28.2 d 
PT103 
 
77.7 ± 9.4 0.06 ± 0.01 1.30 ± 0.25 
0.78 ± 0.08 b 
0.73 ± 0.09 d 
76.9 b 
82.2 d 
PT53 
 
493.7 ± 40.2 0.38 ± 0.03 0.91 ± 0.11 
3.46 ± 0.29 b 
4.53 ± 0.08 c 
17.3 b 
13.2 c 
PT01 
 
120.8 ± 10.1 0.09 ± 0.01 1.01 ± 0.19 
0.94 ± 0.14 b 
0.72 ± 0.08 d 
63.8 b 
83.3 d 
PT02 g 
 
 0.07 1.33 
0.99 b 
0.57 ± 0.09 d 
60.9 b 
105.3 d 
PT03 g 
 
 0.04 f 0.58 
0.20 b 
0.32 ± 0.17 d 
300.0 b 
187.5 d 
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PT04 
 
 0.01 f 1.30 0.13 ± 0.04 d 461.5 d 
PT05 g 
 
 0.82 0.25 
2.03 b 
3.74 ± 0.06 c 
29.6 b 
16.0 c 
PT68 
 
145.2 ± 9.1 0.11 ± 0.01 0.79 ± 0.10 0.87 ± 0.07 b 68.7 b 
PT89 
 
123.2 ± 7.9 0.10 ± 0.01 0.68 ± 0.09 0.64 ± 0.06 b 93.5 b 
PT446 
 
1311.3 ± 
246.6 1.01 ± 0.19 0.30 ± 0.16
 2.99 ± 1.50 b 20.1 b 
PT447 
 
72.0 ± 7.4 0.06 ± 0.01 0.80 ± 0.14 
0.44 ± 0.02 b 
0.47 ± 0.08 d 
136.4 b 
127.7 d 
PT443 g 
 
 0.05 0.62 0.28 b 210.9 b 
PT119 
 
 0.01 f 0.80 
No recovery c 
0.08 ± 0.01 d 
750 d 
PT13 g 
 
 0.12 0.73 0.88 b 68.5 b 
TCL 
 
69.2 ± 5.5 0.05 ± 0.01 0.81 ± 0.22 0.43 ± 0.08 b 139.5 b 
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PT162 g 
 
 0.5 0.57 2.66 b 22.6 b 
a. Fitting errors are reported for each value in the Table, unless otherwise specified. 
b. Mean value calculated from individual progress curves. Errors reflect the standard deviation from the 
mean. 
c. Determined by fitting the jump dilution curve to Eq 1. 
d. Determined by fitting the 32P-NAD-based dissociation curve to Eq 5. 
e. Defined as ≥ 60 hr-1. 
f. Affinity was calculated using the k-1 value obtained from the 32P-NAD dissociation assay since the 
dissociation rate was too slow and/or inhibition was too potent. The k1 value was obtained from forward 
progress curve analysis. 
g. Values estimated from a single progress curve at a single inhibitor concentration. 
h. Errors are propagated from Ki and k-1. 
i. Residence time tR = 1/k-1 
 
 
Figure 3-5. Dissociation kinetics drive changes in thermodynamic affinity. (A) Energy diagram corresponding 
to Mechanism A in Figure 3-2. Residence time (tR = 1/k-1) can be prolonged by either stabilizing EI or 
destabilizing the transition state (TS). (B) A double logarithmic plot depicts a strong correlation between 
thermodynamic affinity and dissociation kinetics (black) and a weak correlation between association and 
dissociation kinetics (blue). On each axis, logarithmic values are adjusted such that their mean is equal to zero. 
 
Hydrophobic 5-substituents enhance residence time and affinity. To obtain a detailed 
understanding of the kinetic and thermodynamic SAR profile, we solved the structures of 
saFabI in complex with the oxidized cofactor NADP+ and 9 diphenyl ethers differing in their 
substitution pattern (Figure 3-6, Table 3-1). All investigated inhibitors bind to the 
predominantly hydrophobic active site pocket and share a common binding pose stabilized 
by a π-π-stacking interaction with the NADP+ nicotinamide ring (interaction distance of 3.4 ± 
0.1 Å) and a central hydrogen bond network between Tyr157, the diphenyl ether hydroxyl 
group and the 2'-OH of the NADP+ nicotinamide ribose (2.6 ± 0.1 Å or 2.5 ± 0.1 Å, 
respectively) (Figure 3-6). Substituents at the 5-position of the diphenyl ether A-ring bind to 
an elongated and very lipophilic binding channel mainly composed of Tyr147, Pro192, 
Val201, Phe204 and Ile207 (Figure 3-7A, B). Accordingly, we observed clear steric and 
hydrophobic contributions to binding at the 5-position of the A-ring (Table 3-1). 
PT51, PT55 and PT104 comprise a subset of diphenyl ethers lacking hydrophobic bulk at this 
position. These compounds are noticeably the least potent of the diphenyl ethers tested. 
Consistently, a similar trend was recently observed for E. coli FabI (ecFabI) (102). Such 
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inhibitors were previously characterized as rapid-binding, rather than slow-binding, 
inhibitors of ftFabI (46). However, similar to slow-onset inhibitors like PT52 (PDB-entry: 4ALJ) 
(19), the binding of PT55 to saFabI resulted in the closure of the substrate binding loop, 
which is believed to be responsible for slow-binding inhibition (67). In accordance, PT55 and 
PT104 exhibited clear slow-binding inhibition of saFabI. Slow-binding kinetics may be more 
difficult to detect with less potent compounds since higher inhibitor concentrations are 
required to observe inhibition. This may explain why slow-binding inhibition could not be 
observed for PT51 and may have been missed in the case of ftFabI (46). 
 
 
 
Figure 3-6. Diphenyl ether binding to the binary saFabI-NADP+ complex. Nine diphenyl ether inhibitors are 
depicted within the saFabI binding pocket (in different colors as defined next to the molecules). All ternary 
complex structures were superimposed for this purpose. Distances between protein, inhibitor and cofactor 
atoms are given as mean values (the standard deviations are defined in the main text). All amino acids within a 
radius of 6 Å of PT04 except the substrate binding loop residues (194-204) are shown in a light blue surface 
representation. The substrate binding loop, which is in a similarly closed state for all nine structures, is 
displayed in gray. Main discrepancies between the depicted saFabI binding pocket of the PT04 structure and 
the remaining structures are discussed in Figure 3-7. 
Among compounds with hydrophobic bulk, a steric effect is very prominent. The stabilization 
conferred by substituting chlorine (PT52; PT447) with bromine (PT103; PT443) provides one 
such example. Additionally, residence time and affinity increased with aliphatic chain length 
up to six carbons. Upon elongation of the 5-substituent from methyl (PT53) to ethyl (PT01, 
PDB-entry: 4ALK), propyl (PT02), pentyl (PT03) and hexyl (PT04), the alkyl chain progressively 
extends into the aforementioned hydrophobic channel thereby explaining the observed koff 
and Ki trends (Figure 3-7A, B, E). Beyond this length, however, the alkyl chain is expected to 
reach the more polar protein surface, rationalizing the decrease in affinity and residence 
time with PT05. Further striking differences were found between the PT53 and PT04 
structures as indicated by an isomorphous difference map. Whereas Ile207 adopts a closed 
state in the PT53 structure, a conformational change in this gatekeeper residue enables the 
longer 5-alkyl chains (e.g. the 5-hexyl group of PT04) to bind (Ile207-Cδ1 shifts by 3.4 ± 0.4 Å) 
(Figure 3-7C, E). The stepwise opening of the hydrophobic channel upon elongation of the 
alkyl chain is accompanied by its widening via movements of residues Tyr147 and Val201 
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(Tyr147-OH shifts by 0.5 ± 0.1 Å and Val201-Cγ1 by 0.9 ± 0.1 Å) (Figure 3-7D). A comparable 
mechanism was observed for the Mycobacterium tuberculosis homolog InhA during the 
binding of 5-octyl-2-phenoxyphenol, which induced a shift of Leu218 (corresponding to 
Ile207 in saFabI) (69). In contrast, ftFabI has a methionine at this position, which might 
explain the preference of the enzyme for PT02 (19,46). The finding that this part of the 
saFabI binding pocket is flexible will be important for future inhibitor design efforts. 
 
 
 
Figure 3-7. Structural changes to saFabI caused by the binding of different 5-alkyldiphenyl ethers. (A) 5-
Methyl-2-phenoxyphenol (PT53) is shown as a stick model within its binding pocket. This view shows an 
intersection through one of the respective saFabI monomers in surface representation. Thus, all parts of the 
molecule which are in front of an imaginary clipping plane are not visible. (B) The corresponding intersection 
for the 5-hexyl-2-phenoxyphenol (PT04) structure reveals a binding pocket enlarged around the 5-substituent. 
(C) Ile207 and the inhibitors of the superimposed PT53 and PT04 structures are shown. Meshes represent 
selected parts of the NCS-averaged isomorphous difference map at 5 σ. Additional experimental electron 
density for each structure is indicated by the associated color and clearly reveals a conformational change of 
Ile207. (D) The same map uncovers supplementary movements of Tyr147 and Val201. In addition, the binding 
of PT04 leads to a reduced occupancy of three water molecules, which are still bound between Tyr147 and 
Gly202 in the case of PT53. (E) Ile207 and 5-alkyl-2-phenoxyphenols with different alkyl chain lengths are 
shown. This view was generated via superposition of single monomers of the respective structures (the PT01 
structure (PDB-code: 4ALK) was published previously (19)) and indicates a successive opening movement of 
Ile207. The color code is defined next to the molecules. 
Diphenyl ethers likely bind in a deprotonated form to saFabI. Electrostatics of the A-ring 5-
position contribute significantly to saFabI binding. Affinity and residence time increase with 
more electron-withdrawing substituents in the two series PT51, PT55, PT104 and PT53, 
PT52. The respective pKa values for the phenolic hydroxyl group are listed in Table S 3-4. We 
can probe the theoretical contribution of electrostatics to thermodynamic binding if we 
assume that only the deprotonated oxyanion species can bind to the enzyme. This kinetic 
simulation resembles the scheme in Figure 3-2 but also includes a rapid equilibrium inhibitor 
deprotonation step preceding binding to the E-NADP+ binary complex. The equilibrium 
distribution depends on inhibitor pKa and buffer pH. Among similarly sized substituents, 
apparent affinity differences can be almost entirely predicted by pKa using this theoretical 
approximation (Table S 3-4), suggesting that the inhibitor is bound in a deprotonated state. 
The slight disparities from experimental values may be rationalized by other factors, such as 
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differences in sterics. This is a theoretical analysis to rationalize the observed magnitude of 
electrostatic stabilization. In reality, the similar association rate constants among the various 
compounds suggest that the protonated species can also bind to the enzyme, followed by 
subsequent deprotonation. The resulting oxyanion species might contribute to the high 
affinity binding of these inhibitors to saFabI due to the formation of a strong charge-assisted 
hydrogen bonding network and an electrostatic interaction between the negatively charged 
phenolic oxygen and the neighboring positive charges of the catalytic triad residue Lys164 
and the oxidized cofactor NADP+ (Figure 3-6). The latter charge-assisted π-π stacking 
interaction between the inhibitor phenolate ring and the planar oxidized nicotinamide ring 
of the cofactor might also explain why diphenyl ethers specifically target E-NADP+ despite its 
lower steady-state abundance relative to E-NADPH. Based on our kinetic parameters (Table S 
3-2), the E-NADPH complex is present at more than 300-fold higher concentrations 
compared to E-NADP+ under our assay conditions (Table S 3-3). However, further studies are 
required to unequivocally demonstrate that diphenyl ethers are bound to saFabI in their 
anionic form and to elucidate when deprotonation might occur. 
 
 
Figure 3-8. Binding modes of different 2'-substituted saFabI diphenyl ether inhibitors. (A-C) Ala95, Ser197 and 
NADP+ are depicted in stick representation (gray) along with the B-ring ortho-substituted inhibitors PT13, PT70 
and PT119 (colored according to Figure 3-6). Distances are given as mean values (standard deviation is 0.1 Å in 
all cases) (D) The 2'-cyano group (shown as space filling model) of PT119 fills the saFabI side pocket created by 
Ala95, Ser197 and NADP+ (shown as gray surface) with a good steric fit. 
Small and slightly polar 2'-substituents contribute to binding. We also obtained interesting 
SAR at the B-ring ortho position of the diphenyl ether analogs (Table 3-1). The introduction 
of a 2'-cyano group enhances affinity and residence time up to 2- and 3-fold, respectively. A 
methyl substituent (PT70, Figure 3-8B) also increased affinity (data not shown), while PT13 
with an amino substituent displayed decreased affinity (Figure 3-8A). All investigated 2'-
substituents bind to a narrow, elongated and slightly polar side pocket created by Ala95, 
Ser197 and the pyrophosphate moiety of NADP+ (Figure 3-8). However, only the linear CN 
group of PT119 reaches the bottom of this cavity with its polar tip, rendering it ideally suited 
to fully occupy this space (Figure 3-8D). In contrast, the steric fit is worse for H, CH3, Cl 
(triclosan, PDB-code: 4ALI), and NH2. In particular, the amino substituent is 12-fold less 
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potent as its polar hydrogens have to be desolvated upon binding and cannot engage in 
geometrically favorable hydrogen bond interactions with surrounding protein residues 
(Figure 3-8A). Due to the clearly limited space in this region of the saFabI binding pocket, we 
advocate the usage of small B-ring ortho substituents in future drug design studies. 
 
Alternative methods confirm the drug-target dissociation rates. Direct dissociation 
methods were used to further validate the forward progress curve-based kinetic 
characterization of diphenyl ethers. In the jump dilution assay, saFabI was pre-incubated 
overnight with inhibitor in the presence of NADP+ prior to dilution into buffer containing 
substrate. For less potent inhibitors, dilution allows for full recovery of enzyme activity 
(Figure 3-9A; see PT55 and PT52). Thus, for these inhibitors, it was found that the kobs values 
obtained using jump dilution analysis were in good agreement with k-1 values obtained via 
forward progress curve experiments (Table 3-1). Unfortunately, compound rebinding 
complicated the use of jump dilution assays to quantify dissociation of more potent 
inhibitors, resulting in only partial recovery of enzyme activity. Since the mechanism of 
inhibition precluded the use of saturating concentrations of substrate to compete against 
rebinding, kobs for these jump dilution curves overestimated the true k-1. Long-residence-
time inhibitors also required a time window extending beyond the feasible assay limits. 
Nevertheless, given the kinetic parameters derived from progress curve analysis and the 
radioactivity-based method described below, we can predict the partially recovered jump 
dilution curve with great accuracy (Figure 3-9A; see PT447). 
 
Figure 3-9. Direct measurements of inhibitor dissociation. (A) Experimental jump dilution progress curves () 
are shown for the pre-formed saFabI-NADP+-PT55, saFabI-NADP+-PT52 and saFabI-NADP+-PT447 ternary 
complexes. Theoretical curves (—) have been superimposed on the experimental data. These curves were 
generated using the kinetic parameters in Table 3-1 and Equation 1. R2 (goodness of fit between theoretical 
curves and experimental data) = 0.98, 0.94 and 0.97 for PT55, PT52 and PT447, respectively. Unlike PT447, 
there is near recovery to the uninhibited reaction velocity for the less potent compounds PT55 and PT52. (B) 
Release of 32P-NAD+ from the pre-formed ternary complex using the saFabI R40Q/K41N/S44L triple mutant is 
plotted as a function of time. The lines represent the best fits of the points to Equation 5 (R2 = 0.97 and 0.98 for 
PT52 and PT447, respectively). Fitted koff values are listed in Table 3-1. 
To enable accurate characterization of long residence time inhibitors, we also developed a 
32P-NAD+-based assay of inhibitor dissociation (Figure 3-9B). This was previously used to 
study dissociation of diphenyl ethers from the FabI homolog in M. tuberculosis, InhA (207). 
Since wild-type saFabI prefers binding to NADP+, we used the R40Q/K41N/S44L triple 
mutant. We showed previously that this mutant behaves exactly as the wild-type enzyme 
except for an exclusive preference for NAD(H) (19,46). For all examined inhibitors, we 
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observed good agreement between the k-1 values obtained via the different methods. This 
direct dissociation method is strongly preferred for the characterization of long-residence-
time inhibitors which have very slow off rates (Table 3-1). For instance, PT119 had a 
residence time exceeding 700 minutes that could only be accurately measured using this 
radioactivity-based direct dissociation technique. For this particular inhibitor, progress curve 
analysis provided a poor estimate of k-1. 
3.6 Discussion 
In the quest for new effective therapeutics against increasingly resistant pathogens, it is 
crucial to understand the precise mechanisms of both pharmacologic and physiologic 
protein-ligand interactions. An improved molecular understanding of drug-target kinetics 
can be particularly valuable. Therefore, we chose saFabI - an important target for the 
development of new anti-staphylococcal drugs (103) - as a model system to rationalize and 
optimize the drug-target residence time on a structural basis. 
A new, multifaceted approach was utilized to obtain a full kinetic characterization of saFabI 
inhibition by a series of diphenyl ethers. Using a precise, predictive mechanistic model, we 
can unravel the key kinetic parameters k1, k-1 and Ki for any given inhibitor from only a single 
progress curve at a single inhibitor concentration. All of this information is contained in the 
uninhibited and steady state velocity and pseudo-first order rate constant. The amount of 
time and substrate required for progress curve analysis has traditionally been limiting given 
the need for multiple progress curves to characterize a single inhibitor. We have, therefore, 
developed an extremely efficient and information-rich kinetic assay for future drug discovery 
efforts. The kinetic information attained via forward progress curve analysis was further 
validated by direct dissociation methods allowing for the accurate characterization of high 
affinity and long-residence-time saFabI inhibitors. 
We found that dissociation rates and thermodynamic affinity are strongly correlated in a 
double logarithmic plot (Figure 3-5B). Very recently, a comparable correlation between Ki 
and koff has been demonstrated for the amino-nucleoside-based inhibitors of the human 
protein methyltransferase DOT1L (48). Interestingly, Maschera and coworkers identified a 
similar relationship for saquinavir binding to wild-type HIV-protease and three different 
resistance-conferring mutants (45,208). Thus, nature may select for mutations that promote 
faster inhibitor dissociation as a primary resistance mechanism. The logarithmic values of k-1 
and Ki are proportional to the dissociation energy barrier of the ligand ΔG-1 and its free 
energy of binding ΔGi. The energy barrier of dissociation, and hence the residence time, can 
be increased by either destabilizing the transition state or stabilizing the ground state of the 
final enzyme-inhibitor complex (10).  
Rational optimization of the residence time is usually difficult as the transition state 
structure is not readily available (10). For the saFabI system, an exact knowledge of this 
transient structure is not essential. Based on the observed correlation between koff and Ki, 
considerations of the saFabI-NADP+-inhibitor complex ground state will be sufficient for the 
rational improvement of both affinity and residence time. We obtained a wealth of 
structural information explaining the observed residence time and affinity trends. For 
example, the addition of bulky hydrophobic diphenyl ether 5-substituents or small slightly 
polar 2'-substituents (e.g. 2'-cyano) lead to a reduced dissociation rate due to a good steric 
fit within the protein active site (Figure 3-7 and Figure 3-8). On the other hand, significant 
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variations in the association rate constants were not observed. Further exploration of 
diverse A-ring and/or B-ring substituents may provide insight on how to modulate the 
transition state barrier. 
In addition, our data suggest that affinity and residence time in this system can be 
significantly enhanced by modifications predictable by a careful consideration of catalysis. 
Utilizing our parameter estimations (Table S 3-2), diphenyl ethers have affinities in the low 
picomolar to low nanomolar range. This is consistent with the expected affinity of transition-
state analogues (209). Certainly, the deprotonated diphenyl ether resembles an enolate 
intermediate (Figure 3-10). This may explain its preference for binding together with the 
oxidized product NADP+. One can, therefore, imagine an enolate-like, late transition state as 
the rate-limiting barrier in catalysis. In such a scenario, the delocalized system of the 
diphenyl ether imitates the breaking and forming of substrate bonds on the way to the 
enolate. In addition, the acidity of the phenol induces a partial negative charge at the 
hydroxyl oxygen similar to the transition state (Figure 3-10). As further evidence, the 
relationship between inhibitor affinity and aliphatic chain length at the A-ring 5-position 
perfectly reflects the relationship between catalytic activity and substrate chain length 
(Figure 3-10). Interestingly, the least potent inhibitor of our series, PT51, corresponds to a 
non-natural substrate smaller than the initial crotonyl-ACP substrate. In this context, the 
observed opening of a hydrophobic channel for long-chain 5-alkyldiphenyl ethers suggests 
that the gatekeeper residue Ile207 might also play a critical role for binding of substrates 
with chain lengths exceeding six carbon atoms (Figure 3-7). Based on our knowledge of 
catalysis, we can also predictably increase potency by stabilizing the oxyanion via electron-
withdrawing substituents on the A-ring. 
 
 
 
Figure 3-10. Diphenyl ethers as transition state analogues of saFabI. The plot depicts the relationship between 
fatty acyl-CoA kcat (black; values obtained from our previous work (19)) and inhibitor affinity, plotted as the 
reciprocal of Ki (blue), as a function of the carbon chain length. An inhibitor with n carbons at the A-ring 5-
position is equivalent to a substrate with n+3 carbon chain length, as depicted on the right. Substrates shorter 
than 4 carbons in length are catalytically inactive. 
Since the diphenyl ethers primarily bind to the E-NADP+ binary complex generated via 
catalysis, we can predict the evolution of unique kinetic mechanisms of resistance involving 
mutations away from the inhibitor binding site that accelerate product release. In the case of 
saFabI, selection experiments have resulted in mutations that do, indeed, lie near the NADP+ 
binding pocket, particularly I193S (78,92). We believe that this mutation decreases diphenyl 
ether inhibition by primarily increasing the rate of NADP+ dissociation. However, these 
mutations are likely to come at a cost since the interactions involved in product binding are 
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also important for binding the reduced cofactor. Accordingly, this mutant was also shown to 
drastically increase the Km of the NADPH cofactor (78). 
From a thermodynamic perspective, it would seem that there is a disadvantage to having a 
drug that binds to the enzyme-product complex since enzymes are designed to bind 
substrates only long enough for catalysis to occur and then release product quickly to allow 
for additional rounds of catalysis. For this and similar cases of enzyme-product-drug ternary 
complex inhibition, the focus must be on slowing the dissociation rate of the ternary 
complex. In the case of saFabI, tighter binding of diphenyl ether transition state analogues 
corresponds to longer residence times because of minimal perturbations in the kinetic 
barrier to association. If long residence times correlate with prolonged cellular effects, 
optimization of residence time may be the key parameter to unlocking in vivo efficacy for 
these series of metabolically labile compounds (210). In this regard, our rigorously 
determined SAR will facilitate further optimization of promising drug candidates with high 
activity against S. aureus. The ultimate hope is that our multipronged strategy will be applied 
to diverse, complex enzyme systems to achieve a thorough understanding of the interplay 
between structure, catalysis and the kinetics and thermodynamics of inhibition. We believe 
it holds great potential to streamline and facilitate the pursuit of rationality in the early 
stages of the drug discovery process. 
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3.11 Supporting Information 
 
Table S 3-1. Data collection and refinement statistics. 
 PT02 PT03 PT04
Inhibitor structure 
 
 
 
 
 
 
 
Data collection  
Cell dimensions  
a, b, c (Å) 90.1, 94.9, 94.8 89.1, 94.4, 94.9 90.5, 94.6, 94.8 
α, β, γ (°) 98.1, 97.3, 112.3 98.6, 97.2, 111.4 98.0, 112.7, 96.9 
Space group P1 P1 P1 
Resolution1 (Å) 38.5-2.30 (2.42-2.30) 46.2-2.20 (2.32-2.20) 33.5-2.15 (2.27-2.15) 
Observed reflections 243,615 (35,310) 239,683 (32,519) 298,031 (43,204) 
Unique reflections 122,748 (17,790) 132,692 (19,124) 150,132 (21,758) 
Completeness (%) 98.0 (97.3) 93.5 (92.3) 97.9 (97.2) 
Average redundancy 2.0 (2.0) 1.8 (1.7) 2.0 (2.0) 
Rmerge
2 (%) 9.7 (41.3) 5.5 (28.0) 6.8 (39.0) 
<I / σ(I)> 5.4 (2.0) 10.2 (2.2) 6.8 (2.0) 
Refinement  
Resolution (Å) 37.1-2.30 46.0-2.20 33.5-2.15 
Rcryst
3
 (%) 15.8 15.5 14.7 
Rfree (%) 21.9 20.8 19.6 
Monomers per AU 8 8 8 
Number of atoms 17,905 17,399 17,737 
Rmsd bond lengths (Å) 0.010 0.012 0.013 
Rmsd bond angles (°) 1.710 1.782 1.854 
Average B-factor (Å2) 33.2 36.6 34.7 
Ramachandran-plot4    
Favored (%) 95.6 96.3 96.6 
Allowed (%) 4.3 3.7 3.4 
Outliers (%) 0.1 0.0 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 0.16 0.13 0.12 
PDB code 4BNF 4BNG 4BNH 
 
  
 Inhibition of SaFabI by Diphenyl Ethers  
69 
 
 PT13 PT53 PT55
Inhibitor structure 
 
 
 
 
 
 
 
 
Data collection  
Cell dimensions  
a, b, c (Å) 90.5, 94.6, 94.9 89.9, 94.5, 94.8 90.6, 95.0, 95.0 
α, β, γ (°) 97.9, 113.0, 96.9 98.2, 111.9, 97.3 98.1, 97.0, 112.8 
Space group P1 P1 P1 
Resolution1 (Å) 38.6-2.20 (2.32-2.20) 50.0-2.40 (2.50-2.40) 46.1-2.50 (2.64-2.50) 
Observed reflections 276,664 (40,119) 421,849 (47,469) 312,430 (45,365) 
Unique reflections 139,578 (20,240) 107,887 (12,316) 94,724 (13,764) 
Completeness (%) 97.6 (96.8) 98.0 (96.8) 96.6 (96.0) 
Average redundancy 2.0 (2.0) 3.9 (3.9) 3.3 (3.3) 
Rmerge
2 (%) 7.5 (39.4) 10.6 (57.1) 12.5 (57.4) 
<I / σ(I)> 6.5 (2.0) 8.7 (2.3) 7.2 (2.0) 
Refinement  
Resolution (Å) 37.5-2.20 49.3-2.40 46.1-2.50 
Rcryst
3
 (%) 14.7 13.8 18.0 
Rfree (%) 20.0 19.2 25.0 
Monomers per AU 8 8 8 
Number of atoms 17,719 17,561 17,079 
Rmsd bond lengths (Å) 0.012 0.011 0.018 
Rmsd bond angles (°) 1.739 1.677 1.814 
Average B-factor (Å2) 34.4 49.5 45.6 
Ramachandran-plot4    
Favored (%) 95.9 96.3 94.8 
Allowed (%) 4.0 3.5 5.1 
Outliers (%) 0.1 0.2 0.1 
Maximum likelihood based 
estimated coordinate error (Å) 0.13 0.14 0.21 
PDB code 4BNI 4BNJ 4BNK 
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 PT68 PT70 PT119
Inhibitor structure 
 
 
 
 
 
 
 
 
Data collection  
Cell dimensions  
a, b, c (Å) 89.8, 94.5, 94.9 89.1, 94.8, 94.6 89.9, 94.6, 94.3 
α, β, γ (°) 97.9, 112.9, 97.0 98.0, 112.2, 97.4 97.9, 112.0, 97.3 
Space group P1 P1 P1 
Resolution1 (Å) 42.8-2.15 (2.27-2.15) 46.4-2.35 (2.48-2.35) 40.9-2.25 (2.37-2.25) 
Observed reflections 290,458 (42,164) 223,766 (32,400) 255,816 (37,092) 
Unique reflections 147,365 (21,435) 113,028 (16,397) 129,530 (18,781) 
Completeness (%) 96.9 (96.2) 97.6 (96.9) 97.5 (96.8) 
Average redundancy 2.0 (2.0) 2.0 (2.0) 2.0 (2.0) 
Rmerge
2 (%) 7.0 (40.5) 8.6 (35.4) 8.6 (43.0) 
<I / σ(I)> 6.6 (1.9) 6.1 (2.0) 6.0 (2.0) 
Refinement  
Resolution (Å) 42.8-2.15 46.4-2.35 40.9-2.25 
Rcryst
3
 (%) 14.6 14.8 15.1 
Rfree (%) 19.6 21.2 20.6 
Monomers per AU 8 8 8 
Number of atoms 17,874 17,629 17,807 
Rmsd bond lengths (Å) 0.012 0.010 0.011 
Rmsd bond angles (°) 1.834 1.694 1.761 
Average B-factor (Å2) 34.5 30.5 34.7 
Ramachandran-plot4    
Favored (%) 96.3 95.8 95.8 
Allowed (%) 3.7 4.1 4.1 
Outliers (%) 0.0 0.1 0.1 
Maximum likelihood based 
estimated coordinate error (Å) 0.12 0.15 0.14 
PDB code 4BNL 4BNM 4BNN 
 
1Values in parenthesis refer to the highest resolution shell 
2  −=
hkl i
i
hkl i
imerge IIIR  
3  −=
hkl
obs
hkl
calcobscryst FFFR  
4According to Molprobity (172) 
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Table S 3-2. SaFabI kinetic parameters for the mechanistic model in Figure 3-2. 
Parameter Estimate Rationale
KS 
0.75 mM for cro-CoA 
100 μM for oct-CoA 
In the case of cro-CoA, Kd is approximated by Km since kcat is small. 
For oct-CoA, a similar approximation is likely to be true since 
Km,S
app stays relatively constant at varying NADPH concentrations.  
KNADPH 250 μM 
Km,NADPH
app stayed relatively constant at varying oct-CoA 
concentrations. Fluorescence-based direct binding experiments 
were consistent with weaker binding of NADPH to saFabI than 
NADH to FabI homologues (< 10 μM). 
KNADP 1 M 
This is a reasonable lower limit estimate consistent with the lack 
of observable product inhibition in the presence of 5 mM NADP+ 
and the minimal effect of 2 mM NADP+ on the kinetics of 500 nM 
PT53. The true affinity may actually be weaker. 
kon,S 6 ∙ 108 M-1 min-1 
This arbitrary estimate is within an order of magnitude of the 
diffusion-limited rate constant, which represents the theoretical 
ceiling. The value will only affect the kinetic system if it is low 
enough to be rate limiting (approx. 6 ∙ 106 M-1 min-1). 
kon,NADPH
 9 ∙ 106 M-1 min-1 
A value less than an order of magnitude lower significantly 
decreases catalytic activity. However, higher values result in 
lower than observed Km,NADPH
app. 
koff, NADP
 3 ∙ 104 min-1 
Off rates slower than 3 ∙ 103 min-1 result in low Km,NADPHapp and 
activity. Faster off rates require higher estimates of inhibitor 
(diphenyl ether) affinity to account for observed levels of 
inhibition. To counterbalance the increased sensitivity of 
inhibition to added NADP+, the NADP+ affinity must also be 
proportionally decreased. Based on the diphenyl ether 
association rate constant, which must not exceed the diffusion-
limited rate constant, the upper limit off rate is in the range of 3 ∙ 
105 min-1.  
kcat
 40 min
-1 for cro-CoA 
4000 min-1 for oct-CoA 
Derived from previously published Michaelis-Menten kinetic 
data. 
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Table S 3-3. Morrison-Walsh analysis of theoretically generated progress curves.a 
[I] (nM) kobs (hr-1) vs (μM hr-1) k-1 (hr-1) b 
0  84.6c  
50 2.7089 67.3 2.1919 
250 4.4315 36.0 1.8838 
500 6.9294 21.8 1.7870 
750 9.4962 15.6 1.7448 
1000 12.1030 12.1 1.7239 
1250 14.7280 9.8 1.7121 
 
a. Parameters: [E] = 65 nM, [Cro-CoA] = 1.5 mM, [NADPH] = 350 μM, [NADP] = 400 μM; for the 
inhibitor, kon = 1.37 x 10
10 hr-1 and koff = 1.70 hr
-1 
b. Calculated as kobs ∙ , where v0 is the uninhibited reaction velocity 
c. At this reaction velocity, steady-state [E-NADP+] = 0.051 nM and steady-state [E-NADPH] = 0.017 
μM 
 
 
 
Table S 3-4. Theoretical analysis of electrostatic contribution to affinity by 
assuming inhibitor binding solely as a deprotonated species (pH 7.5). 
Inhibitor pKa 
Assumed 
Ki (nM) 
Predicted 
Kiapp (nM) 
Experimental 
Kiapp (nM) 
PT51 9.12 a 0.460 24515.0 d 24515.0 
PT55 8.12 a 0.460 3040.8 1851.8 
PT104 7.71 b 0.460 1566.4 1933.4 
     
PT53 9.15 a 0.007 493.7 d 493.7 
PT52 8.32 b,c 0.007 79.4 161.2 
 
a. Experimental value was obtained from (97). 
b. Experimental value was measured in this study. 
c. A similar value was reported in (97). 
d. Experimental value was used to determine a theoretical Ki. This Ki was assumed to hold 
true for similarly grouped compounds (blue or green). 
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Figure S 3-1. In the absence of inhibitor, ten percent deviation from linearity is achieved at ΔA340 of 0.18 and 
0.19 for the lower and higher velocity reactions, respectively. Reaction velocities were varied via changes in 
enzyme concentration. Solid lines depict the experimental fit to Eq. 1; dotted lines depict a linear extrapolation 
of the initial velocity. 
 
 
 
Figure S 3-2. (A) The Michaelis-Menten relationship is plotted for saFabI (20 nM) utilizing octenoyl-CoA (37.5 
μM) and varying concentrations of NADPH in the absence of NADP+ (; trace). Points corresponding to initial 
velocity measurements in the presence of 1.5 mM () and 5 mM () NADP+ are superimposed. (B) The 
progress curves depict saFabI inhibition by 500 nM PT53 in the presence of 400 μM () and 2000 μM NADP+ 
(). Best-fit parameters for the pseudo-first order rate constant (kobs) and steady-state velocity (vs) are 0.139 
min-1 and 0.98 μM min-1, respectively, at 400 μM NADP+ and 0.146 min-1 and 0.87 μM min-1, respectively, at 
2000 μM NADP+. 
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4 Molecular Basis for the Narrow-spectrum Activity of the 
Clinical Candidate CG400549 and the Rational Design of a 
Potent Broad-spectrum Pyridone-based FabI Inhibitor. 
 
This chapter is based on the following publication: 
 
Schiebel, J.*, Chang, A.*, Shah, S., Lu, Y., Liu, L., Pan, P., Hirschbeck, M. W., Tareilus, M., 
Eltschkner, S., Cummings, J. E., Knudson, S. E., Bommineni, G. R., Yu, W., Walker, S. G., 
Slayden, R. A., Sotriffer, C. A., Tonge, P. J., and Kisker, C. (in preparation‡) Molecular Basis for 
the Narrow-spectrum Activity of the Clinical Candidate CG400549 and the Rational Design of 
a Potent Broad-spectrum Pyridone-based FabI Inhibitor. 
 
Author contributions with respect to data collection: 
 
Schiebel, J.:  X-ray crystallography, computational docking 
Chang, A.:  Enzyme kinetics, MIC determination, thermal shift assays 
Shah, S.:  Synthesis of 2-pyridone inhibitors (details not shown) 
Lu, Y.:   In vivo mouse model of infection 
Liu, L.:   Pharmacokinetics 
Pan, P.:  Synthesis of 4-pyridone inhibitors (details not shown) 
Hirschbeck, M. W.: X-ray crystallography (bpFabI-NAD+-PT155) 
Tareilus, M.:  X-ray crystallography (ecFabI-NADH-CG400549) 
Eltschkner, S.:  X-ray crystallography (ecFabI-NADH-PT166) 
Bommineni, G. R.: Synthesis of 2-pyridone inhibitors (details not shown) 
Cummings, J. E.: MIC determination 
Knudson, S. E.: MIC determination 
Yu, W.:  Protein expression and purification 
 
*These authors contributed equally 
‡The printed version might be subject to some changes prior to submission 
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4.1 Keywords 
target selectivity; induced-fit substrate recognition; induced-fit inhibitor binding; fatty acid 
biosynthesis; Staphylococcus aureus FabI; enoyl-ACP reductase; pyridones; diphenyl ethers; 
enzyme kinetics; crystallography; structure based drug design; CG400549 
4.2 Capsule 
Background: The enoyl-ACP reductase FabI is a promising target for the development of 
novel antibiotics. 
Results: Our data reveal the molecular determinants conferring S. aureus FabI selectivity to 
the clinical candidate CG400549. 
Conclusion: The rationally designed FabI inhibitor PT166 has higher intrinsic potency and 
broad-spectrum activity. 
Significance: This study demonstrates how to rationally expand the spectrum of 
antimicrobial activity. 
4.3 Summary 
Determining the molecular basis for target selectivity is of particular importance in drug 
discovery. The ideal antibiotic should be active against a broad spectrum of pathogenic 
organisms with only a minimal effect on human targets. CG400549 - a Staphylococcus-
specific 2-pyridone compound that inhibits the enoyl-ACP reductase (FabI) - has recently 
been confirmed to possess human efficacy for the treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections, which constitute a serious threat to human health. 
In this study, we solved the structures of three different FabI homologues in complex with 
several pyridones including CG400549. Based on these structures we rationalize the 65-fold 
reduced affinity of CG400549 towards Escherichia coli vs. S. aureus FabI and implement 
concepts to improve the spectrum of antibacterial activity. Specifically, the identification of 
different conformational states along the reaction coordinate of the enzymatic hydride 
transfer provides an elegant visual depiction of the relationship between catalysis and 
inhibition, which facilitates rational drug design. Ultimately, we were able to develop the 
pyridone compound PT166 that potently inhibits FabI with broad-spectrum in vitro activity, 
favorable pharmacokinetic profile, and efficacy in a mouse model of S. aureus infection. 
4.4 Introduction 
Staphylococcus aureus can cause a variety of bacterial infections ranging from common skin 
infections to life-threatening pneumonia or bacteraemia (29). In particular, methicillin-
resistant S. aureus (MRSA)7 poses an imminent risk to immuno-compromised patients in 
healthcare settings all over the world. In addition, the incidence of community-acquired 
MRSA infections has increased amongst otherwise healthy individuals (29,211). The initial 
occurrence of S. aureus strains resistant to vancomycin (VRSA), an antibiotic used to treat 
severe MRSA infections (143), underlines the urgent need for novel anti-staphylococcal 
drugs. 
Isoniazid, a first-line prodrug for the treatment of tuberculosis, inhibits the type II fatty acid 
biosynthesis (FAS-II) pathway of Mycobacterium tuberculosis (53). The clinical success of 
isoniazid validates the FAS-II pathway as a valuable target for the development of new 
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antibiotics (54). Importantly, bacterial fatty acid biosynthesis differs from its mammalian 
counterpart and is pivotal for the production of several cellular components, such as 
phospholipids (19,50). In the last step of the FAS-II elongation cycle, the enoyl-acyl carrier 
protein (ACP) reductase (FabI) catalyzes the reduction of the trans-2-enoyl-ACP double bond 
(Figure 4-1) (78,108). The discoveries that activated isoniazid and the antimicrobial agent 
triclosan inhibit FabI (55,71,111,117,212) generated significant interest in this enzyme as a 
potential broad-spectrum target shared among many pathogenic organisms (1,67). However, 
the finding that distinct bacteria like Streptococcus pneumoniae or Vibrio cholerae utilize 
FabI isoenzymes including FabK (64), FabL (65) and FabV (66) or can take up exogenous fatty 
acids from the host blood serum to circumvent the inhibition of FabI (90), has altered the 
perception that FabI could be a broad-spectrum target (1). Nevertheless, for several clinically 
relevant pathogens such as S. aureus, Staphylococcus epidermidis, Escherichia coli, 
Haemophilus influenzae, Francisella tularensis and M. tuberculosis FabI remains a very 
promising drug target since these organisms require endogenous fatty acids (19,53,88,89) 
and contain FabI as the sole enoyl-ACP reductase (101,102). Accordingly, several drug design 
programs have been continued, and three S. aureus FabI (saFabI) inhibitors with different 
scaffolds (Figure 4-1) have been advanced to clinical trials (103). 
 
 
Figure 4-1. Catalyzed reaction and successful inhibitor classes of S. aureus FabI. FabI catalyzes the reduction 
of the trans-2-enoyl-ACP substrate via an enolate intermediate (n = 0 - 8) (51). In the case of saFabI, the hydride 
(shown in red) is delivered by the reducing agent NADPH (19,78,108). During the second step of the reaction 
the enolate intermediate is protonated, which leads to the formation of the final acyl-ACP product (the proton 
is depicted in blue). Examples for the most important FabI inhibitor classes are given in the boxes along with 
their binding mode in the saFabI active site pocket (PDB-codes: 4FS3 and 4ALI (19,101); the CG400549 structure 
was solved during this study). For each of these inhibitor scaffolds, one compound is currently in clinical trials 
(AFN-1252, MUT056399 and CG400549) (103). One common feature of these FabI inhibitors is the formation of 
a hydrogen bond to Tyr157 and the cofactor NADP(H). The oxygen atoms involved in this central interaction are 
colored in magenta. In addition, all depicted inhibitors directly interact with Ala97 (the interacting inhibitor 
atoms are highlighted in orange). 
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Based on the lead compound triclosan, Mutabilis developed the diphenyl ether MUT056399 
(Figure 4-1), which displays activity against S. aureus and several important Gram-negative 
pathogens (92,102). In contrast, the pyridone CG400549 (CrystalGenomics) as well as the 
naphthyridinone AFN-1252 (GlaxoSmithKline and Affinium Pharmaceuticals) were shown to 
be Staphylococcus-specific (Figure 4-1) (1,4,31,100,101,213). Importantly, all three FabI 
inhibitors have been shown to be efficacious in mouse models of infection (92,100,101). 
Very recently, CrystalGenomics announced that the Phase 2a study for CG400549 has been 
completed and confirmed human efficacy without serious adverse events8. 
Extensive studies have been conducted on the molecular recognition of diphenyl ethers by 
(sa)FabI (19,67,188). However, little is known about the binding of pyridone inhibitors such 
as CG400549. These compounds were intended to simply improve pharmacokinetic 
properties by replacing the metabolically labile phenol of the diphenyl ether skeleton with a 
stable pyridone (103). Despite the structural similarity between pyridones and diphenyl 
ethers, we reveal fundamental differences in the molecular recognition of these two 
scaffolds by FabI enzymes, which serve as the underlying basis for their respective narrow- 
and broad-spectrum activities. We report the first pyridone-bound crystal structures of 
saFabI, in addition to a complete kinetic profile of inhibition. In particular, we solved the 
CG400549-bound saFabI and E. coli FabI (ecFabI) structures, which help to rationalize the 
selectivity of this compound for the S. aureus homologue. Based on our cumulative insights, 
we have developed the novel 4-pyridone inhibitor PT166 that exhibits broad-spectrum in 
vitro activity and in vivo efficacy in a murine S. aureus thigh infection model. 
4.5 Experimental Procedures 
4.5.1 Compound synthesis 
The pyridone compounds PT155, PT159, PT166, PT170, PT171, PT172, PT173, PT179, PT191, 
PT420 and CG400549 were synthesized as described in the supplement. 
4.5.2 Expression and Purification 
SaFabI was prepared as described previously (19,144). Briefly, we expressed the safabi gene 
cloned into a pETM-11 vector in E. coli BL21(DE3), disrupted the cells and obtained the > 
95% pure protein in 25 mM Tris pH 8.0 and 200 mM NaCl via Ni2+ affinity and size exclusion 
chromatography. In addition, E. coli FabI (ecFabI) was expressed and purified as described 
previously (109). Burkholderia pseudomallei FabI (bpFabI) was obtained using a previously 
described procedure (214) with the final size exclusion chromatography step (Superdex 200 
26/60, GE Healthcare/ÄKTA) performed in 20 mM Bistris pH 6.5, 500 mM NaCl, 1 mM EDTA. 
4.5.3 Crystallization 
Prior to concentrating saFabI samples from 2 to 15-19 mg/ml, the protein was incubated for 
2 hours at 20 °C with a 12-fold molar excess of NADPH and a 20-fold molar excess of 
inhibitor dissolved in DMSO (CG400549 or PT173, respectively). Diffraction-quality crystals 
were grown in vapor diffusion experiments with a precipitant solution containing 0.1-0.2 M 
Li2SO4 and 20-24% PEG 3350. For CG400549, we obtained crystals of space group P212121 
with two different sets of cell parameters (the resulting structures were named CG400549-I 
and II; Table S 4-1). 
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Similarly, ecFabI samples at a concentration of 13 mg/ml were incubated for 2 hours at 4°C 
with a 10-fold molar excess of NADH and a 20-fold molar excess of CG400549 or PT166 
(dissolved in DMSO), respectively. Hanging-drop vapor diffusion experiments yielded 
diffraction-quality crystals in drops composed of 1 µl of this protein-ligand mixture and 1 µl 
precipitant solution (0.2 M NH4Ac, 0.1 M CAPS pH 10.5 and 20% PEG 8000 in the case of 
CG400549; 0.2 M NH4Ac, 0.1 M sodium citrate pH 5.6 and 10% PEG 8000 in the case of 
PT166). 
BpFabI samples with a concentration of 10-30 mg/ml were incubated for 2 hours at 20 °C 
with a 10-fold molar excess of NAD+ and a 20-fold molar excess of PT155 (dissolved in 
DMSO). Sitting-drop vapor diffusion experiments yielded diffraction-quality crystals in drops 
composed of 0.3 µl of the protein-ligand mixture and 0.3 µl precipitant solution (20% PEG 
3350 and 200 mM (NH4)2HPO4). 
4.5.4 Data Collection and Structure Determination 
Prior to flash-freezing in liquid nitrogen, the saFabI ternary complex crystals were 
successively transferred into solutions composed of mother liquor supplemented with 10 
and 25% ethylene glycol, respectively. Diffraction data were collected at the BESSY II MX 
beamline 14.1 (199) (λ = 0.918 Å, T = 100 K) equipped with a MarMosaic 225 detector, 
integrated with Imosflm (CG400549-II and PT173) (178) or XDS (CG400549-I) (183) and 
further processed using Scala (179). The CG400549 structures were solved by molecular 
replacement with Phaser (180) using our previously published saFabI structure (PDB-code: 
4ALK; lacking amino acids 196-202) as search model (19). For PT173, the fully refined 
CG400549-I structure was used as a template for the molecular replacement procedure. To 
avoid model bias, Rfree flags were copied from the search model (PT173) and assigned in thin 
resolution shells (CG400549-I and II). The final structures were obtained by several alternate 
cycles of model building in Coot (182) and refinement in Refmac 5 (CG400549-bound 
structures) (181) or Phenix (PT173) (185), respectively (including NCS- (PT173, CG400549-II) 
and TLS-refinement (200)). Amplitude-based twin refinement was used in the case of 
CG400549-II, for which we detected slightly twinned data. Cofactors and inhibitors could be 
unambiguously assigned based on the 2Fo-Fc and Fo-Fc electron density maps. 
Crystals of the CG400549 and PT166 ternary complexes were cryo-protected using the 
corresponding mother liquor supplemented by 25% or 30% ethylene glycol, respectively. 
Using a Pilatus 6M detector, diffraction data were collected at the MX beamline 14.1 of the 
BESSY II synchrotron (λ = 0.918 Å, T = 100 K) and at beamline ID 23-1 of the ESRF (λ = 1.064 
Å, T = 100 K), integrated using XDSAPP (215) and scaled with Scala. Initial phases were 
determined by molecular replacement in Phaser with our previously published ecFabI 
structure (PDB-code: 1QSG) as the search model (111). Model building in Coot and 
refinement using Refmac 5 (including TLS-refinement) yielded the final structure. We did not 
model the amino acid range 193 to 209-211 due to only partial and very weak electron 
density. In addition, we note that the CG400549 electron density in subunit B was still 
sufficient but not as good as in monomer A. Dictionaries for the cofactors and inhibitors of 
the S. aureus and E. coli FabI structures were computed using Grade (216,217). 
BpFabI crystals were cryo-cooled in cryo-protectant containing 25% glycerol in the mother 
liquor. Data collection was performed at an in-house X-ray generator (MicroMax-007 HF, 
Rigaku) at a wavelength of 1.54 Å and recorded with an imaging plate detector (R-Axis HTC, 
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Rigaku). Data were integrated with Imosflm and scaled in Scala. Molecular replacement was 
performed in Phaser using the PDB entry 3EK2 as a template. For refinement in Refmac and 
finally Phenix TLS parameters were created using the TLSMD server (200) and a library file 
supplying restraints for the cofactor and inhibitor was generated by the Prodrg server (187). 
The structure was refined until convergence (R/Rfree= 14/16%) and validated using the 
Molprobity server (218). 
To avoid model bias, omit maps were calculated prior to inclusion of cofactors and 
inhibitors. Data collection and refinement statistics are given in the Supplemental Table S 4-1 
(saFabI) and Table S 4-2 (ecFabI and bpFabI). Distances and angles were measured for all 
subunits of the asymmetric unit and are given as mean values ± standard deviation. 
Structural figures were prepared using PyMOL (174). 
4.5.5 Inhibition Kinetics 
Kinetics were performed on a Cary 100 spectrophotometer (Varian) at 20°C. Reaction 
velocities were measured by monitoring the oxidation of NAD(P)H to NAD(P)+ at 340 nm (ε = 
6220 M-1 cm-1). For saFabI, the reaction mixture was identical to that described previously 
for progress curve experiments (19). For ecFabI, the final reaction mixture contained ecFabI 
(75 nM), trans-2-butenoyl-CoA (800 μM; Sigma and Advent Bio), NADH (300 μM; Sigma), 
NAD+ (400 μM; Sigma) and inhibitor (2% v/v DMSO) in 50 mM potassium phosphate pH 7.5, 
150 mM NaCl, 8% glycerol. The resulting curves were fit to the Morrison & Walsh integrated 
rate equation (Equation 1) (202). Kiapp was determined using the standard isotherm equation 
(Equation 2) or Morrison quadratic equation for tight-binding inhibitors (Equation 3) (219). 
For pyridones, the Ki was extracted from Kiapp using Equation 4, where KS and KNAD(P)H values 
are provided in Table S 4-3 or (188). 
 (Eq 1) 
where At and A0 are the absorbance at time t and time 0, vi and vs are the initial and steady-
state velocities and kobs is the pseudo-first order rate constant for the approach to steady-
state. 
 
(Eq 2) 
where vu is the control, uninhibited velocity and Kiapp is the IC50 value. 
 
 (Eq 3) 
 
where [E]T and [I]T are the total enzyme and inhibitor concentrations, respectively. 
 
 (Eq 4) 
 
where KS and KNAD(P)H are the respective dissociation rate constants for the enoyl-CoA 
substrate and NAD(P)H. 
For the jump dilution assay, 10 μM saFabI, 15 μM inhibitor and 500 μM NADPH were 
preincubated overnight at room temperature followed by 1:200 dilution into reaction buffer 
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(50 mM potassium phosphate pH 7.5, 150 mM NaCl, 1 M potassium glutamate, 8% glycerol) 
containing 1.5 mM trans-2-butenoyl-CoA and 350 μM NADPH. The resulting progress curve 
was fitted to Eq 1. All curve fitting was performed using KaleidaGraph Version 4.1. 
4.5.6 Thermal Shift Assay 
ThermoFluor experiments were carried out in 96-well plates (Concord) using the CFX96 Real-
Time PCR Detection System and C1000 Thermal Cycler (Bio-Rad), as described previously 
(188). 
4.5.7 Docking Studies 
A computational docking and scoring procedure was used to generate putative binding 
modes for all pyridone inhibitors investigated in this study. The binding poses were 
generated with FlexX (BioSolveIT, Sankt Augustin, 2009), version 3.1.4 (220), and rescored 
with DrugScoreX (G. Neudert and G. Klebe, University of Marburg, 2008), version 0.21, which 
builds on DrugScore and utilizes the DrugScoreCSD potentials (221-223). To account for the 
flexibility of the substrate binding loop, we docked all inhibitors into subunits A and C of the 
saFabI CG400549-I structure, which represent the two experimentally observed states (for 
details see results section). The selection of the most likely binding pose and receptor was 
based on the DrugScoreX Score combined with visual inspection (Figure S 4-1). A comparison 
with the available experimental binding modes revealed rms deviations below 1.1 Å for the 
ten best-ranked binding poses, with 0.7 Å (CG400549) and 0.8 Å (PT173) for the top-ranked 
pose, respectively (Figure S 4-1A and Figure S 4-1B). These re-/cross-docking experiments 
confirm the validity and reliability of our computational approach. 
The inhibitors were setup with MOE (Chemical Computing Group, Montreal, 2010), version 
2010.10 (224), and energetically minimized (Tripos force field) using SYBYL-X (Tripos, St. 
Louis, 2009), version 1.0 (225). NADPH was protonated within the saFabI environment using 
MOE. The saFabI CG400549-I crystal structure was protonated in FlexX and the binding site 
region defined by NADPH and the amino acids 93-99, 102, 121, 146-147, 154-157, 160, 164, 
190-193, 195, 197-204 and 207. Water molecules within a radius of 6 Å around CG400549 
were included during the docking procedure and treated as displaceable particles. FlexX was 
run in command line mode with a default docking procedure, followed by post-docking 
optimization. Rms deviations were calculated using fconv (G. Neudert and G. Klebe, 
University of Marburg, 2012), version 1.24 (226). 
4.5.8 Determination of MIC Values 
MIC values were determined with the microbroth dilution assay according to the Clinical and 
Laboratory Standards Institute methods for antimicrobial susceptibility tests for aerobically 
growing bacteria (227). 
4.5.9 In vivo Pharmacokinetics 
Pharmacokinetic (PK) studies were conducted in female ICR mice via intraperitoneal 
administration of PT04 (200 mg/kg dose) or PT166 (100 mg/kg dose) in a vehicle of 40% PEG 
/ 40% EtOH / 20% H2O. Blood samples were collected from each animal at eight time points 
(5 min, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-injection). Three 
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mice were sampled per time point. Plasma concentrations for each sample were measured 
by LC/MS/MS, and PK parameters were calculated with WinNonlin (Pharsight Corporation, 
Mountain View, CA, USA). 
4.5.10 In vivo Efficacy 
Anti-bacterial efficacy of 5-hexyl-2-phenoxyphenol (PT04) and PT166 (Table 4-1) was 
evaluated in a neutropenic mouse thigh infection model. Six week old, male Swiss Webster 
mice weighing 23 to 27 g were rendered neutropenic by intraperitoneal injection of 
cyclophosphamide 4 days (150 mg/kg) and 1 day (100 mg/kg) prior to infection. Previous 
studies have shown that this can produce severe neutropenia in mice for at least 5 days 
(228). 
MRSA strain BAA1762 was cultured in Mueller-Hinton (MH) broth to mid log phase (OD600 = 
0.4; 3×108 CFU/ml) and harvested by centrifugation. Cell pellets were resuspended in freshly 
sterilized Brain Heart Infusion (BHI) broth to a final inoculum of 1×107 CFU/ml. 50 µl of this 
suspension (5×105 CFU) was injected intramuscularly into the left thigh of each mouse while 
50 µl of BHI broth was injected into the right thigh as control. Drug was administered by 
subcutaneous injection at 1 hour and 12 hours post-infection (100 mg/kg dose per injection). 
Mice were euthanized 24 hours post-infection. Each thigh muscle was subsequently 
collected and homogenized in saline containing 10% BHI broth. Bacterial load was 
determined by counting colony-forming units of serial dilutions plated on MH sheep blood 
agar. 
For in vivo efficacy and PK studies, all animals were maintained in accordance with criteria 
set by the American Association for Accreditation of Laboratory Animal Care. This study was 
approved by the Institutional Animal Care and Use Committee (IACUC) at Stony Brook 
University. 
4.6 Results 
CG400549 and related 2-pyridones selectively inhibit growth of S. aureus – The 2-pyridone 
CG400549 exhibits potent activity against S. aureus in contrast to many other bacteria such 
as E. coli, Listeria monocytogenes, Helicobacter pylori and Pseudomonas aeruginosa (31). We 
confirmed this disparity by comparing growth inhibition of S. aureus and E. coli by various 2-
pyridone inhibitors (Table 4-1 and Table 4-2). An important question to address is whether 
this narrow-spectrum behavior can be attributed to FabI-specific differences between 
species. 
 
Table 4-1. Thermodynamic parameters for inhibitors of saFabI a 
Name Structure Kiapp (nM) b Ki (nM) MIC (μM) c 
CG400549 4.73 ± 0.50 1.27 ± 0.13 5.87 
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PT173 7.30 ± 1.54 1.97 ± 0.42 6.70 
PT171 
 
44.28 ± 6.57 11.94 ± 1.77 n.d. d 
PT179 
 
70.44 ± 9.83 18.99 ± 2.65 118.79 
PT420 
 
109.75 ± 1.66 29.58 ± 0.45 108.70 
PT172 
 
40.74 ± 1.31 10.98 ± 0.35 26.33 
PT170 
 
848.61 ± 19.32 228.74 ± 5.21 > 500 
PT166 10.05 ± 2.10 2.71 ± 0.57 0.83 
PT159 
 
40.97 ± 3.42 11.04 ± 0.92 12.89 
PT191 
 
729.09 ± 82.39 196.50 ± 22.21 n.d. d 
PT01 e 
 
120.8 ± 10.1 0.09 ± 0.01 2.33 
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PT51 e 
 
24515.0 ± 1359.8 18.86 ± 1.05 687.40 
PT53 e 
 
493.7 ± 40.2 0.38 ± 0.03 19.98 
 
a. Curve fitting errors are reported for each value in the table 
b. [S]/KS = 2 
c. Value reported against S. aureus RN4220 
d. n.d. = not determined 
e. Binds to the E-NADP+ binary complex; Ki and Kiapp values obtained from (188). 
 
 
Table 4-2. Thermodynamic parameters for inhibitors of ecFabI a 
Name Structure Kiapp (nM) b Ki (nM) MIC (μM) c 
CG400549 99.38 ± 2.26 81.85 ± 1.86 > 375 
PT173 246.04 ± 10.13 202.63 ± 8.34 > 425 
PT171 
 
116.23 ± 4.58 95.72 ± 3.77 n.d. d 
PT166 8.51 ± 0.17 7.01 ± 0.14 6.68 
PT01 e 
 
33.58 0.22 0.58 
PT04 e 
 
32.24 0.20 14.79 
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PT52 e 
 
26.88 0.12 0.14 
PT55 e 
 
92.59 1.10 1.22 
 
a. Curve fitting errors are reported for each value in the table 
b. [S]/KS = 0.19 
c. Value reported against E. coli MG1655 ΔacrAB 
d. n.d. = not determined 
e. Binds to the E-NAD+ binary complex. Ki and Kiapp values were determined via single point progress curve 
analysis, as described in (188). Kinetic parameters for each step in the mechanistic model depicted in 
Figure 4-2B are listed in Table S 4-3. 
 
As expected, the apparent inhibition constant (Kiapp) of CG400549 against saFabI was very 
potent (Kiapp = 4.7 nM, Table 4-1) - more so than any of the diphenyl ether compounds 
previously tested (188). In the case of E. coli FabI (ecFabI), the apparent inhibition was 
weaker relative to saFabI (Kiapp = 99.4 nM). However, diphenyl ethers with similar Kiapp values 
still exhibit potent inhibition of E. coli cell growth (Table 4-2). This provided the first hint that 
pyridones may act via a different mode of action. 
 
In contrast to the diphenyl ethers, 2-pyridones bind to the E-NADPH complex and exhibit fast-
off kinetics – Very recently, we found that diphenyl ethers bind exclusively to the E-NADP+ 
enzyme-product complex generated via catalysis (188). Despite the obvious structural 
similarity between pyridone and diphenyl ether inhibitors (Figure 4-1), thermal shift assays 
revealed preferable binding of pyridones to the E-NADPH complex (Figure 4-2A, Table 4-1). 
Thus, these inhibitors are uncompetitive with respect to NADPH but competitive with 
respect to the acyl substrate (Figure 4-2B). Our kinetic studies confirmed this pattern of 
saFabI inhibition, showing enhanced inhibition with increasing concentrations of NADPH and 
decreasing concentrations of the substrate trans-2-octenoyl-CoA used in the assay (data not 
shown). Moreover, we were able to co-crystallize pyridones with saFabI using the reduced 
form of the cofactor. Accordingly, the saFabI target can be productively inhibited at two 
different stages of the catalytic cycle, as exemplified by pyridones and diphenyl ethers 
(Figure 4-2B). This finding is of particular importance for the development of improved FabI 
inhibitors since most known scaffolds bind adjacent to the nicotinamide ring of the cofactor 
(67). The absence or presence of a buried positive charge in the E-NADPH vs. E-NADP+ binary 
complexes likely will have a critical influence on the affinity of potential inhibitors (152). 
Since NADPH binds with higher affinity to the enzyme compared to NADP+, the E-NADPH 
binary complex exists at a higher population (78,188). Thus, despite weaker thermodynamic 
affinity, the apparent inhibition of PT166 and CG400549 was much more potent than 
observed for the diphenyl ethers (Table 4-1) and required classical tight binding analysis 
(Figure 4-3D) (188). 
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Figure 4-2. Mechanisms of saFabI inhibition. (A) Thermal shift analyses of saFabI bound to NADPH, NADP+ 
and/or inhibitor (CG400549). The measurement variability is approximately ±0.2 °C. (B) Distinct mechanisms of 
saFabI inhibition. In contrast to diphenyl ethers (highlighted in red), which bind to the enzyme-product complex 
generated via catalysis (E-NADP+, depicted in blue) (188), pyridone compounds (shown in red) preferentially 
inhibit saFabI at the enzyme-substrate complex state (E-NADPH, depicted in blue). (C) Structural differences 
between diphenyl ether and pyridone ternary complexes. Per-residue rmsd values between our triclosan- 
(PDB-code: 4ALI, subunit H) and CG400549-bound (CG400549-I, subunit C) structures were calculated using 
Theseus (14) and are plotted against the residue number. The inhibitor-bound structures of these two scaffolds 
differ considerably in three regions of the protein (PRH = phosphate recognition helix α2, SBL-2 = substrate 
binding loop 2, SBL = substrate binding loop). (D) Pyridone and diphenyl ether inhibitors resemble different 
species along the enzymatic reaction coordinate. In contrast to the enolate-like diphenyl ethers which are 
transition state analogs (188), pyridones are more substrate-like. The corresponding moieties of inhibitors and 
species along the reaction coordinate are highlighted in green. 
 
Pyridone and diphenyl ether saFabI inhibitors also differ with respect to their apparent 
association and dissociation kinetics. Diphenyl ethers exhibit slow-binding kinetics and bind 
with long residence times to their target (Figure 4-3B and Figure 4-3C) (19,188). In contrast, 
progress curves of saFabI in the presence of pyridones are linear, displaying apparent rapid-
onset kinetics (Figure 4-3A). This is likely attributed to the higher population of E-NADPH 
compared to E-NADP+. In fact, an estimate of the actual association rate constant yields a 
value in the same range as for the diphenyl ethers (188). Moreover, the rapid appearance of 
activity following jump dilution is highly indicative of fast-off kinetics (Figure 4-3C), which 
may simply reflect the weaker thermodynamic affinity of pyridones compared to diphenyl 
ethers. 
The mode of action has significant implications for cell growth inhibition. In open systems, 
substrate accumulation may eventually diminish the effect of competitive inhibitors (229). It 
is, therefore, important to consider the relationship between substrate concentration and 
Kiapp (Figure 4-4B). In Figure 4-4A, we see a strong linear correlation for the double 
logarithmic plot of Ki vs. MIC for both 2-pyridones and diphenyl ethers, consistent with on-
target effects. However, higher overall ternary complex affinity (Ki ∙ Kd,NADP(H)) is needed for 2-
pyridones to obtain a similar cellular potency as diphenyl ethers. This observation can be 
readily explained by substrate accumulation. The MIC is a thermodynamic parameter that is 
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essentially equivalent to a physiological apparent inhibition constant (Kiapp). In the substrate 
concentration range of 40 to 80 times KS the relative Kiapp values are very predictive of the 
pattern of MIC values for both 2-pyridones and diphenyl ethers (Figure 4-4C). This may, thus, 
estimate the levels of substrate accumulation in the cell. Additionally, we can now translate 
Ki to Kiapp values that can be readily compared despite different modes of action. 
 
 
Figure 4-3. Progress curve kinetics. (A) Representative set of forward progress curves with pyridone-based 
inhibitors of saFabI. The plot depicts rapid-onset inhibition at different PT173 concentrations. (B) As a 
reference, this plot illustrates the slow-onset inhibition of saFabI by the diphenyl ether PT04 (188). Note the 
clear observation of curvature that is absent in panel A. (C) Jump dilution curve for CG400549 (black) following 
pre-incubation with NADPH and saFabI. The jump dilution curve for the slow-off diphenyl ether inhibitor PT52 
(gray) following pre-incubation with NADP+ and saFabI is shown as reference (full recovery of activity; tR=30 
min) (188). The lack of curvature for CG400549 is consistent with rapid-off kinetics. (D) Representative plot of 
fractional velocity (v/v0) as a function of inhibitor concentration for a potent pyridone (CG400549, in this 
example). The shape is characteristic of tight-binding inhibition. The best-fit curve to the Morrison quadratic 
equation (Eq. 3) yields Ki
app = 4.73 ± 0.50 nM and [E]T = 92.73 ± 2.52 nM (R
2 = 0.99). 
 
The utility of a scaffold for lead optimization is related, in part, to its intrinsic potency. We 
define this as the potency of a relatively unmodified scaffold – i.e. the starting point that 
determines how much affinity optimization is needed. For instance, PT170 and PT53 
represent relatively unmodified 2-pyridone and diphenyl ether scaffolds, respectively. The 
competitive mode of inhibition likely contributes to the weakening of the intrinsic potency of 
the 2-pyridone relative to the diphenyl ether scaffold by more than 20-fold (Figure 4-4B). 
Thus, further optimization of 2-pyridones is needed to achieve potent cellular activity. As we 
demonstrate below, such optimization is much more easily attained in the case of saFabI 
compared to other FabI homologues, providing rationale for the narrow spectrum activity of 
CG400549 and related 2-pyridone compounds. 
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Figure 4-4. Rationalizing the in vitro cellular potency of competitive and uncompetitive FabI inhibitors. (A) A 
double logarithmic plot depicts a strong linear correlation between Ki of the overall ternary complex (Ki ∙ 
Kd,NADP(H)) and MIC for the 2-pyridone series () and diphenyl ethers (). Points corresponding to 4-pyridones 
(X) are superimposed. Note that in this plot, the MIC for PT170 was assumed to be 550 μM, which is a lower 
limit estimate. (B) The relationship between acyl substrate concentration as a multiple of KS ([S]/KS) and the 
apparent affinity (Ki
app) of pyridones (PT170, PT172, CG400549) and diphenyl ethers (PT51, PT53, PT01) is 
illustrated. The plots are simulated based on Ki values against saFabI (Table 4-1 and (188)), the mechanism of 
inhibition shown in Figure 4-2B and the kinetic model described in (188). The range of substrate concentration 
that best correlates relative Ki
app to relative MIC for both classes of compounds is shaded gray. (C) This double 
logarithmic plot of Ki
app and MIC illustrates how 2-pyridones and diphenyl ethers can lie on the same linear 
correlation at the correct substrate concentration [S]. Data points correspond to inhibitor Ki
app values at [S]/KS 
of 1 (), 10 (X) and 100 (). The linear correlation for points corresponding to [S]/KS = 100 is depicted. 
 
The clinical trial compound CG400549 interacts tightly with saFabI – CG400549 binds with 
high affinity (Ki = 1.27 nM) to saFabI (Table 4-1). To provide insight into the underlying 
molecular interactions, we solved two different saFabI-NADPH-CG400549 ternary complex 
structures (CG400549-I and CG400549-II, respectively; unless stated otherwise, the 
CG400549-I structure was used for the following analyses; see also Table S 4-1). Based on 
the associated 2Fo-Fc omit maps, we unambiguously reveal the binding mode of CG400549 
(Figure 4-5B), which enables the formation of two central hydrogen bonds of the pyridone 
carbonyl oxygen with the Tyr157 hydroxyl and the NADPH nicotinamide ribose 2'-OH at 
distances of 2.74 ± 0.07 and 2.69 ± 0.10 Å, respectively (Figure 4-5A). Although reminiscent 
of interactions found for other inhibitor scaffolds (Figure 4-1), these hydrogen bonds are 
0.15 Å longer for pyridones in comparison to diphenyl ethers. This supports our suggestion 
that diphenyl ethers bind to saFabI in their deprotonated form (188) leading to shorter 
charge-assisted hydrogen bonds. Additional long-range hydrogen bonds are formed between 
the 3'-amino group of CG400549 (Figure 4-1) and the main chain oxygen and nitrogen of 
Ala97 at distances of 3.56 ± 0.06 and 3.32 ± 0.09 Å, respectively (Figure 4-5A). Moreover, a 
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water molecule is frequently bound between this B-ring NH2 group and Ala95 at 3.36 ± 0.18 
Å (Figure 4-5A). Interestingly, Ala97 engages in direct interactions for several potent saFabI 
inhibitors (Figure 4-1). Triclosan and AFN-1252 form halogen and hydrogen bonds with 
Ala97, respectively, and the amide group of MUT056399 was similarly suggested to interact 
with this residue (Figure 4-1) (19,101,102). 
 
 
 
Figure 4-5. Molecular interactions of the S. aureus and E. coli FabI homologues with the pyridone inhibitor 
CG400549. (A) Binding mode of CG400549 (cyan) in complex with saFabI and NADPH. Interactions between 
inhibitor, cofactor and protein are highlighted by yellow dashed lines. Selected residues of the saFabI binding 
pocket are shown as gray sticks (CG400549-I structure, subunit G). (B) 2Fo-Fc omit map for CG400549 bound to 
saFabI. According to the omit map (shown as mesh at 1 σ), CG400549 (cyan) unambiguously binds to the 
hydrophobic saFabI active site pocket. An intersection of the CG400549-I structure (subunit G, depicted in gray 
surface representation) provides insight into this cavity. (C) CG400549 (lilac) in its complex with ecFabI and 
NADH. The 2Fo-Fc omit map is depicted for CG400549 (shown as mesh at 1 σ) and clearly reveals the presence 
of this molecule although the substrate binding loop (SBL) region was found to be disordered in this structure 
(starting after residue 192 highlighted in red; subunit A of the ecFabI-NADH-CG400549 structure is shown in 
yellow cartoon representation). As a reference, the SBL of a superimposed ecFabI-NAD+-triclosan structure is 
shown in green (PDB-code: 1QSG) (111). Together with the SBL, the loop comprising Ala95 defines a portal 
towards the solvent. (D) Comparison between the CG400549-bound S. aureus (inhibitor in cyan - for clarity only 
present in insert, amino acids in gray) and ecFabI (inhibitor in lilac, amino acids in yellow) ternary complexes. 
The insert contains a comparison between the CG400549 binding modes, which differ in their B-ring 
conformations via changes in the torsion angles between the two aromatic rings (indicated by red arrows). 
Met256' of the subunit on the opposite side of the ecFabI homo-tetramer is depicted in pink. Residues Ile200 
and Met206 of the 1QSG structure are shown as reference in green. 
 
The unique 5-substituent of CG400549 binds to a hydrophobic pocket with the thiophene 
moiety trapped between the three aromatic amino acids Tyr147, Tyr157 and Phe204 (Figure 
4-5A and Figure 4-5B). The side-on π-stacking interaction between Tyr157 of the catalytic 
triad and the thiophene ring may contribute to the high affinity of CG400549 towards saFabI 
(Figure 4-5, Table 4-1). In particular, the thiophene sulfur interacts with the edge of Tyr157 
(Cδ) at a distance of 3.97 ± 0.11 Å (152). A similar interaction is found between this sulfur 
atom and Phe204 (Cδ) at 4.15 ± 0.16 Å (Figure 4-5A). Remarkably, amongst thirteen 
CG400549 resistant S. aureus strains ten were characterized by a single F204L mutation, 
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whereas the residual three had no mutations in the fabi gene (4,100). In contrast, multiple 
resistance mutations are known for diphenyl ethers (28,78,92,108,230). Accordingly, the 
Phe204 - thiophene interaction seems to be critical for the activity of CG400549. 
In addition to the CG400549 structures, we solved a saFabI structure in complex with NADPH 
and PT173, which contains a 5-hexyl group that mimics the natural enoyl-ACP substrate 
(Figure 4-1) (188). Although the resolution was much lower (Table S 4-1), there was clear 
density for cofactor and inhibitor (Figure 4-6B). The binding mode of PT173 in the saFabI 
active site pocket is similar to CG400549, and we observed the same central hydrogen 
bonding network between the inhibitor, cofactor and Tyr157 (Figure 4-6A). 
 
 
 
Figure 4-6. Binding modes of different pyridone inhibitors within the FabI active site pocket. (A) Experimental 
binding geometry of PT173 (green). Selected residues of the saFabI-NADPH-PT173 structure (gray, subunit F) 
and the central hydrogen bonding network (yellow dashed lines) are depicted. (B) NCS-averaged 2Fo-Fc omit 
map for PT173. The omit map is shown at 1 σ and reveals the presence of PT173 (shown in green). Subunit F of 
the PT173 structure is depicted in gray cartoon representation. (C) Putative binding mode of PT166 (yellow 
sticks) within the saFabI pocket (CG400549-I structure, subunit A). PT166 was docked into the saFabI binding 
cavity using the validated approach described in the Experimental Procedures section. The radii of the blue 
(red) spheres indicate the values of the favorable (unfavorable) score for each individual atom, as determined 
with DrugScoreX. Our bpFabI-NAD+-PT155 structure (cyan sticks) confirms this binding mode and suggests a 
rotation of Phe204 to avoid the steric interference with the N-methyl group of 4-pyridone inhibitors (indicated 
by the red sphere). Moreover, the putative binding mode is in accordance with our PT166-bound ecFabI 
structure (orange sticks, subunit A). The docking results for the residual pyridone inhibitors of Table 4-1 are 
summarized in Figure S 4-1. (D) 2Fo-Fc omit map for PT166 (orange sticks) bound to ecFabI (shown as mesh at 1 
σ). An intersection of the ecFabI-NADH-PT166 structure (subunit A, depicted in yellow surface representation) 
is shown. The SBL, which usually covers the binding site (in front of the cavity), was found to be disordered. 
 
Despite the prospects of CG400549, little is known about pyridone FabI inhibitors and their 
structure-activity relationships (SAR) (123,231,232). Thus, we synthesized a series of 
pyridone compounds and investigated their ability to inhibit saFabI (Table 4-1). To rationalize 
the SAR results, we generated putative binding modes for all investigated inhibitors using a 
validated docking procedure, which could reproduce the CG400549 and PT173 binding 
geometries with low rms deviations (0.71 Å and 0.83 Å, respectively) (Figure S 4-1). Due to 
the lipophilic environment, bulky and hydrophobic substituents are preferred at the 5-
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position. Hence, PT170 is the least potent compound of our pyridone series. Replacing the 5-
methyl group by a 5-hexyl group (PT172) leads to a 21-fold affinity enhancement, which is 
underlined by the favorable scores for the additional carbon atoms (Figure S 4-1). Similar to 
the 2'-chloro substituent of PT172, the 2'-methyl group of PT171, which is also present in 
CG400549, increases affinity by a factor of 2 compared to the unsubstituted analog PT179. In 
comparison to the 2'-Cl and 2'-Me groups, a 2'-CN substituent leads to decreased potency. 
Interestingly, the SAR at this position is different from diphenyl ethers for which 2'-cyano is 
the best substituent (188). Pyridone 2'-substituents are predicted to bind in a similar 
orientation (Figure S 4-1) as observed for diphenyl ethers. The introduction of a 3'-amino 
group as present in CG400549 and PT173 further enhances the affinity of PT171 by a factor 
of 6, which highlights the energetically favorable character of the observed long-range 
hydrogen bonds between those inhibitors and Ala97 (Figure 4-5A). Interestingly, PT173 was 
also found to be a competitive inhibitor of Yersinia pestis FabV (Ki = 1.5 µM), which raises the 
possibility of developing compounds that inhibit both FabI and the FabV isoenzyme (118). 
Replacement of the PT173 5-hexyl group with the thiophene containing 5-substituent of 
CG400549 further improves the affinity of the clinical trial compound 1.5-fold and might be 
explained by the additional aromatic interactions we observed. 
 
SaFabI conformational states differ between pyridone and diphenyl ether ternary complex 
structures – In accordance with the distinct kinetic behavior of pyridone and diphenyl ether 
inhibitors, we observed considerable structural differences between the corresponding 
ternary complex structures. A per-residue rmsd plot reveals variations in mainly three 
regions of the protein (Figure 4-2C) - the two substrate binding loops (SBL and SBL-2; 
residues 194-204 and 94-108) and the phosphate recognition helix α2 (PRH; residues 40-54), 
which confers the unique NADPH specificity to saFabI (19). The full closure of the substrate 
binding loop has been proposed to constitute the rate-limiting step of slow-binding FabI 
inhibition by diphenyl ethers (67). Indeed, we found more 'open' SBL states in the saFabI-
NADPH-CG400549 structures compared to the triclosan-bound structure (Figure 4-7A). Most 
likely the observation of the 'open' state can be attributed to steric interference between 
the thiophene moiety of CG400549 and the side chain of Val201 in the SBL if it would adopt 
the completely 'closed' state (Figure 4-7A, gray). Hence, Val201 is shifted by 2.9 ± 0.1 Å into 
the more 'open' CG400549-bound structure (Figure 4-7A, cyan). Interestingly, some subunits 
of the CG400549-I structure reveal a second, even more 'open' SBL state - the rmsd 
increases from 1.6 to 2.0 Å compared to the triclosan-bound reference structure - with an 
additional shift in helix α7, which we previously identified to be very flexible prior to ligand 
binding (Figure 4-7A, yellow) (19). Both SBL conformations in the saFabI-NADPH-CG400549 
complex seem to be energetically equally favorable due to the observation of subunits with 
both states in equilibrium. The more 'closed' state is stabilized by a sulfate ion, which is 
bound to backbone amides of the SBL; this state differs from the completely 'closed' 
triclosan-bound structure by a Lys199-Gly200 backbone flip (Figure 4-7A, right insert; ψK199 
and φG200 change by 156° and 159°, respectively), which is observed for seven of the eight 
CG400549-I monomers and might be responsible for the opening movement. An additional 
shift of residues 202-208 with extensive variations for Gly202 and Gly203 leads to the most 
'open' form (Figure 4-7A, left insert), which is related to the conformation observed for the 
AFN-1252 structure (101). 
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Figure 4-7. Structural variations between pyridone and diphenyl ether ternary complex structures. (A) 
Conformational states of the substrate binding loop. The different subunits of our CG400549-I structures reveal 
two distinct states of the substrate binding loop (SBL) and the attached helix α7 (shown in cyan and yellow for 
subunits A and C, respectively; residual parts of the protein are displayed in transparent colors for clarity). 
Compared to these conformations, the substrate binding loop is more closed in our triclosan-bound structure 
(shown in gray; PDB-code: 4ALI, subunit H). Detailed views of the three different conformations are displayed 
in the inserts. Red arrows indicate the conformational changes from the 'closed' to the 'open' substrate binding 
loop states. Blue arrows highlight backbone flips. (B) Conformational states of the substrate binding loop 2 
(SBL-2). Selected residues, the inhibitors and the substrate binding loop 2 are shown for the CG400549-I (cyan; 
subunit A) and triclosan-bound structures (gray; PDB-code: 4ALI, subunit H). 
 
Similar to the SBL, a second loop that also contributes to the substrate binding pocket (SBL-
2) was almost exclusively found to be in an 'open' conformation in the saFabI-NADPH-
CG400549 structures (Figure 4-7B, cyan). In contrast, we observed alternative 'closed' and 
'open' SBL-2 conformations for the diphenyl ether-bound structures (19). An Arg103-Gly104 
backbone flip (Figure 4-7B, left insert; ψR103 and φG104 change by 180° and 144°, respectively) 
clearly differentiates those two states. This flip is induced by (or induces) a 1.5 ± 0.5 Å shift 
of Leu102 out of the binding pocket, which in turn might be caused by (or causes) a 
considerable movement of the CG400549 B-ring towards this residue (Figure 4-7B). The 
resulting differences between the pyridone and diphenyl ether binding poses (Figure 4-7B) 
rationalize the varying SAR-profiles at the 2'-position for both scaffolds and the success of 
the 3'-amino substituent in the case of pyridones. In particular, the 2' and 3'-carbon atoms 
are relocated by 1.3 ± 0.1 Å and 1.6 ± 0.1 Å, respectively, which places the CG400549 3'-
carbon at the position of the triclosan 4'-carbon. Consequently, 3'-pyridone and 4'-diphenyl 
ether substituents are ideally oriented to interact with the important anchor residue Ala97. 
For instance, the triclosan 4'-Cl is halogen bonded to the free electron pair of the Ala97 
carbonyl oxygen via the favorable linear geometry (Figure 4-7B, right insert) (19,152). To 
enable an equally favorable angular geometry for a hydrogen bond between the CG400549 
3'-NH2 group and Ala97 along one amino hydrogen atom (152), the Ala97 carbonyl oxygen is 
shifted by 0.8 ± 0.1 Å towards the B-ring of the inhibitor, which in turn approaches Ala97 to 
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reduce the interaction distance (Figure 4-7B, right insert). As exemplified by these 
considerations, exact knowledge of the different conformations that can be attained by a 
protein target is pivotal for the design of improved inhibitors. 
 
Comparison of ecFabI and saFabI inhibition by 2-pyridones - To determine whether the 
narrow-spectrum behavior of CG400549 can be partly attributed to target-specific 
differences between species, we obtained and compared the structures and inhibition 
kinetics of CG400549 with respect to E. coli and S. aureus FabI. Indeed, CG400549 shows a 
65-fold reduced affinity to E. coli FabI (ecFabI) in comparison to saFabI (Table 4-1 and Table 
4-2). Nevertheless, the inhibitor clearly bound to the binary ecFabI-NADH complex with a 
similar binding geometry as observed for saFabI (Figure 4-5C and Figure 4-5D). However, in 
contrast to the related saFabI ternary complex, the substrate binding loop and the attached 
helix α7 were found to be disordered in this ecFabI structure (Figure 4-5C). Based on a 
comparison of these structures, we propose that Val201 and Ile207 contribute to the 
specificity of CG400549 towards saFabI. The more bulky Ile200 and Met206 ecFabI residues 
(corresponding to saFabI positions 201 and 207, respectively) restrict the available space for 
large 5-substituents as present in CG400549 (Figure 4-5D). Accordingly, the elongation of the 
5-substituent in 5-ethyl-2-phenoxyphenol (PT01) to 5-hexyl-2-phenoxyphenol (PT04) does 
not enhance the affinity towards ecFabI (Table 4-2), whereas affinity increases approx. 10-
fold for saFabI (188). We have recently shown that these inhibitors are transition-state 
analogues with the 5-substituent alkyl chain extending towards the fatty acyl binding 
channel (188). Consistently, whereas the kcat increases for longer enoyl-substrates in the 
case of saFabI (188), it is similar among the different substrate chain lengths for E. coli and F. 
tularensis FabI, which also carries the V201I and I207M substitutions and is inhibited by PT01 
and PT04 with similar potency (19,46,109,175). Thus, the enlarged binding pocket of saFabI 
might partially explain the specific action of the comparatively bulky CG400549 and AFN-
1252 clinical candidates (Figure 4-1). Interestingly, the C-terminus of the ecFabI monomer 
located on the opposite side of the homo-tetrameric protein (in particular, Met256') seals 
this acyl-binding cavity and likely restricts the side chain mobility of Met206 (Figure 4-5D). 
The resulting steric interference between the substrate binding loop residues Met206 and 
Ile200 and the thiophene moiety of CG400549 presumably results in the experimentally 
observed enhanced mobility of this loop. In contrast, the C-terminus of saFabI is shorter and 
lacks a residue corresponding to Met256', thus enabling Ile207 to move away from bulky 5-
substituents. Consequently, important contacts between this inhibitor and the substrate 
binding loop (e.g. with Phe204; see also Figure 4-5A) are more easily attained, partially 
explaining the selectivity of CG400549 towards the saFabI homologue. 
Moreover, hydrogen bonding interactions with Ala97 seem to be particularly favorable in the 
case of saFabI and are exploited by the three clinical trial compounds, as indicated by 
crystallographic and computational studies (Figure 4-1) (101,102). In the case of CG400549, 
the more rigid Pro96 of ecFabI (Asn98 in the case of saFabI) slightly changes the orientation 
of the Ala95 carbonyl (Ala97 for saFabI) (Figure 4-5D). This might explain the observed 
rotation in the B-ring of CG400549, which seems to be required for the maintenance of the 
hydrogen bond to this residue. Interestingly, this interaction is solvent-exposed (Figure 4-5C) 
and less buried for ecFabI due to the presence of Gly97, which corresponds to Met99 in 
saFabI (Figure 4-5D). This rationalizes why the 3'-amino substituent decreases affinity in the 
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case of ecFabI (Table 4-2). Furthermore, treatment of S. aureus with AFN-1252, which is also 
hydrogen bonded to Ala97 (Figure 4-1), selects for a M99T mutation (101). Thus, the buried 
hydrogen bonding interaction with Ala97 likely plays an important role in the selective 
affinity of CG400549 and AFN-1252 towards saFabI. 
 
The 4-pyridone PT166 is a potent FabI inhibitor with broad-spectrum activity and in vivo 
efficacy – In contrast to saFabI, the possibilities to optimize binding affinity of 2-pyridones 
for ecFabI and related homologues may be too limited due to the more constricted space in 
the binding crevice combined with the relatively low intrinsic potency of 2-pyridones 
compared to the diphenyl ether scaffold. Instead, to attain broad-spectrum activity, we can 
design a modified scaffold that possesses a higher intrinsic potency for all FabI homologues. 
One possibility is to replace the methylene bridge with an ether linkage, thereby changing 
the conformational preference prior to binding. The biologically active Ar-X-Ar conformation 
(Figure 4-5 and Figure 4-6) is more readily available for the bisaryl ether system thus leading 
to an entropic advantage upon binding (9). This was implemented in the design of C-
substituted 2-pyridone (2-pyridones such as CG400549 are substituted at the N-atom) and 4-
pyridone analogues. As expected, both prefer to bind in a ternary complex with NADPH 
(similar thermal shift pattern to that depicted in Figure 4-2A for CG400549), thus preserving 
the 2-pyridone mode of action. Compared to the analogous N-substituted 2-pyridone PT179, 
the C-substituted 2-pyridone PT191 binds 10-fold less tightly to saFabI (Table 4-1). Although 
its enol form has a similar putative binding geometry as PT179 (Figure S 4-1) and more 
closely resembles the potent diphenyl ether PT04 (188,231), the increased desolvation costs 
for this more polar compound are likely responsible for the decreased affinity. In contrast, 
the 4-pyridones PT166 and PT159 have 3 to 4-fold enhanced affinities for saFabI with respect 
to the analogous 2-pyridones PT171 and PT420 (Table 4-1), consistent with a higher intrinsic 
potency of this scaffold. PT166 also potently inhibited ecFabI (Table 4-2), suggesting that the 
higher intrinsic potency may, indeed, translate to broad-spectrum activity. Thus, substituting 
the methylene bridge of the initially reported 4-pyridones (123) with an ether linkage (233) 
seems to be a successful strategy to further improve FabI pyridone inhibitors. 
Based on our docking studies, we suggest a binding mode for the 4-pyridones similar to 
those observed for 2-pyridones (Figure 4-6C). However, despite the enhanced affinity of 
PT166 with respect to PT171, the additional 4-methyl group is characterized by an 
unfavorable score. Thus, we hypothesized that Phe204 will change its conformational state 
upon 4-pyridone binding to avoid the steric interference with the N-methyl group. Since 4-
pyridones did not co-crystallize with saFabI, we initially used PT155, which carries an 
additional 4'-NH2 group compared to PT166, and determined a ternary complex structure 
with Burkholderia pseudomallei FabI (bpFabI). Indeed, this structure confirmed the predicted 
4-pyridone binding mode and Phe203 (corresponding to the saFabI residue Phe204) was 
found to adopt a different conformation presenting one of its π-faces to the N-methyl group 
of PT155 (Figure 4-6C). Moreover, we were able to solve an ecFabI-NADH-PT166 structure 
(Figure 4-6D), which further validated the proposed PT166 binding mode (Figure 4-6C). 
Similar to the ecFabI-NADH-CG400549 structure, the substrate binding loop was found to be 
disordered or in a very open conformation in these ecFabI and bpFabI structures, 
respectively (Figure 4-6D). 
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For the 4-pyridone analogues, in vitro MIC measurements against S. aureus RN4220 lie near 
the 2-pyridone linear correlation, consistent with its similar mode of action (Figure 4-4A). In 
addition, relative to CG400549, PT166 had a >50-fold lower MIC against an efflux pump 
deficient strain of E. coli MG1655, consistent with its more potent inhibition of ecFabI (Table 
4-2). At an acyl substrate concentration of 40 to 80 times Km, the predicted Kiapp ranges from 
7.6 to 13.9 times higher for PT166 relative to PT01, and in agreement the MIC of PT166 is 
11.5 times higher than that of PT01, suggesting that the estimated level of substrate 
accumulation in E. coli is similar to S. aureus. Remarkably, PT166 also exhibited antibacterial 
activity against a broad spectrum of pathogenic organisms, including F. tularensis, M. 
tuberculosis and B. pseudomallei (Table 4-3). This is a significant finding, as we were able to 
rationally design a more broad-spectrum pyridone scaffold. 
 
Table 4-3. Spectrum of antibacterial activity for the 4-pyridone PT166 
Organism MIC (μM) 
S. aureus RN4220 0.83 
E. coli MG1655 ΔacrAB a 6.68 
F. tularensis LVS 0.85 
M. tuberculosis H37Rv 10.02 
B. pseudomallei Bp400 a 6.68 
 
a. Efflux pump knockout strains 
 
 
Table 4-4. In vivo pharmacokinetic profile for PT166 and PT04 
PK parameter PT04 PT166 
Dosage (mg/kg) 200 100 
AUC0-24 (μg hr/mL) a 11.8 53.0 
t1/2 (hr) b 4.5 2.7 
Tmax (hr) c 1.0 0.25 
Cmax (μg/mL) d 5.1 45.9 
 
a. AUC0-24 is the area under the plasma concentration-time curve over 24 hours. 
b. t1/2 is the time taken for plasma concentration to fall to 50% of its original value.  
c. Tmax is the time at which Cmax occurs. 
d. Cmax is the maximum plasma concentration of drug. 
 
Pyridones are a metabolically stable alternative to diphenyl ethers, which contain a hydroxyl 
group susceptible to glucuronidation and sulfonation (210). This pharmacokinetic (PK) 
advantage may be key to the success of the clinical candidates CG400549 and AFN-1252. 
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Importantly, PT166 maintained a superior PK profile compared to the diphenyl ether PT04 
(Table 4-4). Cmax and AUC0-24h of PT166 
are 9-fold and 5-fold higher than that of 
PT04, respectively, despite the fact that 
the dose of PT04 was double that of 
PT166. We also tested the efficacy of 
PT166 in a neutropenic mouse model of 
MRSA infection. As a control, no bacteria 
were observed in the right thigh muscle 
of both treated and untreated mice, 
confirming the lack of significant bacteria 
migration. In the infected thigh, 
however, significant bacterial burden 
was observed in the different treatment 
groups. As expected, oxacillin, a clinical 
antibiotic similar to methicillin, exhibited no in vivo anti-bacterial efficacy (Figure 4-8). 
However, PT166 significantly decreased the bacterial burden in the infected thigh by 2.8 Log 
CFU/g tissue. In comparison, the potent diphenyl ether PT04 only decreased bacterial 
burden by 0.9 Log CFU/g tissue. 
4.7 Discussion 
Pyridones constitute a very promising and relatively new class of FabI inhibitors (67). It has 
already advanced further along the clinical pipeline than any inhibitor based on the diphenyl 
ether scaffold. For instance, CG400549 has superior pharmacokinetic properties and proven 
clinical efficacy against S. aureus infection8. However, it also has lower activity against many 
other important pathogens. Understanding the molecular basis for such selectivity can guide 
the development of pyridone-based FabI inhibitors with greater broad-spectrum potential. 
Despite the structural similarity of the pyridone and diphenyl ether scaffolds, we observed 
surprising differences with respect to their mode of inhibition, which have significant 
implications for the spectrum of activity. Pyridones bind predominantly to the E-NADPH 
complex, whereas diphenyl ethers exclusively interact with E-NADP+ generated via catalysis 
(Figure 4-2A and Figure 4-2B) (188). We recently proposed that diphenyl ethers bind in a 
deprotonated state to their target (188). In such a scenario, the positively charged and thus 
electron-deficient oxidized nicotinamide ring of the cofactor forms a charge-assisted π-π 
stacking interaction with the electron-rich phenolate A-ring (Figure 4-1). The inability of the 
much less acidic pyridones to form this ionic interaction might explain their reduced affinity 
for E-NADP+. In fact, pyridones may bind to the E-NADP+ and E-NADPH complexes with 
similar affinity. Since the E-NADPH complex is energetically more stable and exists at a 
higher population than E-NADP+ (188), E-NADPH-I is still the predominant and physiologically 
relevant ternary complex. 
The diphenyl ether and pyridone-bound saFabI ternary complexes likely reflect different 
stages during the hydride transfer step of the enzymatic reaction (Figure 4-2D). We have 
recently shown that diphenyl ethers are analogs of a late, enolate-like transition state (188). 
In contrast, the pyridone structure more closely resembles the enoyl-ACP substrate (Figure 
4-2D) and thus binds preferably in a ternary complex with the reduced cofactor, which is 
 
Figure 4-8. In vivo efficacy. The efficacy of selected 
compounds against MRSA strain BAA1762 in a 
neutropenic mouse thigh infection model is shown. Error 
bars represent the standard deviation for replicate data 
(n = 5 in each group). 
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present prior to the hydride transfer. We envision an incremental closure of the SBL during 
substrate binding and hydride transfer in which the loop is fully 'closed' at the transition 
state to minimize its energy (Figure 4-9). 
 
 
Figure 4-9. Conformational states sampled along the reaction coordinates of inhibitor binding and substrate 
turnover. (A) Approximate energy diagrams for saFabI in complex with NADPH and pyridone (black) or NADP+ 
and diphenyl ether inhibitor (red). The overall affinities of both ternary complexes are assumed to be identical. 
By shifting stabilization from cofactor to inhibitor, the residence time of the overall complex is increased. This 
rationalizes the difference in off-rate kinetics between the diphenyl ethers and pyridones. Note that, 
technically, koff for the pyridone complex (E-NADPH-I) is equal to k-2 since the E-NADPH complex is catalytically 
active. C is defined as a constant with a value greater than 1. The numbers 1 to 5 indicate the conformational 
states (colors according to panel C), which are likely sampled along the reaction coordinate of inhibitor binding 
(see also panel C). (B) Qualitative energy diagram for substrate turnover by saFabI. The numbers 1 to 5 indicate 
the conformational states (colors according to panel C), which are likely sampled along the reaction coordinate 
of the enzymatic reaction (see also panel C). (C) Conformational states sampled by the SBL and the attached 
helix α7 of saFabI. Red arrows indicate the conformational changes we propose to occur during the enzymatic 
reaction (see also panel B). Prior to the binding of cofactor and substrate or inhibitor, the SBL is disordered and 
helix α7 attains a very open conformation (state 1 colored in pink = PDB-entry 4ALM, subunit B; state 2 colored 
in lilac = PDB-entry 4ALM, subunit C; further details about the conformational changes upon ligand binding are 
provided in our previous report (19)). The more substrate-like pyridone inhibitors likely induce a 
conformational state between the ternary E-NADPH-S complex and the transition state of the hydride transfer 
(state 3 colored in yellow = CG400549-I structure, subunit C; state 4 colored in cyan = CG400549-I structure, 
subunit A; see also Figure 4-7A). In contrast, the transition state analog triclosan and several other diphenyl 
ethers (19,188) induce the likely fully closed state of the SBL (state 5 colored in gray = PDB-entry 4ALI, subunit 
H). 
 
In this respect, the different conformations of the SBL presented in this study define 
important structural snapshots along the reaction coordinate of enzyme catalysis (Figure 
4-7A). The observation of an 'opened' substrate binding site for pyridones confirms our 
hypothesis that these inhibitors are more substrate-like compared to the diphenyl ethers. In 
the light of the two alternatively ordered SBL conformations vs. the disordered loop in the 
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apo enzyme (Figure 4-9C, states 1 and 2) (19,144), it could be argued that the pyridone 
ternary complexes represent a state between the substrate complex and the transition state 
for enolate formation (Figure 4-9B). The electron-donating effect of the pyridone nitrogen, 
which leads to a phenolate-like resonance structure, might thereby mimic the transfer of the 
negatively charged hydride ion (Figure 4-2D). 
As the hydride transfer reaction proceeds, the increasing positive charge on the 
nicotinamide ring and the closure of the substrate binding loop shifts the balance of ternary 
complex stabilization more towards the fatty acyl relative to the cofactor component. 
Diphenyl ethers display affinities which are three orders of magnitude higher compared to 
analogous 2-pyridones, whereas NADP+ binds approx. 1000-fold less tightly to saFabI with 
respect to NADPH (Figure 4-9A) (188). Accordingly, the cumulative affinities (Ki ∙ Kd,NADP(H)) of 
comparable E-NADP+-diphenyl ether and E-NADPH-pyridone complexes are calculated to be 
very similar. For instance, there is only a two-fold difference in the cumulative affinity of the 
E-NADP+-PT04 complex compared to the analogous E-NADPH-PT179 complex. Diphenyl 
ethers are stabilized to a greater extent partly because of the closure of the SBL that occurs 
farther along the reaction coordinate. At this stage, NADP+ exists in the ternary complex, 
which also contributes to enhance the binding affinity of deprotonated diphenyl ethers. 
However, in comparison to E-NADPH, the steady-state concentration of E-NADP+ is very 
small due to the fast dissociation of the oxidized cofactor generated via catalysis (188). 
Hence, the resulting apparent inhibitor association rate (kon∙[E-NADP+]∙[I]) of diphenyl ethers 
is slow explaining the observed slow-binding phenomenon, although the actual association 
rate constants kon of pyridones and diphenyl ethers are very similar. Thus, in saFabI the 
ordering of the substrate binding loop is likely correlated rather than causative with respect 
to the observation of slow-onset kinetics with diphenyl ethers. 
Among the three clinical trial saFabI inhibitors, CG400549 and AFN-1252 have been shown to 
be Staphylococcus-specific (4,31,100,101), whereas the diphenyl ether MUT056399 is also 
active against several Gram-negative pathogens (102). As shown in Figure 4-4, this is mainly 
attributed to different modes of inhibition. Substrate accumulation weakens the intrinsic 
potency of competitive inhibitors in contrast to uncompetitive inhibitors. Thus, relatively 
unmodified diphenyl ethers are already able to potently inhibit cell growth. In fact, the 
intrinsic potency of diphenyl ethers is greater in the case of ecFabI compared to saFabI 
because of the higher kcat with first-round substrates (crotonyl-CoA) and smaller koff, NAD 
(Table S 4-3). This may contribute to the lower MIC values for the E. coli pump mutant 
relative to S. aureus. On the other hand, further optimization of binding affinity is necessary 
for pyridones to achieve cellular efficacy. This argument likely extends to the 
naphthyridinones, such as AFN-1252, which was recently crystallized in complex with saFabI 
and 3'-NADPH (Figure 4-1) (101). Our structural data rationalizes the pyridone SAR-profile 
and clearly reveals the ability of the CG400549 5-, 2'- and 3'-substituents to enhance its 
affinity towards saFabI (Figure 4-5 and Figure 4-6, Table 4-1). In particular, the CG400549 
and PT173 3'-amino group is hydrogen bonded to Ala97, thus leading to a 6-fold increase in 
affinity (Figure 4-5A). In the case of ecFabI, this hydrogen bond is not protected from 
solvent-exposure due to a M99G substitution (Figure 4-5D), thereby reducing the affinity of 
such compounds and increasing the selectivity of CG400549 for saFabI (Table 4-2). Due to 
the amino acid residues Ile200 and Met206 and an elongated C-terminus including Met256', 
ecFabI also harbors a smaller binding pocket compared to saFabI (Figure 4-5D). The wider 
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acyl-cavity of saFabI facilitates the accommodation of longer acyl-substrates or, analogously, 
diphenyl ether 5-substituents (19,109,175,188). Importantly, CG400549 and AFN-1252 
contain large moieties at this position, which might further contribute to the Staphylococcus-
specific spectrum of these two clinical trial inhibitors (Figure 4-1). In fact, bulky pyridone 5-
substituents interfere with the ecFabI and bpFabI SBL, whereas it is in a relatively closed 
state for saFabI with bound AFN-1252 (101) and CG400549 (Figure 4-5C and Figure 4-7A). 
This important difference might be explained by the presence of an additional C-terminal 
extension occluding the binding sites of typical FabIs such as ecFabI and bpFabI. In contrast, 
saFabI contains a significantly shorter C-terminus compared to most other structurally 
characterized FabI proteins. The wider acyl-cavity, and thus, the enhanced affinity of 
CG400549 can be related to the ability of saFabI to efficiently utilize bulky branched-chain 
fatty acyl substrates (19). This is further supported by the relatively mild resistant mutations 
(F204L) that emerge upon selection with pyridones (4,100). Disrupting the 5-substituent 
interactions is likely sufficient to abrogate potency against S. aureus (see PT170, Table 4-1). 
On the other hand, more drastic mutations (F204S, A95V) are needed to disrupt the activity 
of the more intrinsically potent diphenyl ethers (28,78,92,108,230). 
Based on the SAR profile of ecFabI, the ability to optimize binding affinity via substituents on 
the scaffold is very limited. A pyridone-based compound with broad-spectrum activity must 
necessarily have higher intrinsic potency than the 2-pyridones. To achieve this, we 
developed a 4-pyridone scaffold that retains the bridging oxygen of diphenyl ethers, thus 
providing an entropic advantage upon binding to FabI. As expected, the SAR and predicted 
binding mode is highly reminiscent of the 2-pyridone series, but 4-pyridones possess 
superior potency at the enzymatic and cellular levels (Table 4-1 and Table 4-2). Importantly, 
the higher intrinsic potency also translates into broad-spectrum activity for the promising 
lead compound PT166 (Table 4-3). As with CG400549 (234), replacement of the 
metabolically labile hydroxyl group with a carbonyl successfully improved the 
pharmacokinetic profile of PT166 compared to the diphenyl ether PT04 (Table 4-4). 
Additionally, this compound significantly reduced bacterial burden in a murine model of 
MRSA infection (Figure 4-8), validating its potential as a drug lead for future optimization 
and development. Further in vivo studies are needed to more precisely compare the 
pharmacokinetics and efficacy of the diverse FabI inhibitor scaffolds. 
In summary, we have elucidated the structural and mechanistic basis for selective saFabI 
inhibition by pyridones, including the clinical candidate CG400549. Our study has yielded an 
insightful glimpse into conformational states along the coordinate of the saFabI enzymatic 
reaction, providing yet another reminder of the elegant connection between catalysis and 
inhibition. Importantly, we were able to rationally design the promising lead compound 
PT166, which merges the pharmacokinetic advantages of a pyridone with greater broad-
spectrum potential. A similar approach can be applied in the development of much needed 
narrow- and broad-spectrum antibiotics against novel targets. 
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4.10 Supplementary Information 
4.10.1 Supplemental Tables 
Table S 4-1. Data Collection and Refinement Statistics (S. aureus FabI). 
 PT173 CG400549-I CG400549-II 
Data collection   
Cell dimensions   
a, b, c (Å) 61.5, 109.2, 289.4 61.9, 108.5, 296.8 77.0, 113.1, 117.7
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Space group P212121 P212121 P212121 
Resolution1 (Å) 60.3-3.10 (3.27-3.10) 47.6-1.95 (2.06-1.95) 45.6-2.20 (2.32-2.20)
Observed reflections 146,382 (20,325) 2,435,819 (313,695) 257,814 (36,976)
Unique reflections 36,439 (5,219) 146,661 (21,138) 52,885 (7,580) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (99.9) 
Average redundancy 4.0 (3.9) 16.6 (14.8) 4.9 (4.9) 
Rmerge
2 (%) 10.4 (48.8) 16.1 (134.8) 13.0 (46.6) 
Rpim
3 (%) 6.0 (28.2) 4.0 (36.1) 6.6 (23.5) 
<I / σ(I)> 9.4 (2.7) 15.6 (2.4) 8.7 (3.2) 
Monomers per AU 8 8 4 
Refinement   
Resolution (Å) 60.1-3.10 47.6-1.95 45.6-2.20 
Rcryst
4
 (%) 20.7 16.8 19.4 
Rfree (%) 25.8 23.1 26.1 
Number of atoms 16,154 17,795 8,665 
Twin fraction NA5 NA5 0.09 
rmsd bond lengths (Å) 0.006 0.011 0.018 
rmsd bond angles (°) 1.05 1.63 1.78 
Average B-factor (Å2) 81.8 30.1 35.9 
Ramachandran-plot6   
Favored (%) 95.2 96.8 95.2 
Allowed (%) 4.4 3.1 4.7 
Outliers (%) 0.4 0.1 0.1 
Maximum likelihood based 
estimated coordinate error (Å) 0.27 0.13 0.18 
 
1Values in parenthesis refer to the highest resolution shell 
2  −=
hkl i
i
hkl i
imerge IIIR  
3 ( )[ ]   −−=
hkl i
i
hkl i
ipim IIINR
2/111  (173) 
4  −=
hkl
obs
hkl
calcobscryst FFFR  
5NA = not applicable 
6According to Molprobity, version 3.19 (218) 
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Table S 4-2. Data Collection and Refinement Statistics (E. coli and B. pseudomallei FabI). 
 ecFabI-NADH-CG400549 ecFabI-NADH-PT166 bpFabI-NAD+-PT155
Data collection  
Cell dimensions  
a, b, c (Å) 80.1, 80.1, 320.2 79.7, 79.7, 330.2 74.3, 76.0, 89.4
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 90 
Space group P6122 P6122 I222 
Resolution1 (Å) 47.1-1.80 (1.90-1.80) 47.7-1.95 (2.06-1.95) 38.0-1.84 (1.94-1.84)
Observed reflections 818,706 (97,180) 306,907 (46,321) 108,611 (14,641)
Unique reflections 56,987 (7,945) 46,243 (6,503) 22,291 (3,219) 
Completeness (%) 98.7 (96.6) 99.5 (98.6) 100.0 (100.0) 
Average redundancy 14.4 (12.2) 6.6 (7.1) 4.9 (4.5) 
Rmerge
2 (%) 12.5 (109.7) 9.6 (64.7) 6.9 (26.1) 
Rpim
3 (%) 3.2 (30.4) 4.0 (25.6) 3.5 (13.7) 
<I / σ(I)> 12.6 (2.3) 12.6 (2.7) 14.6 (5.0) 
Monomers per AU 2 2 1 
Refinement  
Resolution (Å) 69.4-1.80 69.0-1.95 38.0-1.84 
Rcryst
4
 (%) 17.5 17.6 13.7 
Rfree (%) 20.7 21.2 16.2 
Number of atoms 4,057 3,943 2,367 
Twin fraction NA5 NA5 NA5 
rmsd bond lengths (Å) 0.012 0.015 0.008 
rmsd bond angles (°) 1.60 1.77 1.14 
Average B-factor (Å2) 33.0 37.9 13.8 
Ramachandran-plot6  
Favored (%) 97.4 97.4 97.3 
Allowed (%) 2.6 2.6 2.7 
Outliers (%) 0.0 0.0 0.0 
Maximum likelihood based 
estimated coordinate error 
(Å) 
0.08 0.09 0.18 
 
1Values in parenthesis refer to the highest resolution shell 
2  −=
hkl i
i
hkl i
imerge IIIR  
3 ( )[ ]   −−=
hkl i
i
hkl i
ipim IIINR
2/111  (173) 
4  −=
hkl
obs
hkl
calcobscryst FFFR  
5NA = not applicable 
6According to Molprobity, version 3.19 (218) 
  
 Modulating the Spectrum of FabI Inhibition by Pyridones  
103 
 
Table S 4-3. EcFabI kinetic parameters for the mechanistic model in Figure 4-2B. 
Parameter Estimate Rationale 
KS 4.25 mM for cro-CoA 
Approximated based on a previously reported Km 
value (175).  
KNADH 7.8 μM Based on a previously reported Kd value (175). 
KNAD 1.8 mM Based on a previously reported Kd value (175). 
kon,S 6 ∙ 108 M-1 min-1 
This arbitrary estimate is within an order of magnitude 
of the diffusion-limited rate constant, which 
represents the theoretical ceiling. The value will only 
affect the kinetic system if it is low enough to be rate 
limiting (approx. 6 ∙ 105 M-1 min-1). 
kon,NADH 9 ∙ 107 M-1 min-1 This value approximates the Km,NADPH
app previously 
obtained with 500 μM cro-CoA (175). 
koff, NAD 8 ∙ 103 min-1 
We noticed that the dissociation rate of PT52 from 
saFabI was similar to ecFabI. Thus, we made the 
assumption that the Ki is identical for the two FabI 
homologues. Based on this assumption, we 
determined the value of koff, NAD that best replicates 
the experimental progress curves. Consistently, the 
ratio of koff, NAD for ecFabI to koff, NADP for saFabI is 
calculated to be very similar to the ratio of koff, NADH for 
ecFabI to koff, NADPH for saFabI (188).  
kcat 600 min-1 for cro-coA  Based on a previously reported kcat value (175). 
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4.10.2 Supplemental Figures 
 
 
Figure S 4-1. Putative binding modes of pyridone inhibitors bound to saFabI. All pyridone inhibitors 
investigated in this study (Table 4-1) were docked into the saFabI binding pocket as described in the 
Experimental Procedures section. The radii of the blue (red) spheres represent the value of the favorable 
(unfavorable) per-atom score, as determined by DrugScoreX. Selected residues of the saFabI binding pocket 
(CG400549-I structure; according to the score, the more 'open' subunit C was selected for the bulky CG400549 
compound, whereas subunit A was preferred for the other inhibitors) are depicted as gray sticks along with the 
putative inhibitor binding mode (yellow sticks). (A) Comparison of the generated CG400549 docking pose 
(yellow stick model) with the experimentally observed binding mode (cyan stick model). The best-ranked 
docking pose differs only slightly from the CG400549 binding geometry observed in the crystal structure (rmsd 
= 0.71 Å). (B) Comparison of the generated PT173 docking pose (yellow) with the experimental binding 
geometry (cyan). The top-ranked docking pose is very similar to the PT173 binding geometry observed in the 
crystal structure (rmsd = 0.83 Å). (C) Putative binding mode of PT171 (best-ranked pose). (D) Putative binding 
mode of PT179. The six highest-ranked docking poses were excluded due to the lack of the central hydrogen 
bonding network between the inhibitor, Tyr157 and NADPH. (E) Putative binding mode of PT420 (best-ranked 
pose). (F) Putative binding mode of PT172 (top-ranked pose). (G) Putative binding geometry of PT170. The 
best-ranked docking pose was excluded via visual inspection due to the absence of a hydrogen bond with 
Tyr157 and the cofactor. (H) Putative binding mode of PT159 (best-ranked pose). (I) Docking results for PT191. 
The FlexX docking procedure exclusively generated "unexpected" binding poses (the best-ranked pose is shown 
as pink stick model) without the central hydrogen bonding network. We attribute this to the free NH group and 
the low affinity of this particular C-substituted 2-pyridone (Table 4-1). However, docking of the tautomeric 
hydroxypyridine form of PT191, which likely exists in equilibrium with the pyridone form (235), resulted in the 
"expected" binding mode (cyan sticks; best-ranked docking pose was observed with subunit C of CG400549-I). 
Interestingly, the most favorable score was achieved when mutating PT179 in its putative binding mode (panel 
D) to PT191 (yellow sticks; subunit A of CG400549-I) (DrugScore of -261,110 compared to -246,554 and -
225,496 for the best-ranked docking poses with the pyridone and hydroxypyridine forms of PT191, 
respectively). 
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5 Protons and Hydrides - Wherefrom and Whereto: From a 
Chemical Binding Pocket Analysis to a Biological Substrate 
Recognition Process 
 
This chapter is based on the following publication: 
 
Schiebel, J., Chang, A., Merget, B., Baxter, M. V., Bommineni, G. R., Yu, W., Spagnuolo, L. A., 
Tareilus, M., Tonge, P. J., Kisker, C., and Sotriffer, C. A. (in preparation‡) Protons and 
Hydrides - Wherefrom and Whereto: From a Chemical Binding Pocket Analysis to a Biological 
Substrate Recognition Process. 
 
Author contributions with respect to data collection: 
 
Schiebel, J.:  X-ray crystallography, molecular dynamics simulations, docking 
Chang, A.:  Enzyme kinetics, mutagenesis 
Merget, B.:  Molecular dynamics simulations (mutants) 
Bommineni, G.R.: Synthesis of inhibitors 
Yu, W.:  Radioactive dissociation assay (results not available yet) 
Spagnuolo, L.A.: Synthesis of inhibitors 
Baxter, M.V.:  Enzyme kinetics, mutagenesis 
Tareilus, M.:  X-ray crystallography (ecFabI-NAD+-PT449, saFabI-NADP+-PT449) 
 
‡The printed version might be subject to some changes prior to submission 
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5.1 Abstract 
One third of all drugs in clinical use target enzymatic processes thus highlighting their 
importance towards future drug development efforts. Based on the close relationship 
between inhibition and catalysis, it is key to understand enzymatic substrate recognition and 
its turnover. Although the Staphylococcus aureus enoyl-acyl carrier protein (ACP) reductase 
(saFabI), which is involved in bacterial fatty acid biosynthesis, constitutes a very promising 
drug target for the development of novel, urgently needed anti-staphylococcal agents, the 
substrate binding mode and catalytic mechanism remained unclear for this enzyme. Using a 
combined crystallographic, kinetic and computational approach, we explored the chemical 
properties of the saFabI binding cavity resulting in a consistent mechanistic model for 
substrate binding and turnover. A water-network, which links the active site with a water 
basin inside the homo-tetrameric protein, is likely crucial for the closure of a flexible loop as 
well as for an effective hydride and proton transfer during catalysis. Based on our results, we 
derived a new model for the FabI-ACP complex that reveals how the ACP-bound acyl-
substrate is injected into the FabI binding crevice. These findings facilitate the development 
of novel FabI inhibitors that target the FabI-ACP interface and disrupt the interaction 
between these two proteins. 
5.2 Introduction 
Understanding the functionality of enzymes is of particular importance since one third of all 
currently used drugs target such proteins (209). Enzymes are tailored to stabilize the 
transition state (TS) of the catalyzed reaction, which should, according to Fischer's lock-and-
key model, exhibit a perfect shape complementarity to the corresponding binding pocket 
(238). Based on this model, one would assume that enzyme catalysis is readily understood 
using the growing number of structural data. However, substrate binding and turnover are 
often accompanied by induced-fit effects, which are insufficiently characterized at the 
structural level (239). Many enzymes harbor flexible loops that close upon substrate binding 
and are most likely required for precise substrate orientation, avoidance of the release of 
reaction intermediates and exclusion of water from the binding-site (240). Members of the 
short-chain dehydrogenase/reductase (SDR) superfamily contain such a flexible loop, termed 
the substrate binding loop (SBL) (105). Two distinct SDR proteins are involved in the bacterial 
fatty acid biosynthesis (FAS-II) pathway, namely the β-ketoacyl-ACP reductase (FabG) and 
the enoyl-ACP reductase (FabI, EC 1.3.1.9/10) (51). Since the FAS-II acyl substrates are 
attached to the small acidic acyl carrier protein (ACP) via a 4'-phosphopantetheine linker 
(PPant, Figure 5-1A), protein-protein interactions are additionally involved in substrate 
recognition and turnover. However, little is known about the interaction of ACP with FAS-II 
enzymes. This additional complexity in the substrate recognition process has led to 
conflicting reports concerning the mechanism of FabI proteins, for which two fundamentally 
different substrate binding modes were suggested (70,107). 
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Figure 5-1. The FabI-catalyzed reaction (107,112,113). (A) Syn-addition of H2 by a 2-step mechanism (n = 0-8). 
Dashed arrows indicate an attack from below the paper plane. The pro-4S hydride of NAD(P)H (highlighted in 
red) is transferred from the 3-si face. In a second step, the formed enolate intermediate is protonated 
stereospecifically from the re face at C2 (the proton is shown in blue). The thioester oxygen, which is hydrogen 
bonded to either Tyr157 (panel B) or Tyr147 (panel C), is indicated in cyan. During the reaction, the substrate is 
attached to ACP via a phosphopantetheine moiety depicted in the box. (B) Substrate delivery via the major 
portal. Given that the cofactor is located below the substrate in the chosen view (Figure 5-2B), the trans-2-
enoyl-ACP has to be in the s-cis conformation to enable the correct stereochemical outcome in a scenario 
where ACP binds close to the major portal, and the thioester carbonyl is, thus, bound to Tyr157. Dashed arrows 
indicate attack vectors from below. (C) Substrate delivery via the minor portal. If ACP is located at the minor 
portal, the thioester carbonyl will be hydrogen bonded to Tyr147 and thus the substrate has to be in the s-trans 
conformation for consistency with the observed stereochemistry. 
 
Enoyl-ACP reductases catalyze the last step of the FAS-II elongation pathway - the reduction 
of the trans-2-enoyl-ACP double bond (51). According to an ordered bi-bi mechanism, 
binding of the cofactor NAD(P)H precedes substrate binding (51). The catalyzed reaction 
proceeds via the transfer of the pro-4S hydride of NAD(P)H from the 3-si face to the C3 
carbon of the C2-C3 enoyl-ACP double bond followed by the stereospecific protonation of 
the formed enolate intermediate via the 2-re face (Figure 5-1A) (70,112,113). To enable an 
effective hydride transfer, the catalytic triad residue Lys164 likely plays a crucial role in the 
correct positioning of the cofactor's reactive nicotinamide ring (residues will be numbered 
according to the Staphylococcus aureus homologue throughout the manuscript) (70). 
NAD(P)H is known to bind at the bottom of an elongated cavity with two channels leading to 
the solvent - a minor portal adjacent to the nicotinamide ring and a major portal next to the 
adenine ring (Figure 5-2B) (70). However, it is currently unclear whether the enoyl-substrate 
enters via the minor or major portal (70,107). A structure of the substrate analog trans-2-
hexadecenoyl-(N-acetylcysteamine)-thioester (C16-NAC) bound to the FabI homologue of 
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Mycobacterium tuberculosis (InhA) indicated that ACP should be located at the major portal 
(70). However, in an Escherichia coli FabI (ecFabI) - NAD+ - trans-2-dodecenoyl-ACP (DD-ACP) 
structure, ACP was oriented for substrate delivery to proceed via the minor portal. Based on 
this structure which lacked the ACP amino acid side chains, the enoyl-substrate and the 
PPant linker due to the lack of electron density in a presumably very flexible complex, a 
model of the FabI-ACP complex was generated via molecular dynamics (MD) simulations 
(107). According to this model the thioester carbonyl oxygen would interact with the 
catalytic residue Tyr147 and the partial C1-C2 double bond has to be in s-trans conformation 
due to the defined stereochemical outcome of the reaction (Figure 5-1C) (107,112,113). 
However, if the ACP is located at the major portal, the substrate would be in the 
energetically more favorable s-cis conformation, and the thioester carbonyl would be 
hydrogen bonded to Tyr157, complementing the catalytic triad (Figure 5-1B) (70,107,113). 
 
 
 
Figure 5-2. SaFabI binding pocket characteristics. (A) The catalytic tyrosines Tyr157 and Tyr147 and their 
orientation with respect to the binding pocket. Povme (241) was used to calculate the binding pocket volume 
indicated in blue surface representation (PT400-bound structure). (B) Hydrogen bonding hotspot. PT400 
(yellow) binds to the saFabI cavity and is hydrogen bonded to Tyr157 (gray; saFabI-NADP+-PT400 structure). The 
protonated Tyr147 and Tyr157 residues are shown for the representative structure of the largest cluster from a 
hierarchical clustering analysis of the saFabI4-NADP
+-PT400 MD simulation (Figure S 5-3). Red (blue) spheres are 
shown for all oxygen (nitrogen) FabI inhibitor atoms within a radius of 3.5 Å around Tyr147 or Tyr157, 
respectively (for this purpose, all structurally known inhibitor-bound FabI complexes were superimposed on 
the saFabI-NADP+-PT400 structure). The water occupancy map for one monomer of the saFabI4-NADP
+ MD 
simulation is depicted as red mesh at the 50% level. (C) Probing the pocket characteristics with diphenyl ether 
inhibitors. The lipophilic, left subpocket (defined by the residues shown in gray) is occupied by hydrophobic 
alkyl chains. In contrast, the 4'-nitro substituent of PT12 as well as the fluoropyridine moiety of MUT37307 
highlight the less hydrophobic character of the right subpocket (residues defining this part of the pocket are 
indicated in green; saFabI-NADP+-PT12 structure). (D, E) Dials plots for Tyr147 and Tyr157. The dihedral angles 
Cε-Cζ-O-H (Ar-OH), χ1 and χ2 (indicated by the arrows in panel A) are exemplarily plotted for one monomer of 
the saFabI4-NADP
+-PT400 trajectory. Red lines indicate the simulation averages (χAr-OH(Y147/Y157) = -7 ± 11°/11 
± 11°, χ1 (Y147/Y157) = -178 ± 8°/-167 ± 7°, χ2 (Y147/Y157) = 63 ± 10°/71 ± 10°) whereas blue lines depict the 
corresponding values for the crystal structure (for χAr-OH the reference values were set to 0° since no hydrogen 
atoms were observed during the crystallographic experiments, χ1 (Y147/Y157) = 172°/-166°, χ2 (Y147/Y157) = 
63°/56°). (F) Summary of the saFabI binding pocket properties. The expected substrate binding mode based on 
these observations is indicated in gray. 
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During our efforts to develop inhibitors against the drug target S. aureus FabI (saFabI) for 
which three drug candidates reached clinical trials (103), we identified a close relationship 
between catalysis and inhibition (188,242). Hence, small-molecule inhibitors can be used as 
chemical probes to explore substrate recognition and catalysis of this enzyme. Using a 
combined crystallographic, kinetic and computational approach, we can clearly show that 
Tyr157 stabilizes the enolate intermediate, which in turn is likely protonated via a water-
chain that is replenished via a water chamber inside the homo-tetrameric enzyme. 
Consequently, we re-analyzed the ecFabI-NAD+-DD-ACP structure which led to a new FabI-
ACP model fully consistent with our findings and supporting the notion that the ACP should 
be located at the major portal. This newly derived model of substrate recognition and 
turnover will enhance our fundamental understanding of FabI catalysis and aid in the design 
of new inhibitors that can disrupt its interaction with the ACP-substrate. 
5.3 Results and Discussion 
5.3.1 Analysis of the SaFabI Binding Pocket Characteristics 
Small-molecule inhibitors are valuable tools to investigate the mechanism of enzymatic 
reactions (239,242). In the case of saFabI, diphenyl ether-based inhibitors (188) were used to 
probe substrate binding and turnover for this important drug target. These TS-analogues 
trigger the full closure of the SBL (19) and establish an elongated binding pocket in contact 
with solvent via the minor and major portals (Figure 5-2B). Given the conserved binding 
mode of the diphenyl ethers (188), substituents in the 5-position of the A-ring can be used to 
explore the chemical properties of the left part of the pocket (left subpocket) (Figure 5-2C, 
surrounded by gray residues), whereas substituted B-rings are ideal probes for the right part 
of the pocket (right subpocket) (Figure 5-2C, surrounded by green residues). Thus, we 
kinetically investigated a series of diphenyl ethers (Table 5-1) and solved five associated 
saFabI-NADP+-inhibitor structures (with the inhibitors PT12, PT400, PT404, MUT37307 (102), 
and PT449). Due to the very hydrophobic environment of the left subpocket, lipophilic alkyl 
chains are optimal substituents at the 5-position (Figure 5-2B and Figure 5-2C, Table 5-1), 
whereas the more hydrophilic 5-nitro and 5-fluoro substituents led to a decrease in binding 
affinity by one order of magnitude compared to more hydrophobic similarly sized 5-
substituents (188). A similar trend was observed for ecFabI (102) indicating that the 
hydrophobicity of the left subpocket is conserved across species and that this pocket is 
ideally suited to bind the hydrophobic enoyl chain of the substrate. In contrast, the right 
subpocket is less hydrophobic as highlighted by the tolerance for the hydrophilic B-rings of 
PT12 and MUT37307 (Figure 5-2C, Table 5-1). Our crystal structures reveal that the 4'-nitro 
groups of PT12 and PT404 are hydrogen bonded to the amide nitrogen of Ala97 at a distance 
of 3.0 ± 0.1 Å (Figure 5-2C and Figure S 5-1A). Importantly, the three saFabI inhibitors, which 
are currently investigated in clinical trials, were also suggested to interact with the backbone 
of Ala97 (chapter 4), thus defining an important hydrophilic anchor in the right subpocket 
and a possible contribution to PPant-binding. In agreement with this suggestion, the clinical 
candidate MUT056399, which carries a hydrophilic 4'-amide group, displays high affinity 
towards saFabI (Table 5-1). The lower affinity of the inhibitor PT18 (Table 5-1) indicates the 
importance of the carbonyl oxygen being separated by just one atom from the B-ring to 
enable the hydrogen bond with Ala97 as observed for PT12 (Figure 5-2C). 
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Table 5-1. Kinetic parameters for saFabI inhibition by diphenyl ether analogues a 
 
Name Structure kon (x 1010 M-1 hr-1) koff (hr-1) Ki (nM) 
PT449 
 
0.25 0.43 0.17 
PT104 b 
 
0.61 9.03 1.49 
PT01 b 
 
1.01 0.94 0.09 
PT411 
 
0.61 0.55 0.09 
MUT37307 0.17 0.60 0.35 
MUT056399 0.34 0.27 0.08 
PT04 b 
 
1.30 0.13 ± 0.04 c 0.01 d 
PT12 1.69 0.86 0.05 
PT18 0.67 9.98 1.50 
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PT400 
 
NA NA NA 
 
a. Determined via single point progress curve analysis, as described in (188) 
b. Data obtained from (188) 
c. Calculated by fitting the 32P-NAD-based dissociation curve as described in (188) 
d. Determined using the koff value obtained from the 32P-NAD dissociation assay as described in (188) 
 
Based on these experimental observations we speculated that the substrate enters the 
protein via the major portal (Figure 5-1B and Figure 5-2F) and performed five different 16 ns 
MD simulations using our saFabI-NADP+-PT400 structure. Since saFabI is a tetramer in its 
ligand-bound state but can exist as a dimer in the apo-form (19), MD simulations were 
conducted for different oligomeric states of the protein (indicated by a subscript) including 
or excluding cofactor and/or inhibitor. We refer to the simulations as saFabI4-NADP+-PT400, 
saFabI1-NADP+-PT400, saFabI4-NADP+, saFabI4 and saFabI2 (details about the trajectories are 
given in the supplement). The orientation and dynamic behavior of the Tyr147 and Tyr157 
hydroxyl groups are of particular importance for inhibitor and substrate recognition since 
the substrate thioester carbonyl oxygen has to be held in a fixed position by one of these 
two residues to enable the precise orientation of the enoyl-ACP double bond with respect to 
the NAD(P)H pro-4S hydride. As expected for tyrosine OH-groups (243), an analysis of the 
five MD trajectories revealed that the hydroxyl hydrogens of both active site tyrosines are 
exclusively located almost within the phenyl-ring plane (in both cases, the Cε-Cζ-O-H dihedral 
angle approximates 0° and was rarely found to be ~180° for Tyr147; see also Figure 5-2D and 
Figure 5-2E). In addition, the average χ1 and χ2 torsion angles are close to the 
crystallographically observed values and are very stable along the MD trajectories, leading to 
the precise orientation of the OH hydrogens. Preciseness in the orientation of catalytic 
residues seems to be a crucial component of enzymatic activity (240). In agreement, the 
saFabI catalytic triad residues were found to be amongst the least flexible binding-site 
residues in the saFabI4-NADP+-PT400 simulation (Figure S 5-2 and Figure S 5-3D). 
Importantly, only the Tyr157 but not the Tyr147 hydroxyl group points towards the saFabI 
binding pocket and, thus, displays an ideal geometry to bind the substrate thioester carbonyl 
group (Figure 5-2A). Accordingly, all investigated diphenyl ether inhibitors bind with their 
hydroxyl groups to the oxyanion hole formed by Tyr157 and the 2'-OH of the nicotinamide 
ribose, which likely mimics the interaction with the enolate intermediate (Figure 5-2 and 
Figure S 5-1). The resulting hydrogen bonds were conserved during the saFabI4-NADP+-PT400 
MD simulation to 79% and 67%, respectively, leading to low rmsd values for the PT400 A-
ring (1.30 ± 0.55 Å; all-atom fit) including the 5-hexyl group (1.47 ± 0.40 Å) compared to the 
B-ring (2.11 ± 1.11 Å). If PT400 was omitted during the MD simulation (saFabI4-NADP+), a 
water molecule binds to the oxyanion hole instead (Figure 5-2B). An analysis of all 
structurally characterized inhibitor-bound FabI-complexes revealed that all inhibitors from 8 
different scaffold classes bind with an oxygen or nitrogen atom (rarely water-mediated) to 
this oxyanion hole, whereas only two polar atoms are found in the vicinity of Tyr147 
(spheres in Figure 5-2B). These findings are therefore highly indicative of substrate delivery 
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via the major portal (Figure 5-1B and Figure 5-2F), which also explains why Tyr147 is not 
conserved in the M. tuberculosis homologue InhA, where this residue is a phenylalanine (70). 
5.3.2 Putative Substrate Binding Modes 
 
 
 
Figure 5-3. Putative substrate binding mode. (A) Enoyl-substrate analogs bound to saFabI-NADPH (gray). The 
selected docking poses for S-trans-4-methyl-2-hexenoyl-NAC (1), trans-5-methyl-2-hexenoyl-NAC (2) and trans-
2-octenoyl-NAC (3) are depicted (color code according to the legend). (B) Comparison with the InhA-NAD+-C16-
NAC complex (orange). The putative saFabI-NADPH-3 complex is shown in gray and blue, respectively. Red 
arrows indicate shifts in the substrate binding mode and SBL conformations. (C) Model of the octanoyl-NAC 
enolate intermediate (4) bound to saFabI-NADP+ (gray). The inhibitor PT12 is shown as reference (cyan). (D) 
Superposition of saFabI (gray; saFabI-NADP+-PT400 structure), FabG (light brown; PDB-code: 1Q7B) and 7α-
hydroxysteroid dehydrogenase (HSDH) (pink; PDB-code: 1FMC). The proposed substrate binding modes (for 
HSDH, the carbonyl group of the reaction product 7-oxo glycochenodeoxycholic acid is shown), hydrogen 
bonding networks and catalytic triad residues are depicted. (E, F) Substrate binding to FabI and FabG, 
respectively. The geometrically different oxyanion holes of FabI and FabG likely bind the thioester carbonyl and 
β-keto oxygens, respectively. 
 
Since the proceeding chemical reaction aggravates the structural characterization of 
enzyme-substrate complexes, we decided to use our validated computational docking 
approach to generate meaningful substrate binding modes. An octanoyl-NAC enolate 
intermediate (4, Figure 5-3) was docked into the saFabI-NADP+-PT400 structure (omitting 
PT400) whereas four different substrate analogs (S-trans-4-methyl-2-hexenoyl-NAC = 1, 
trans-5-methyl-2-hexenoyl-NAC = 2, trans-2-octenoyl-NAC = 3, trans-2-octenoyl-PPantMe = 
oct-PPantMe) were docked into the same receptor containing NADPH (details are given in 
the Methods section). Putative binding poses were selected based on the DrugScoreX score 
and the following three criteria: (1) the thioester carbonyl group has to bind to Tyr157 or 
Tyr147; (2) to fulfill the stereochemical requirements (112,113), the C1-C2 bond of the 
substrate has to be in s-cis (Figure 5-1B) or s-trans (Figure 5-1C) conformation, respectively; 
and (3) the C3 atom of the substrate has to be adjacent to the reactive pro-4S NADPH 
hydride. As expected, all selected binding modes exhibit an interaction between the 
thioester carbonyl and the oxyanion hole formed by Tyr157 and the nicotinamide ribose 2'-
OH (Figure 5-3A and Figure 5-3C, interaction distances are given for 3 throughout the 
manuscript: 3.2 Å and 2.7 Å, respectively). Remarkably, even when forcing the hydroxyl 
 Substrate Recognition and Turnover by SaFabI  
114 
 
hydrogen of Tyr147 to point towards the binding pocket with an artificial, energetically 
unfavorable Tyr147-OH torsion angle of 120° (243), the docking program generated no poses 
where the thioester carbonyl binds to this residue. Similar to the PT12 and PT404 4'-nitro 
substituents, the amide group of the substrate analogs interacts with the Ala97 backbone 
nitrogen (d = 2.9 Å) and is additionally bound to Ser197 (Figure 5-3A and Figure 5-3C). 
Overall, the created binding modes confirmed our expectations derived from the chemical 
mapping of the binding pocket (Figure 5-2F). A comparison with the InhA-NAD+-C16-NAC 
structure revealed consistency with the experimental substrate binding mode (Figure 5-3B). 
Interestingly, the InhA SBL and the substrate are located more towards the solvent indicating 
that this complex is catalytically inactive, which is in agreement with the fact that NAD+ was 
used during co-crystallization (70). 
5.3.3 Hydride Transfer and Proton Delivery 
The putative saFabI-NADPH-3 complex is consistent with the transfer of the pro-4S hydride 
to the C3 atom of the substrate in the s-cis conformation (d = 3.9 Å), whereas the thioester 
carbonyl should be protected from reduction (d = 5.0 Å, Figure 5-3E and Figure 5-4A). 
However, the question remains how the enolate-like TS is stabilized by the action of FabI. 
Clearly, the oxyanion hole is ideally suited to stabilize the evolving negative charge of the 
enolate. The 2'-OH of the nicotinamide ribose is involved in a hydrogen-bonding network 
consisting of Lys164 and two structurally and temporally conserved water molecules 
presumably leading to a delocalization of the evolving negative charge of the enolate (Figure 
5-4A). In contrast to FabI, the negative charge is developing on the β-keto group in the case 
of the related FabG protein (51). Since the β-carbon of the FabG β-ketoacyl-ACP substrate 
should be similarly positioned with respect to the reactive pro-4S hydride as the FabI enoyl-
ACP substrate C3 carbon, one would expect that the oxyanion hole has to be shifted two 
carbon atoms towards the minor portal in the case of FabG (Figure 5-3E and Figure 5-3F). 
Indeed, as for the classical SDR protein 7α-hydroxysteroid dehydrogenase (HSDH) (244), the 
oxyanion hole is created directly above the reactive NADPH hydride (Figure 5-3D). This is 
achieved by a substitution of Tyr147 by a serine and the exchange of the YX6K-motif in FabI 
to YX3K in FabG (51). Both FabI and FabG contain a SBL and the closure of a similar loop in 
triosephosphate isomerase (TIM) was proposed to be responsible for the stabilization of the 
two transition states (240,245). In this regard, the desolvation of the binding-site, which can 
be effectively achieved by the gradual closure of a flexible loop, was suggested to transfer 
the substrate from solvent into a protein cavity characterized by a much lower dielectric 
constant resulting in a strengthening of electrostatic interactions (238,245). The negative 
charge of the enolate generated during the FabI-catalyzed reaction might therefore be most 
effectively stabilized upon full closure of the SBL. Importantly, a strong electrostatic 
interaction develops between the enolate and the evolving positive charge on the NAD(P)δ+-
H nicotinamide ring (Figure 5-4B). Several enzymes take advantage of positively charged 
moieties to stabilize negatively charged intermediates including enolates (245,246). 
Electrostatic interactions in a desolvated protein environment might thus be key 
contributors to lower the transition state energy of enzyme-catalyzed reactions. 
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Figure 5-4. Hydride and proton transfer. (A) Hydride transfer. The pro-4S hydride of NADPH is transferred to 
the C3-atom of the substrate (indicated by red arrows; the putative saFabI-NADPH-3 complex is shown, see 
also Figure 5-3). Two highly conserved water molecules bound to Lys164 are depicted as red spheres. The 
corresponding water occupancy maps for one monomer of the saFabI4-NADP
+-PT400 MD trajectory are 
depicted as red meshes at the 50% level. (B) Water-wire originating from Tyr147. In the saFabI-NADP+-PT400 
structure, a chain of water molecules (red spheres) connects Tyr147 with a water basin inside the tetramer 
(blue spheres; cyan dashes) and with the bulk solvent (green dashes), respectively. Whereas the water-chain 
towards the interior of the tetramer is highly conserved during the saFabI4-NADP
+-PT400 MD simulation 
(occupancy maps are shown as gray meshes at 50%), the water-wire towards the exterior seems not to be 
established permanently. Blue arrows indicate possible proton sources and the red arrow the C2 atom of the 
enolate intermediate (4 shown in green, see Figure 5-3), which is protonated during the reaction. Cyan spheres 
represent water molecules of the ecFabI-NAD+-PT449 structure towards the inside of the tetramer. (C) Overall 
water occupancies for the four monomers of the wild-type and mutant saFabI4-NADP
+-PT400 MD simulations in 
a box surrounding the water-chain. Water occupancies were calculated for 5376 grid points within the boxes 
depicted in panels E-H and averaged to yield the plotted overall water occupancy per monomer (shown as 
individual bars). Mean values for each tetramer are indicated by horizontal dashed lines. (D) Schematic 
representation of the water-network towards the inside of the homo-tetramer. Simulation-averaged distances 
and occupancies of the hydrogen bonding interactions in the saFabI4-NADP
+-PT400 MD simulation (monomer 
2) are given as: 2.8 ± 0.1 Å, 76% (1); 2.8 ± 0.1 Å, 69% (2); 2.7 ± 0.1 Å, 80% (3); 2.8 ± 0.1 Å, 88% (4); 2.8 ± 0.1 Å, 
55% (5); 2.8 ± 0.1 Å, 76% (6); 2.7 ± 0.1 Å, 96% (7); 2.7 ± 0.1 Å, 95% (8); 2.7 ± 0.1 Å, 96% (9). (E-H) Water 
occupancies for the wild-type and variant (D249A, Y147F, S189A; highlighted in cyan) saFabI4-NADP
+-PT400 MD 
simulations. The corresponding water occupancy maps (averaged for all monomers) are shown as gray meshes 
at the 50% level. 
 
Since the saFabI enzyme has evolved to stabilize the enolate intermediate, its slow intrinsic 
rate of dissociation may limit the rate of catalysis. Thus, an alternate route to dissociation via 
protonation of the enolate intermediate is very important. To effectively enable protonation 
of this intermediate in the desolvated saFabI binding pocket, a defined water-mediated 
connection to bulk solvent can be envisioned. Indeed, our saFabI structures reveal a 
conserved water-chain originating from Tyr147 and extending towards the inside of the 
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homo-tetramer and the exterior of the protein (Figure 5-4B). We therefore propose the 
following model: After the transfer of the hydride, the natural fluctuations along the 
reaction coordinate will cause a slight opening of the SBL, which is further triggered by the 
re-hydration of the binding-site via this water-chain. The water molecule directly bound to 
Tyr147 will be the first to enter the active site and due to steric reasons will only be able to 
intercalate between the enolate and nicotinamide, thus enabling the stereospecific 
protonation from the 2-re face as observed for ecFabI and InhA (Figure 5-1B and Figure 5-4B) 
(112,113). In principle, the NADP+ amide group could be alternatively responsible for the 
protonation step, but its hydrogen atoms are involved in a tight hydrogen bonding network. 
In addition, an enol formed by protonation of the enolate oxygen via the oxyanion hole 
cannot be the final product dissociating from the enzyme due to the defined stereochemical 
outcome of the reaction (113). In fact, it has been proposed that water-networks linking 
substrate binding-sites with bulk solvent might be a general feature of all enzymes to enable 
protonation steps as well as dehydration and rehydration of the active site upon substrate 
binding and product release, respectively (247). 
To improve our understanding of such networks, we investigated the FabI water-wire using a 
combined experimental and computational approach. Interestingly, our saFabI4-NADP+-
PT400 MD simulation clearly indicates that only the water-chain towards the water chamber 
inside the tetrameric protein is conserved over time (Figure 5-4B, cyan dashes). Accordingly, 
the crystallographically observed water molecule that defines the branch of the water-wire 
towards the exterior of the protein is quickly released, leading to a network consisting of 
four water molecules and Ser189 (Figure 5-4D), which is similarly present in our ecFabI 
structure (Figure 5-4B, cyan spheres). Residues Tyr147, Glu168 (rarely an aspartate), Ser189 
and Asp249 involved in the formation of the water-chain are strictly conserved within the 
FabI-familiy (mycobacterial enoyl-reductases are an exception and harbor a different water-
system (70)). Thus, we explored the kinetic and dynamic behavior of the saFabI Y147F, 
S189A and D249A variants. A comparison of wild-type and mutant saFabI4-NADP+-PT400 MD 
simulations (Table S 5-1), clearly indicates that the water occupancies and, thus, the stability 
of the directed water-chain towards the interior of the tetramer are reduced for all three 
mutants (Figure 5-4E-H) although the overall water occupancy in this region of the protein 
(characterizing the complete water content of the boxes depicted in Figure 5-4E-H) remains 
similar to the wild-type level for Y147F and S189A (Figure 5-4C). Accordingly, the catalytic 
efficiency decreased for each of the water-channel mutants (Table 5-2). Both thermal shift 
assays and CD-spectra suggest that each mutant comprises a folded and stable structure 
(Table 5-3 and Figure S 5-4). Pyridone- and diphenyl ether-based TS analogues (chapter 4) 
were used to probe the ability of the mutant saFabI enzymes to stabilize the TS of the 
hydride transfer. Thermal shifts of the S189A and D249A ternary complexes are significantly 
diminished, suggesting increased TS energies (Table 5-3). Moreover, the increased Km, oct-CoA 
suggests decreased binding affinity for the acyl-CoA substrate. Since these residues are 
located outside of the active site and substrate binding pocket, these findings suggest that 
the water-chain may be crucial for SBL closure and, consequently, hydride transfer. Although 
one could argue that these mutations might cause slight structural perturbations that may 
be transferred to the active site, the remote locations and drastic effects of the mutated 
residues suggest that more global processes are compromised. The particularly dramatic 
effect of the D249A mutation (> 10,000-fold reduced catalytic efficiency) is consistent with 
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our prediction that this residue has the greatest impact on water occupancy (Figure 5-4). We 
propose that water molecules, which are trapped in between the entering substrate and the 
left subpocket, cannot properly leave the binding-site via the disrupted water-channel of the 
D249A and S189A variants thereby hindering substrate binding and the closure of the SBL. In 
agreement with this hypothesis, mutations of residues that are up to 20 Å away from the 
active site of dihydrofolate reductase (DHFR) were suggested to impair catalytic activity by 
changing the mobility of loop regions that are important for catalysis (238). 
 
Table 5-2. Kinetic characterization of saFabI water-channel mutants. 
 Km,oct-CoA (µM) a,b kcat (min-1) a kcat/Km,oct-CoA (min-1 µM-1) 
wt saFabI c 20.7 ± 2.7 2645.4 ± 107.3 127.8 ± 17.5 
saFabI D249A > 100  0.012 ± 0.001 d 
saFabI S189A > 100  1.50 ± 0.04 d 
saFabI Y147F 44.2 ± 14.5 723.9 ± 73.3 16.4 ± 5.6 
 
a. Km,oct-CoA and kcat values were determined at a fixed NADPH concentration (350 μM) 
b. Oct-CoA = trans-2-octenoyl-CoA 
c. Data obtained from (19). 
d. Estimated based on linear slope of the Michaelis-Menten plot at low oct-CoA concentrations 
 
 
Table 5-3. Thermal shifts of saFabI water-channel mutants upon ternary complex formation. a, b, c 
 Wild-type saFabI saFabI D249A saFabI S189A saFabI Y147F
E 62.60 63.40 61.20 63.20 
E-NADPH-CG400549 71.20 64.60 64.20 71.20 
E-NADP+-PT119 70.40 63.60 61.80 72.20 
 
a. Values correspond to Tm measurements (°C) 
b. Experiments were performed in duplicate. Data variability is approximately ± 0.2 °C. 
c. PT119 is a representative potent diphenyl ether (188), whereas CG400549 is a representative potent 2-
pyridone (chapter 4). 
 
Interestingly, the Y147F saFabI variant maintains a thermal shift similar to the wild-type 
enzyme upon ternary complex formation with a TS analogue (Table 5-3). Thus, the TS energy 
for the hydride transfer is likely unchanged in this mutant relative to wild-type. One of the TS 
mimics is more enolate-like (PT119) and the other more substrate-like (CG400549) (chapter 
4). Thus, the 2-fold increased Km, oct-CoA (Table 5-2) may also uniquely be reflected in the 
higher thermal shift of the E-NADP+-PT119 complex relative to E-NADPH-CG400549 (Table 
5-3) indicating that substrate binding affinity is altered more than the enolate binding 
affinity. Given an increased Km, oct-CoA and unchanged TS energy, a smaller barrier to hydride 
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transfer is expected. The opposing experimental observation of a smaller kcat for the Y147F 
variant likely reflects a shift in the rate limiting step. This result suggests that we successfully 
and rationally increased the barrier to enolate protonation, thereby making it the new 
bottleneck step in saFabI catalysis. 
5.3.4 Protein Fluctuations Relevant for Substrate Recognition 
 
 
 
Figure 5-5. Conformational variability of saFabI. (A) Visualization of the B-factors for the five wild-type MD 
simulations. B-factors were averaged over the four monomers and plotted on monomer 3 of the saFabI-NADP+-
PT400 structure. Colors indicate the B-factor value of each residue (blue to red = 5 to 85 Å2). (B) Visualization of 
the B-factor for the saFabI-NADP+-PT400 crystal structure. B-factors were averaged over the four monomers 
and plotted on monomer 3 of the structure. Colors indicate the B-factor value of each residue (blue to red = 20 
to 85 Å2). (C) Essential dynamics of saFabI (calculated with ptraj and IED (248)). The first (blue) and last (red) 
frames along the principal mode of the 16 ns saFabI2 MD trajectory are shown for one monomer exemplarily. 
Blue arrows indicate the anti-correlated movement of the SBL and helix α2. NADP+ of the saFabI-NADP+-PT400 
structure is shown as reference (colored ball-and-stick model). See also Movie S 5-1. (D) Dynamic cross-
correlation map (shown for the same monomer of the saFabI2 MD simulation). This graph was generated using 
the statistical framework R. 
 
Although the presented results concerning the FabI binding-site clearly indicate that the 
substrate should be delivered via the major portal, the ecFabI-NAD+-DD-ACP structure 
suggested that the ACP residue Ser36 carrying the substrate is located adjacent to the minor 
portal (107). To resolve this issue, we first had a closer look at the intrinsic protein 
fluctuations since protein-protein interactions usually require structural adaptations (249). 
The MD trajectories of the saFabI apo-enzyme (NADP+ and PT400 omitted) are characterized 
by significantly increased simulation-averaged rmsd values and standard deviations 
compared to the ternary complex simulations indicating an enhanced conformational 
variability and mobility (Table S 5-2 and Figure S 5-5). A comparison of the B-factors for the 
five different MD trajectories (Figure 5-5A) revealed that this behavior can mainly be 
attributed to the increasing flexibility of the SBL, the attached helix α7 as well as helix α2. In 
line with our previous structural observation that rearrangements of two loops (substrate 
binding loop 2 = SBL-2; active site loop = ASL) and of the attached helices α4 and α6 are 
involved in a dimer-tetramer transition (19), we additionally observed enhanced B-factors 
for these regions when simulating the monomeric or dimeric protein molecule (most 
pronounced for η3; Figure 5-5A). While the substantial mobility of the SBL confirmed our 
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expectations, we were rather surprised to observe enhanced B-factors for helix α2. Indeed, 
the experimental B-factors of the PT400-bound saFabI structure emphasized the mobility of 
this helix (Figure 5-5B). In addition, our recently reported saFabI structure in complex with 
NADPH and a substrate-like pyridone inhibitor (chapter 4) reveals a more opened α2 
conformation compared to the saFabI-NADP+-diphenyl ether structures (Figure S 5-6D). 
Importantly, dynamic cross-correlation maps and essential dynamics analyses revealed an 
anti-correlated opening movement of the SBL and helix α2, which was most pronounced for 
the saFabI2-simulation (Figure 5-5C and Figure 5-5D, Movie S 5-1). This concerted opening 
results in a widening of the major portal that might facilitate the binding of the cofactor and 
the substrate (see also Figure S 5-6 and Supplemental Results). In addition, the flexible α2 
and SBL regions provide an ideal platform for the interaction with ACP adjacent to the major 
portal. 
5.3.5 Location and Binding Process of ACP-substrates 
Since all our results clearly indicate that ACP delivers the enoyl-substrate via the major 
portal, we revisited the ecFabI-NAD+-DD-ACP structure (PDB-entry 2FHS). Importantly, we 
found that ACP not only contacts the FabI molecule in the asymmetric unit, which was 
interpreted as biologically relevant interaction partner (Figure 5-6A-B, yellow), but also 
interacts with a symmetry-related FabI (Figure 5-6A-B, gray). Since the complex with the 
symmetry-related monomer, in contrast to the original interpretation (107), enables the 
binding of four ACP molecules per homo-tetramer without any clashes (Figure 5-6D-E), this 
could likely be the biologically relevant assembly. We superimposed a decanoyl-ecACP 
structure (PDB-entry 2FAE) onto the partial ACP model of the 2FHS-structure to create a full 
model for the FabI-ACP complex (Figure 5-6B), which displays a much larger interaction 
surface for the assembly with the symmetry-related monomer compared to the original 
FabI-ACP complex (344 vs. 93 Å2 according to the PISA-server (157), Figure 5-6C). In this new 
complex the ACP is located at the major portal and interacts with the SBL and helix α2 as 
proposed by our MD simulations (Figure 5-6F). An analysis of all structurally known ACP 
complexes (PDB-entries 3NY7, 3EJB, 3EJD, 3EJE, 1F80, 4ETW, 4DXE, 2XZ0, 2XZ1) indicated 
that ACP helix α2ACP, which includes Ser36 carrying the substrate at its N-terminus, is 
consistently involved in the protein-protein interface (76) with frequent contributions from 
the N-terminal part of helix α3ACP. Since these helices contain three conserved acidic regions 
(including 2-4 acidic residues each; red ACP portions in Figure 5-6F), the interaction interface 
of the FAS-II enzymes is required to be electropositive (76). FabI proteins harbor several 
basic residues surrounding the major portal, which are distributed over three secondary 
structure elements - α2 with 2-4 basic residues, the SBL including the attached N-terminus of 
helix α7 with 1-4 basic residues and the loop containing residues 17-18 with up to two basic 
amino acids (Figure 5-6F). Whereas in the original FabI-ACP model only the N-terminus of 
helix α2ACP was able to interact with FabI, the new model permits the interaction of the full 
helix α2ACP and the N-terminus of α3ACP with the basic FabI interface surrounding the major 
portal. Based on the original model, the ecFabI residues Lys201, Arg204 and Lys205 (part of 
helix α7) were mutated to analyze the proposed interface (107). Unfortunately all three 
residues would be involved in the interaction of FabI with the ACP molecule through both 
the minor and the major portal and therefore also supported the original model. We note 
that for the closely related FabG protein stereochemistry alone can reveal the location of 
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ACP since the positions of the pro-4S hydride donor and β-keto acceptor groups are fixed as 
depicted in Figure 5-3F. Indeed, the R-β-hydroxyacyl-ACP is formed during the FabG-
catalyzed reaction (250), providing evidence that ACP is located at the major portal as we 
propose for FabI. 
 
 
 
Figure 5-6. The ecFabI-ACP encounter complex. (A) Symmetry-related ecFabI homo-tetramer (gray) within the 
ecFabI-NAD+-DD-ACP structure (yellow, PDB-code: 2FHS; two FabI monomers and one ACP in the asymmetric 
unit). The partial ACP model is depicted in cyan. (B) ACP environment in the 2FHS-structure. To derive a full ACP 
model, decanoyl-ecACP (lilac, PDB-code: 2FAE) was superimposed onto the partial ACP model of the 2FHS-
structure considering only main chain atoms. (C) Superposition of the two crystallographically feasible FabI-ACP 
interaction models. The originally proposed model is depicted in yellow, the model derived from the 
interaction with a symmetry related FabI monomer is colored in gray. (D, E) FabI-ACP clash-test. The 
simultaneous interaction of the FabI homo-tetramer with four ACP substrates will lead to severe clashes for the 
original model (panel D) (107), whereas no clashes are observed for the new model (panel E). These figures 
were created by superimposing both models (panel C) on each subunit of the full FabI homo-tetramer. (F) ACP 
binds close to the major portal. According to the new model, the conserved acidic ACP patches (depicted in 
red) interact with basic FabI regions mainly located on helices α2, α7 and the SBL (golden sticks; PDB-code: 
1QSG). The disordered SBL of the 2FHS-structure is highlighted in magenta. The 1QSG ecFabI-NAD+-triclosan 
structure (golden) displays a closed SBL and was superimposed onto the FabI monomer of the new model 
(gray) as a reference. Red and golden arrows indicate the proposed movements of ACP and the SBL upon 
substrate injection, respectively. The putative trans-2-octenoyl-PPantMe binding mode is depicted in green. (G) 
Proposed substrate delivery. The ACP residue Ile54 (cyan) is located in the FabI-ACP interface and likely 
contributes to the binding of the substrate inside the ACP-fold (cyan). 
 
A comparison of the new FabI-ACP complex with the putative substrate binding modes 
suggests that ACP has to move by approximately 12 Å to reach the relatively conserved basic 
residue at position 43 (indicated by red arrows in Figure 5-6F), which should be ideally suited 
to bind to the PPant phosphate group in the final complex based on distance considerations. 
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Hence, we propose that the new FabI-ACP model is not in a catalytically competent state but 
rather constitutes the initial encounter complex prior to substrate injection (Figure 5-6F). In 
line with this suggestion, the SBL was found to be disordered in the 2FHS-structure and no 
electron density was observed for the cofactor or substrate (107). This is not very surprising 
since the oxidized cofactor was used during the crystallization of the complex. We thus 
propose that binding of the reduced cofactor will initiate the formation of the catalytically 
competent complex via the concerted closure of the SBL and injection of the substrate to the 
FabI binding-site. The highly conserved ACP residue Ile54, which displayed the largest 
chemical shift perturbation in NMR experiments with FabG and ACP (76), contacts the acyl-
substrate within the ACP-fold and is located close to the SBL in the FabI-ACP complex 
indicating that this residue might be involved in this concerted process (Figure 5-6G). In FabI, 
the conserved basic residue at position 194 (193 for ecFabI) might also be crucial for this 
process since it can interact electrostatically with the ACP and was suggested to function as a 
hinge for SBL closure together with a hydrogen bond acceptor at position 205 (153). 
Whereas ACP in the initial encounter complex mainly interacts with basic residues located 
on helix α2, the closure of the SBL might enable ACP to move closer to the newly created 
positively charged amino acid patch surrounding this loop (indicated by the red and golden 
arrows in Figure 5-6F). We note that the essential dynamics observed for the SBL and helix 
α2 might be directly involved in this substrate recognition process. 
5.3.6 Concluding Remarks 
In the course of these studies we analyzed the chemical binding pocket properties and 
conformational dynamics of saFabI and applied this knowledge to clarify the catalytic 
mechanism of this important drug target involving hydride and proton transfer steps. 
Ultimately, this led to a model where we clearly show that the FabI-ACP encounter complex 
is formed via the major portal and not as previously suggested through the minor portal. The 
vastly improved knowledge about substrate binding and turnover can now facilitate 
medicinal chemistry efforts aiming to mimic important substrate moieties within the 
adaptable FabI binding pocket or to block the essential interaction of this enzyme with ACP. 
Addressing Ala97, that likely stabilizes the terminal PPant peptide (Figure 5-3A), can be one 
strategy to design new saFabI inhibitors, which has already proven successful during the 
development of three drug candidates which are currently in clinical trials for the treatment 
of MRSA infections (103). 
5.4 Methods 
5.4.1 Crystallization, Data Collection and Structure Determination 
SaFabI was purified and crystallized as described previously (19,188). Briefly, protein samples 
(15 mg/ml in 20 mM citrate pH 5.6, 280 mM NaCl, 280 mM potassium glutamate and 1 mM 
EDTA; 19 mg/ml in 20 mM citrate pH 5.6, 250 mM NaCl, 250 mM potassium glutamate and 1 
mM EDTA for PT449) were incubated for 2 hours at 4 °C with a 10-fold molar excess of 
NADP+ (dissolved in water) and a 15-20-fold molar excess of inhibitor (dissolved in DMSO). 
Using the vapor diffusion method, crystals were obtained in 0.1 M Na/K-phosphate pH 6.5 
and 39 - 47% 2-methyl-2,4-pentanediol (MPD) (Table S 5-3). For diffraction experiments, 
crystals were directly flash-frozen without the addition of a cryoprotectant. Similarly, ecFabI 
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(purified as described previously (109), 13 mg/ml in 20 mM PIPES pH 7.5, 200 mM NaCl and 
1 mM EDTA) was incubated with a 10-fold molar excess of NAD+ (dissolved in water) and a 
20-fold molar excess of PT449 (dissolved in DMSO). Crystals grew in a precipitant solution 
composed of 0.1 M CAPS pH 10.5, 0.08 M NH4Ac and 20% PEG 3350 and were cryo-
protected using the mother liquid supplemented by 20% ethylene glycol. 
Diffraction data were collected at beamline 14.1 of the BESSY II synchrotron (λ = 0.918 Å, T = 
100 K) using a MarMosaic 225 (PT12, PT400, PT404, MUT37307) or Pilatus 6M detector 
(PT449), integrated with Imosflm (178) or XDSAPP (215), respectively, and scaled with Scala 
(179). After molecular replacement with Phaser (180) (search models: PDB-entries 4ALK and 
1QSG for saFabI and ecFabI, respectively), alternate cycles of model building in Coot (182) 
and refinement using Refmac 5 (181) led to the final models. Since the electron density for 
the ecFabI amino acid region 193-210 was only weak, this part of the protein could not be 
fully modeled. Data collection and refinement statistics are given in Table S 5-3. All structural 
figures were prepared using PyMOL (174). 
5.4.2 Site-Directed Mutagenesis, Expression and Purification of SaFabI 
Variants 
Site-directed mutagenesis was performed using the QuikChange Mutagenesis Kit from 
Stratagene to construct the D249A, S189A and Y147F mutants from a pET-16b plasmid 
containing the wild-type fabI gene. The primers are listed in Table S 5-4. Expression and 
purification of the variants were performed as described for the wild-type enzyme (19). 
5.4.3 Steady-State Kinetics 
Kinetic experiments were performed as described previously (19). Briefly, reaction velocities 
were measured by monitoring the oxidation of NAD(P)H to NAD(P)+ at 340 nm (ε = 6220 M-1 
cm-1). Kinetic parameters for saFabI D249A, S189A and Y147F were determined by 
measuring initial velocities at varying concentrations of trans-2-octenoyl CoA and a constant 
concentration of NADPH (350 μM). 
5.4.4 Inhibition Kinetics 
Progress curves at a single inhibitor concentration were used to determine the kinetics and 
thermodynamics of inhibition by the compounds in Table 5-1, as described previously (188). 
5.4.5 Thermal Shift Assay 
ThermoFluor experiments were carried out in 96-well plates (Concord) using the CFX96 Real-
Time PCR Detection System and C1000 Thermal Cycler (Bio-Rad), as described previously 
(188). 
5.4.6 Circular Dichroism 
Prior to analysis, saFabI was dialyzed in low salt buffer (10 mM potassium phosphate pH 7.5, 
100 mM KCl) to a concentration of 5-10 μM. Circular dichroism (CD) was performed using a 
Chirascan CD spectrophotometer (Applied Photophysics) at 20°C. The cells had a path length 
of 1 cm, and spectra were recorded from 260 to 200 nm for far-UV. 
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5.4.7 Molecular Dynamics Simulations 
All eight MD simulations conducted were based on the saFabI-NADP+-PT400 structure. The 
full homo-tetramer (subunits E-H, referred to as monomers 1-4) was simulated for the wild-
type protein as well as the Y147F, S189A and D249A variants with bound NADP+ and PT400. 
Moreover, simulations were initiated using the tetrameric complex structure without PT400 
or NADP+ and PT400, respectively. Since saFabI can exist as a dimer in the apo form (19), we 
also simulated the dimeric protein lacking both ligands (subunits F-G). As a reference, we 
additionally performed a simulation for the monomeric saFabI-NADP+-PT400 complex 
(subunit G). For the setup of the MD simulations only those water molecules of the binding 
pocket and water-chain were included from the original structure, which had clear electron 
density (56 waters for the tetrameric protein). The binding-site of the protein was defined by 
residues 93-99, 102, 121, 146-147, 154-157, 160, 164, 190-193, 195, 197-204, 207 and 
NADP+. Guided by visual inspection, the most likely asparagine, glutamine and histidine 
conformations and protonation states were assigned (in particular His247 was assumed to 
be doubly protonated due to its interactions with Glu151 and Glu244'). 
The MD simulations were performed according to a standard procedure of the working 
group of Prof. Christoph A. Sotriffer as, for instance, described in references (236,237) 
explaining the partially similar wording. Using the tleap module of AMBER11 (251), 
hydrogens were added and ff99SB force field parameters assigned to the protein atoms. 
Atomic charges for NADP+ and PT400 were determined with Gaussian 03 (252) using the 
RESP methodology (253) at the HF/6-31G* level. The AMBER11 parmchk module (254) was 
used to assign the missing force field parameters according to the GAFF force field (255). The 
correct GAFF atom and bond types were determined using antechamber (254). A short 
energy minimization over 200 steps using a generalized Born implicit solvent model was 
performed with the SANDER module of AMBER11 (251). Using tleap, the minimized systems 
were then solvated in a box of TIP3P water molecules and neutralized using sodium counter 
ions. The wild-type and mutant simulations were performed using the SANDER module of 
AMBER11 (251) or the PMEMD module of AMBER12 (256), respectively. First, the solvent 
molecules were disordered in a 25 ps constant-volume simulation, keeping the protein 
atoms fixed using the ibelly option. This was achieved by heating the systems from 100 to 
300 K over 20 ps and then cooling back to 100 K within 5 ps, applying the Berendsen weak 
coupling algorithm with a 0.5 ps time constant. In a second step, the whole system was 
allowed to move freely and was heated gradually to 300 K over 25 ps. To enable a time step 
of 2 fs during the following MD run, all bonds involving hydrogen atoms were constrained by 
the SHAKE algorithm (257). Moreover, the constant-volume periodic boundary conditions 
were switched to constant-pressure by applying isotropic position scaling with a reference 
pressure of 1 bar and a relaxation time of 1 ps. In addition, the temperature was fixed by 
coupling to a heat bath with a time constant of 1 ps. An 8 Å cutoff was used for van der 
Waals interactions and long-range electrostatic interactions were treated using the particle 
mesh Ewald method (258). Coordinates were saved at intervals of 1 ps and MD trajectory 
data were collected over a period of 16 ns for each system. Processing and analyses of the 
trajectories were performed using the ptraj module of AMBER11, carnal of AMBER7 and 
VMD (259). Hierarchical clustering analysis was conducted using SYBYL-X (Tripos, St. Louis, 
2009), version 1.0 (225). 
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5.4.8 Computational Docking 
Putative substrate binding poses were generated using our validated approach described 
previously for the docking of pyridone inhibitors to saFabI (chapter 4). Briefly, binding poses 
were produced using FlexX (BioSolveIT, Sankt Augustin, 2009), version 3.1.4 (220), and 
rescored with DrugScoreX (G. Neudert and G. Klebe, University of Marburg, 2008) (221). The 
most likely binding mode was selected based on the DrugScoreX score and the selection 
criteria specified in the results section. Re-docking of PT400 yielded rmsd values below 0.77 
Å for the 10 best-ranked poses (0.60 Å for the top-ranked pose) and thus confirms the 
reliability of our approach. 
During the docking procedure, the hydroxyl dihedral angles of Tyr147 and Tyr157 were set to 
0° or 120° and 0°, respectively. An octanoyl-NAC enolate intermediate (4 in Figure 5-3) was 
docked into the saFabI-NADP+-PT400 structure (omitting PT400) whereas the S-trans-4-
methyl-2-hexenoyl-NAC (anteiso, 1), trans-5-methyl-2-hexenoyl-NAC (iso, 2), trans-2-
octenoyl-NAC (3) and trans-2-octenoyl-PPantMe substrate analogs were docked into the 
same receptor containing the reduced cofactor NADPH (derived from a superimposition with 
a NADPH-bound saFabI structure; saFabI-NADPH-CG400549 structure, subunit C; see also 
chapter 4). For the five compounds mentioned above, the docking poses with rank 1, 18, 5, 2 
and 1 (with respect to the DrugScoreX score) were chosen for further analysis, respectively. 
5.5 Associated Content 
5.5.1 Supporting Information 
The supplement contains four tables, six figures, a movie and supporting results. 
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5.8 Supplementary Information 
5.8.1 Supplemental Tables 
 
Table S 5-1. Simulation averages of the rmsd values for the tetrameric wild-type and mutant saFabI MD 
simulations (saFabI4-NADP
+-PT400) with respect to the saFabI-NADP+-PT400 starting structure [Å]. 
 
rmsd 
(vs. X-ray) D249A Y147F S189A wild-type 
Cα atoms of 
all residues 1.29 ± 0.17 1.14 ± 0.09 1.27 ± 0.13 1.25 ± 0.12 
 
 
 
Table S 5-2. Simulation averages of the rmsd values for the five wild-type saFabI MD simulations with respect 
to the saFabI-NADP+-PT400 starting structure [Å]. 
 
rmsd 
(vs. X-ray) saFabI2 saFabI4 saFabI4-NADP
+ saFabI-NADP
+-
PT400 
saFabI4-NADP
+-
PT400 
 all atoms 
Cα 
atoms 
all 
atoms 
Cα
atoms 
all 
atoms 
Cα
atoms 
all 
atoms 
Cα 
atoms 
all 
atoms 
Cα
atoms 
all protein 
residues 
2.55 ± 
0.32 
1.97 ± 
0.31 
2.15 ± 
0.22 
1.61 ± 
0.18 
1.74 ± 
0.18 
1.26 ± 
0.15 
1.87 ± 
0.15 
1.25 ± 
0.14 
1.72 ± 
0.15 
1.25 ± 
0.12 
less flexible 
residues a 
1.71 ± 
0.16 
1.18 ± 
0.13 
1.62 ± 
0.15 
1.19 ± 
0.11 
1.46 ± 
0.13 
1.05 ± 
0.09 
1.60 ± 
0.12 
1.04 ± 
0.08 
1.44 ± 
0.11 
1.01 ± 
0.08 
flexible 
residues b 
4.52 ± 
0.67 
3.78 ± 
0.70 
3.52 ± 
0.42 
2.71 ± 
0.39 
2.50 ± 
0.35 
1.85 ± 
0.33 
2.70 ± 
0.34 
1.91 ± 
0.36 
2.52 ± 
0.27 
1.94 ± 
0.25 
β-strands c 1.01 ± 0.11 
0.69 ± 
0.10 
1.41 ± 
0.15 
1.09 ± 
0.13 
1.13 ± 
0.13 
0.85 ± 
0.10 
0.79 ± 
0.08 
0.46 ± 
0.05 
1.12 ± 
0.11 
0.85 ± 
0.10 
 
a the most flexible regions (residues 3-7, 40-47, 99-113, 152-156 and 194-210) were omitted during fitting and 
rmsd calculation 
b rmsd for the most flexible regions with fitting according to a 
c rmsd for β-strand residues only (37 residues) 
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Table S 5-3. Data Collection and Refinement Statistics. 
 saFabI-NADP+-PT12 saFabI-NADP+-PT400 saFabI-NADP+-PT404
Inhibitor 
   
Crystallization   
Protein concentration (mg/ml) 15.0 15.0 15.0 
Crystallization condition 0.1 M K/Na-phosphate
pH 6.5 
47% MPD 
0.1 M K/Na-phosphate
pH 6.5 
39% MPD 
0.1 M K/Na-phosphate
pH 6.5 
47% MPD 
Cryoprotectant none none none 
Data collection   
Cell dimensions   
a, b, c (Å) 89.4, 94.8, 94.8 90.4, 94.9, 94.9 89.2, 94.9, 94.9 
α, β, γ (°) 98.3, 111.4, 97.5 98.2, 97.2, 112.5 98. 5, 111.5, 97.3
Space group P1 P1 P1 
Resolutiona (Å) 40.8-2.30 (2.42-2.30) 38.6-2.02 (2.13-2.02) 40.7-2.15 (2.27-2.15)
Observed reflections 266,684 (38,821) 360,497 (52,058) 327,098 (47,457)
Unique reflections 120,978 (17,617) 181,260 (26,181) 148,864 (21,614)
Completeness (%) 96.8 (96.1) 97.8 (97.0) 97.5 (96.7) 
Average redundancy 2.2 (2.2) 2.0 (2.0) 2.2 (2.2) 
Rmerge
b (%) 10.7 (43.5) 5.7 (37.6) 11.0 (41.7) 
Rpim
c (%) 9.6 (39.1) 5.7 (37.6) 9.8 (37.4) 
<I / σ(I)> 6.1 (2.0) 7.5 (2.0) 6.0 (2.1) 
Monomers per AU 8 8 8 
Refinement   
Resolution (Å) 40.8-2.30 38.4-2.02 40.7-2.15 
Rcryst
d
 (%) 15.2 14.5 17.0 
Rfree (%) 21.3 18.5 23.0 
Number of atoms 17,717 18,217 18,382 
rmsd bond lengths (Å) 0.010 0.013 0.012 
rmsd bond angles (°) 1.68 1.78 1.74 
Average B-factor (Å2) 38.7 33.5 23.3 
Ramachandran-plote   
Favored (%) 95.7 96.6 96.3 
Allowed (%) 4.1 3.4 3.4 
Outliers (%) 0.2 0.0 0.3 
Maximum likelihood based 
estimated coordinate error (Å) 0.15 0.10 0.13 
 
  
 Substrate Recognition and Turnover by SaFabI  
127 
 
 saFabI-NADP+-MUT37307 saFabI-NADP+-PT449 ecFabI-NAD+-PT449
Inhibitor 
   
Crystallization   
Protein concentration (mg/ml) 15.0 19.0 13.0 
Crystallization condition 0.1 M K/Na-phosphate
pH 6.5 
41% MPD 
0.1 M K/Na-phosphate 
pH 6.5 
47% MPD 
0.08 M NH4Ac
0.1 M CAPS pH 10.5 
20% PEG 3350 
Cryoprotectant none none 20% ethylene glycol
Data collection   
Cell dimensions   
a, b, c (Å) 90.0, 94.7, 94.8 90.1, 95.2, 95.2 79.1, 79.1, 322.3
α, β, γ (°) 98.1, 97.4, 112.2 98.4, 97.5, 111.5 90, 90, 120 
Space group P1 P1 P6122 
Resolutiona (Å) 33.6-1.80 (1.90-1.80) 46.6-2.15 (2.27-2.15) 47.0-2.00 (2.11-2.00)
Observed reflections 1,011,220 (146,182) 543,061 (80,880) 794,472 (114,237)
Unique reflections 254,237 (36,744) 152,227 (22,139) 41,818 (5,947)
Completeness (%) 97.5 (96.4) 98.2 (97.6) 100.0 (100.0) 
Average redundancy 4.0 (4.0) 3.6 (3.7) 19.0 (19.2) 
Rmerge
b (%) 7.1 (61.7) 9.7 (56.0) 13.7 (124.6) 
Rpim
c (%) 4.1 (35.7) 6.1 (34.1) 3.2 (29.0) 
<I / σ(I)> 11.4 (2.3) 8.3 (2.2) 16.2 (2.4) 
Monomers per AU 8 8 2 
Refinement   
Resolution (Å) 33.6-1.80 46.6-2.15 68.5-2.00 
Rcryst
d
 (%) 14.0 17.4 16.6 
Rfree (%) 17.0 22.7 20.6 
Number of atoms 18,237 17,357 3,996 
rmsd bond lengths (Å) 0.015 0.012 0.015 
rmsd bond angles (°) 1.87 1.68 1.75 
Average B-factor (Å2) 28.8 36.8 41.6 
Ramachandran-plote   
Favored (%) 97.2 96.6 97.3 
Allowed (%) 2.8 3.4 2.7 
Outliers (%) 0.0 0.0 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 0.06 0.14 0.10 
 
a Values in parenthesis refer to the highest resolution shell 
b  −=
hkl i
i
hkl i
imerge IIIR  
c ( )[ ]   −−=
hkl i
i
hkl i
ipim IIINR
2/111  (173) 
d  −=
hkl
obs
hkl
calcobscryst FFFR  
e According to Molprobity (172) 
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Table S 5-4. Nucleotide primers for site-directed mutagenesis 
Name Primer sequence 
D249A forward 5' CAGGTGAAAATATTCATGTAGCGAGCGGATTCCACGCAATTAA 3' 
D249A reverse 5' TTAATTGCGTGGAATCCGCTCGCTACATGAATATTTTCACCTG 3' 
S189A forward 5' CGCGTTAATGCAATTGCGGCTAGTCCAATCCG 3' 
S189A reverse 5' CGGATTGGACTAGCCGCAATTGCATTAACGCG 3' 
Y147F forward 5' GCATTGTTGCAACAACATTTTTAGGTGGCGAATTCGC 3' 
Y147F reverse 5' GCGAATTCGCCACCTAAAAATGTTGTTGCAACAATGC 3' 
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5.8.2 Supplemental Figures 
 
 
 
Figure S 5-1. Inhibitor binding modes. (A) SaFabI inhibition by PT404 (green). Direct interactions are 
highlighted by yellow dashed lines. The PT404 A-ring hydroxyl group is hydrogen bonded to the Tyr157 
hydroxyl group and the 2'-OH of the nicotinamide ribose at distances of 2.50 ± 0.05 Å and 2.57 ± 0.03 Å, 
respectively. The 4'-nitro group interacts with the amide nitrogen of Ala97 at a distance of 2.99 ± 0.10 Å. In 
addition, the 4-F substituent forms weak hydrogen bonds with one of the two Phe204 Cε hydrogens as well as 
with the Ala198 Cα hydrogen (distances of 3.20 ± 0.12 Å and 3.38 ± 0.05 Å, respectively; for details about such 
interactions see also reference (152)). (B) SaFabI inhibition by PT449 (yellow). As for PT404, the OH group of 
PT449 is bound to Tyr157 and the 2'-OH of the NADP+ nicotinamide ribose at distances of 2.59 ± 0.14 Å and 
2.64 ± 0.10 Å, respectively. Furthermore, a linear halogen bond is formed between the Ala97 carbonyl oxygen 
and the 4'-Br group of PT449 at a distance of 3.16 ± 0.11 Å (152). 
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Figure S 5-2. SaFabI binding pocket mobility. (A) Per-residue rmsd values for the binding-site residues. The 
calculation of the rmsd values was based on an all-atom fit of the 31 binding-site residues for the saFabI4-
NADP+-PT400 MD snapshots. Conformational variability is indicated by the rmsd values, whereas the flexibility 
of the individual residues is represented by the corresponding standard deviations. This graph was generated 
using R. (B) Binding-site residue classification by flexibility. This classification is based on per-residue root mean 
square fluctuations (rmsf). Rigid, medium flexible and the most flexible residues are depicted as blue, green 
and yellow sticks, respectively (the same color code was also used for panel A). To enable a classification in 
three similarly sized groups, 0.6 and 1.0 Å rmsf-cutoffs were chosen. The SBL is shown in transparent cartoon 
representation and the cofactor and inhibitor as ball-and-stick model. 
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Figure S 5-3. Hierarchical clustering analysis. (A) Combined 2D-rmsd plot for the Cα-atoms of the 31 binding-
site residues of the four monomers within the saFabI4-NADP
+-PT400 MD simulation. The binding pockets of 
monomers 1 to 4 are represented by the black-framed squares. Calculation of rmsd values was performed in 
100 ps intervals. Black arrows indicate the chosen cluster representatives (numbered consecutively according 
to cluster size; cluster 1 accounts for 44% of all snapshots, 2 = 13.7%, 3 = 11.1%, 4 = 9.7%, 5 = 9.6%, 6 = 4.1%, 7 
= 3.5%, 8 = 2.7%, 9 = 0.6%, 10 = 0.5%, 11 = 0.4%). (B) Representative inhibitor and cofactor geometries. The 
binding modes of PT400 and NADP+ are shown for clusters 1-4 (colored according to the legend). The ligands of 
the saFabI-NADP+-PT400 crystal structure are shown as a reference in gray. (C) Conformations of selected 
flexible binding-site residues for the first four cluster representatives. (D) Conformations of selected rigid 
binding-site residues for the first four cluster representatives. 
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Figure S 5-4. CD spectra showing a similar folding pattern for the water channel mutants compared to the 
wild-type saFabI enzyme. 
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Figure S 5-5. Trajectory rmsd values. (A) Rmsd values for the five wild-type MD simulations (saFabI4-NADP
+-
PT400, blue; saFabI1-NADP
+-PT400, magenta; saFabI4-NADP
+, cyan; saFabI4, orange; saFabI2, red). Calculations 
were performed using all protein Cα-atoms. (B) Rmsd values for selected atoms of the saFabI2 simulation. 
Calculations were performed using all protein Cα-atoms (orange, 254 atoms per monomer), all Cα-atoms 
excluding the most flexible residues (see below) (cyan, 204 atoms per monomer) or the Cα-atoms of β-strand 
residues only (blue, 37 atoms per monomer). In addition, rmsd values for the most flexible saFabI residues (3-7, 
40-47, 99-113, 152-156 and 194-210) were calculated based on a fitting procedure using all Cα-atoms excluding 
those residues (red, 50 atoms per monomer), which allows an evaluation of the conformational variability of 
these protein regions. Both plots were generated using R and averaging over 100 ps (260). 
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Figure S 5-6. Cofactor and substrate binding process. (A) Closed state of the major portal. Red and white 
arrows indicate the location of the major and minor portal, respectively. The saFabI-NADP+-PT400 crystal 
structure is shown in blue surface representation with the SBL and helix α2 indicated in cyan (including 
hydrogens added using tleap). PT400 and NADP+ are shown as green sticks. (B) Opened state of the major 
portal. The structural representative of a hierarchical clustering analysis of the saFabI2 MD trajectory with the 
most opened major portal (t = 14.7 ns, same monomer as in Figure 5-5C-D and Movie S 5-1) is shown in yellow 
surface representation with the SBL and helix α2 highlighted in orange. The same scale and view was used as 
for panel A. PT400 and NADP+ are shown as reference in green. (C) Minor portal opening. The minor portals of 
the structures shown also in panels A and B are depicted using the same color code and scale. (D) 
Conformational variability of the saFabI helix α2. The conformations of helix α2 as well as the interactions with 
the NADP(H) 2'-phosphate (19) differ between the saFabI-NADP+-PT400 (gray) and saFabI-NADPH-CG400549 
(yellow; see also chapter 4) structures. Red arrows indicate the shift of helix α2 in the CG400549-bound 
structure. 
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5.8.3 Supplemental Movies 
 
 
Movie S 5-1. Essential dynamics of saFabI (calculated with ptraj and IED (248)). The dynamics along the 
principal mode of the 16 ns saFabI2 MD trajectory are shown for one monomer exemplarily (colored according 
to its secondary structure). The view is similar to that depicted in Figure 5-5C. Please note the widening of the 
central binding cavity located on top of the β-sheet (yellow) via the anti-correlated movements of the helix α2 
and the SBL (labeled in the still frame during the first four seconds of the movie). This movie was produced 
using VMD and has been smoothed (trajectory smoothing window size = 10 frames). 
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5.8.4 Supplemental Results and Discussion 
5.8.4.1 Inhibition of SaFabI 
 
During the development of the drug candidate MUT056399 by Mutabilis, MUT37307 was 
found to be one of the most promising FabI inhibitors amongst a large series of diphenyl 
ether inhibitors (102). Both compounds contain more hydrophilic B-rings leading to lowered 
clogD values and, thus, to the decoupling of the FabI activity from a non-specific mode of 
action. We solved the structure of saFabI in complex with NADP+ and MUT37307 revealing 
the binding mode of this promising compound. Interestingly, the fluoropyridine B-ring does 
not engage in direct interactions with the protein but is well tolerated at this position (Figure 
5-2C, Table 5-1). MUT056399, MUT37307, PT400 and PT404 share the same phenolic A-ring 
comprising a 4-fluoro and 5-ethyl group. The former substituent was suggested to act as a 
metabolic regulator (119) and did not affect the affinity significantly (Table 5-1 - PT01 and 
PT04 compared to PT411 and PT400, respectively). Since fluorine has only a slightly 
increased atomic radius compared to hydrogen, it is well tolerated in a small side pocket 
created by Phe204 and Ala198 without affecting the closed state of the substrate binding 
loop (Figure S 5-1A). The PT404 fluoro-substituent contacts one of the Phe204 Cε-H atoms at 
a C-F distance of 3.20 ± 0.12 Å. Moreover, a direct weak hydrogen bonding interaction of the 
F with the Cα-H of Ala198 was observed at a C-F distance of 3.38 ± 0.05 Å. 
In order to strengthen the linear halogen bond observed between the 4'-Cl substituent of 
the antimicrobial agent triclosan and the Ala97 carbonyl oxygen (19,152), we introduced a 
4'-Br substituent combined with the potent 2'-CN group leading to PT449. However, 
compared to the corresponding analogue lacking the bromine substituent (PT447) (188), 
PT449 displayed a 3-fold increased Ki value although a halogen bond was observed with 
preferable geometry (152) for saFabI (d = 3.16 ± 0.11 Å, Figure S 5-1B) and ecFabI (d = 3.26 
Å). Importantly, the reduced affinity towards saFabI arises purely from a slowed association 
(kon) while the dissociation kinetics are unchanged (koff). The transition state barrier to 
association and, thus, Ki might be increased due to the bulky bromine substituent, which 
needs to be placed into the saFabI binding crevice (Figure S 5-1B). 
5.8.4.2 Molecular Dynamics Simulations 
 
We initiated eight saFabI MD simulations for mainly three reasons: (1) To learn more about 
the dynamics involved in the inhibition of saFabI (saFabI4-NADP+-PT400 and saFabI1-NADP+-
PT400 simulations), (2) to explore the process of cofactor and substrate binding as well as 
product release (saFabI4-NADP+, saFabI4 and saFabI2 simulations), and (3) to investigate the 
catalytic mechanism of this important drug target (all wild-type and mutant simulations). 
The MD trajectories of saFabI excluding cofactor and PT400 displayed larger conformational 
variability and mobility as highlighted by the simulation-averaged rmsd values and standard 
deviations, respectively (Table S 5-2). In particular the apo-simulations were characterized by 
a rising rmsd over time indicating a directional movement as described in the main text 
(Figure 5-5 and Figure S 5-5A). However, when omitting the most flexible regions 
participating in these motions during the calculation of the rmsd values, this effect was 
diminished (Table S 5-2, Figure S 5-5B). 
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To gain insights into the motions characterizing the binding-site, we analyzed the dynamic 
behavior of the corresponding amino acids. Although we only explicitly discuss the dynamic 
profile of the binding-site residues for the saFabI4-NADP+-PT400 simulation, similar 
observations were made for all trajectories. As expected, the SBL residues (amino acids 194-
204) sealing the binding-site displayed the largest conformational diversity and mobility as 
revealed by an analysis of the per-residue rms deviations and fluctuations (Figure S 5-2). 
Interestingly, Leu102, which was found to be present in an alternative, more opened state in 
our diphenyl ether-bound saFabI structures, also showed enhanced fluctuations. Moreover, 
Met99 is characterized by an increased conformational variability and mobility. This residue 
was shown to be involved in conferring selectivity to two clinical trial inhibitors towards the 
saFabI homologue (chapter 4) and, thus, its flexibility might change upon binding of such 
compounds contacting Ala97. Importantly, most residues surrounding the reactive site of 
the cofactor including the catalytic triad residues (amino acids 190-193, 146-147, 157 and 
164) were found to be rather rigid facilitating the precise relative orientation of substrate 
and cofactor and, thus, enabling the proceeding of the catalyzed reaction from a 
stereoelectronic perspective. In addition, the amino acid stretch including residues 93-97 
displays relatively low rmsd values and standard deviations and might, thus, act as a 
platform for the binding of the PPant moiety of the substrate. 
These trends were confirmed by a hierarchical clustering analysis based on the 2D-rmsd 
values for all four subunits of the saFabI4-NADP+-PT400 simulation (Figure S 5-3A). Whereas 
monomers 1-3 displayed relatively homogenous binding-site snapshots, monomer 4 was 
characterized by increased heterogeneity and, thus, accounted for over 50% of all cluster 
representatives. A detailed analysis of the dynamics sampled by this monomer revealed that 
the anti-correlated opening of the binding-site (Figure 5-5C) partially occurs for this subunit 
(data not shown). The MD trajectory for this monomer might, thus, represent the start of an 
inhibitor dissociation process. Interestingly, the electron density of the starting crystal 
structure was less well defined for this monomer compared to all other subunits. Hence, 
subtle structural perturbations might have led to the relatively quick dissociation in the light 
of the high experimental residence time of PT400. Figure S 5-3 shows selected residues of 
the structural representatives for the four largest clusters of the hierarchical clustering 
analysis (numbered consecutively from 1 to 4) compared to the crystal structure. The 
enhanced conformational diversity of the PT400 B-ring described in the main text is clearly 
visible in Figure S 5-3B. Moreover, the cluster representatives 2 and 4 reveal that Leu102 can 
indeed be present in a more opened state (Figure S 5-3C). In contrast, the enhanced Met99 
mobility is particularly due to extensive side chain motions. The catalytic triad residues, 
however, were found to be in a relatively conserved conformation for all clusters. In 
summary, the sampled conformations of the binding-site residues and in particular the 
cluster representatives may serve as an ideal starting point for the development of new 
saFabI inhibitors since induced-fit effects are very dominant for saFabI (19,188) (chapter 4). 
5.8.4.3 Cofactor Binding Process 
 
Given the limited size of both portals towards the closed saFabI binding pocket (Figure S 
5-6A and Figure S 5-6C, top), it is unclear how the much larger cofactor may actually enter 
this crevice. The anti-correlated opening of the SBL and helix α2 described in the main text 
may not only be important for substrate recognition but could additionally facilitate binding 
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of NADPH (Figure 5-5C, Movie S 5-1). Indeed, with respect to the closed character of the 
starting crystal structure that likely resembles a state close to the TS sampled during the 
hydride transfer of the reaction, the most opened structural representative of a hierarchical 
clustering analysis of the saFabI2 MD snapshots displays a vastly enlarged major portal 
opening (Figure S 5-6B), whereas the minor portal remains in its relatively closed state 
(Figure S 5-6C, bottom). Our structures of saFabI in complex with the more substrate-like 2-
pyridone inhibitors (chapter 4) indeed are characterized by a more opened conformation of 
helix α2 compared to the diphenyl ether-bound structures (Figure S 5-6D). Interestingly, the 
structural variation of helix α2 entails a change in the recognition pattern of the additional 
NADPH 2'-phosphate by the RKXXS-motif located at the N-terminus of this helix. The 
specificity for NADPH compared to the commonly used reducing agent NADH is unique for 
saFabI and closely related homologues (19). An important question, thus, is whether the 
flexibility of helix α2 may contribute to NADPH specificity and cofactor binding. We assumed 
that the nature of the cofactor would not affect binding of the diphenyl ether. This was the 
basis for directly measuring residence times using the saFabI R40Q/K41N/S44L mutant (188), 
which overlapped well with values measured via progress curve analysis in the wild-type 
enzyme. Moreover, the dissociation rate of PT52 (koff = 0.03 min-1) from the E (wild-type)-
NAD+-PT52 ternary complex is very similar to that from E (wild-type)-NADP+-PT52. 
Interestingly, the onset and degree of inhibition both increased in the presence of 
NADH/NAD+ relative to NADPH/NADP+. This is most likely attributed to a 2-fold slower rate 
of dissociation of NAD+ from the wild-type enzyme compared to NADP+. Consistently, the 
dissociation rate of NAD+ from E. coli FabI is estimated to be 4-fold slower than the 
dissociation of NADP+ from saFabI (188) (chapter 4). Thus, the higher binding affinity of 
NADPH/NADP+ to saFabI is mostly the result of a faster rate of association. The observed 
mobility of helix α2 explains why the selectivity for NADPH is based on an enhanced 
association rate. The additional negative charges of the NADPH 2'-phosphate may be 
attracted by the more solvent-exposed RKXXS-motif taking advantage of the long-range 
character of electrostatic interactions (Figure S 5-6D). Indeed, this phenomenon has been 
described as electrostatic steering and can particularly lead to an increase in on-rates 
(44,261). However, bound NADP+ may be more quickly released from the wild-type saFabI 
enzyme compared to NAD+ due to the transient character of these interactions (Figure S 
5-6D) and since charge-assisted hydrogen bonds are not as favorable when exposed to bulk 
solvent (152). 
5.8.4.4 Substrate Recognition 
 
An important question concerning the binding of the substrate is whether FabI recognizes its 
correct interaction partner based on slightly varying ACP conformations for different FAS-II 
intermediates or just after injection of each substrate (76). During our kinetic experiments, 
we found that the octenoyl-CoA substrate and its saturated octanoyl-CoA product bind with 
similar affinity to the enzyme (estimated Kd, octenoyl-CoA = 100 μM (188), Ki, octanoyl-CoA = 96 ± 21 
μM). The inability of saFabI to differentiate these two CoA-species indicates that substrate 
recognition has to occur at the ACP level prior to substrate delivery, which is much more 
efficient than scanning all substrates inside the binding pocket. 
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6 Acyl Channel Opening Reveals How the Condensing 
Enzyme KasA from Mycobacterium tuberculosis Recognizes 
Mycolic Acid Precursors 
 
This chapter is based on the following publication: 
 
Schiebel, J., Kapilashrami, K., Fekete, A., Bommineni, G. R., Schaefer, C. M., Mueller, M. J., 
Tonge, P. J., and Kisker, C. (in preparation‡) Acyl Channel Opening Reveals How the 
Condensing Enzyme KasA from Mycobacterium tuberculosis Recognizes Mycolic Acid 
Precursors. 
 
Author contributions with respect to data collection: 
 
Schiebel, J.:  X-ray crystallography, mass spectrometric analysis 
Kapilashrami, K.: Inhibition kinetics 
Fekete, A.:  Mass spectrometric analysis (experimental details not shown) 
Bommineni, G. R.: Synthesis of thiolactomycin analogs 
Schaefer, C. M.: Protein expression 
 
‡The printed version might be subject to some changes prior to submission 
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6.1 Keywords 
induced-fit substrate recognition; enzyme dynamics; β-ketoacyl-ACP synthase; KasA; KAS 
enzyme; condensing enzyme; phospholipid; type 2 fatty acid biosynthesis; mycolic acid 
synthesis; Mycobacterium tuberculosis; thiolactomycin 
6.2 Capsule 
Background: Although induced-fit binding is central to molecular recognition, in most cases 
the structural basis for this process remains to be elucidated. 
Results: We characterized the dynamics of substrate recognition for the important drug 
target M. tuberculosis KasA. 
Conclusion: KasA binds extra-long fatty acid substrates via the induced-fit concerted opening 
of a hydrophobic cavity. 
Significance: The improved understanding of induced-fit effects is crucial for inhibitor 
design. 
6.3 Summary 
The survival of Mycobacterium tuberculosis depends critically on C60-C90 mycolic acids - one 
of nature's longest fatty acids. However, despite considerable effort, little is known about 
how enzymes involved in mycolic acid biosynthesis recognize and bind their hydrophobic 
fatty acyl substrates. The condensing enzyme KasA is pivotal for the synthesis of very long 
(C38-42) fatty acids, that are the precursors of mycolic acids. To probe the mechanism of 
substrate and inhibitor recognition by KasA, we determined the structure of this protein in 
complex with a long chain phospholipid, and with several thiolactomycin derivatives that 
were designed as substrate analogs. Our structures provide consecutive snapshots along the 
reaction coordinate for the enzyme-catalyzed reaction, and support an induced-fit 
mechanism in which a wide cavity is established through the concerted opening of three 
gatekeeping residues and several α-helices. The stepwise characterization of the binding 
process provides mechanistic insight into the induced-fit molecular recognition in this 
system and serves as an excellent foundation for the development of high affinity KasA 
inhibitors. 
6.4 Introduction 
Mycobacterium tuberculosis is dependent on mycolic acids, long-chain C60-90 α-alkyl-β-
hydroxy fatty acids that are essential components of the unusually waxy mycobacterial cell 
wall, which confers pathogenicity, intrinsic antibiotic resistance and the ability to persist 
within the human macrophage (23). The biosynthesis of mycolic acids requires the presence 
of two distinct fatty acid synthesis pathways, the mammalian-like type I (FAS-I)5 and the 
bacterial type II (FAS-II) systems (Figure 6-1). The C16-18 acyl-CoA primers produced by the 
FAS-I system are elongated by the FAS-II pathway to C50-56 mycolic acid precursors 
(meromycolic acids) (11). In contrast to the FAS-I system, which consists of one large 
multifunctional dimer, the FAS-II system is constituted by monofunctional enzymes, which 
can be targeted selectively (22). After its activation within the mycobacterial cell, the first-
line anti-tuberculosis drug isoniazid inhibits the enoyl-ACP reductase InhA, thereby validating 
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the FAS-II pathway as a promising target for the development of novel antibiotics (Figure 
6-1) (69). 
 
 
 
Figure 6-1. Mycolic Acid Biosynthesis in Mycobacterium tuberculosis. FAS-I, which is also responsible for 
phospholipid biogenesis, generates C16-18 and C24-26 acyl-CoA substrates de novo (11). Subsequently, FAS-II 
elongates the C16-18 acyl-CoA primers to the very long C50-56 meromycolate chains (upper part of the depicted 
mycolic acid; the terminal portion synthesized via FAS-I is highlighted in red), which are attached to the shorter 
C24-26 aliphatic α-branch originating from FAS-I (lower part of the mycolic acid) to yield the mature mycolic acids 
(23). α-Mycolic acid is the most frequent mycolic acid in M. tuberculosis (11). Three β-ketoacyl-ACP synthases 
are involved in the FAS-II system, namely FabH, KasA and KasB (highlighted in blue). They are inhibited by the 
natural products cerulenin, thiolactomycin and platensimycin (shown in the lower blue box) and catalyze a 
Claisen condensation reaction between acyl-AcpM (acyl-CoA for FabH) and malonyl-AcpM via the 3-step 
mechanism depicted in the upper box (13,59). The reduction of the generated β-keto group to a methylene 
group is achieved via the subsequent actions of MabA, HadAB/BC and InhA (8,68). 
Like InhA, the KasA enzyme is also essential for mycobacterial survival and is thus an 
attractive drug target (135). This homo-dimeric β-ketoacyl-ACP synthase (KAS) catalyzes a 
Claisen condensation reaction between acyl-AcpM and malonyl-AcpM in each elongation 
cycle of the FAS-II pathway, during which the substrates are attached to Ser41 of the small 
acidic acyl carrier protein (ACP; AcpM in M. tuberculosis) via a phosphopantetheine linker 
(Figure 6-1) (75). The KasA catalytic triad consisting of Cys171, His311 and His345 facilitates 
the formation of the new carbon-carbon bond via a 3-step mechanism (Figure 6-1) 
(13,59,60,140). During this process, the active site cysteine is acylated and subsequently 
attacked by the decarboxylated malonyl-AcpM to yield a β-ketoacyl-AcpM which is extended 
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by two carbon atoms. The acylated enzyme intermediate is mimicked by a C171Q KasA 
variant in which Gln171 forms hydrogen bonds with the KasA oxyanion hole (17,131,262). 
This acyl-enzyme mimic is particularly important for future drug design as the natural 
products thiolactomycin (TLM) and platensimycin inhibit KAS enzymes by binding 
preferentially to the acyl-enzyme (Figure 6-1) (59,131,132). Interestingly, the antibiotic TLM, 
which has been shown to possess efficacy in Serratia marcescens and Klebsiella pneumoniae 
murine models of infection (137), inhibits both classes of condensing enzymes, the KAS I/II 
enzymes (FabB/F in Escherichia coli, KasA/B in M. tuberculosis) that participate in the 
elongation cycle and the FAS-II initiating KAS III enzymes (FabH) (24,58,136). TLM and similar 
antibacterials, which interact with multiple targets, are ideal lead compounds because 
single-target mutations will not lead to full resistance (4). 
For the development of improved TLM-based drug candidates it is critical to understand the 
substrate recognition process, catalytic mechanism and inhibition of KAS enzymes. Clearly, a 
certain amount of flexibility is an important requirement for FAS-II enzymes in order to bind 
and process their long chain hydrophobic substrates. This is supported by the observation 
that the FAS-II enoyl-ACP reductases are highly flexible proteins prior to substrate binding 
(19,207,263). In the present work, we probe the KasA ligand binding mechanism using TLM-
analogs substituted at the 3-position which were designed to mimic the two KasA substrates 
acyl-AcpM and malonyl-AcpM. We reveal a unique process of substrate binding including 
extensive structural changes which can be triggered by one of our most potent inhibitors 
(16), laying the foundation for the development of new anti-mycobacterial agents. 
6.5 Experimental Procedures 
6.5.1 Expression and Purification 
Following a previously described procedure, the proteins KasA and C171Q KasA were 
expressed in Mycobacterium smegmatis mc2155 and subsequently purified using affinity, 
anion exchange and size-exclusion chromatography (17,59). 
6.5.2 Crystallization and Data Collection 
Crystallizations were performed using the vapor diffusion method. Prior to crystallization, 
KasA (8.6 mg/ml) was incubated for 2 hours with a 200-fold molar excess of TLM5 (dissolved 
in DMSO). Crystals grew in 10% PEG 3350, 0.2 M K/Na-tartrate and 1.5 mM TCEP. Two 
separate crystals were exposed to a cryoprotectant solution that additionally contained 30% 
ethylene glycol and 40 mM TLM5 and soaked for 1 (KasA - TLM5 - I) and 5 min (KasA - TLM5 - 
II), respectively. Using a MarMosaic 225 detector, diffraction data were collected to 2.4 and 
2.7 Å at the ESRF beamline ID 23-2 (λ = 0.873 Å, T = 100 K) and BESSY II beamline 14.1 (λ = 
0.918 Å, T = 100 K), respectively. 
Similarly, C171Q KasA was incubated with a 20-fold molar excess of TLM, TLM18 (dissolved 
in DMSO), TLM3, TLM4, TLM5 and TLM6 (dissolved in isopropanol). Crystals of space group 
P212121 grew under varying conditions (Table S 6-1), were briefly transferred into a 
cryoprotectant solution (Table S 6-1) and cryocooled in liquid nitrogen. Diffraction data were 
collected to resolutions between 1.5 Å and 2.0 Å at MX beamline 14.1 (BESSY II) using a 
MarMosaic 225 detector (λ = 0.918 Å, T = 100 K). Data collection statistics are given in Table 
S 6-1. 
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6.5.3 Structure Determination 
Data were integrated with XDS (KasA - TLM5 - I) (183), XDSAPP (C171Q KasA - TLM) (215) or 
Imosflm (178), respectively. Scaling was performed using Scala (179). For the Phaser 
molecular replacement (180), we used our previously determined TLM-bound KasA and 
C171Q KasA structures (lacking all ligands) as search models (PDB-entries 2WGE and 2WGG) 
(17). Alternate cycles of model building and maximum likelihood refinement (including 
preceding TLS-refinement (200)) were performed with Coot (182) and Refmac 5 (181). Based 
on the electron density maps, inhibitor binding sites could be identified unambiguously. As 
reported in our preliminary study, inhibitor densities were lower but sufficient for KasA 
compared to C171Q KasA (17). Hence, we used a 200-fold molar inhibitor excess during the 
co-crystallization of the KasA - TLM5 complex. In addition, soaking (for 1 and 5 min; KasA - 
TLM5 - I and II structures, respectively) was performed to enhance inhibitor occupancy. As 
expected, the TLM5 electron density improved with longer soaking times whereas the 
resolution dropped from 2.4 to 2.7 Å. Refinement statistics are given in Table S 6-1. 
To avoid model bias, omit maps were calculated prior to inclusion of the respective ligand. 
Distances and angles are given as mean values for both subunits and as mean values ± 
standard deviations if multiple structures were analyzed. All structural figures were prepared 
with PyMol (174). 
6.5.4 Lipidomics 
Two different and equally successful protocols were used to extract bound ligands from the 
protein samples. Ten µl KasA (100 µM), C171Q KasA (150 µM) or buffer reference samples 
were incubated for 30 min at 20 °C with 10 µl of a papain solution (1 mg/ml in 50 mM PIPES 
pH 7.0, 300 mM NaCl and 10 mM DTT). Alternatively, the samples were treated for 5 min at 
55 °C with 10 µl of a 10 M urea solution. After the addition of 30 µl isopropanol, 10 min 
sonication and centrifugation, the supernatants were analyzed by LC-MS. 
To analyze the phospholipid content of the KasA expression host, liquid cultures of M. 
smegmatis mc2155 with induced C171Q KasA expression were prepared as described 
previously (17). Thirty mg of wet cell pellet were treated with 1 ml Folch solution 
(chloroform : methanol = 2 : 1) and subjected to 10 ultrasonic pulses. After centrifugation 
and separation from the cell debris, the supernatant was evaporated and the pellet 
dissolved in methanol and analyzed by LC-MS. Further details are provided in the 
Supplemental Experimental Procedures. 
6.5.5 Synthesis of 3-Substituted TLM-Derivatives 
Enantiomerically pure 5(R)-TLM and TLM analogs were synthesized using a reported protocol 
(16) and will be reported in a separate publication. 
6.5.6 Inhibition Kinetics 
Binding of TLM18 to wild-type and mutant KasA was quantified by monitoring changes in the 
intrinsic tryptophan fluorescence of the enzyme using 280 nm excitation and 337 nm 
emission as described previously (16). Briefly, the data were collected using a Quanta Master 
fluorimeter (Photon Technology International). Inhibitors were dissolved in DMSO and 
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titrated into 1 μM solutions of KasA and C171Q KasA in buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1 mM dithiothreitol, pH 8.5). 
6.6 Results 
6.6.1 KasA Inhibition by 3-Substituted TLM-Derivatives 
Thiolactomycin (TLM) is a natural product that binds preferentially to the KasA acyl-enzyme 
with low micromolar affinity (59). To improve the affinity of TLM for KasA, elucidate the 
validity of KasA as a drug target and to develop chemical tools to investigate the substrate 
binding and catalytic mechanism of KasA, we designed and synthesized two classes of 3-
substituted TLM-derivatives that display structural features reminiscent of either the acyl- or 
the malonyl-AcpM substrates for the enzyme (16). The linear, hydrophobic 3-substituents of 
TLM3, TLM4 and TLM18 were attached to the thiolactone scaffold to mimic the long acyl 
chain of acyl-AcpM (Figure 6-2A, upper box). In contrast, the 1,3-dioxo group of malonyl-
AcpM is more closely reproduced by TLM5 and TLM6 carrying 3-acetyl and 3-trifluoroacetyl 
moieties (Figure 6-2A, lower box). Therefore, to facilitate our mechanistic studies, we used 
the previously recognized malonyl-mimicking features of TLM and optimized the interactions 
by incorporating an additional exocyclic carbonyl group (Figure 6-2A, lower box) (132,138). 
 
 
 
Figure 6-2. KasA Inhibition by Thiolactomycin Substrate Analogs. (A) TLM-derivatives studied here which were 
designed to resemble the natural KasA substrates. Corresponding moieties are depicted in red. The 3-
substituents R1 were chosen to either mimic the hydrophobic linear chain (R2) of acyl-AcpM (TLM3, 4 and 18) or 
the malonyl-group of malonyl-AcpM (TLM5 and 6). (B) Comparison of the TLM3 (yellow) and TLM5 (green) 
binding poses. The binding modes of the two inhibitor groups (see panel A) vary with respect to the orientation 
of the 3-substituent (indicated by black arrows). (C) Possible TLM species. TLM and its derivatives are 
vinylogous acids (the vinylogous system is highlighted in red) and might, therefore, be present in a 
deprotonated form at physiological pH (236). The two tautomers of protonated TLM (1 and 2) and the 
resonance structures of deprotonated TLM (3 and 4) are shown. (D) Acyl-AcpM analogs bound to C171Q KasA. 
As reference, the TLM structure is depicted in gray. Significantly deviating binding site residue conformations 
are shown for the inhibitor structure with the largest variance. The color code is depicted in panel A. 
Conformational changes and the differences in the TLM-binding pose are indicated by red arrows. (E) Malonyl-
AcpM analogs bound to C171Q KasA. As reference, the TLM structure is shown in gray. The inhibitor color code 
is described in panel A. 
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We subsequently solved the structures of the C171Q KasA acyl-enzyme mimic in complex 
with these TLM-derivatives with resolutions of up to 1.5 Å. The basic TLM binding mode is 
conserved for all investigated inhibitors with the isoprenoid chain intercalating between two 
peptide bonds and the thiolactone carbonyl group hydrogen bonded to His345 and His311 
(Figure 6-2D and Figure 6-2E) (17). 
To reduce steric clashes between the new 3-position substituents and the KasA binding site, 
small but significant shifts in the TLM binding mode can be observed including 
rearrangements of water molecules and slight conformational changes mainly observed for 
Phe237 and its adjacent residues Phe210, Ala215, Met216 and Phe239 (Figure 6-2D and 
Figure 6-2E). In addition, TLM5 and 6 move slightly away from Phe237 thereby increasing the 
hydrogen bonding distance between the thiolactone carbonyl and His345 from 2.74 ± 0.07 Å 
to 2.93 ± 0.04 Å but simultaneously enabling the formation of a hydrogen bond between the 
acetyl carbonyl oxygen and His345 at a distance of 2.96 ± 0.08 Å (Figure 6-2E). The 
observation of this bifurcated three-centered hydrogen bond between the 1,3-dioxo group 
and His345 rationalizes the observed 2 to 4-fold gain in affinity compared to TLM (16) and 
validates these compounds as good malonyl-AcpM analogs. In accordance, the carboxyl 
group of platensimycin, which was also suggested to mimic the malonyl-substrate, was 
found to be located at a comparable position in an E. coli FabF structure (PDB-entry 2GFX) 
(131). The additional weak hydrogen bonds between one of the TLM6 fluorines and the 
hydroxyl groups of Thr313 and Thr315 might explain why this compound displayed the most 
potent Ki* value (460 nM (16)) of the investigated inhibitor series (Figure 6-2E). 
In contrast to these malonyl-AcpM analogs, the inhibitors TLM3, 4 and 18 are characterized 
by a 4 to 18-fold decrease in affinity with respect to TLM (Table 6-1) (16). However, the 
residence time, which was suggested to be a particularly important kinetic quantity for the 
prediction of in vivo drug efficacy (10,45), increased 4-fold for TLM3 with a value of 33 min 
for this C171Q KasA slow-onset inhibitor. Consistently, our structures also emphasize that 
this subset of compounds behaves differently compared to TLM5 and 6 (Figure 6-2B). Slight 
changes in the central TLM binding mode enable the extension of the more hydrophobic 3-
substituents into an orthogonal direction towards an aromatic box consisting of Phe210, 
Phe237, Phe239 and His345 (Figure 6-2B and Figure 6-2D). In addition, the TLM18 azide 
group forms a hydrogen bond to Gln171 and takes part in a π - π stacking interaction with 
Phe237 and His345. However, these interactions seem to be overcompensated by 
desolvation costs for the additional azide since the binding affinity of TLM18 is reduced 
compared to TLM (Ki* = 34 µM compared to 1.9 µM, respectively) (Table 6-1 and (16)). 
 
Table 6-1. Interaction kinetics for TLM18 with wild-type and C171Q KasA. 
Compound 
Kinetic constants 
KasA C171Q KasA 
Kd (µM) Slow-onset Ki (µM) Ki* (µM) kon (sec-1) koff (sec-1) 
TLM* 226.0±9.0 Yes 175.4±3.0 1.9±0.3 0.18±0.002 0.0020±0.0001 
TLM3* 330.0±4.0 Yes 357.0±35.0 7.1±1.3 0.025±0.002 0.0005±0.0001 
TLM4* 233.0±7.0 Yes 305.0±8.0 16.0±2.0 0.012±0.002 0.0011±0.0001 
TLM5* 25.6±0.5 Yes 8.2±0.8 0.9±0.2 0.035±0.010 0.0039±0.0003 
TLM6* 21.8±2.1 Yes 12.1±0.6 0.46±0.05 0.145±0.03 0.0056±0.0002 
TLM18 112.0±3.0 Yes 384.0±12.0 34.0±3.0 0.025±0.005 0.0024±0.0002 
 
*data reproduced from (16) 
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We note that the geometry of the observed interactions for all investigated complexes 
indicates that the thiolactone ring might be present as the enolate with the negative charge 
delocalized between the thiolactone carbonyl oxygen and the C-4 hydroxyl group (Figure 
6-2C). The short distance of the thiolactone carbonyl oxygen to His311 (2.85 ± 0.07 Å) clearly 
indicates the presence of a hydrogen bond (Figure 6-2D). However, the thiolactone carbonyl 
double bond is not optimally oriented for hydrogen bond formation given that the lone pairs 
of electrons are in the plane of the bond (152). Taken together with the observation of a 
short (2.58 ± 0.15 Å) and therefore likely charge-assisted hydrogen bond between the TLM 
hydroxyl oxygen in the 4-position and a conserved water molecule bound below the 
thiolactone plane (Figure 6-2D), it seems likely that TLM-analogs bind in a delocalized and 
deprotonated fashion to KasA (structures 3 and 4 in Figure 6-2C). This is consistent with the 
knowledge that TLM and its analogs are vinylogous acids which can be deprotonated at 
physiological pH (Figure 6-2C, according to the program Moka (264) the predicted pKa of 
TLM is 5.94) (236). In this regard, His311, which is believed to act as a general base during 
catalysis (13), may facilitate deprotonation of the tautomeric form of the inhibitors where 
the hydroxyl group is located next to the thiolactone sulfur (tautomer 2 in Figure 6-2C). 
6.6.2 Identification of a Phospholipid Bound to KasA 
The electron density maps of our C171Q KasA structures also indicated the presence of a 
long-chain molecule close to the active site (Figure 6-3). Due to the need to add 
polyethylene glycol (PEG) during C171Q 
KasA crystallization, we initially 
interpreted this density as a long PEG 
chain (17). However, the observation 
that this molecule was present in 
protein crystals obtained in the 
absence of PEG suggested that it was a 
host-derived lipid. Intriguingly, using 
mass spectrometry, we demonstrated 
that, in contrast to wild-type KasA, the 
C171Q variant protein samples 
contained significant amounts of 
phospholipids (Table 6-2 and Table S 
6-2, Figure S 6-1). Co-purification and 
crystallization of these phospholipids 
with C171Q KasA suggested that they 
bound specifically to the enzyme. Three 
main phospholipids are observed with 
respect to the identity of the head group (Figure 6-3), while the acyl chains are primarily 
palmitic (16:0) and tuberculostearic acids (19:0) (Table 6-2). Interestingly, the latter methyl-
branched fatty acid is a lipid component of Actinomycetales such as mycobacteria and can 
be used for the diagnosis of tuberculosis meningitis (265,266). The C171Q variant preferably 
binds glycerophospholipids containing acyl chains with 16, 17 and 19 carbon atoms (Table 
6-2), which likely were co-purified from the expression host Mycobacterium smegmatis 
mc2155 and crystallized with the C171Q KasA protein. Importantly, the major 19:0,16:0 
 
Figure 6-3. Identification of a Phospholipid Bound to 
C171Q KasA. The 2Fo-Fc omit map for an initially unknown 
ligand is depicted for the C171Q KasA - TLM5 structure at 
1σ. Using mass spectrometry, this molecule was identified 
as a phospholipid with different head groups and acyl 
chains. Among the fatty acid chains, a preference for 
tuberculostearic acid and palmitic acid is apparent. 
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phospholipids perfectly fit the observed electron density with 16:0 attached to the central 
glycerol hydroxyl group (sn-2) and 19:0 at the terminal position (sn-1), which is in agreement 
with the previous finding that mycobacterial phospholipids are mainly comprised of fatty 
acids with 18 or 19 carbons at position sn-1 and with 16 carbon atoms at position sn-2 
(Figure 6-3) (266,267). For model building we used a 19:0,16:0 phospholipid without a head 
group since it was not visible in the electron density presumably due to its exposed position 
at the C171Q KasA surface (Figure 6-3). 
 
Table 6-2. Mass-spectrometric identification of phosphatidylethanolamines 
(PEs) and phosphatidylinositols (PIs) bound to C171Q KasA and present in the 
total lipid extracts of M. smegmatis mc2155. 
 mol% of PE and PIs 
 C171Q KasA M. smegmatis 
   
(16:0,19:0)PI 60.35 ± 0.52 34.65 ± 4.34 
(16:0,17:0)PI 20.34 ± 0.35 4.09 ± 0.55 
(16:1,19:0)PI 7.66 ± 0.35 1.98 ± 0.14 
(16:0,16:1)PI 3.91 ± 0.07 0.48 ± 0.20 
(16:1,17:0)PI 3.49 ± 0.13 0.32 ± 0.07 
(16:0,19:0)PE 1.55 ± 0.22 11.75 ± 1.96 
(16:0,16:0)PE 1.16 ± 0.06 14.20 ± 0.39 
(16:0,18:1)PI 0.98 ± 0.09 1.61 ± 1.06 
(16:0,16:1)PE 0.42 ± 0.06 1.93 ± 0.61 
(16:0,19:1)PE 0.13 ± 0.02 0.50 ± 0.13 
(19:0,19:0)PE n.d.a 13.51 ± 1.44 
(16:0,18:1)PE n.d. 5.65 ± 2.74 
(16:0,18:0)PE n.d. 3.07 ± 0.33 
(18:0,19:0)PE n.d. 1.81 ± 0.23 
(19:0,17:0)PE n.d. 1.13 ± 0.11 
(18:1,19:0)PE n.d. 1.05 ± 0.29 
(16:1,18:1)PE n.d. 0.72 ± 0.34 
(19:0,19:1)PE n.d. 0.54 ± 0.05 
(16:1,18:1)PI n.d. 0.32 ± 0.09 
(16:0,17:1)PE n.d. 0.23 ± 0.07 
(18:0,18:1)PE n.d. 0.23 ± 0.03 
(18:0,19:1)PI n.d. 0.14 ± 0.10 
(18:1,19:1)PI n.d. 0.07 ± 0.10 
 
a n.d. = not detected 
6.6.3 Location of the KasA Substrate Binding Sites 
Clearly, the identified phospholipid represents a very long acyl chain bound to KasA and 
defines the long KasA acyl-binding channel which is created by hydrophobic residues mainly 
located in the capping region - a part of the KAS enzymes which is formed by genetically 
variable insertions (Figure 6-4A, Figure 6-5 and Figure S 6-2) (17). A similar location of the 
cavity has also been observed in the E. coli FabB (ecFabB) C12-acyl-enzyme structure (Figure 
6-4A) (13). 
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To characterize the phosphopantetheine-channel, which is additionally necessary for the 
binding of both AcpM-substrates (236), we superimposed the active site cysteines of KasA 
and a coenzyme A (CoA) bound E. coli FabH structure (Figure 6-4C) (15). Consistently, the 
CoA molecule points into the cavity which contains the TLM-inhibitors underlining their 
potential as substrate analogs. We recently validated this model by NMR-experiments 
showing interligand NOEs between a pantetheine analog and TLM bound to KasA 
simultaneously (16). According to this model, and in line with FabF docking studies (68), 
Thr313 and Thr315, which are strictly conserved for KAS I and II enzymes (Figure S 6-2) and 
 
Figure 6-4. Location of the KasA Acyl- and Phosphopantetheine-channels. (A) The acyl-binding channel. The two 
KasA subunits are shown as blue and yellow surfaces. An intersection of the KasA dimer reveals an acyl-channel 
containing the phospholipid (PL) molecule. The solvent-exposed opening of this channel is indicated by a blue arrow. 
The structure of an E. coli FabB acyl-intermediate (PDB-entry 1EK4) was superimposed on C171Q KasA - TLM5 (13). 
The respective C12-acyl chain is depicted in gray and the carbon atom count for the KasA acyl chains resulting from 
this comparison is provided adjacent to the phospholipid (42 = 4 [missing to reach Gln171] + 18 [19:0 methyl-
branched acyl chain of the phospholipid] + 4 [glycerol of phospholipid] + 16 [16:0 acyl chain]). The location of the 
KasA active site is indicated by Gln171 and His345 in stick representation. (B) KasA substrate binding sites. This 
intersection of the C171Q KasA - TLM18 structure shows both binding channels. The channel entrances are indicated 
by a blue and green arrow, respectively (see also panel A and C). Red arrows indicate the locations of major kinks in 
the observed phospholipid conformation. For Ile347 only the terminal side chain methyl group in its alternate 
conformation is shown. (C) The phosphopantetheine-binding channel. A superposition of the active site cysteines 
from KasA and E. coli FabH (PDB entries 2WGE and 2EFT) shows that the CoA molecule bound in the FabH structure, is 
pointing towards the KasA active site (15-17). The CoA molecule, which resembles the phosphopantetheinylated 
AcpM, is depicted in gray along with an intersection of the C171Q KasA - TLM5 structure. The entrance of the 
phosphopantetheine-channel is indicated by a green arrow. (D) Proposed AcpM binding site. Basic residues located 
on α3' and η3' likely bind to the acidic AcpM protein, which is believed to deliver its substrate to the adjacent subunit 
(18). A HEPES buffer molecule (shown in cyan) bound to the α3' basic patch was observed for the C171Q KasA and 
C171Q KasA - TLM structures. The flexible regions of KasA are highlighted by red arrows in one subunit (C171Q KasA - 
TLM5 is shown in yellow, KasA - TLM (PDB-entry 2WGE) shown in gray) and as orange surface in the other subunit 
(see also Figures 5, 6 and S2). Blue and green arrows indicate the openings towards the acyl- and 
phosphopantetheine-pockets, respectively. 
 Induced-fit Substrate Binding Mechanism of KasA  
150 
 
were proposed to be involved in ACP-substrate binding (141), contact the terminal 
phosphopantetheine peptide carbonyl oxygen (Figure 6-4C), which is represented by one of 
the TLM6 fluorines (Figure 6-2E). 
In a recent kinetic study, Borgaro et al. proposed that the binding of the acidic ACP protein 
to one ecFabB monomer leads to the delivery of its substrate to the active site of the 
adjacent subunit (18). They identified several basic amino acids on the protein surface that 
are important for ACP binding. Similarly, the corresponding KasA arginines 74', 78' and 79' 
on α-helix 3', as well as Arg135', Lys136' and Arg214 (the prime designates the second KasA 
monomer) are ideally positioned to interact with the AcpM molecule. In this orientation the 
bound AcpM would then permit the entrance of the substrates via the phosphopantetheine-
tunnel opening (indicated by the green arrow in Figure 6-4D) of the neighboring monomer. 
In two of our nine crystal structures, a negatively charged HEPES molecule is bound to this 
basic KasA patch where the acidic AcpM is expected to bind (cyan stick model in Figure 
6-4D). Importantly, we exclude the possibility that one or both substrates are delivered 
through the acyl-pocket opening (blue arrow in Figure 6-4D) due to distance considerations 
to reach the active site cysteine. An entrance through the acyl-pocket opening would require 
to bridge the large distance between the phospholipid head group and the active site 
cysteine of ~30 Å (corresponding to 25 atoms) by the phosphopantetheine linker which has a 
maximal length of ~16 Å (14 atoms) (Figure 6-1, Figure 6-4A and Figure 6-4B). 
6.6.4 Structural Explanation for the KasA Substrate Preferences 
The mycobacterial β-ketoacyl-ACP synthases KasA and KasB are striking examples of 
enzymes that produce very hydrophobic meromycolates with up to 56 carbon atoms in 
length in a cytosolic, i.e. hydrophilic environment. KasA was found to extend short FAS-I 
primers to C38-42 monounsaturated acyl chains, whereas KasB can produce full-length 
meromycolates (268). The unambiguous identification of phospholipids bound to the acyl-
channel of C171Q KasA sheds light on the observed substrate preferences of this enzyme. 
Remarkably, the number of carbon atoms between the mutated active site cysteine and the 
terminal end of the sn-2 phospholipid acyl chain coincides with the maximal acyl chain 
length of 42 carbons generated by KasA (Figure 6-4A). We assume that the C42 chain cannot 
be further elongated because the acyl-channel is capped by the peptide backbone of 
residues 239-241, thus explaining why KasA is not able to produce full-length meromycolic 
acids. Consistently, phospholipids mimicking the C44 acyl-enzyme intermediate (e.g. 
(19:0,19:0)PE and (19:0,18:0)PE) do not bind to C171Q KasA although they are present in the 
total lipid extract of M. smegmatis (Table 6-2). 
Furthermore, we observed that the phospholipid does not bind in an extended manner but 
rather contains several kinks as pre-defined by the geometry of the surrounding KasA cavity 
(Figure 6-4B). This non-linear architecture of the acyl-channel might facilitate the binding of 
unsaturated primers as exemplified by the presence of phospholipids with unsaturated fatty 
acids (Table 6-2). Indeed, it has been proposed that the cis ω-19 double bond is already 
introduced at the C22 stage of meromycolate synthesis (11) and the observed non-linear 
shape of the acyl-cavity could thus facilitate the binding of kinked unsaturated substrates 
with a migration of the cis double bond by two carbon atoms along the channel in each new 
elongation round. 
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In contrast to KasA, its homolog KasB produces full meromycolates with up to 56 carbons 
(268). Unfortunately, the available KasB crystal structure was not solved in its 'open' acyl-
channel conformation as observed for C171Q KasA and thus the preference for longer 
substrates cannot be directly deduced (22,269). However, most residues that create the 
'open' C171Q KasA acyl-binding pocket are conserved in KasB. Among the few differences 
between KasA and KasB, E124F, P201R and I347V are particularly interesting. The first two 
residues are located at the opening of the acyl-pocket and might elongate the cavity in KasB. 
In contrast, Ile347 lies between the aromatic box containing the hydrophobic TLM 3-
substituents (Figure 6-2D) and the terminal part of the hypothetical C42-acyl chain (Figure 
6-4B), suggesting that the acyl chain could be extended towards the aromatic box and TLM 
binding site in KasB due to distinct sequence variations (I145Y, G200T, I347V). The 
hydrophobic 3-substitutent of TLM18 might mimic this alternative acyl binding mode (Figure 
6-4B). 
6.6.5 Acyl-Channel Opening Mechanism 
Our structures unambiguously establish the location of all substrate binding sites which 
immediately leads to two 
important questions - how 
does KasA achieve the uptake 
of its hydrophobic substrates 
given that neither the long 
acyl chain nor its lipophilic 
binding pocket should be 
exposed to solvent for too 
long and why do 
phospholipids not bind equally 
well to the wild-type enzyme? 
To address these questions, 
we solved the structure of 
TLM5 bound to wild-type 
KasA. Intriguingly, this 
malonyl-AcpM analog induces 
conformational changes which 
define an intermediate state 
between the wild-type KasA - 
TLM structure (PDB entry 
2WGE), which is characterized 
by a 'closed' acyl-channel, and 
the 'open' structure observed 
for the acyl-enzyme analog 
C171Q KasA which binds 
phospholipids (17). A per-
residue rmsd plot of the three 
structures reveals five regions 
in close vicinity to the 
Figure 6-5. Flexible KasA Regions Involved in Substrate Recognition. (A) 
Flexible KasA regions surrounding the substrate binding sites. The 
highlighted regions (color coded as defined in panel C) exhibit different 
conformations in the KasA and C171Q KasA structures. For clarity, one of 
the two C171Q KasA -TLM5 monomers is shown in transparent colors. (B) 
KasA capping region. The three N-terminal KasA insertions (26-80, 115-
145 and 200-240) are depicted in cyan, yellow and lilac, the C-terminal 
insertion (366-391) in brown. (C) Differences between KasA and C171Q 
KasA structures. The per-residue rmsd, calculated with Theseus, is shown 
for the KasA (PDB entry 2WGD), KasA - TLM5 - I and C171Q KasA - TLM5 
structures (14). KasA - TLM (PDB entry 2WGE) was used as the reference 
structure. The five highlighted regions reveal significant differences 
between the investigated structures. 
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substrate binding sites which differ in their conformation between the enzyme and acyl-
enzyme states (Figure 6-5). This is the first time that a partially 'open' acyl-channel has been 
observed, thus revealing that the acyl-substrate interacts with KasA through an induced-fit 
binding mechanism. Although adaptive substrate recognition is a well-known phenomenon, 
structural information about the dynamics of such processes is rare (239). 
 
 
 
Figure 6-6. The KasA Acyl-substrate Recognition Mechanism. (A-F) The phospholipid and C12-acyl chain (Figure 
6-4) are shown in gray. Gatekeeper residues Leu116, Phe404 and Tyr126' are labeled in blue. Red arrows 
indicate the stepwise conformational changes apparent from the structures KasA - TLM (lilac, PDB-entry 
2WGE), KasA (green, PDB-entry 2WGD), KasA - TLM5 - I (yellow) and C171Q KasA - TLM5 (orange). For the 
second subunit, pale colors were used. The phosphopantetheine-channel opening is indicated by a green arrow 
(Figure 6-4). Panel E contains a detailed view of the KasA dimer interface along a 2-fold axis of symmetry. The 
conformational changes observed for Tyr126 and Asp127 lead to a short hydrogen bond in both subunits. 
 
We characterized this mechanism and the associated conformational changes in a stepwise 
manner using the four different structures KasA - TLM (PDB-entry 2WGE), apo KasA (PDB-
entry 2WGD), KasA - TLM5 - I (nomenclature of all structures according to Table S 6-1) and 
C171Q KasA - TLM5 of which only the final 'open' state permits the binding of long acyl 
chains. Similar to the KasA - TLM complex, the unliganded KasA structure is almost 'closed' 
(Figure 6-5). The conformational changes towards the 'open' state can be triggered by either 
the C171Q mutation, which mimics acylation of the active site cysteine (C171Q KasA - TLM5) 
or by the binding of TLM5 (KasA - TLM5 - I). Since the natural malonyl-substrate preferably 
binds to the 'open' acyl-enzyme state during catalysis (Figure 6-1) (262), its close analog 
TLM5 seems to have the capability to select for or to actively induce a partially opened 
conformation in the wild-type enzyme. The improved potency of this inhibitor (16) might be 
the cause for these conformational changes, which enabled us to trap an intermediate state 
between the wild-type and acyl-enzyme forms. In contrast, similar rearrangements were not 
observed with TLM which has a lower affinity (16,17). Compared to the 'closed' state, the 
three subsequent structures are characterized by a Phe404 conformation in which the 
phenyl-ring plane is rotated by 5°, (-)19° and 59°, respectively (henceforth, we will indicate 
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the stepwise changes observed for these three structures compared to the 'closed' KasA - 
TLM state using the following notation: 5° → 19° → 59°) (Figure 6-6A and Figure 6-6C). The 
introduction of the C171Q mutation that mimics acylation of the active site cysteine as well 
as the binding of TLM5 in a slightly different orientation compared to TLM, apparently 
induce the rotation of the Phe404 phenyl-ring. This conserved residue was suggested to play 
an important role as a gatekeeper between the active site cysteine and the acyl-binding 
cavity opening upon acylation (17). 
The alteration in the Phe404 conformation induces a cascade of structural changes (Figure 
6-6). Initially, the adjacent residues Phe210, Met213, Val142' and Met146' are shifted due to 
the rotation of Phe404 (Figure 6-6C, Figure 6-6D and Figure 6-6F). Compared to the 'closed' 
reference state, the Cα atom of Phe210 moves by 0.4 → 0.5 → 1.8 Å and the Cα atom of 
Val142' by 0.1 → 0.6 → 1.6 Å. Together with Ile347, these three residues comprise a binding 
cavity for Leu116 in the initial KasA - TLM structure. Due to the subsequent shift and 
tightening of this pocket, Leu116 is successively expelled from the acyl-channel (Leu116 Cα 
moves by 1.5 → 3.3 → 4.3 Å) (Figure 6-6C), which creates space for the binding of an acyl 
chain and, hence, Leu116 can be regarded as a second gatekeeper residue. This observation 
validates experimentally a similar proposal by Schaefer et al. based on a molecular dynamics 
simulation (236). 
Simultaneously, the Phe404-induced shifts of Phe210 and Met213 directly lead to a 
movement of an entire range of residues including amino acids 202-239 (rmsd change of 0.2 
→ 0.4 → 1.1 Å) and therefore helix α9 (residues 204-211) (Figure 6-5, Figure 6-6D and Figure 
S 6-2). In particular, the conformational change of residues 212-216 causes a widening of the 
phosphopantetheine-pocket which accounts for the enhanced TLM affinity towards the acyl-
enzyme intermediate (17). Helix α9 is in close proximity to a region containing residues 46-
63 (including α2 and β3) and 122'-148' (including α5', α6' and the 310-helix η3') which 
consequently move in a similar direction supported by the spatial rearrangements of Val142' 
and Met146', which in turn are triggered by the rotation of the Phe404 phenyl-ring plane 
(rmsd values change by 0.1 → 0.5 → 1.0 Å and 0.4 → 0.9 → 2.1 Å, respectively) (Figure 6-6F). 
The extensive alterations in helices α5' and α6' in turn induce a slight shift of helix α3' (rmsd 
change of 0.2 → 0.4 → 0.6 Å) and, together with the movement of Leu205 located on helix 
α9, the extrusion of Tyr126' from the acyl-binding channel, which is stabilized in this final 
conformation by a hydrogen bond to Asp127 (Figure 6-6E and Figure 6-6F). During this 
process, the distance between the hydroxyl group of Tyr126' and the Asp127 carboxyl 
oxygen decreases from 11.5 Å via 10.9 Å and 5.6 Å to ultimately 2.6 Å. Related via a 2-fold 
axis of symmetry, the exact same modifications are observed between Tyr126 and Asp127', 
which indicates that the proposed cascade of conformational changes, and therefore the 
opening of the substrate binding pockets, take place in the neighboring monomer at the 
same time. 
Importantly, Tyr126' may be envisioned as a third gatekeeper that protects the hydrophobic 
acyl-cavity from solvent exposure by its hydrophilic OH group. According to the proposed 
mechanism, all three gatekeepers (Phe404, Leu116 and Tyr126') exit concertedly from the 
acyl-channel to permit the simultaneous uptake of an acyl chain as exemplified by the C171Q 
KasA bound phospholipid (Figure 6-6B, Movie S 6-1 and Movie S 6-2). This concerted process 
is facilitated by considerable shifts of the helices surrounding both acyl-channels and would 
avoid excessive exposure of the hydrophobic channel to the solvent (Figure 6-5A, Movie S 
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6-1). Interestingly, these helices are part of the capping region, a genetically variable part of 
the KAS enzymes, that may have evolved specifically to enable the binding of meromycolate 
precursors to KasA (Figure 6-5B and Figure S 6-2) (68). The vastly different but also flexible 
FabH capping domain, which is formed from insertions located at distinct sites in the primary 
sequence (Figure S 6-2), has similarly been suggested to be involved in substrate binding 
(263,270). Moreover, a sequence alignment of the KAS enzymes shows that the three 
gatekeeping residues are conserved in KasB, thus suggesting that a similar substrate 
recognition mechanism may be present in this enzyme (Figure S 6-2). Consistent with this 
proposal, it has been suggested that Leu115 (corresponding to Leu116 in KasA) has to 
undergo conformational changes upon binding of cerulenin, which contains a long 
hydrophobic chain (Figure 6-1) (269). 
6.7 Discussion 
To address the question of how the β-ketoacyl-ACP synthase KasA ensures the binding of 
very hydrophobic long-chain mycolic acid precursor molecules, we utilized analogs of the 
natural product TLM that recapitulate key aspects of the structure of the two KasA 
substrates, acyl-AcpM and malonyl-AcpM. Our structural data support an induced-fit 
substrate binding mechanism which involves the concerted rearrangement of three 
gatekeeping residues. This mechanism includes the movement of several helices thereby 
creating the acyl-binding pocket and thus accounting for the ability of the C171Q KasA acyl-
enzyme mimic to bind phospholipids that are similar in size to the C42 acyl chain of the 
natural substrate (Table 6-2, Movie S 6-1 and Movie S 6-2). 
Strikingly, these conformational changes take place in the KasA region where AcpM is 
expected to bind (Figure 6-4D) (18), and thus it is likely that AcpM binding initiates this 
process. Based on this hypothesis, we propose the following mechanism: The acidic AcpM 
protein interacts via the helices α2 and α3 with the basic KasA surface region containing 
helices α9, α3', α5', η3' and α6' and thereby delivers both substrates through the 
phosphopantetheine-tunnel (green arrow in Figure 6-4D) of the adjacent subunit. Since all 
the KasA helices mentioned above undergo conformational changes during the acyl-channel 
opening process, it is tempting to speculate that AcpM might be the trigger for the observed 
substrate binding mechanism and specifically could induce the opening of the three 
gatekeepers. The acyl-substrate could thus be injected simultaneously to the opening of the 
acyl-pocket upon AcpM binding, ensuring that neither the hydrophobic acyl-chain, nor the 
acyl-cavity are exposed to the solvent. In support of this hypothesis we observe that the acyl 
chain itself is not able to induce these conformational changes as exemplified by the absence 
of the phospholipids in the wild-type KasA binding cavity. Furthermore, our model explains 
why acyl-CoA substrates are not efficiently processed by KasA (18). In contrast, the FabH 
enzyme has a fundamentally different capping region (Figure S 6-2) which likely accounts for 
the altered specificity towards acyl-CoA primers (270). 
In conjunction with the proposed substrate binding mechanism, our C171Q KasA structures 
provide an excellent model for the investigation of the 3-step catalytic mechanism. In 
particular, the decarboxylation step of KAS enzymes has not been fully elucidated due to the 
lack of structural information to establish the location of the malonyl group. The 1,3-dioxo 
TLM5 moiety is an excellent mimic of the malonyl group, and consistent with previous 
studies, is hydrogen bonded to His345 in the active site (141). However, it is not possible to 
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distinguish between the two oxo groups - i.e. which of the two represents the malonyl 
carboxylate thus leading to the two geometric possibilities depicted in Figure 6-7C and 
Figure 6-7D. These possibilities represent the two conflicting mechanistic models which have 
been proposed for the decarboxylation reaction - either His311 or Phe237, which are both 
strictly conserved among KAS I and II enzymes (Figure S 6-2), were suggested to trigger the 
decarboxylation of malonyl-ACP (59,132,141). 
 
 
 
Figure 6-7. Mechanistic Insights. (A) Hydrogen bond network surrounding His311. Positively (Lys340; depicted 
in blue) and negatively (Asp319, Glu322 and Glu354; depicted in red) charged amino acids, which were 
proposed to be important for decarboxylation (141), interact with His311 via a complex hydrogen bonding 
network, which includes a potassium ion located in a conserved cation binding site (Figure S 6-3). This 
environment likely leads to the modulation of the electronic properties of the His311 ε-nitrogen (magenta) to a 
catalytically ideal state (139). (B) Mechanistic consequences of TLM5 being a malonyl-AcpM analog. His345 
binds to the 1,3-dioxo group of TLM5, which mimics the malonyl group of the natural substrate. The side chain 
amide carbonyl oxygen of Gln171 is located in the oxyanion hole formed by residues 171 and 404 (the side 
chain of Phe404 is omitted for clarity). The proposed attack vector geometry of the acetyl-carbanion forming 
via decarboxylation is depicted in cyan. (C-D) Geometric possibilities for malonyl-AcpM binding. Two different 
models of malonyl-AcpM binding to KasA via the phosphopantetheine-tunnel are displayed on top of TLM5. In 
addition, panel C depicts six water molecules of the C171Q KasA apo structure which are not present in the 
binary complex. Water molecules which are likely displaced by the malonyl-substrate are colored in red, water 
molecules which might still be present upon malonyl-AcpM binding are highlighted in cyan. The red arrow 
indicates the water which was suggested to attack the carboxylate group of malonyl-AcpM (271). 
 
In the orientation depicted in Figure 6-7C the ε-nitrogen of His311 could trigger the 
decarboxylation, whereas this role is indicated for one of the Phe237 π-faces in the 
alternative case (Figure 6-7D). For both models decarboxylation leads to the generation of 
the carbanion at the carbon atom located between the two TLM5 carbonyl groups (Figure 
6-7B). Interestingly, the evolving carbanion could approach the acylated cysteine with a 
Buergi-Dunitz trajectory of 110° (Figure 6-7B), which is within the expected range of 100 - 
110° for the transition state attack vector angle of a carbonyl group by a nucleophile (Nu → 
C=O) (272,273). For similar stereoelectronic reasons, the carbanion should attack the Cys171 
thioester carbonyl with an obtuse angle as assumed for the related aldol reactions (274). 
Thus, we reason that the malonyl-group of the AcpM-substrate is positioned with the 
carboxylate pointing towards His311 (enolate attack angle of 92° vs. 54°, see also Figure 6-7B 
and 7C) and therefore exclude the possibility depicted in Figure 6-7D. Strikingly, all residues, 
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which were proposed to play an important role during decarboxylation (the charged amino 
acids Asp319, Glu322, Lys340 and Glu354, which are conserved amongst KAS I/II proteins) 
(141) and an octahedrally bound potassium ion identified in this study (Figure S 6-3), are 
involved in a complex hydrogen bonding network contacting His311 (Figure 6-7A) and might 
thus be responsible to tailor the catalytically ideal His311 electronic state (139). Since the 
residues participating in catalysis are different for KAS III enzymes and other thiolase 
superfamily members such as chalcone synthase (CHS), these enzymes presumably operate 
via an alternative reaction mechanism (13,60,141,246). In particular, the catalytic residue 
His345 is replaced by an asparagine in FabH proteins and the residues corresponding to 
Asp319, Glu322, Lys340 and Glu354 as well as the cation binding site are not conserved 
(Figure S 6-2) (141). 
 
 
 
Figure 6-8. Proposed KasA Reaction Mechanism. This mechanistic scheme is strongly supported by our 
structural work and builds on previous studies (51,139,141,262,271). Gray dashed lines indicate hydrogen 
bonds. It was proposed that the dipole moment of helix α8 acidifies Cys171 (Figure S 6-2) (68) leading to a 
zwitterionic His311H+-Cys171- ion pair in the free enzyme (box 1) which activates Cys171 for the nucleophilic 
attack of the acyl-AcpM (box 2) (139). The His311 ε-nitrogen (depicted in magenta as in Figure 6-7A) likely 
destabilizes the malonyl-AcpM carboxylate during decarboxylation as highlighted by the dashed line in 
magenta, in box 4. In contrast to a previous hypothesis regarding the decarboxylation reaction (271), our KasA 
binary complex structures contain no appropriately positioned water molecule which could be activated by the 
His311 ε-nitrogen to trigger the decarboxylation reaction directly (box 4). Consequently, we suggest that the 
initial product is CO2 which can then be hydrated after decarboxylation (in between steps 4 and 5). The 
evolving enolate (box 5) is stabilized by the neutral His345 which is protonated at its ε-nitrogen since the δ-
nitrogen is hydrogen bonded to the backbone NH of Ile347 (139). Geometric considerations based on our 
structures suggest that the nucleophilic attacks of Cys171 and of the acetyl-carbanion occur from the Si- and 
Re-faces of the thioester carbonyl groups, respectively (boxes 2 and 5; see also Figure 6-7). 
 
Based on our structural results concerning the binding mode of the malonyl group and taking 
previous findings into account (139,141,262,271), we propose the mechanism depicted in 
Figure 6-8. A mechanistic study of the mammalian fatty acid synthase β-ketoacyl synthase 
domain, which shares the Cys-His-His catalytic triad and the important active site residues 
with KAS I enzymes (138), revealed that bicarbonate is the product of the condensation 
reaction (262). Subsequently, a similar outcome has been proposed and confirmed for 
Streptococcus pneumoniae FabF (spFabF) where it was shown that 14C-labeled bicarbonate is 
incorporated into malonyl-ACP in the reverse reaction of the condensing enzyme (271). 
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Thus, an activated water molecule either directly attacks the carboxylate of malonyl-ACP or 
hydrates CO2 after decarboxylation (262). The identification of a structured water molecule 
bound to the ε-nitrogen of His311 (according to the KasA numbering) in most apo KAS I/II 
crystal structures, has previously been used to support this mechanism (51,271). Indeed, our 
C171Q KasA apo structure confirms the presence of such a water molecule (indicated by the 
red arrow in Figure 6-7C). However, in the binary complex it is displaced by the thiolactone 
oxygen of TLM5 mimicking one of the malonyl-AcpM carboxylate oxygens. Assuming a 
neutral His311 (deprotonated at Nε) prior to decarboxylation, as proposed for ecFabB and 
spFabF (13,51,271), we suggest that the ε-nitrogen lone pair electrons directly destabilize 
the adjacent malonyl-AcpM carboxylate (Figure 6-8 - box 4, dashed line in magenta) leading 
to the transfer of the negative charge to the thioester carbonyl which in turn is stabilized by 
His345. After decarboxylation, one of the water molecules surrounding the substrate might 
re-enter the binding site and could hydrate the CO2 molecule facilitated by a His311-
mediated activation (Figure 6-7C). In support, an ecFabB H298Q mutant was decarboxylation 
deficient whereas a H298E mutant displayed residual decarboxylation activity at pH values 
between 6 and 8, which highlights the necessity for an electron-rich lone pair at the position 
of the His311 ε-nitrogen (corresponding to ecFabB His298) enabling both decarboxylation 
and binding of a water molecule (141). 
Most enzymes are inherently flexible systems tailored to accommodate substrates and 
undergo catalysis (275). In light of the fact that the free energy of the transition state along 
the reaction coordinate has to be lowered efficiently, it is not very surprising that the 
dynamics of substrate binding and catalysis is also reflected in the inhibition of enzymes 
(209,238,239). This is nicely illustrated by recent studies concerning the induced-fit binding 
of peptide deformylase (PDF) and enoyl-ACP reductase (FabI) inhibitors (19,188,239). For 
instance, the picomolar affinity of diphenyl ether FabI inhibitors can be related to their 
capability to mimic the transition state of the catalyzed reaction and to trigger the correlated 
ordering of a flexible loop (19,188). In the present study we reveal snapshots of the dynamic 
process which is involved in the recognition of very long chain fatty acyl substrates by the 
important drug target KasA. This investigation of induced-fit substrate recognition and 
turnover has important implications for the design of optimized KasA inhibitors. For 
instance, TLM 3-acyl substituents can trigger the opening of the phosphopantetheine and 
acyl-channels in the wild-type KasA enzyme. This observation now suggests ways in which 
these inhibitors can be tailored in order to occupy the hydrophilic and hydrophobic cavities 
in the active site, thus leading to compounds with improved affinity for KasA and ultimately 
to the development of urgently needed drug candidates for the treatment of tuberculosis. 
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6.10 Supplementary Information 
6.10.1 Supplemental Tables 
Table S 6-1. Data Collection and Refinement Statistics. 
 KasA - TLM5 - I KasA - TLM5 - II C171Q KasA 
Crystallization   
Protein concentration (mg/ml) 8.6 8.6 8.1 
Crystallization condition 0.2 M K/Na-tartrate
10% PEG 3350 
1.5 mM TCEP 
0.2 M K/Na-tartrate
10% PEG 3350 
1.5 mM TCEP 
0.1 M HEPES pH 7.5
40% PEG 200 
Cryoprotectant 30% ethylene glycol 30% ethylene glycol none 
Data collection   
Cell dimensions   
a, b, c (Å) 77.6, 77.6, 147.7 77.2, 77.2, 146.9 74.2, 89.1, 183.5
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 90 
Space group P3121 P3121 P212121 
Resolutiona (Å) 49.2-2.40 (2.53-2.40) 49.4-2.70 (2.85-2.70) 32.9-1.70 (1.79-1.70)
Observed reflections 148,026 (17,845) 78,398 (11,448) 555,297 (79,724)
Unique reflections 20,763 (2,978) 14,534 (2,084) 134,076 (19,388)
Completeness (%) 99.8 (99.9) 100.0 (100.0) 100.0 (100.0) 
Average redundancy 7.1 (6.0) 5.4 (5.5) 4.1 (4.1) 
Rmerge
b (%) 9.9 (59.6) 13.6 (58.0) 8.7 (56.4) 
Rpim
c (%) 3.7 (25.3) 6.3 (26.5) 4.8 (31.7) 
<I / σ(I)> 13.9 (2.7) 9.2 (2.5) 10.5 (2.3) 
Monomers per AU 1 1 2 
Refinement   
Resolution (Å) 67.2-2.40 66.9-2.70 91.7-1.70 
Rcryst
d
 (%) 16.4 17.6 14.3 
Rfree (%) 21.6 24.2 17.0 
Number of atoms 3,172 3,139 7,276 
rmsd bond lengths (Å) 0.010 0.016 0.019 
rmsd bond angles (°) 1.52 1.66 1.82 
Average B-factor (Å2) 52.2 42.3 19.5 
Ramachandran-plote   
Favored (%) 95.9 96.4 97.2 
Allowed (%) 3.9 3.1 2.8 
Outliers (%) 0.2 0.5 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 
0.15 0.23 0.05 
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 C171Q KasA - TLM C171Q KasA - TLM3 C171Q KasA - TLM4
Crystallization   
Protein concentration (mg/ml) 8.1 4.6 7.1 
Crystallization condition 0.1 M HEPES pH 7.5
30% PEG 400 
20 % PEG 3350
 
0.1 M HEPES pH 7.5
0.2 M NaCl 
13% isopropanol 
Cryoprotectant 5% PEG 400 25 % ethylene glycol 30% glycerol 
Data collection   
Cell dimensions   
a, b, c (Å) 74.3, 89.3, 183.0 74.7, 89.3, 183.5 74.5, 89.5, 183.3
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Space group P212121 P212121 P212121 
Resolutiona (Å) 48.5-1.95 (2.06-1.95) 36.1-1.80 (1.90-1.80) 33.8-1.75 (1.84-1.75)
Observed reflections 370,790 (53,438) 469,728 (66,187) 512,768 (73,736)
Unique reflections 87,684 (12,482) 114,325 (16,510) 123,806 (17,911)
Completeness (%) 98.3 (97.0) 99.9 (100.0) 99.9 (100.0) 
Average redundancy 4.2 (4.3) 4.1 (4.0) 4.1 (4.1) 
Rmerge
b (%) 8.4 (41.1) 10.1 (51.0) 8.0 (47.3) 
Rpim
c (%) 4.6 (22.4) 5.6 (29.1) 4.5 (26.3) 
<I / σ(I)> 15.6 (3.7) 9.1 (2.4) 11.3 (2.9) 
Monomers per AU 2 2 2 
Refinement   
Resolution (Å) 91.5-1.95 91.7-1.80 91.7-1.75 
Rcryst
d
 (%) 13.8 16.0 14.0 
Rfree (%) 17.3 19.6 16.6 
Number of atoms 7,131 7,295 7,303 
rmsd bond lengths (Å) 0.014 0.014 0.018 
rmsd bond angles (°) 1.64 1.64 1.86 
Average B-factor (Å2) 19.8 25.9 19.9 
Ramachandran-plote   
Favored (%) 97.0 97.7 97.2 
Allowed (%) 3.0 2.3 2.8 
Outliers (%) 0.0 0.0 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 
0.07 0.06 0.05 
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 C171Q KasA - TLM18 C171Q KasA - TLM5 C171Q KasA - TLM6
Crystallization   
Protein concentration (mg/ml) 8.1 7.1 4.9 
Crystallization condition 0.1 M Mg-formate
15% PEG 3350 
0.2 M KSCN
15% PEG 3350 
0.1 M Tris pH 7.5
15% PEG 6000 
Cryoprotectant 27% ethylene glycol 25% ethylene glycol 25% ethylene glycol
Data collection   
Cell dimensions   
a, b, c (Å) 74.3, 88.9, 184.3 74.3, 89.1, 183.6 74.5, 89.1, 183.8
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Space group P212121 P212121 P212121 
Resolutiona (Å) 33.7-1.80 (1.90-1.80) 28.5-1.50 (1.58-1.50) 36.0-1.80 (1.90-1.80)
Observed reflections 565,025 (81,773) 730,880 (92,296) 463,195 (66,841)
Unique reflections 113,762 (16,455) 194,886 (28,227) 113,933 (16,471)
Completeness (%) 100.0 (100.0) 99.9 (99.8) 100.0 (100.0) 
Average redundancy 5.0 (5.0) 3.8 (3.3) 4.1 (4.1) 
Rmerge
b (%) 11.3 (61.1) 6.8 (43.6) 9.9 (58.9) 
Rpim
c (%) 5.6 (29.9) 4.0 (28.2) 5.6 (33.2) 
<I / σ(I)> 10.0 (2.5) 11.1 (2.6) 10.2 (2.3) 
Monomers per AU 2 2 2 
Refinement   
Resolution (Å) 92.2-1.80 91.8-1.50 91.9-1.80 
Rcryst
d
 (%) 13.9 13.6 14.5 
Rfree (%) 16.8 15.6 17.3 
Number of atoms 7,387 7,518 7,269 
rmsd bond lengths (Å) 0.016 0.016 0.017 
rmsd bond angles (°) 1.71 1.78 1.73 
Average B-factor (Å2) 24.1 23.6 20.0 
Ramachandran-plote   
Favored (%) 97.1 97.2 96.7 
Allowed (%) 2.9 2.7 3.3 
Outliers (%) 0.0 0.1 0.0 
Maximum likelihood based 
estimated coordinate error (Å) 
0.05 0.03 0.06 
 
a Values in parenthesis refer to the highest resolution shell 
b  −=
hkl i
i
hkl i
imerge IIIR  
c ( )[ ]   −−=
hkl i
i
hkl i
ipim IIINR
2/111  (173) 
d  −=
hkl
obs
hkl
calcobscryst FFFR  
e According to Molprobity (172) 
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Table S 6-2. Mass-spectrometric quantification of PEs and PIs bound to wild-type KasA, C171Q KasA and in 
the total lipid extracts of M. smegmatis mc2155. 
 amount of PE and PIs 
 KasA 
(pmol/nmol protein) 
C171Q KasA 
(pmol/nmol protein) 
M. smegmatis 
(pmol/mg pellet) 
    
(16:0,19:0)PI 59.84 2042.34 ± 585.82 752.22 ± 222.19 
(16:0,17:0)PI 28.57 690.78 ± 206.10 88.85 ± 27.18 
(16:1,19:0)PI n.d.a 256.52 ± 68.71 42.70 ± 10.37 
(16:0,16:1)PI n.d. 132.67 ± 39.17 9.58 ± 3.48 
(16:1,17:0)PI n.d. 116.81 ± 29.70 6.61 ± 0.91 
(16:0,19:0)PE n.d. 50.27 ± 9.34 244.38 ± 24.07 
(16:0,16:0)PE n.d. 39.20 ± 11.86 302.62 ± 55.58 
(16:0,18:1)PI n.d. 33.52 ± 10.91 31.71 ± 20.81 
(16:0,16:1)PE n.d. 13.68 ± 2.58 38.92 ± 6.85 
(16:0,19:1)PE n.d. 4.40 ± 0.78 10.27 ± 1.33 
(19:0,19:0)PE n.d. n.d. 291.83 ± 80.70 
(16:0,18:1)PE n.d. n.d. 110.33 ± 42.82 
(16:0,18:0)PE n.d. n.d. 65.04 ± 10.99 
(18:0,19:0)PE n.d. n.d. 39.14 ±11.17 
(19:0,17:0)PE n.d. n.d. 24.41 ± 6.44 
(18:1,19:0)PE n.d. n.d. 21.30 ± 2.82 
(16:1,18:1)PE n.d. n.d. 14.13 ± 4.86 
(19:0,19:1)PE n.d. n.d. 11.72 ± 3.08 
(16:1,18:1)PI n.d. n.d. 6.54 ± 1.50 
(18:0,18:1)PE n.d. n.d. 4.86 ± 0.22 
(16:0,17:1)PE n.d. n.d. 4.60 ± 0.64 
(18:0,19:1)PI n.d. n.d. 2.78 ± 2.01 
(18:1,19:1)PI n.d. n.d. 1.29 ± 1.82 
 
a n.d. = not detected 
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6.10.2 Supplemental Figures 
 
Figure S 6-1. Total ion chromatogram (TIC) of lipid extracts of M. smegmatis pellets (a) and protein fractions 
(b-c). TICs are depicted for samples of M. smegmatis total lipid extract (a), C171Q KasA variant (b), wild-type 
KasA protein (c) and the extraction buffer (d). Peaks unique for C171Q KasA and detectable in the total lipid 
extract of M. smegmatis were identified measuring the exact mass of deprotonated ions (accuracy of 3 mDa) 
and fragments of molecule ions (presence of fatty acyl chains). Identified lipids shown in the TICs are 1 = 
(16:0,17:0)PI, 2 = (16:0,19:0)PI. 
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Figure S 6-2. Sequence Alignment of KAS Enzymes. Secondary structure matching (SSM) alignment of β-
ketoacyl-ACP synthases I, II and III (PDB-entries: 2WGE, 2VB7, 3OYT, 2GP6, 1KAS, 2GQD, 1M1M, 3IL9, 3IL7) was 
performed by PDBe Fold (149). The bacterial sources are indicated by the first two letters of the protein names 
(mt = Mycobacterium tuberculosis, ec = Escherichia coli, yp = Yersinia pestis, sa = Staphylococcus aureus). The 
KasA secondary structure calculated with DSSP is depicted above the aligned sequences (150). The secondary 
structure elements accentuated in red reflect the N- and C-terminal KasA insertions. Flexible KasA regions 
contributing to acyl-substrate recognition are highlighted below the aligned sequences as bars colored in 
magenta, cyan, green, yellow and lilac (the same color code as in Figure 6-5). The catalytic and gatekeeper 
residues are indicated by black stars and triangles, respectively. This Figure was prepared using ESPript (151). 
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Figure S 6-3. Potassium Cation Binding Site. A potassium ion is bound close to His311 in all obtained KasA 
structures. The octahedral K+ binding site (highlighted with cyan dashes) consists of the main chain carbonyl 
oxygens of Asn309, Ala310 and Asn400 (distances of 2.76 ± 0.02 Å, 2.97 ± 0.05 Å and 2.71 ± 0.03 Å for all 
C171Q KasA-structures) and the side chain oxygens of Asn309, Glu354 and Asn399 (distances of 2.68 ± 0.04 Å, 
2.58 ± 0.04 Å and 2.59 ± 0.04 Å). A water molecule and Lys340 connects the K+ ion with the catalytic residue 
His311 via Glu354. Similar cation binding sites are present in all structurally characterized KAS I and II enzymes 
(141). However, the identification of the bound cation has, to our knowledge, never been addressed 
thoroughly and most studies interpreted the cation density as NH4
+, Na+ or Mg2+ depending on the 
crystallization conditions (17,68,141). We unambiguously identified a potassium cation by analyses of the 
cation binding site and coordination geometry (276-278), crystal diffraction data and results from inductively-
coupled plasma optical emission spectrometry (ICP-OES). An anomalous difference omit map (λ = 1.7 Å) is 
depicted at 5σ as a gray mesh. 
 
 
6.10.3 Supplemental Movies 
Movie S 6-1. Opening Movement of the Gatekeeping Units. Using LSQMAN, the frames for this animation 
were produced by the calculation of 'semi-plausible' intermediate states (morphing with internal coordinates 
including Cα and side chain atoms) between the structures KasA - TLM (PDB-entry 2WGE), KasA (PDB-entry 
2WGD), KasA - TLM5 - I and C171Q KasA - TLM5 (148). The phospholipid molecules (which only were observed 
for the final state but are displayed throughout the animation for clarity) are shown as ball-and-stick models in 
gray, the gatekeeping residues Leu116, Phe404 and Tyr126' as yellow sticks, Asp127' as orange stick model and 
the two subunits of KasA as a Cα ribbon model in cyan and green, respectively. 
 
Movie S 6-2. Acyl-Channel Opening Mechanism. This movie was produced using the same trajectory as for 
Movie S 6-1 and shows an intersection of KasA. The phospholipid molecules (which only were observed for the 
final state but are displayed throughout the animation for clarity) are shown as ball-and-stick models in gray, 
the gatekeeping residues Leu116, Phe404 and Tyr126' as yellow sticks, Asp127' as orange stick model and the 
two subunits of KasA in cyan and green surface representation, respectively. 
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6.10.4 Supplemental Experimental Procedures 
6.10.4.1 Lipidomics 
Processing of chromatograms and peak detection were performed using the MassLynx 
software (version 4.1, Waters, Manchester, U.K.). Defined lipid species were searched for in 
the samples based on their exact m/z in the low energy function and two integral fragments 
(fatty acyl side chains) in the high energy function with an error tolerance of 3 mDa. The 
main lipid species were diacyl-glycero-3-phosphoethanolamines (PEs) and diacyl-glycero-3-
phosphoinositols (PIs) with acyl side chains of hexadecanoate (C16:0), hexadecenoate 
(C16:1), hexadecadienoate (C16:2), hexadecatrienoate (C16:3), heptadecanoate (C17:0), 
heptadecenoate (C17:1), octadecanoate (C18:0), octadecenoate (C18:1), octadecadienoate 
(C18:2), octadecatrienoate (C18:3), nonadecanoate (C19:0), nonadecenoate (C19:1). The 
species defined as their m/z and RT were then assembled into an automated method within 
QuanLynx embedded in MassLynx for the systematic integration of the identified lipid 
species in the extracts. For quantification of the PIs and PEs in the injected samples, 25 ng of 
(16:0,18:0)PI and (18:1,18:1)PE were used as internal standards. 
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7 Discussion 
7.1 S. aureus FabI 
7.1.1 Substrate, Cofactor and Inhibitor Recognition 
The enoyl-ACP reductase FabI catalyzes the NAD(P)H-dependent reduction of the trans-2-
enoyl-ACP double bond (51). In contrast to classical FabI proteins, the S. aureus homologue 
uses NADPH instead of NADH for this purpose (78,108). Thus, we investigated the molecular 
basis for this unique cofactor specificity and revealed that an RKXXS-motif is responsible for 
the favorable binding of the additional 2'-phosphate of NADPH (chapter 2, Figure 2-7). Due 
to the long-range character of the electrostatic interactions between the negatively charged 
cofactor and the positively charged residues Arg40 and Lys41, cofactor specificity is mainly 
conferred via an increased kon value (chapter 5). The electrostatically steered binding 
process of the bulky NADPH cofactor (261) presumably is accompanied by structural 
rearrangements (e.g. of helix α2) leading from a wide major portal opening (Figure 2-5A-E, 
Figure 4-9 and Figure S 5-6) to a more closed form of the enzyme. Although a structure of 
the binary saFabI-NADPH complex is needed to finally prove this hypothesis, a study of 
Debaryomyces hansenii xylose reductase points out that NADPH has the ability to pre-form 
the enzyme conformation that is required for the binding of the substrate (279). 
According to the ordered bi-bi mechanism observed for FabI (51), the cofactor is bound first 
and is followed by the substrate. Based on the chemical and dynamic properties of the 
saFabI binding crevice, the substrate binding mode was established using a validated docking 
approach (Figure 5-3A). The presented studies clearly reveal that the enoyl-ACP thioester 
carbonyl of the substrate binds to an oxyanion hole formed by the Tyr157 hydroxyl group 
and the 2'-OH of the NADPH nicotinamide ribose (Figure 5-3E). In addition, the terminal 
phosphopantetheine peptide is hydrogen bonded to Ser197 and the backbone of Ala97, 
which may serve as a polar anchor in the predominantly hydrophobic saFabI binding pocket 
(Figure 5-3A). Taken together with the known stereochemistry of the catalyzed reaction 
(Figure 5-1) (112,113,280), the relative orientation of cofactor and substrate unambiguously 
suggests how the reaction has to proceed mechanistically (chapter 5). Furthermore, a 
structurally and temporally conserved chain of water molecules towards a water-basin inside 
the homo-tetrameric enzyme was found to be important for hydride and proton transfer 
(Figure 5-4B). Similar water-networks connecting the active site with bulk solvent are 
commonly observed for enzymatic systems (247). Such water-chains might therefore be 
essential for the desolvation and re-hydration of the binding site upon substrate uptake and 
product release as well as for the delivery or uptake of protons needed for or formed during 
the catalytic reaction, respectively (247). Thus it is not very surprising that the D249A 
mutant, which led to the disruption of the FabI water-chain (Figure 5-4F), displayed a 
severely compromised catalytic activity. 
Such a mutant, which hinders water molecules from flowing out of or into the binding 
pocket, likely will also be characterized by impaired loop dynamics (comparable to a blocked 
air-pump). For many enzymes it was suggested that the closure of a flexible loop 
accompanies the catalytic reaction. Loop closure might, thus, be an important mechanism to 
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lower the energy of the transition state by placing the substrate into a desolvated protein 
environment (240). The FabI substrate binding loop (SBL) may fulfill a similar function and it 
is therefore particularly interesting to investigate the conformational states that are sampled 
along the reaction coordinate of substrate binding and turnover. Remarkably, the saFabI 
binding site is completely rearranged in the apo enzyme with respect to the presumably fully 
'closed' state of the diphenyl ether bound structures (Figure 2-5). Since inhibitor binding can 
be assumed to closely resemble substrate recognition (239), different inhibitors were used 
as a tool to sample and provide several structural snapshots for induced-fit ligand binding 
and substrate turnover (Figure 4-9). These snapshots were highly informative since the 
conformational states involved in such processes are rarely known at the molecular level due 
to their transient nature (239). MD-simulations of saFabI with removed cofactor and 
inhibitor (PT400) consistently recapitulated key features of the crystallographically observed 
states (Figure 4-7, Figure 5-5 and Figure S 5-6). Given the lipophilicity and size of the enoyl-
substrate, the observed structural variations will be required for substrate uptake, but may 
in addition be involved in the recognition process of the acyl carrier protein (ACP) carrying 
this cargo. Based on a FabI-ACP complex structure (107), a reinterpreted model for the 
interaction between FabI and ACP could be derived (Figure 5-6), which is fully consistent 
with the chemical binding site characteristics, the proposed mechanism, and the 
conformational adaptability of saFabI (chapter 5). 
A comparison of saFabI with FabI proteins from other bacteria revealed unique properties of 
the S. aureus homologue, which can be related to its exceptional mobility (chapter 2, Figure 
2-2C). SaFabI undergoes a dimer-tetramer transition upon ligand uptake that might cause 
the observed positive cooperativity of cofactor and substrate binding (Figure 2-6, Figure S 
2-3, Figure S 2-5). Based on a comparison of the ternary saFabI-NADP(H)-inhibitor complexes 
with the apo-structures, it can be assumed that cofactor and enoyl-ACP binding to one 
subunit triggers structural rearrangements of two loop regions establishing the full tetramer 
interface and thereby facilitating the same conformational changes in the neighboring 
monomers (Figure 2-5G and Figure 2-6). Consistently, these loops were found to display 
enhanced flexibility in MD-simulations of monomeric and dimeric saFabI assemblies 
compared to simulations of the homo-tetramer (Figure 5-5A). For both, crystal structures 
(Figure 2-5G) and MD-simulations (Figure 5-5A), the conformational change of the SBL-2 
propagates from the dimer-dimer interface (Figure 2-6) to the amino acid stretch 95-97, 
which contributes to the binding of the phosphopantetheine (Figure 5-2C and Figure 5-3C). 
These unique characteristics of saFabI might have evolved to enable the turnover of 
branched-chain substrates required for the production of branched-chain fatty acids (BCFA) 
(chapter 2). Indeed, in contrast to classical FabI enzymes, the S. aureus homologue is 
qualified to process branched first-round substrates efficiently (Table 2-3). Importantly, 
BCFAs are required for the fitness of Staphylococci and related BCFA-producing bacteria 
(146,166). Since the human blood serum only contains a minimal amount of BCFA (147), the 
uptake of exogenous fatty acids might not fully satisfy the requirements of such bacteria 
during infection. A key question thus is whether unsaturated fatty acids can effectively 
replace branched-chain fatty acids to allow S. aureus growth in vivo despite the inhibition of 
FAS-II. Very recently, Sun et al. explicitly showed that the survival of Listeria monocytogenes, 
a pathogen that produces BCFAs (86), is compromised during an infection if BCFAs are 
lacking (281). Hence, it seems very likely that the need of S. aureus for the rarely occurring 
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BCFAs provides a rationale why this organism, in contrast to other Gram-positive bacteria 
such as Streptococci, developed a strategy to limit the uptake of exogenous fatty acids 
(chapter 1.3.4) (89) and, thus, is sensitive to the inhibition of the FAS-II pathway as 
demonstrated by the in vivo efficacy of several saFabI inhibitors (chapter 4) (92,100,101). 
Indeed, the lack of a block of the AccABCD function by exogenous fatty acids in the case of S. 
aureus led to a residual proportion of 37.7% BCFAs amongst all fatty acids of this organism 
when supplying oleic acid in the growth medium (89). Similarly, B. subtilis requires at least 
28% BCFA for growth (86) and thus a minimal amount of approx. 30% BCFAs may be 
essential for BCFA-producing bacteria in general. Hence, the fatty acid profile of the human 
blood serum containing only 1% BCFAs does not fulfill the requirements of these bacteria 
(147) assuming that they have not developed a mechanism to accumulate BCFAs (90). In 
summary, these findings suggest that saFabI remains a valid drug target for the development 
of antibacterials that interfere with the integrity of the bacterial cell membrane, which is a 
known concept for antibiotics such as polymyxins (Table 1-1). 
7.1.2 Molecular Determinants of Affinity and Selectivity 
The numerous saFabI structures in complex with different diphenyl ether and pyridone 
inhibitors solved in this thesis served as a basis to rationalize the inhibitory and kinetic 
characteristics of these compounds (in particular chapters 3 and 4). Using various 4-, 5-, 2'-, 
3'- and 4'-substituents, the saFabI binding cavity was probed thoroughly, providing a 
platform to design molecules with improved pharmacological properties. Similar to the 
thioester carbonyl of the substrate (Figure 5-3), all investigated inhibitors were found to be 
hydrogen bonded to the oxyanion hole formed by Tyr157 and the 2'-OH of the NADP(H) 
nicotinamide ribose (e.g. Figure 3-6). This result extends to all structurally characterized 
FabI-inhibitor complexes (Figure 5-2B) underlining the hotspot characteristics of the 
oxyanion hole. Guided by this central interaction, all analyzed inhibitors display a conserved 
overall binding mode. For instance, B-ring 2'-substituents were uniformly found to be 
directed towards a small pocket formed by the cofactor, Ala95 and Ser197 (Figure 3-8). This 
highlights that even though saFabI is a remarkably flexible enzyme, shape complementarity 
remains a fundamental principle. PT119, which carries a 5-hexyl and a 2'-cyano substituent 
on the diphenyl ether scaffold, constitutes an impressive example underlining the potential 
of this simple concept. Compared to 5-methyl-2-phenoxyphenol (PT53), the larger 5- and 2'-
substituents of PT119 nicely fill additional side pockets (Figure 3-7B and Figure 3-8) leading 
to a 40-fold increase in affinity and residence time (Table 3-1). 
Despite the structural similarity between diphenyl ether and pyridone saFabI inhibitors, 
diphenyl ethers are slow-binding inhibitors whereas pyridones display rapid-reversible 
characteristics (Figure 4-3). Moreover, these two scaffolds target different states of the 
catalytic cycle - pyridones preferably interact with the E-NADPH complex and diphenyl 
ethers with E-NADP+ after product release (Figure 4-2B). This differing mechanism of 
inhibition likely explains the slow onset of saFabI inhibition by diphenyl ethers since the 
binary E-NADP+ complex generated via catalysis is present at a much lower concentration 
compared to E-NADPH (chapter 4). Thus, the closure of the SBL presumably is not the slow 
step of diphenyl ether binding. Accordingly, the opening of the SBL was found to occur on 
the ns-timescale in an MD-simulation of saFabI excluding cofactor and inhibitor. The distinct 
modes of inhibition additionally suggest that pyridone and diphenyl ether-bound structures 
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may represent different states along the reaction coordinate of the hydride transfer 
reaction. Whereas pyridones are more substrate-like, diphenyl ethers closely resemble the 
transition state of the reaction (Figure 4-2D). In line with this hypothesis, the corresponding 
crystal structures differ with respect to the conformation of the SBL (Figure 4-9). A 
comparison of the diphenyl ether and pyridone inhibitors is also very informative with 
respect to their spectrum of antibacterial activity (chapter 4). Whereas the clinical candidate 
CG400549 displays a Staphylococcus-restricted spectrum, diphenyl ethers such as 
MUT056399 are active against a broader range of pathogenic bacteria (4,31,102). On a 
molecular basis, the specificity of CG400549 can be explained by the enlarged saFabI cavity, 
which facilitates binding of the bulky CG400549 inhibitor and is likely also required for the 
synthesis of BCFAs (Figure 4-5). 
For future drug design projects it is key to unravel the molecular determinants conferring 
high affinity to saFabI inhibitors. In combination with the observed SAR-profile, a close 
inspection of all structures presented here reveals that small substituents are tolerated 
sterically at the 4- and 2'-positions of the basic bisaryl system. However, in line with an SAR-
study of Bacillus anthracis FabI (6), larger 5- and 3'/4'-groups can be used since they extend 
towards the minor and major portal, respectively (Figure 3-7A and Figure 5-2C). Consistently, 
an SAR-study with a large series of diphenyl ethers indicated that different substituents are 
tolerated at the B-ring 4'-position (102). 
 
As highlighted above, potent saFabI inhibitors should contain a hydrogen bond acceptor that 
can bind to the oxyanion hole (Figure 7-1). Interestingly, the binding crevice of saFabI 
comprises two further polar amino acid patches towards the major and minor portal, 
respectively. The former hydrophilic region mainly consists of Ser197 and the backbone of 
Ala97, which are contacted by the phosphopantetheine moiety of the substrate (Figure 
5-3A). In particular, Ala97 has been shown to provide an interaction platform for the potent 
inhibitors triclosan (Figure 2-4B and Table 3-1) and CG400549 (Figure 4-5A, Table 4-1). The 
 
Figure 7-1. Determinants of saFabI affinity. This scheme summarizes molecular features 
that led or may lead to enhanced saFabI affinity. Hydrogen bond donors are depicted in 
blue, hydrogen bond acceptors in red and hydrophobic features in orange. Additional 
important characteristics of the basic diphenyl ether or pyridone bisaryl system are 
highlighted in magenta. The scheme contains the results from the work presented here (in 
particular chapters 3 and 4) and knowledge derived from further computational analyses 
(e.g. hotspot analyses); in addition, it takes similar SAR-studies into account (5,6). 
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4'-chlorine of triclosan and the 3'-NH2 group of CG400549 interact with the Ala97 carbonyl 
group via a halogen and hydrogen bond, respectively. Furthermore, naphthyridinones are 
ideally suited to interact with Ala97 in a dual hydrogen bonding network (Figure 4-1) (5,101). 
Thus, an elaborate choice of 3'- and 4'-substituents containing distinct hydrogen bond 
donors/acceptors or halogens/sulfur can lead to an improvement of affinity in particular for 
the S. aureus homologue, for which the interactions with Ala97 are protected from solvent 
by the side chain of Met99 (Figure 4-5D). At the minor portal, the backbone carbonyl 
oxygens of Asn155 and Gly202 as well as the free electron pair of the Tyr147 hydroxyl group 
might be additional anchor points for hydrogen bond donors (Figure 7-1). Accordingly, three 
water molecules were found to be present in this region of the ternary complex structures 
for inhibitors with small 5-substituents such as PT53 (Figure 3-7D). The finding that the 5-
hexyl group of PT04 expels these water molecules suggests that hydrophilic moieties might 
be used at the terminus of this elongated alkyl chain to mimic the interactions observed for 
the expelled water molecules. Closer towards the bisaryl scaffold, however, high-affinity 
inhibitors commonly exhibit hydrophobic features including aromatic rings, alkyl groups or 
halogens (Figure 7-1, chapters 3 and 4) (5,6,102), which reflect the lipophilic properties of 
the corresponding part of the saFabI crevice accommodating also the fatty acyl chain (Figure 
5-2C and Figure 5-3C). In contrast, small substituents are favorable at the 4- and 2'-positions. 
The SAR at these positions is slightly different for diphenyl ethers and pyridones, presumably 
due to the different SBL conformations (chapters 3 and 4). Whereas a 2'-CN group increases 
the affinity of diphenyl ethers, this group is less favorable for pyridones for which a 2'-
methyl substituent provides a good choice. Finally, the characteristics and interactions of the 
bisaryl system itself are highly informative. The A-ring can engage in π-π stacking 
interactions with the nicotinamide ring of the cofactor and, thus, the electronic properties of 
this ring might influence binding affinity depending on the oxidation state of the cofactor. 
Furthermore, it should be noted that the nature of the atom linking the two aromatic rings 
of the basic bisaryl scaffold is of particular 
importance. In the biologically active 
conformation, the two rings display an 
approximately orthogonal geometry (Figure 3-6). 
As mentioned previously (9) and confirmed by a 
search of the Cambridge Structural Database 
(CSD), this is the preferred geometry for a bisaryl system with a bridging oxygen whereas a 
methylene bridge induces a "clamp-like" structure (Figure 7-2). Hence, the bridging oxygen 
seems to be ideally suited to pre-form the biologically active conformation as highlighted by 
the higher intrinsic potency of 4-pyridones compared to 2-pyridones (chapter 4). Similarly, 
early work with diphenyl ethers indicated that a bridging oxygen is superior compared to 
sulfur or methylene linkages (97,99), which can be related to an entropic advantage upon 
binding. 
7.1.3 Rational Residence Time Optimization - a Case Study with SaFabI 
Drug-target kinetics are crucial during the lead optimization phase of a drug discovery 
project (chapter 1.2.4) (44). Importantly, the correlation between affinity and residence time 
observed for diphenyl ether saFabI inhibitors (Figure 3-5) permits the rationalization of the 
differing dissociation kinetics using the knowledge gained from the ground-state ternary 
      
Figure 7-2. Preferred geometries of 
diphenylethers and diphenylmethanes (9). 
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complex structures (chapter 3). Thus, the saFabI SAR-profile can be extended to a structure-
kinetic relationship (SKR; term used in (261)) (Figure 7-1). Since the kon values are very 
similar among diphenyl ethers and pyridones (chapter 4), the transition state barrier to 
association seems to be relatively invariant suggesting that the slow-off behavior of diphenyl 
ethers is exclusively determined by their potent affinities (Figure 4-9A). Consequently, it is 
very important to answer the question where the higher intrinsic potency of diphenyl ethers 
with respect to pyridones originates from. As for many enzymes (238,245), the closure of the 
flexible SBL will lead to the extrusion of water molecules from the binding site and, thus, to a 
strengthening of electrostatic interactions via a lowered effective dielectric constant. The 
fully closed SBL for diphenyl ether-bound ternary complex structures (Figure 4-7A) and the 
resulting buried electrostatic interaction between the presumably deprotonated diphenyl 
ethers (see also chapter 3) and the positive charge of the oxidized cofactor might therefore 
explain the long residence times of these inhibitors. Within the investigated diphenyl ether 
series, the residence time was shown to increase using bulky, hydrophobic 5-substituents or 
small and slightly polar 2'-groups based on their good steric fit (chapter 3). 
Since only little is known about the molecular principles that govern drug-target kinetics 
(44), this case study should also be discussed in more general terms. Based on a recent 
review, we point out that to date only one convincing strategy exists how to rationally 
modulate residence time (44). Schmidtke and coworkers demonstrated that water-shielded 
hydrogen bonds provide kinetic traps leading to a decrease in off-rates (261). Water 
molecules, which usually initiate the dissociation process, are hindered to access such buried 
interactions. In agreement, the closed SBL shields the saFabI binding site and thus the 
central hydrogen bonding network to the diphenyl ether inhibitors. In contrast, the rapid-
reversible pyridone inhibitors do not induce the fully closed state of the SBL (Figure 4-7A). 
Moreover, elongating the diphenyl ether 5-alkyl substituent from methyl (PT53) to hexyl 
(PT04) leads to a progressively shielded central hydrogen bond and consequently to a 25-
fold enhancement of residence time (Figure 3-7, Table 3-1). However, this concept may not 
be limited to hydrogen bonds since the buried electrostatic interaction between NADP+ and 
the negatively charged phenolate oxygen likely contributes to the slow off-rates of diphenyl 
ethers. Furthermore, the introduction of a 2'-cyano group which binds to a water-shielded 
side pocket of the saFabI cavity results in a decrease of the dissociation constant (Figure 3-8, 
Table 3-1). Thus, the concept suggested by Schmidtke et al. may be extended to water-
shielded interactions with electrostatic contributions in general, which seem to be 
thermodynamically (lowered dielectric constant) and kinetically (hindered water access) 
favored in a desolvated, buried environment. Importantly, this concept can be directly 
related to the functionality of many enzymes since shielding from water - often via flexible 
loops - seems to be a fundamental principle promoting enzymatic processes by stabilizing 
the transition state(s) of the reaction (238,240,245). At the transition state the shielding will 
be maximal explaining why transition state analogues frequently exhibit slow-off, tight-
binding characteristics (209,239,282). Hence it is pivotal to implement the knowledge with 
respect to catalysis in the design of new drugs targeting enzymatic systems. 
7.1.4 New Concepts for Inhibitor Design 
Which strategies can be derived from these studies to further improve or to develop novel 
saFabI inhibitors? Clearly, one focus must be on lowering the logP value of such compounds 
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without affecting the affinity towards the rather hydrophobic saFabI binding pocket too 
much. This is an important factor to enhance the bioavailability and to decouple the FabI-
specific mode of action from a non-specific biocidal effect observed for more hydrophobic 
compounds such as triclosan (102). In this regard, the two additional hydrophilic patches 
located close to the major and minor portal, respectively, can provide a platform to 
rationally design inhibitors with lower lipophilicity (Figure 7-1). It will be pivotal to identify 
the right balance between hydrophobic moieties binding to the fatty acyl pocket and more 
hydrophilic substituents taking advantage of the interactions observed for the 
phosphopantetheine linker (Figure 5-3A). Interestingly, the amide group of the cofactor's 
nicotinamide ring is rotated slightly out-of-plane in all observed saFabI crystal structures 
thereby presenting the amide oxygen to the binding pocket (Figure 5-2). An appropriately 
positioned hydrogen bond donor might hence be able to bind to this acceptor. For pyridone 
inhibitors, electron-donating groups on the A-ring might decrease the logP value and 
concomitantly strengthen the central hydrogen bonding network by enhancing the 
nucleophilicity of the pyridone oxygen, which would, thus, more closely mimic the oxyanion 
of the enolate intermediate (Figure 4-2D). Consequently, the introduction of a 5-alkoxy 
substituent might further improve inhibitors that are based on the very promising 4-
pyridone scaffold (see also chapter 4). 
Assuming that future studies can establish the relevance of the saFabI dimer-tetramer 
transition during ligand binding in vivo, the central cavity of the homo-tetramer might be 
accessible and provide an additional target site remote from the actual substrate binding 
crevice (Figure 2-2A). In fact, the same cavity was suggested to be druggable in InhA (115). 
Targeting this pocket in the case of saFabI might be promising for mainly two reasons. 
Firstly, compounds that would block the association of two dimers might hinder the 
cooperative structural changes establishing the substrate binding sites upon ligand uptake 
(Figure 2-5 and Figure 2-6). Furthermore, molecules that would still allow the association of 
two saFabI dimers but block the exchange of water molecules between the active site and 
the cavity inside the tetramer via the conserved water-chain (Figure 5-4), likely will impair 
the motions that are involved in substrate recognition and turnover and hinder the delivery 
of protons for catalysis (chapter 5) (247). 
An additional aspect, which could be considered for the development of new inhibitors, is 
the required interaction between FabI and ACP. In recent years considerable progress has 
been made in the design of molecules that disrupt protein-protein interactions, which are 
essential for most biological processes (283). The protein-protein interface revealed by the 
new FabI-ACP model might serve as an additional target site for the development of 
compounds that interfere with substrate binding to enoyl-ACP reductases at the ACP level. 
In summary, such strategies may guide future drug design studies to combat the increasing 
clinical problem of MRSA-infections. 
7.2 M. tuberculosis KasA 
7.2.1 Substrate and Inhibitor Recognition 
In contrast to common bacterial FAS-II condensing enzymes, the mycobacterial KasA protein 
can synthesize very hydrophobic fatty acids with up to 42 carbon atoms in length (268). For 
this purpose KasA has to enable the binding of long-chain acyl-AcpM substrates. Using a 
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combined crystallographic and mass-spectrometric approach, co-purified phospholipids 
were identified inside the acyl binding cavity of the KasA C171Q variant (Figure 6-3). These 
molecules clearly delineate the geometry and extraordinary length of this hydrophobic 
channel, providing a rationale for the observed substrate specificity (Figure 6-4A). 
Furthermore, structural snapshots of an induced-fit binding mechanism were revealed, 
which explain how the hydrophobic acyl-chain can enter the KasA binding site without 
excessive solvent exposure. This was a fortuitous finding since transient states along the 
reaction coordinate of substrate binding are rarely characterized for enzymatic systems 
although substrate recognition frequently involves conformational changes (239). 
Incremental structural changes in the capping region of KasA involving considerable 
movements of three gatekeeper residues (Leu116, Tyr126' and Phe404) lead to the opening 
of the acyl-binding channel (Figure 6-6). AcpM likely triggers this process and injects the 
attached acyl-chain into the evolving cavity (for details see chapter 6 and Figure 6-4D). A 
similar concerted process can also be envisioned for FabI proteins, which are involved in the 
same biosynthetic pathway. The new FabI-ACP model suggests that ACP might trigger the 
closure of the substrate binding loop thereby establishing the tube-like binding cavity, which 
simultaneously can take up the enoyl-substrate (for details see chapter 5 and Figure 5-6F). 
Hence, similar induced-fit processes that couple the formation of an elongated binding site 
with the uptake of the fatty acyl chain, might have evolved for most FAS-II enzymes to allow 
the binding of their large and hydrophobic substrates. Indeed, different conformational 
states of the substrate binding site are known for many FAS-II enzymes such as InhA (207), 
FabL (156), FabG (284) and FabH (15,263,270). 
Compared to the lead compound thiolactomycin, TLM5 and TLM6 display enhanced affinities 
towards the wild-type and C171Q KasA forms (16), which could be rationalized by additional 
hydrogen bonding interactions with the catalytic triad residue His345 (Figure 6-2E). 
Furthermore, the binding mode of these compounds suggests how the second substrate of 
the ping-pong reaction, malonyl-AcpM, may be oriented with respect to the KasA catalytic 
triad residues and, thus, provides a molecular basis to clarify the mechanism of the 
decarboxylation reaction (Figure 6-8). 
7.2.2 New Concepts for Inhibitor Design 
The investigation of the substrate recognition and turnover process by the drug target KasA 
has important impacts on the design of optimized KasA inhibitors. To enhance the affinity of 
inhibitors via cation-π interactions, quaternary ammonium substituents have been 
successfully used in the past to address protein pockets with a high content of aromatic 
amino acids (152). Thus, the design of molecules with a positive charge placed appropriately 
in the KasA aromatic box binding TLM 3-substituents (Figure 6-2D) could help to increase the 
affinity of KasA inhibitors. As exemplified by the 3-trifluoroacetyl group of the most potent 
inhibitor TLM6 (Figure 6-2E) (16), the conserved threonines 313 and 315 involved in 
phosphopantetheine binding might additionally be ideal anchors for dual hydrogen bond 
acceptors. Most importantly, however, the 3-acetyl group of TLM5 induces a partial opening 
of the acyl-binding channel in the wild-type enzyme which might be filled by hydrophobic 
moieties. To achieve a pharmacologically reasonable balance between hydrophobic and 
hydrophilic groups, the phosphopantetheine binding cavity should be addressed 
simultaneously. 
 Discussion  
175 
 
In addition, the sampled structural snapshots along the reaction coordinate of the acyl-
transfer may provide good starting points for virtual screening studies. It should also be 
noted that thiolactomycin provides an ideal lead compound for the development of 
molecules that inhibit all three mycobacterial condensing enzymes in order to reduce the 
propensity for resistance formation (4). Molecules inhibiting KasA should therefore always 
be tested against KasB and mtFabH. To avoid the development of molecules with 
pharmacologically problematic properties, it should additionally be analyzed whether such 
inhibitors interfere with the human FAS-system. Using the knowledge with respect to 
substrate recognition, a long-term goal might also be to block the interaction between 
condensing enzymes and AcpM by small molecules in order to develop novel anti-TB drugs. 
7.3 Interaction between ACP and FAS-II Enzymes 
The established models for the binding of ACP-substrates to saFabI (chapter 5) and KasA 
(chapter 6) do not only facilitate the design of novel compounds interfering with the 
interaction between FAS-II enzymes and ACP but also suggest strategies how structural 
information of the corresponding complexes could be gained. 
 
 
Given that the C171Q KasA variant exhibits opened acyl- and phosphopantetheine-cavities 
(chapter 6) (17), malonyl-AcpM might easily access the binding site. Accordingly, analytical 
size-exclusion chromatography (aSEC) experiments indicated complex formation between 
the inactivated substrate analogue acetoacetyl-AcpM (acac-AcpM; Figure 7-4) and C171Q 
KasA (Figure 7-3; see chapter 9.2 for the purification of acac-AcpM). However, despite 
various attempts, the crystallization of the complex did not result in a structure with bound 
substrate. Thus, alternative strategies are necessary to finally obtain a KasA-AcpM complex 
structure. To further improve the stability of the resulting KasA-AcpM complex, the 
 
Figure 7-3. Interaction between the C171Q KasA variant and acetoacetyl-AcpM. 
Analytical size-exclusion chromatograms clearly indicate an interaction between these 
two components. Please note that the absorption at 280 nm and staining of the small, 
acidic AcpM is much weaker compared to KasA. Experiments were conducted in 20 mM 
Tris pH 7.8 and 200 mM NaCl with a C171Q KasA : acac-AcpM ratio of 1 : 2 
(concentrations of 60 and 120 µM [according to photometric measurement, please see 
Chapter 9.2.2 for details], respectively).
C171Q   
KasA
acac-AcpM
complex
C171Q KasA
acac-AcpM
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acetoacetyl-moiety could be extended to TLM5, which was shown to effectively mimic 
malonyl-AcpM (Figure 6-7C and Figure 7-4). 
Alternatively, a reactive chemical group might 
be attached to the phosphopantetheine linker 
of AcpM such that it selectively reacts with 
KasA amino acids (e.g. Thr313, Thr315 or 
Cys171) leading to a stable covalent complex. 
Finally, a study of Borgaro et al. suggests the 
usage of short peptides with the primary 
sequence of the AcpM helix α2 including 
Ser42 carrying the substrate (18). The 
reduction in size of the KasA interaction 
partner might facilitate crystal packing of the 
complex, in particular since the acyl carrier protein is known to be an intrinsically flexible 
protein (76). 
In contrast to the KasA interaction studies mentioned above, aSEC experiments with 150 µM 
saFabI and 300 µM crotonoyl-saACP (cro-saACP; see chapter 9.2 for the purification of cro-
saACP) in the presence of 1.5 mM NADP+ did not indicate complex formation (in 20 mM Tris 
pH 7.5 and 200 mM NaCl). However, co-crystallization of saFabI with cro-saACP and NADP+ in 
a 1 : 3.5 : 10 ratio yielded a new crystal form using a precipitant solution composed of 0.1 M 
NaAc pH 4.5, 0.1 M MgCl2 and 8% PEG 8000. Unfortunately, diffraction experiments with 
these very small crystals resulted in only a few weak reflections close to the center of the 
diffraction pattern indicating that the crystals contain protein molecules. Further 
optimization of these crystals might ultimately lead to the determination of a saFabI-saACP 
complex structure. The coupling of a potent inhibitor with ACP via a phosphopantetheine-
like linker might be an even more promising 
strategy to achieve this goal. For instance, a 
comparison of the PT12-bound saFabI-
structure with the putative enoyl-ACP 
substrate binding mode (Figure 5-3C) 
suggests that diphenyl ethers might be 
linked to ACP via a 4'-acyl moiety mimicking 
the phosphopantetheine (Figure 7-5). Similarly, isoniazid could be attached to AcpM as a 
warhead that could react with NAD+ for interaction studies with the mycobacterial enoyl-
reductase InhA (Table 1-2) (125). Even without the synthetically challenging coupling 
between an inhibitor and ACP, it might be worthwhile to use NAD(P)+ and a diphenyl ether 
to trigger the closure of the SBL and thus to create the full electropositive surface for the 
interaction with ACP (Figure 5-6F). Alternatively, reproducing and soaking the encounter 
complex crystals of ecFabI-dodecenoyl-ACP (107) with NADH might initiate partial loop 
closure and substrate delivery and could, in principle, result in structural snapshots along the 
reaction coordinate. Moreover, trying to crystallize the FabI isoenzyme FabV in complex with 
its natural substrate could constitute a promising strategy since FabV is, in contrast to FabI, a 
monomer and thus crystal packing might occur more readily for the corresponding complex 
(118). 
Figure 7-4. Malonyl-AcpM analogues for 
interaction studies with KasA. The acetoacetyl 
group of acetoacetyl-AcpM and the corresponding 
moiety of TLM5-AcpM is shown in red. 
 
Figure 7-5. Diphenyl ether analogue coupled to ACP 
for the structural study of FabI-ACP complexes. The 
diphenyl ether moiety is depicted in red. 
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Complex structures between FAS-II enzymes and their natural ACP-substrates would reveal 
important information about substrate recognition and turnover that can be utilized in the 
development of novel drug candidates to combat multidrug-resistant pathogens. 
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9 Appendix 
9.1 Abbreviations 
AAS acyl-ACP synthetase
acac acetoacetyl 
AccABCD acetyl-CoA carboxylase
ACP Acyl carrier protein
AcpM Acyl carrier protein of M. tuberculosis
AFN Affinium Pharmaceuticals
Ala (A) alanine 
APS ammonium persulfate
Arg (R) arginine 
aSEC analytical size-exclusion chromatography
ASL active site loop
Asn (N) asparagine 
Asp (D) aspartate 
AU asymmetric unit
BAT branched-chain aminotransferase
BCA bicinchoninic acid
BCFA branched-chain fatty acid
BESSY Berliner Elektronen-Speicherring Gesellschaft für Synchrotronstrahlung
BKD branched-chain α-ketoacid dehydrogenase
BSA bovine serum albumin
BSA buried surface area
CA-MRSA community-acquired methicillin-resistant Staphylococcus aureus 
CD circular dichroism
CG CrystalGenomics
CHS chalcone synthase
CoA coenzyme A 
cpm counts per minute
CPP 5-chloro-2-phenoxyphenol
cro crotonyl 
CS conformationally sensitive
CSD Cambridge Structural Database
CV column volume
Cys (C) cysteine 
DD dodecenoyl 
DH β-hydroxyacyl-ACP dehydratase
DHFR dihydrofolate reductase
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
EDTA ethylenediaminetetraacetic acid
EMBL European Molecular Biology Laboratory
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ENR enoyl-ACP reductase
EPP 5-ethyl-2-phenoxyphenol
ER enoyl-ACP reductase
ESI electrospray ionization
ESRF European Synchrotron Radiation Facility
FabA β-hydroxyacyl-ACP dehydratase
FabB β-ketoacyl-ACP synthase I
FabD malonyl-CoA:ACP transacylase
FabF β-ketoacyl-ACP synthase II
FabG β-ketoacyl-ACP reductase
FabH β-ketoacyl-ACP synthase III
FabI trans-2-enoyl-ACP reductase
FabK trans-2-enoyl-ACP reductase
FabL trans-2-enoyl-ACP reductase
FabM trans-2, cis-3-decenoyl-ACP isomerase
FabV trans-2-enoyl-ACP reductase
FabZ β-hydroxyacyl-ACP dehydratase
FAS-I type-I fatty acid biosynthesis pathway
FAS-II type-II fatty acid biosynthesis pathway
FDA Food and Drug Administration
Gln (Q) glutamine 
Glu (E) glutamate 
Gly (G) glycine 
GroEL1 mycobacterial Hsp60 chaperone
GSK GlaxoSmithKline
HadAB β-hydroxyacyl-ACP dehydratase of M. tuberculosis
HadBC β-hydroxyacyl-ACP dehydratase of M. tuberculosis
His (H) histidine 
HIV human immunodeficiency virus
HSDH 7α-hydroxysteroid dehydrogenase
HTS high-throughput screening
ICP-OES inductively-coupled plasma optical emission spectrometry 
IEC ion exchange chromatography
Ile (I) isoleucine 
IMAC immobilized metal affinity chromatography
INH isoniazid 
InhA trans-2-enoyl-ACP reductase of M. tuberculosis
IPTG isopropyl-β-D-1-thiogalactopyranoside
KAS β-ketoacyl-ACP synthase
KasA β-ketoacyl-ACP synthase I of M. tuberculosis
KasB β-ketoacyl-ACP synthase II of M. tuberculosis
KatG mycobacterial catalase/peroxidase
KR β-ketoacyl-ACP reductase
KS β-ketoacyl-ACP synthase
LB Luria-Bertani 
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LC liquid chromatography
Leu (L) leucine 
Lys (K) lysine 
MabA β-ketoacyl-ACP reductase of M. tuberculosis
MALDI matrix-assisted laser desorption/ionization
MAT malonyl-acetyl transferase
MD molecular dynamics
MDR multidrug-resistant
Me methyl 
Met (M) methionine 
MetRS methionyl-tRNA synthetase
mFAS mammalian fatty acid synthase
MIC minimal inhibitory concentration
MPD 2-methyl-2,4-pentanediol
MRSA methicillin-resistant Staphylococcus aureus
MS mass spectrometry
MSSA methicillin-sensitive Staphylococcus aureus
MUT Mutabilis 
NA not applicable 
NAC N-acetylcysteamine
NAD+ nicotinamide adenine dinucleotide
NADH nicotinamide adenine dinucleotide, reduced form
NADP+ nicotinamide adenine dinucleotide phosphate
NADPH nicotinamide adenine dinucleotide phosphate, reduced form 
NCS non-crystallographic symmetry
NIH National Institutes of Health
NMR nuclear magnetic resonance
NOE Nuclear Overhauser Effect
oct octenoyl 
OD optical density
PAGE polyacrylamide gel electrophoresis
PDB Protein Data Bank
PDF peptide deformylase
PE phosphatidylethanolamine
PEG polyethylene glycol
Phe (F) phenylalanine 
PheRS phenylalanyl-tRNA synthetase
PI phosphatidylinositol
PIM phosphatidylinositol oligomannosides
PK pharmacokinetics
PL phospholipid 
PPant 4'-phosphopantetheine
PPTase phosphopantetheinyl transferase
PRH phosphate recognition helix
Pro (P) proline 
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RESP restrained electrostatic potential
rmsd root mean square deviation
rmsf root mean square fluctuation
rpm rounds per minute
RT retention time
SAR structure-activity relationship
SBDD structure-based drug design
SBL substrate binding loop
SBL-2 substrate binding loop 2
SCFA straight-chain fatty acid
SDR short-chain dehydrogenase/reductase
SDS sodium dodecyl sulfate
SEC size exclusion chromatography
Ser (S) serine 
SFB Sonderforschungsbereich (Collaborative Research Center) 
SKR structure-kinetic relationship
SSM secondary structure matching
TB tuberculosis 
TCEP tris(2-carboxyethyl)phosphine
TCL triclosan 
TDR totally drug-resistant
TEMED N,N,N',N'-tetramethylethylenediamine
TEV tabacco etch virus
TG Tris-glycine 
Thr (T) threonine 
TIC total ion chromatogram
TIM triosephosphate isomerase
TLM thiolactomycin
TLS translation liberation screw
TMEDA N,N,N',N'-tetramethylethylenediamine
TOF-MS time-of-flight mass spectrometer
tR residence time
Trp (W) tryptophan 
TS transition state
Tyr (Y) tyrosine 
UFA unsaturated fatty acid
UPLC ultra performance liquid chromatography
UV ultraviolet light
Val (V) valine 
VIS visible light 
VMD visual molecular dynamics
VRE vancomycin-resistant Enterococci
VRSA vancomycin-resistant Staphylococcus aureus
WHO World Health Organization
XDR extensively drug-resistant
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9.2 Supplementary Materials and Methods 
9.2.1 Expression and Purification of Crotonyl-saACP 
S. aureus ACP (saACP) was purified similar to a previously described procedure (78). The 
pET23b plasmid containing the acp gene fused to a C-terminal His5-tag was kindly provided 
by the group of Prof. Peter J. Tonge (Stony Brook University, USA). All media were 
supplemented with 100 µg/ml ampicillin. The plasmid was heat-shock transformed into E. 
coli BL21 (DE3) cells, which were cultivated overnight on an LB agar plate at 37 °C. 200 ml 
sterile LB-medium was inoculated with a single colony of the grown bacteria and shaken 
overnight with 200 rpm at 37 °C. 40 ml of this pre-culture were used to inoculate 2 l of fresh 
LB-medium. The culture was shaken with 200 rpm at 37 °C and when reaching an OD600 nm of 
0.8, isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 
mM. Following induction, the temperature was reduced to 25 °C and the bacteria were 
grown overnight. On the next day, cells were harvested at 4 °C with the centrifuge Avanti J-
26 XP and the rotor JLA 8.1000 at 5,000 g, flash-frozen in liquid nitrogen and stored at - 80 
°C. 
 
 
20 g wet cell pellet was thawed and resuspended in 75 ml lysis buffer (20 mM Tris pH 7.9, 
500 mM NaCl, 5 mM imidazole) including 3 µl DNaseI (Invitrogen). Subsequently, cells were 
lysed using a cell disruptor at a working pressure of 1.5 kbar (sonication did work equally 
well). Cell debris was removed via a further centrifugation step (centrifuge Avanti J-26 XP, 
rotor JA 25.50, 50,000 g) before the supernatant was loaded onto a 5 ml HisTrap FF crude 
 
Figure 9-1. Purification of saACP via immobilized Ni2+ metal ion affinity chromatography (Ni2+-
IMAC). The chromatographic elution profile is shown at the top and the corresponding SDS-
PAGE gel at the bottom. The letters A and B link the fractions shown in the gel with the 
corresponding peaks of the chromatogram. Lanes 1 and 2 of the gel contain the lysate and the 
flow-through, respectively. The UV-absorptions at 230 nm, 260 nm and 280 nm are highlighted 
in purple, red and blue, respectively. The gradient is shown in black. 
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column (GE Healthcare). Using the Äkta purifier system (GE Healthcare), a step gradient from 
5 mM to 40 mM imidazole (7% buffer B, 8 column volumes (CV)) was followed by linear 
gradients from 40 mM to 250 mM (approaching 50% B within 13 CV) and from 250 mM to 
500 mM imidazole (approaching 100% B within 7 CV) (IMAC-buffer A = lysis buffer; IMAC-
buffer B = 20 mM Tris pH 7.9, 500 mM NaCl, 500 mM imidazole). An 18% SDS-PAGE revealed 
that apo-saACP elutes as a single peak at an imidazole concentration of approximately 100 
mM (20% B; Figure 9-1). Please note that the UV-absorption at 230 nm was measured since 
the small ACP protein does not contain any amino acids absorbing at a wavelength of 280 
nm. 
Fractions containing apo-saACP were pooled and dialyzed in reaction buffer (75 mM MES pH 
6.0, 10 mM MgCl2). Prior to the modification reaction, the protein concentration was 
determined via the BCA-assay (285) since the extinction coefficient of saACP at a wavelength 
of 280 nm is too low to allow a spectrophotometric approach. In order to modify Ser37 of 
saACP with the acylated phosphopantetheine moiety of crotonyl-CoA (cro-CoA), the 
phosphopantetheinyl transferase (PPTase) Sfp was used to catalyze this reaction (Figure 
9-2). 
 
 
For this purpose Sfp (the corresponding pET29b(+) plasmid was kindly provided by Prof. 
Peter J. Tonge) was expressed and purified as described previously (286,287) with an 
additional final size-exclusion chromatography (SEC) step in a buffer composed of 10 mM 
Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and 10% glycerol. The modification reaction mixture 
containing 77 µM apo-saACP, 179 µM cro-CoA and 0.78 µM Sfp was incubated for 2 h at 37 
°C. Since an 18% SDS-PAGE was not capable of separating apo-saACP from the product of the 
reaction, an 18% conformationally sensitive polyacrylamide gel electrophoresis (CS-PAGE) 
experiment was used to analyze the success of the reaction (Figure 9-2), which indicated a 
yield of ≤ 50%. CS-PAGE is a method known for at least 20 years (63,288,289) and enables 
the separation of different ACP-intermediates based on the slightly different conformations 
induced by the individual acyl-chains (76). The corresponding gels were produced by 
consecutively polymerizing a CS-PAGE resolving gel (18% 29:1 acrylamide/bis-acryamide; 375 
mM Tris pH 8.8; 0.5 M urea) and stacking gel solutions (5% 29:1 acrylamide/bis-acryamide; 
125 mM Tris pH 6.8; 0.5 M urea) by the addition of 0.1% (w/v) ammonium persulfate (APS) 
Figure 9-2. Acyl-phosphopantetheinylation of apo-saACP. The scheme on the left shows the chemical 
reaction to accomplish the coupling of apo-saACP with a defined substrate. An SDS-PAGE was not able to 
separate apo-saACP and cro-saACP. The respective gel is shown in the middle (lane 1 = saACP, lane 2 = 
reaction mixture after the addition of Sfp and cro-CoA to apo-saACP, lane 3 = reaction mixture after 2 h at 
37 °C). In contrast, an 18% CS-PAGE could separate apo- from cro-saACP (shown on the right; lane 1 = 
reaction mixture after the addition of Sfp and cro-CoA to apo-saACP, lane 3 = reaction mixture after 2 h at 
37 °C). 
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and 0.1% (w/v) N,N,N',N'-tetramethylethylenediamine (TEMED or TMEDA, respectively). 
After the protein samples had been supplemented with loading buffer (5x loading buffer = 
250 mM Tris pH 6.8, 0.5% (w/v) bromophenol blue, 50% glycerol and 250 mM urea), 
electrophoresis was carried out in 1x Tris-glycine buffer (TG-buffer = 25 mM Tris and 192 
mM glycine). Staining was performed using a standard Coomassie solution (50% (w/v) 
methanol, 10% (w/v) acetic acid and 1% (w/v) Coomassie Brilliant Blue). To enhance the 
yield of the reaction, further experiments were conducted with acetyl-CoA, which revealed 
that a 100 : 3 : 400 ratio of saACP : Sfp : acyl-CoA (saACP concentration of 77 µM was also 
used in these experiments) in a modified buffer (75 mM Tris pH 7.5, 10 mM MgCl2) resulted 
in much better yields (≥ 85%) after 3 h incubation of the reaction mixture at 37 °C. 
Alternatively, the reaction can be performed in 20 mM Tris pH 8.0, 10 mM MgCl2 and 30 mM 
NaCl thereby allowing to skip the dialysis step prior to anion exchange chromatography (IEC). 
After dialysis in IEC-buffer A (20 mM Tris pH 8.0 and 50 mM NaCl), the modified protein 
sample was loaded onto a MonoQ 10/100 GL column (GE Healthcare). A very shallow NaCl-
gradient was used to separate apo-saACP from cro-saACP (IEC-buffer B = 20 mM Tris pH 8.0 
and 1 M NaCl; linear gradient from 0% to 5% B (1 CV) followed by a shallow gradient from 
5% to 45% B (40 CV) and a steep gradient from 45% to 100% B (2 CV)). Apo- and cro-saACP 
eluted with their maxima at approximately 250 mM (21% B) and 280 mM NaCl (24% B), 
respectively. An 18% CS-PAGE was used to evaluate the success of the separation procedure 
(Figure 9-3). 
 
 
 
Pooled fractions containing cro-saACP were loaded onto a HiLoad 26/60 Superdex 200 prep 
grade column pre-equilibrated with SEC-buffer (20 mM Tris pH 7.0, 150 mM NaCl, 1 mM 
EDTA). Cro-saACP eluted at a volume of approximately 245 ml. An 18% SDS-PAGE and CS-
 
Figure 9-3. Separation of cro-saACP from apo-saACP via IEC. The chromatogram is shown at the 
top and the related 18% CS-PAGE gel at the bottom. The letters A and B indicate which lanes of 
the gel correspond to which peak in the elution profile. Curves corresponding to UV-absorptions 
at wavelengths of 230 nm, 260 nm and 280 nm are highlighted in purple, red and blue, 
respectively. The NaCl-gradient is depicted in black (percentage of buffer B).
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PAGE was used to assess the purity of the samples (Figure 9-4). Finally, the pooled fractions 
containing relatively pure cro-saACP were concentrated to 0.5 mM (4.8 mg/ml), flash-frozen 
in liquid nitrogen and stored at - 80 °C. 
 
 
 
Mass-spectrometric experiments with cro-saACP (MALDI-TOF, conducted at Stony Brook 
University) indicated a mass of 10,150 Da (highest peak), which is close to the expected 
value of 10,122 Da. However, methods such as ESI-MS might be better suited to clearly 
confirm the nature of the purified saACP-substrate (personal communication). 
9.2.2 Expression and Purification of Acetoacetyl-AcpM 
The purification of acetoacetyl-AcpM (acac-AcpM) described here was guided by previously 
published protocols (59,75,290). The native AcpM protein was expressed in E. coli BL21 
(DE3) cells. For this purpose, a pET24b(+) plasmid containing the acp-gene (obtained from 
the group of Prof. Peter J. Tonge) was heat-shock transformed into these cells, which were 
subsequently cultured on an LB-agar plate at 37 °C overnight. To select only those bacteria 
that took up the plasmid, solid and liquid media were supplemented with 50 µg/ml 
kanamycin. 40 ml of a 200 ml overnight culture were used to inoculate 2 l of sterile LB-
medium, which was subsequently shaken with 200 rpm at 37 °C. After induction with 0.7 
mM IPTG at an OD600 nm of 0.9 and further growth for 3-4 h at 37 °C, cells were harvested by 
centrifugation (centrifuge Avanti J-26 XP, rotor JLA 8.1000, 5,000 g), flash-frozen in liquid 
nitrogen and stored at - 80 °C. 
60 ml lysis buffer (20 mM Bis-Tris pH 6.5, 200 mM NaCl, 1 mM DTT) and 2 µl DNaseI 
(Invitrogen) were used to resuspend 13 g thawed cells. After the bacteria were lysed by one 
passage through a cell disruptor (1.5 kbar), cell debris was removed by centrifugation 
(centrifuge Avanti J-26 XP, rotor JA 25.50, 50,000 g). 60 ml ice-cold isopropanol was added 
dropwise to the lysate over a period of approximately 20 min. The resulting solution was 
slowly stirred for 2 h at 4 °C followed by the removal of aggregated protein via centrifugation 
(centrifuge Avanti J-26 XP, rotor JA 25.50, 10,000 g). By adding 120 ml dilution buffer (20 
mM Bis-Tris pH 6.5, 1 mM DTT) the NaCl concentration of the supernatant was adjusted to 
50 mM for the following IEC-step with the Äkta purifier system (GE Healthcare). The protein 
sample was loaded onto a 5 ml Q-sepharose XL column (GE Healthcare) and eluted by a 
shallow gradient from 50 mM to 1 M NaCl (25 CV; Q-buffer A = 20 mM Bis-Tris pH 6.5, 50 
Figure 9-4. Isolation of cro-saACP via a final SEC-step. The chromatogram is shown on the left and the 18% 
SDS- (top) and CS-PAGE gels (bottom) on the right. Lanes 1 to 9 of both gels contain the same samples, which 
correspond to the main peak in the elution profile (indicated by the letter A). Purple, red and blue curves 
were obtained via measurements of the absorption at 230, 260 and 280 nm, respectively. 
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mM NaCl, 1mM DTT, Q-buffer B = 20 mM Bis-Tris pH 6.5, 1 M NaCl, 1 mM DTT). A mixture of 
holo-AcpM (= phosphopantetheinylated AcpM), apo-AcpM and acyl-AcpM co-eluted at 
approximately 400 mM NaCl (37% B) as indicated by an 18% SDS-PAGE analysis (Figure 9-5) 
(59). 
 
 
 
The pooled fractions of peak A were dialyzed into IEC-buffer A (20 mM Tris pH 8.0, 50 mM 
NaCl) and loaded onto a MonoQ 10/100 GL column (GE Healtcare) using the sample pump 
P960 (GE Healtcare). A shallow NaCl-gradient enabled the separation of apo-AcpM (IEC-
buffer B = 20 mM Tris pH 8.0, 1 M NaCl; linear gradient from 0% to 5% B (1 CV) followed by a 
shallow gradient from 5% to 45% B (40 CV) and a steep gradient from 45% to 100% B (2 CV)), 
which eluted first (peak A at approximately 17% B = 210 mM NaCl in Figure 9-6). 
 
 
 
Figure 9-6. Isolation of apo-AcpM via IEC. Lanes of the 18% SDS-PAGE gel (bottom) 
corresponding to peaks A and B of the chromatogram (top) are labeled with A and 
B. UV-absorption was detected at wavelengths of 260 nm (red) and 280 nm (blue). 
For clarity, the elution profile is shown from 100 ml to 350 ml and the NaCl-
gradient (in % buffer B) is colored in black. Two gels are depicted side by side (M = 
marker, PageRulerTM Prestained Protein Ladder from Fermentas). Since the applied 
salt gradient was too steep during the first AcpM purification, the results are shown 
and discussed for the already optimized gradient. 
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Figure 9-5. Isolation of a mixture of different AcpM-species via IEC. The chromatogram (left) and the 
related SDS-PAGE gel (right) are depicted. Lanes 1-13 of the gel correspond to peak A in the elution profile. 
Absorptions at 260 and 280 nm are colored red and blue, respectively. The NaCl-gradient is shown in black. 
M = marker, PageRulerTM Prestained Protein Ladder (Fermentas). 
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After the pooled fractions containing only apo-AcpM were dialyzed into reaction buffer (50 
mM Tris pH 8.5, 25 mM MgCl2, 5 mM MnCl2, 1 mM DTT), the protein concentration was 
determined using a photometric approach (NanoDrop ND 1000 from Peqlab). Because the 
AcpM extinction coefficient at 280 nm is relatively 
low according to theoretical calculations (ε = 2980 
M-1 cm-1) (291), acyl-AcpM samples were used to 
compare the photometric method with the BCA-
assay. As the resulting concentrations varied by a 
factor of approximately 2 between the two 
different approaches, an acyl-AcpM sample was 
lyophilized to determine the "true" concentration 
for calibration of the BCA-assay and the 
photometric experiments. Resulting correction 
factors were 1.2 and 0.6, respectively. For the modification reaction catalyzed by the PPTase 
AcpS, a mixture of 0.58 mM apo-AcpM (0.96 mM measured photometrically), 6 µM AcpS and 
0.72 mM acetoacetyl-CoA (acac-CoA, 1.2-fold molar excess) was incubated for 90 min at 30 
°C. AcpS purified according to (73) was kindly provided by the group of Prof. Peter J. Tonge. 
Apo-AcpM and the formed acac-AcpM could be separated via 18% SDS-PAGE, which 
indicated a yield ≥ 60% (Figure 9-7). Hence, an approximately 2-fold molar excess of acac-
CoA should be used to enable a more quantitative reaction (59). However, further small-
scale experiments are recommended to derive the minimal amount of acac-CoA needed for 
a full conversion of apo-AcpM due to the high costs of CoA compounds. 
After the reaction, the protein sample was again dialyzed into IEC-buffer A to enable the 
isolation of acac-AcpM by MonoQ IEC performed as described above. Apo- and acac-AcpM 
could be separated and eluted with their maxima at approximately 290 mM (25% B) and 320 
mM NaCl (28% B), respectively (Figure 9-8). Please note that the peaks corresponding to 
AcpM-species were shifted towards approximately 100 mM higher NaCl concentrations 
compared to the initial MonoQ run (Figure 9-6), which indicates that parameters such as 
temperature, sample composition and column condition might influence the exact elution 
profiles. Taken together with the findings for saACP (Figure 9-3), ACP-species seem to elute 
in the range of 200 to 400 mM NaCl (16 to 37% B) using the presented IEC protocol. 
 
 
 
Fractions corresponding to peak B were pooled and loaded onto a HiLoad 26/60 Superdex 
200 prep grade column equilibrated with SEC-buffer (20 mM Tris pH 7.4, 150 mM NaCl, 2 
Figure 9-8. Separation of acac-AcpM and apo-AcpM via IEC. Labels A and B indicate those fractions of the 
18% SDS-PAGE gel (right) that correspond to peaks A and B of the chromatogram (left). UV-absorption curves 
are shown at wavelengths of 260 nm (red) and 280 nm (blue). The NaCl-gradient profile is depicted in black. M 
= marker, PageRulerTM Prestained Protein Ladder from Fermentas. 
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Figure 9-7. Acyl-Phosphopantetheinylation of 
apo-AcpM. This 18% SDS-PAGE gel section 
shows apo-AcpM (lane 1), apo-AcpM including 
AcpS and acac-CoA (lane 2) and the reaction 
mixture after 1.5 h of incubation (lane 3). 
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mM EDTA, 10% glycerol). Acac-AcpM eluted as a single peak at a volume of approximately 
230 ml (Figure 9-9). Fractions containing relatively pure acac-AcpM were pooled, 
concentrated to 0.32 mM (0.54 mM determined via the photometric procedure), flash-
frozen in liquid nitrogen and stored at - 80 °C. 
 
 
 
Acac-AcpM was further analyzed by mass spectrometry (MALDI-TOF, Stony Brook University) 
indicating a mass of 13,059 Da (highest peak), which is close to the calculated value of 
13,047 Da. However, ESI-MS might be better suited to determine the exact mass of the 
purified AcpM-species (personal communication). 
9.3 DNA and Protein Sequences 
9.3.1 SaFabI 
For all shown sequences, the start and stop codons are underlined (dashed for the original 
start/stop codon), the His-tag is colored in green and mutations with respect to the 
reference gene are highlighted in red. The safabI gene (S. aureus N315, gene ID = 1123686) 
cloned into a pET16b plasmid (kindly provided by Prof. Peter J. Tonge) was found to have the 
following DNA base sequence(Seqlab, Goettingen): 
 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGTT
AAATCTTGAAAACAAAACTTATGTCATCATGGGAATCGCTAATAAGCGTAGTATTGCTTTTGGTGTCG
CTAAAGTTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAACGTAGCCGTAAAGAG
CTTGAAAAATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAATTGATGTTCAAAGCGA
TGAAGAGGTTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATTGATGGTGTATATCATT
CAATCGCATTTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTCACGTGAAGGCTTCTTG
TTAGCTCAAGACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTAAAAAATTAATGCCAGA
AGGTGGTAGCATTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCAAAACTATAATGTGATG
GGTGTTGCTAAAGCGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGACTTAGGTCCAGATAATA
TTCGCGTTAATGCAATTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGGTGTGGGTGGTTTCAAT
ACAATTCTTAAAGAAATCGAAGAGCGTGCACCTTTAAAACGTAATGTTGATCAAGTAGAAGTAGGTA
AAACTGCGGCTTACTTATTAAGTGATTTATCAAGTGGCGTTACAGGTGAAAATATTCATGTAGATAGC
GGATTCCACGCAATTAAATAA 
 
Figure 9-9. Final SEC purification step. The major peak A of the chromatogram (left) 
contains mainly acac-AcpM as shown by the 18% SDS-PAGE (right; pooled and 
concentrated peak A fractions). Red and blue curves represent the measured UV-
absorption profiles at wavelengths of 260 and 280 nm, respectively. M = marker, 
PageRulerTM Prestained Protein Ladder from Fermentas.
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The resulting protein sequence thus is: 
 
MGHHHHHHHHHHSSGHIEGRHMLNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKERSRKEL
EKLLEQLNQPEAHLYQIDVQSDEEVINGFEQIGKDVGNIDGVYHSIAFANMEDLRGRFSETSREGFLLAQD
ISSYSLTIVAHEAKKLMPEGGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRVNAISA
GPIRTLSAKGVGGFNTILKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK* 
 
The safabI gene (S. aureus N315, gene ID = 1123686) was cloned into a pETM-11 plasmid 
(diploma thesis) resulting in the following DNA (Seqlab, Goettingen) and protein sequences: 
 
ATGAAACATCACCATCACCATCACCCCATGAGCGATTACGACATCCCCACTACTGAGAATCTTTATTTT
CAGGGCGCCATGGTAAATCTTGAAAACAAAACTTATGTCATCATGGGAATCGCTAATAAGCGTAGTA
TTGCTTTTGGTGTCGCTAAAGTTTTAGATCAATTAGGTGCTAAATTAGTATTTACTTACCGTAAAGAAC
GTAGCCGTAAAGAGCTTGAAAAATTATTAGAACAATTAAATCAACCAGAAGCGCACTTATATCAAAT
TGATGTTCAAAGCGATGAAGAGGTTATTAATGGTTTTGAGCAAATTGGTAAAGATGTTGGCAATATT
GATGGTGTATATCATTCAATCGCATTTGCTAATATGGAAGACTTACGCGGACGCTTTTCTGAAACTTC
ACGTGAAGGCTTCTTGTTAGCTCAAGACATTAGTTCTTACTCATTAACAATTGTGGCTCATGAAGCTA
AAAAATTAATGCCAGAAGGTGGTAGCATTGTTGCAACAACATATTTAGGTGGCGAATTCGCAGTTCA
AAACTATAATGTGATGGGTGTTGCTAAAGCGAGCTTAGAAGCAAATGTTAAATATTTAGCATTAGAC
TTAGGTCCAGATAATATTCGCGTTAATGCAATTTCAGCTGGTCCAATCCGTACATTAAGTGCAAAAGG
TGTGGGTGGTTTCAATACAATTCTTAAAGAAATCGAAGAGCGTGCACCTTTAAAACGTAATGTTGATC
AAGTAGAAGTAGGTAAAACTGCGGCTTACTTATTAAGTGATTTATCAAGTGGCGTTACAGGTGAAAA
TATTCATGTAGATAGCGGATTCCACGCAATTAAATAA 
 
MKHHHHHHPMSDYDIPTTENLYFQGAMVNLENKTYVIMGIANKRSIAFGVAKVLDQLGAKLVFTYRKER
SRKELEKLLEQLNQPEAHLYQIDVQSDEEVINGFEQIGKDVGNIDGVYHSIAFANMEDLRGRFSETSREGF
LLAQDISSYSLTIVAHEAKKLMPEGGSIVATTYLGGEFAVQNYNVMGVAKASLEANVKYLALDLGPDNIRV
NAISAGPIRTLSAKGVGGFNTILKEIEERAPLKRNVDQVEVGKTAAYLLSDLSSGVTGENIHVDSGFHAIK* 
9.3.2 SaACP 
The saacp gene (S. aureus NCTC8325, gene ID = 3919468) cloned into a pET23b plasmid 
(kindly provided by Prof. Peter J. Tonge) has the following DNA (Seqlab, Goettingen) and 
protein sequences: 
 
ATGGTGGAAAATTTCGATAAAGTAAAAGATATCATCGTTGACCGTTTAGGTGTAGACGCTGATAAAG
TAACTGAAGATGCATCTTTCAAAGATGATTTAGGCGCTGACTCACTTGATATCGCTGAATTAGTAATG
GAATTAGAAGACGAGTTTGGTACTGAAATCCCTGATGAAGAAGCTGAAAAAATCAACACTGTTGGTG
ATGCTGTTAAATTTATTAACAGTCTTGAAAAACTCGAGCGCCACCACCACCACCATTGA 
 
MVENFDKVKDIIVDRLGVDADKVTEDASFKDDLGADSLDIAELVMELEDEFGTEIPDEEAEKINTVGDAVK
FINSLEKLERHHHHH* 
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9.3.3 EcFabI 
The ecfabi gene (E. coli BL21 (DE3), gene ID = 8180124) cloned into a pET23b plasmid (kindly 
provided by Prof. Peter J. Tonge) has the following DNA (Eurofins MWG DNA sequencing) 
and protein sequences: 
 
ATGGGTTTTCTTTCCGGTAAGCGCATTCTGGTAACCGGTGTTGCCAGCAAACTATCCATCGCCTACGG
TATCGCTCAGGCGATGCACCGCGAAGGAGCTGAACTGGCATTCACCTACCAGAACGACAAACTGAA
AGGCCGCGTAGAAGAATTTGCCGCTCAATTGGGTTCTGACATCGTTCTGCAGTGCGATGTTGCAGAA
GATGCCAGCATCGACACCATGTTCGCTGAACTGGGGAAAGTTTGGCCGAAATTTGACGGTTTCGTAC
ACTCTATTGGTTTTGCACCTGGCGATCAGCTGGATGGTGACTATGTTAACGCCGTTACCCGTGAAGGC
TTCAAAATTGCCCACGACATCAGCTCCTACAGCTTCGTTGCAATGGCAAAAGCTTGCCGCTCCATGCT
GAATCCGGGTTCTGCCCTGCTGACCCTTTCCTACCTTGGCGCTGAGCGCGCTATCCCGAACTACAACG
TTATGGGTCTGGCAAAAGCGTCTCTGGAAGCGAACGTGCGCTATATGGCGAACGCGATGGGTCCGG
AAGGTGTGCGTGTTAACGCCATCTCTGCTGGTCCGATCCGTACTCTGGCGGCTTCCGGTATCAAAGA
CTTCCGCAAAATGCTGGCTCATTGCGAAGCCGTTACCCCGATTCGCCGTACCGTTACTATTGAAGATG
TGGGTAACTCTGCGGCATTCCTGTGCTCCGATCTCTCTGCCGGTATCTCCGGTGAAGTAGTCCACGTT
GACGGCGGTTTCAGCATCGCTGCAATGAACGAACTCGAACTGAAACTCGAGCACCACCACCACCACC
ACTGA 
 
MGFLSGKRILVTGVASKLSIAYGIAQAMHREGAELAFTYQNDKLKGRVEEFAAQLGSDIVLQCDVAEDASI
DTMFAELGKVWPKFDGFVHSIGFAPGDQLDGDYVNAVTREGFKIAHDISSYSFVAMAKACRSMLNPGS
ALLTLSYLGAERAIPNYNVMGLAKASLEANVRYMANAMGPEGVRVNAISAGPIRTLAASGIKDFRKMLA
HCEAVTPIRRTVTIEDVGNSAAFLCSDLSAGISGEVVHVDGGFSIAAMNELELKLEHHHHHH* 
9.3.4 KasA 
The kasa gene (M. tuberculosis H37Rv, gene ID = 887269) cloned into a pFPCA1 plasmid 
(292) (kindly provided by Prof. Peter J. Tonge) has the following DNA (Eurofins MWG DNA 
sequencing) and protein sequences: 
 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTA
GCGTGAGTCAGCCTTCCACCGCTAATGGCGGTTTCCCCAGCGTTGTGGTGACCGCCGTCACAGCGAC
GACGTCGATCTCGCCGGACATCGAGAGCACGTGGAAGGGTCTGTTGGCCGGCGAGAGCGGCATCCA
CGCACTCGAAGACGAGTTCGTCACCAAGTGGGATCTAGCGGTCAAGATCGGCGGTCACCTCAAGGA
TCCGGTCGACAGCCACATGGGCCGACTCGACATGCGACGCATGTCGTACGTCCAGCGGATGGGCAA
GTTGCTGGGCGGACAGCTATGGGAGTCCGCCGGCAGCCCGGAGGTCGATCCAGACCGGTTCGCCGT
TGTTGTCGGCACCGGTCTAGGTGGAGCCGAGAGGATTGTCGAGAGCTACGACCTGATGAATGCGGG
CGGCCCCCGGAAGGTGTCCCCGCTGGCCGTTCAGATGATCATGCCCAACGGTGCCGCGGCGGTGAT
CGGTCTGCAGCTTGGGGCCCGCGCCGGGGTGATGACCCCGGTGTCGGCCTGTTCGTCGGGCTCGGA
AGCGATCGCCCACGCGTGGCGTCAGATCGTGATGGGCGACGCCGACGTCGCCGTCTGCGGCGGTGT
CGAAGGACCCATCGAGGCGCTGCCCATCGCGGCGTTCTCCATGATGCGGGCCATGTCGACCCGCAAC
GACGAGCCTGAGCGGGCCTCCCGGCCGTTCGACAAGGACCGCGACGGCTTTGTGTTCGGCGAGGCC
GGTGCGCTGATGCTCATCGAGACGGAGGAGCACGCCAAAGCCCGTGGCGCCAAGCCGTTGGCCCGA
TTGCTGGGTGCCGGTATCACCTCGGACGCCTTTCATATGGTGGCGCCCGCGGCCGATGGTGTTCGTG
CCGGTAGGGCGATGACTCGCTCGCTGGAGCTGGCCGGGTTGTCGCCGGCGGACATCGACCACGTCA
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ACGCGCACGGCACGGCGACGCCTATCGGCGACGCCGCGGAGGCCAACGCCATCCGCGTCGCCGGTT
GTGATCAGGCCGCGGTGTACGCGCCGAAGTCTGCGCTGGGCCACTCGATCGGCGCGGTCGGTGCGC
TCGAGTCGGTGCTCACGGTGCTGACGCTGCGCGACGGCGTCATCCCGCCGACCCTGAACTACGAGAC
ACCCGATCCCGAGATCGACCTTGACGTCGTCGCCGGCGAACCGCGCTATGGCGATTACCGCTACGCA
GTCAACAACTCGTTCGGGTTCGGCGGCCACAATGTGGCGCTTGCCTTCGGGCGTTACTGA 
 
MGSSHHHHHHSSGLVPRGSHMASVSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHAL
EDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVV
GTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAH
AWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALML
IETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPI
GDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGE
PRYGDYRYAVNNSFGFGGHNVALAFGRY* 
9.3.5 AcpM 
The acpm gene (M. tuberculosis H37Rv, gene ID = 888272) cloned into a pET24b plasmid 
(kindly provided by Prof. Peter J. Tonge) has the following DNA (Seqlab, Goettingen) and 
protein sequences: 
 
ATGGTGCCTGTCACTCAGGAAGAAATCATTGCCGGTATCGCCGAGATCATCGAAGAGGTAACCGGTA
TCGAGCCGTCCGAGATCACCCCGGAGAAGTCGTTCGTCGACGACCTGGACATCGACTCGCTGTCGAT
GGTCGAGATCGCCGTGCAGACCGAGGACAAGTACGGCGTCAAGATCCCCGACGAGGACCTCGCCGG
TCTGCGTACCGTCGGTGACGTTGTCGCCTACATCCAGAAGCTCGAGGAAGAAAACCCGGAGGCGGC
TCAGGCGTTGCGCGCGAAGATTGAGTCGGAGAACCCCGATGCCGTTGCCAACGTTCAGGCGAGGCT
TGAGGCCGAGTCCAAGTGA 
 
MVPVTQEEIIAGIAEIIEEVTGIEPSEITPEKSFVDDLDIDSLSMVEIAVQTEDKYGVKIPDEDLAGLRTVGDV
VAYIQKLEEENPEAAQALRAKIESENPDAVANVQARLEAESK* 
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